COMMONWEALTH OF MASSACHUSETTS

SUFFOLK, ss.

SUPERIOR COURT
CIVIL ACTION NO. _____

TAMAR MASSOYAN-ARTINIAN, on behalf of her children, and MADISON SCHILTZ,

Plaintiffs,

v.

MONICA BHAREL, in her official capacity as Commissioner of the Massachusetts Department of Public Health and the MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH,

Defendants.

JURY TRIAL DEMANDED

PLAINTIFFS' MEMORANDUM OF LAW IN SUPPORT OF THEIR EMERGENCY MOTION FOR PRELIMINARY INJUNCTION

SIRI & GLIMSTAD LLP
ATTORNEYS AT LAW
200 PARK AVENUE, 17TH FLOOR
NEW YORK, NEW YORK 10166

Attorneys for Plaintiffs

TABLE OF CONTENTS

TABLE OF AUTHORITIES

CASES

OTHER AUTHORITIES

Plaintiffs Tamar Massoyan-Artinian, on behalf of her children, and Madison Schiltz (collectively, "**Plaintiffs**"), by and through their attorneys, Siri & Glimstad LLP, respectfully submit this memorandum of law in support of their motion for a preliminary injunction against Monica Bharel in her official capacity as Commissioner of the Massachusetts Department of Public Health and the Massachusetts Department of Public Health ("**Defendants**").

PRELIMINARY STATEMENT

The Massachusetts Legislature has carefully considered which vaccinations should be mandatory for students attending both K-12 schools in the Commonwealth, and its world-renowned colleges and universities. For K-12 schools, the Legislature created a list of required vaccinations but then granted the Department of Public Health ("**DPH**") authority to add additional vaccinations to that list through the usual process of adopting regulations. On the other hand, the Legislature required a different set of vaccinations for post-secondary students and did not give the DPH any authority to alter or enlarge that list.

The Legislature pointedly did not include the influenza vaccine in any of its lists. Nevertheless, on August 19, 2020, the DPH took it upon itself to issue a "press release" announcing it now required all children in K-12 schools, and all students attending colleges and universities to receive the influenza vaccine before December 31, 2020 (the "**Flu Shot Mandate**" or the "**Mandate**"). The problem is that the DPH has no authority to create a new vaccination mandate for students attending colleges and universities – only the Legislature can do that. Furthermore, all it did was issue a press release. It never took the steps needed to adopt a new regulation, such as providing prior notice or a public comment period. Thus, the Flu Shot Mandate is not a formal "regulation" and as such is unenforceable.

In addition to its other deficiencies, the DPH enacted the Flu Shot Mandate as a measure to prevent transmission of the flu and thereby decrease the burdens on the Commonwealth's

healthcare system. However, over the past decade, multiple published surveys of all available medical studies have "found no evidence that vaccines prevent viral transmission" of influenza. This means that mandating the influenza vaccine does not serve to prevent its transmission. Further, independent reviews have repeatedly concluded that there is no reliable evidence that the influenza vaccine reduces the burden on healthcare resources. And since the DPH cannot support that the Flu Shot Mandate will prevent the spread of influenza or reduce the burden on the healthcare system, it has no rational basis or other grounds to vitiate the fundamental constitutional rights to bodily integrity, informed consent, parental choice, and substantive due process by forcing unwilling individuals to receive the influenza vaccine. Nor does it have grounds to so burden the right to an education enshrined in the Massachusetts Constitution.

Plaintiffs are an adult graduate student at Springfield College and a parent of two elementary school students in Waltham Public Schools. Each of these three students has received all the required vaccines to attend school but has not received the influenza vaccine. Nothing in the Commonwealth's laws requires them to receive the influenza vaccine in order to exercise their constitutional right to an education. Nevertheless, the Flu Shot Mandate wrongfully threatens to prevent Plaintiffs from attending school on January 1, 2021, because they made the informed choice to not receive the influenza vaccine. Plaintiffs now bring this action seeking a declaration that the Flu Shot Mandate is invalid and *ultra vires* along with an injunction preventing its enforcement.

Plaintiffs do not question the need for robust public health tools to cope with the COVID 19 pandemic. However, the Flu Shot Mandate is neither legally adopted nor scientifically supported. If instead proper legislative and regulatory process had been followed, there would have been an opportunity to present to legislators and regulators powerful evidence that the Flu

Shot Mandate infringes on protected constitutional rights for no demonstrable public health benefit.

By granting the instant motion and enjoining the DPH from enforcing the Flu Shot Mandate, this Court will merely be maintaining the status quo. Plaintiffs do not oppose any individual choosing to receive the influenza vaccine. In fact, currently by employing non-coercive means, the DPH has achieved one of the highest levels of child influenza vaccination in the nation. Even with an injunction, the DPH will be free to continue to non-coercively encourage parents and students to receive the influenza vaccine just as it does now. Plaintiffs merely ask that they, and other students like them, be allowed to continue to attend their same schools during the pendency of this action without having to sacrifice their constitutionally protected rights in the process.

FACTS

A. Statutory Framework for Requiring Influenza Vaccine for School

The Massachusetts Legislature determined that in order to attend a K-12 school, absent an exemption, a child shall have been "immunized against diphtheria, pertussis, tetanus, measles, and poliomyelitis and *such other communicable diseases as may be specified from time to time by the department of public health*." G.L. c. 76, § 15 (emphasis added). As for students attending colleges and universities in the State, the Legislature provided that all college students under thirty years of age, and all students in undergraduate or graduate health science programs need to have "been immunized against measles, mumps, rubella, tetanus and diphtheria," and all college or university students who live in a dormitory must also be immunized against "meningococcal disease." G.L. c. 76, §§ 15C, 15D. Thus, the Legislature chose a different set of vaccinations to apply to students in higher education settings as opposed to children in lower schools, and it did not grant the DPH authority to require additional immunizations for higher education students. *Compare* G.L. c. 76, § 15 *with* G.L. c. 76, § 15C.

The Massachusetts Administrative Procedures Act ("**MAPA**"), G.L. c. 30A, § 1 *et seq.*, provides the statutory scheme for an administrative agency to adopt regulations. Among other requirements, prior to adopting any regulation, MAPA requires an administrative agency, like the DPH, to provide notice to the public and a period of time during which the public has an opportunity to comment on the proposed regulations. G.L. c. 30A, § 3.

B. <u>The Flu Shot Mandate</u>

On August 19, 2020, without adopting a regulation, the DPH issued a press release entitled "*Flu Vaccine Now Required for all Massachusetts School Students Enrolled in Child Care, Pre-School, K-12, and Post-Secondary Institutions*." (Ex. A.)[1] The press release declared that:

> State public health officials today announced that influenza immunization will be required for all children 6 months of age or older who are attending Massachusetts child care, pre-school, kindergarten, K-12, and colleges and universities. …
>
> All students in K-12 must receive the seasonal influenza vaccine annually by December 31. …
>
> For older students, the flu vaccine requirement applies to all full-time undergraduate and graduate students under 30 years of age and all full- and part-time health science students. … The only exception is for college and university students who exclusively attend classes online and never visit campus in person. College students who attend any classes or activities on campus, even once, must be vaccinated by December 31.

(*Id*.) The DPH also issued an FAQ which made clear that this requirement will apply perpetually henceforth. (Ex. B.)

At no point did the DPH adopt any regulation to codify this new purported requirement in this press release, nor were any of the MAPA requirements for adopting a regulation followed –

[1] All exhibits referenced herein refer to exhibits appended to the Declaration of Elizabeth A. Brehm filed herewith.

no prior notice to the public, no public comment period, no business impact statement published, nor anything filed with the secretary of state regarding any proposed regulation.

C. Plaintiffs Will Be Wrongfully Excluded from School or College on January 1, 2021

Plaintiffs and their affected children have received all immunizations required to attend college or school pursuant to G.L. c. 76, § 15 and § 15 C. None of them, however, have received an influenza vaccine. It is on that basis alone that Plaintiffs or their children will be excluded from their public K-12 schools or from their graduate program on January 1, 2021.

Plaintiff Tamar Massoyan-Artinian is the mother of two children, R.A., age 7 and H.A., age 11. (*See* Affidavit of Tamar Massoyran-Artenian, hereinafter "**TMA Aff.**", at ¶ 1.) Both of the children have received all of the vaccinations required to attend their public schools in Massachusetts as of December 11, 2020. *Id*. Both children have a history of allergies and adverse reactions to medications, including amoxicillin and influenza vaccines. (*Id*. at ¶ 2.)

Plaintiff Massoyan-Artinian's older child previously experienced intense adverse reactions to the influenza vaccine. (*Id*. at ¶ 3.) This child developed asthma at a young age and the conditioned worsened over time. (*Id*.) Each year, after receiving the influenza vaccine, the child suffered complications including bronchitis, bacterial pneumonia, respiratory infections, and asthma attacks. Most of these reactions led to Emergency Room visits, and one led to a hospitalization at Boston Children's Hospital. *Id*. Her younger child had adverse reactions to the influenza vaccine as well, including high fevers, rashes, and asthmatic tendencies such as requiring a nebulizer and steroids to stabilize breathing. (*Id*. at ¶ 4.)

After the last adverse response to the influenza vaccine, Plaintiff Massoyan-Artinian stopped having it administered to both of her children. (*Id*. at ¶ 5.) She inquired about a medical exemption to the influenza vaccine from her pediatrician based on her children's prior experiences

but was told that the medical practice "decided that it will not provide exemptions for the flu vaccine." (*Id*. at ¶ 6.)

If the DPH mandate is enforced, it will make Plaintiff Massoyan-Artinian face the Hobson's Choice to either (i) comply against her judgment as their parent and risking her children's' health, or (ii) continue to refuse and have her children excluded from school. (*Id*. at ¶ 7.)

If the children are excluded from school, it will have devastating real-world effects on the family whether they leave or stay in the state. (*Id*. at ¶¶ 8-14.) They have many strong ties to their local cultural and religious communities. (*Id*. at ¶ 9.) Plaintiff Massoyan-Artinian's husband's parents live close to them, and they are the reason the family is living where they are. (*Id*.) Leaving their family and community would be devastating. (*Id*.)

On the other hand, if they stay in the state and are excluded from school other irreparable harm will result. (*Id*. at ¶¶ 10-12.) Both Plaintiff Massoyan-Artinian and her husband work. (*Id*. at ¶ 10.) If their children are excluded from school, they will be forced to homeschool the children. (*Id*.) This will come at great expense as one of them would likely have to give up his or her salary to stay home and educate the children. (*Id*.) Neither of the parents is trained as an educator and homeschooling is outside their life plans and abilities. (*Id*.)

Furthermore, if the children are excluded from their school in January, they will be devastated. (*Id*. at ¶ 11.) Like other students, they have already experienced upheaval due to the COVID-19 restrictions, but now as there is light at the end of the tunnel on COVID, they will be told they can never go back with their friends, or their teachers. (*Id*.) The children will suffer emotionally and will experience anxiety if this new dramatic change is foisted upon them, especially after the very challenging and trying year they have already experienced. (*Id*. at ¶ 12.)

Plaintiff Madison Schiltz is a 27-year-old student, teacher, and coach. (*See* Affidavit of Madison Schiltz, hereinafter "**MS Aff.**", at ¶ 1.) She is fully vaccinated and has received every vaccine recommended to her by her doctors except for the influenza vaccine. (*Id*. at ¶ 2.) She is a master's graduate student at Springfield College, pursuing a masters in strength and conditioning. (*Id*. at ¶ 3.) She is completing her third semester, has a 3.78 g.p.a. which she has worked hard for, and currently expects to graduate with her master's degree in May 2021. (*Id*.)

Plaintiff Schiltz grew up getting vaccinated "on schedule." (*Id*. at ¶ 5.) She understands the risks and benefits involved with her medical choices, including vaccines, and typically feels the benefit outweighs the risks. She has not reached that conclusion with regard to the influenza vaccine. (*Id*.) She has worked very hard to get where she is, and to know she may be unable to complete her education due to something she does not consent to is troubling. (*Id*. at ¶ 6.) Thus, the fact that her education is being threatened by an unlawful mandate has caused her mental and emotional distress. (*Id*.)

When Plaintiff Schiltz first heard about the DPH mandate, she took action. (*Id*. at ¶ 7.) She contacted her student body government, other students, and eventually the President of Springfield College to discuss her concerns and her objection to this mandate. (*Id*.) Plaintiff Schiltz was told that this was a mandate from the DPH and so the school's hands were tied. (*Id*.)

When Plaintiff Schiltz was accepted at Springfield College, an influenza vaccine was not required. (*Id*. at ¶ 8.) She cannot comply with this mandate and will continue to stand up for what she believes in: informed consent, bodily autonomy, and her constitutional rights to liberty. (*Id*. at ¶ 9.) If she is merely excluded from campus, and forced to complete her degree remotely, that too will cause her numerous harms. *Id*. Specifically, as she is currently a Graduate Assistant she will lose that position and the thousands of dollars in free tuition and monthly stipend that comes with the position. (*Id*. at ¶¶ 4, 11.) Without these, she likely would be unable to afford to complete

her degree. (*Id*. at ¶ 11.) Therefore, if the mandate is enforced, Plaintiff Schiltz will be forced out of her school and will be unable to complete the degree that she has already expended significant time and resources to obtain. (*Id*. at ¶¶ 11-13.)

D. The "Flu" and Influenza Vaccines

The DPH repeatedly refers to influenza vaccines as an approach for dealing with the "flu." (*See* Expert Affidavit of P. Doshi, T. Jefferson, P. Gotzsche, and C. Heneghan, hereinafter "**Doshi et al. Aff.**" at ¶ 7.) However, most cases of the "flu," respiratory infections, and illnesses are not caused by influenza virus but rather by other viruses. (*Id*.) Every year, hundreds of thousands of respiratory specimens are tested across the United States and, on average, only 16% are found to be influenza positive. *Id*. Hence, the influenza vaccine, even if it were an effective product, could only address a small fraction of the "flu" cases in Massachusetts. (*Id*.)

The influenza vaccine also changes every year to target new strains of influenza virus. (*Id*. at ¶¶ 7-9.) One implication of this variation is that influenza vaccines are manufactured each year without knowing their efficacy or safety profile. (*Id*. at ¶ 10.) This can only be discovered after the fact. *Id*. Moreover, as discussed in the accompanying expert affidavits by world-renown scientists, there is no credible evidence these products reduce the incidence of hospitalization or mortality. (*Id*. at ¶¶ 14-16.) On the other hand, those same experts detail how influenza vaccines can cause serious injury and death, including various autoimmune and neurological disorders (*Id*. at ¶¶ 17-22) and can have serious unintended consequences including increasing susceptibility to other infections. (*Id*. at ¶¶ 23-26.)

ARGUMENT

I. PLAINTIFFS ARE ENTITLED TO A PRELIMINARY INJUNCTION

Given the December 31, 2020 deadline established by the DPH, Plaintiffs are forced to seek a preliminary injunction to stay enforcement of the Flu Shot Mandate so as to avoid the

irreparable harm of being precluded from attending school. To be awarded an injunction, the Plaintiffs must satisfy the familiar three-part test: "(1) a likelihood of success on the merits; (2) that irreparable harm will result from denial of the injunction; and (3) that, in light of the [moving party's] likelihood of success on the merits, the risk of irreparable harm to the [moving party] outweighs the potential harm to the [nonmoving party] in granting the injunction." *Loyal Order of Moose, Inc., Yarmouth Lodge #2270 v Bd. of Health of Yarmouth*, 439 Mass. 597, 601 (2003) (quotations omitted). "When a party seeks to enjoin governmental action, a judge is also required to determine that the requested order promotes the public interest, or, alternatively, that the equitable relief will not adversely affect the public." *Id.* (quotations omitted)

"A preliminary injunction ordinarily is issued to preserve the status quo pending the outcome of litigation." *Doe v. Superintendent of Sch. of Weston*, 461 Mass. 159, 164 (2011). That is all that Plaintiffs seek here, to preserve their ability to receive an education while the court adjudicates the DPH's mandate.

II. PLAINTIFFS HAVE A HIGH LIKELIHOOD OF SHOWING THAT THE FLU SHOT MANDATE IS INVALID AND UNENFORCEABLE

Plaintiffs are highly likely to succeed in the instant action because the Flu Shot Mandate is invalid and unenforceable for three separate reasons. First, the DPH lacked authority to apply the Mandate to post-secondary students and did so *ultra vires*. Second, for K-12 students, the DPH failed to comply with the MAPA procedures, making the Mandate unenforceable. Third, the Mandate is unconstitutional.

A. The DPH Lacked Authority To Adopt The Mandate For Post-Secondary Students

1. The Legislature Chose Not To Grant DPH Discretion to Mandate Any New Vaccines for College Students

It is settled law that "an administrative agency has no authority to promulgate rules or regulations that conflict with the statutes or exceed the authority conferred by the statutes by which

the agency was created." *Massachusetts Mun. Wholesale Elec. Co. v. Energy Facilities Siting Council*, 411 Mass. 183, 194 (1991); *Goldberg* v. *Board of Health of Granby*, 444 Mass. 627, 633 (2005) (if a court "conclude[s] that the statute is unambiguous, [it] give[s] effect to the Legislature's intent").

With regard to requiring immunizations for attending K-12 school, the Legislature provided a list of required vaccinations, but then also permitted "such other communicable diseases as may be specified from time to time by the" DPH. G.L. c. 76, § 15. However, it made a different choice for immunizations required to attend colleges and universities. *Compare* G.L. c. 76, § 15 *with* § 15C. There, the Legislature did not grant the DPH any role in selecting the required vaccinations. Instead, it identified a finite list of required vaccinations. Specifically, the Legislature mandated that post-secondary students need to have "been immunized against measles, mumps, rubella, tetanus and diphtheria," and "meningococcal disease" if they live in a dormitory. G.L. c. 76, §§ 15C, 15D.

It is axiomatic that a statute should be read in accordance with its plain meaning in light of the whole statutory scheme. *ENGIE Gas & LNG LLC v. Dep't of Pub. Utils.*, 475 Mass. 191, 199, (2016). Clearly the Legislature knew full well how to grant the DPH authority in Chapter 76 to expand the list of required vaccinations through duly promulgated regulations and did so for K-12 students in Section 15. The fact that Section 15D is silent as to the DPH's involvement, necessarily means that the Legislature intended to *not* empower the DPH to require additional immunizations to attend colleges and universities. Without such authorization to act, the DPH lacked authority to enact the Flu Shot Mandate for post-secondary students, and Plaintiffs will be able to establish that the Mandate cannot be enforced against such students.

2. The Legislative History Further Makes Plain the DPH's Lack of Authority to Mandate the Flu Shot to College Students

The vaccine requirements for a "child" to attend K-12 "school" in Section 15 was last amended in 1972. (1972 Mass. Acts 77.) When the Legislature, in 1985, wanted to require immunizations for attending college, it promulgated a new Section 15C. (1985 Mass. Acts 98.) At that time, bills were introduced to grant the DPH similar authority under Section 15C as it already enjoyed under Section 15. *See* MA H.B. 6099 (1984) and MA H.B. 222 (1985) (seeking to have Section 15C include in the list of required vaccines "such other communicable diseases as may be specified from time to time by the department of public health."). But such language did not make it into the final bill. Thus, the Legislature's choice to withhold authority from the DPH in this latter statute was not an oversight, but rather a deliberate choice.

Furthermore, during the thirty-five years since its enactment, the Legislature has had numerous opportunities to amend Section 15C to again grant the DPH a role in selecting the required vaccines. Numerous bills have been introduced to amend Section 15C to adopt language similar to Section 15, but each bill has failed to pass. For example, MA H.B. 180, introduced January 1, 1992, proposed amending Section 15C to add that the required vaccinations would include "other such communicable diseases, in accordance with regulations of the department of public health."[2]

Given the Legislature's unambiguous choice to withhold authority from the DPH regarding vaccinations for college students, that agency cannot now simply appropriate to itself the authority long denied it. For this reason, the Court must hold that the DPH cannot now be allowed to apply the Flu Shot Mandate to post-secondary students.

[2] The following bills also attempted to add the above language to Section 15 C: MA H.B. 192 (1993); MA H.B. 204 (1994); MA H.B. 170 (1997); MA H.B. 123 (1999); MA H.B. 133 (2001); MA H.B. 74 (2003).

B. The Flu-Shot Mandate Is Invalid Because The DPH Did Not Comply With MAPA

In order for the Flu Shot Mandate to apply to K-12 students, DPH should have enacted a "regulation" promulgated pursuant to the procedure required by the MAPA. G.L. c. 30A, § 1 *et seq*. However, DPH chose to not enact the Flu Shot Mandate as a regulation. It failed to provide prior notice to the public, an opportunity for the public to comment, and it never entered the Flu Shot Mandate into the Code of Massachusetts Regulations ("**CMR**"), all steps required by the MAPA. The DPH's failure to follow such procedures means that the Flu Shot Mandate is nothing more than an *ultra vires* fiat with no legal force.

1. DPH Was Required to Follow the MAPA

When the provisions of the agency's enabling legislation "prescribe a mode and method for the procedure for the promulgation of rules or regulations," the agency must follow those procedures. *New England Milk Dealers Ass'n* v. *Department of Food & Agric.*, 33 Mass. App. Ct. 935, 936 (1992). "But where no mode and method of procedure for rulemaking are provided, the provisions of the Massachusetts Administrative Procedure Act are generally applicable." *Id.*

G.L. c. 76, § 15 is the enabling legislation by which the DPH is authorized to regulate which additional immunizations – beyond those already required by that section – shall be required to attend K-12 school in Massachusetts. Because this enabling legislation does not specify the "mode and method" for adopting a regulation to require an additional immunization for school attendance, the DPH was bound to abide by the procedures contained in the MAPA before adopting the Flu Shot Mandate. *See New England Milk Dealers*, 33 Mass. App. Ct. at 936.

2. The Flu Shot Mandate is a Regulation

The MAPA, broadly defines a "regulation" as "the whole or any part of every rule, regulation, standard or other requirement of *general application and future effect*, including the amendment or repeal thereof, adopted by an agency to implement or interpret the law enforced or

administered by it." G.L. c. 30A, § 1 (5) (emphasis added); *Carey* v. *Comm'r of Correction*, 479 Mass. 367, 371 (2018) ("Given the purpose of the APA, we interpret its definition of regulation broadly."). Just because an agency chooses not to call something a regulation does not mean the requirements of the MAPA do not apply to it, rather a court must determine for itself whether the agency's action falls within the definition of a regulation. *Carey*, 479 Mass. at 371 (holding that contrary to the commissioner's contention, enacting a policy regarding visitors to prisons had to conform to the MAPA's rules).

Even though the DPH only released it as a press release, the Flu Shot Mandate squarely falls within the definition of a "regulation" as defined by the MAPA. *Id.* It is a rule or standard of "general application and future effect," and thus the DPH was required to comply with the procedures in the MAPA before adopting the Flu Shot Mandate. *See, e.g., Id.*; *Kneeland Liquor, Inc. v. Alcoholic Beverages Control Comm'n*., 345 Mass. 228 (1962) (finding that alcohol price schedules that require agency approval set down public policy with legal consequences and thus are regulations under the MAPA); *Allied Theatres of New England, Inc.* v. *Commissioner of Labor & Indus.*, 338 Mass. 609, 611 (1959) (holding that labor department's order setting minimum wages was a regulation under the MAPA).

3. Public Comment was a Prerequisite to Adopting the Flu Shot Mandate

The MAPA requires that "[p]rior to the adoption, amendment, or repeal of any regulation … the agency shall … afford interested persons an opportunity to present data, views or arguments in regard to the proposed action orally or in writing" and "[i]f the agency finds that oral presentation is unnecessary or impracticable, it may require that presentation be made in writing." G.L. c. 30A, § 3. These notice and comment procedures are not mere formalities. Indeed, failure to abide by these requirements results in the invalidation of the regulation. *See, e.g., Carey*, 479 Mass. at 371 (holding that notice and hearing procedures under the MAPA are required to be

followed prior to adopting a new policy and deeming the new regulation unenforceable until it was reenacted by following the MAPA's procedures).

Here, the DPH never provided notice that it intended to adopt the Flu Shot Mandate, nor did it provide an opportunity for comment on the mandate prior to its adoption. These procedural lapses, among others, are fatal to the Flu Shot Mandate because, by failing to abide by the MAPA procedures, the Flu Shot Mandate was *never* properly adopted and so it is invalid.

Consequently, the Flu Shot Mandate does not carry the force of law as a "regulation." As explained by the Supreme Judicial Court, rules issued by an administrative agency without following procedures under the MAPA "do not have the same status as regulations adopted pursuant to the [MAPA]. . . . they do not carry the force of law." *Global NAPs, Inc. v. Awiszus,* 457 Mass. 489 (2010); *see also Evans v. Mayer Tree Service, Inc.,* 89 Mass. App. Ct. 137, 149 (2016) (agency protocols not formally promulgated do not carry force of law); *Massachusetts Gen. Hosp. v. Rate Setting Comm'n*., 371 Mass. 705, 707 (1977) (finding that non-regulation agency guidance does not "have the binding force attributable to full-blown regulation").

Furthermore, the lack of public comment had substantive consequences here because it allowed the DPH to act based on faulty assumptions about the effects of the influenza vaccine, including that it would reduce hospitalization and the transmission of the flu. However, as discussed below, Plaintiffs' experts' reports show that these assumptions are not supported by scientific studies, a fact that could have been brought to the DPH's attention if it allowed the public to comment. (*Infra* § C.1.)

4. DPH Failed to Follow Procedures for Adopting an Emergency Regulation

The DPH's press release announcing the Flu Shot Mandate stated that "[t]he new vaccine requirement is an important step to reduce flu-related illness and the overall impact of respiratory

illness during the COVID-19 pandemic."[3] However, even assuming *arguendo* the DPH was entitled to a waiver from the formal deliberative processes of notice, hearing and public comment required by MAPA, due to the ongoing COVID-19 public health emergency, the DPH failed even to comply with requirements of the MAPA applicable to issuing emergency regulations.

Pursuant to sections 2 and 3 of the MAPA, an administrative agency may dispense with the notice, hearing, and public comment phases in the process of adopting an "emergency regulation" so long as "the agency's finding and a brief statement of the reasons for its finding [are] incorporated in the emergency regulation as filed with the state secretary under section five" and any emergency regulation "shall not remain in effect for longer than three months." G.L. c. 30A, §§ 2-3. The DPH did not comply with any of these when adopting the Flu Shot Mandate. It did not include a brief statement of the reasons to support an emergency regulation, did not file any such statement with the secretary of state, nor did it in fact promulgate any regulation, emergency or otherwise, to incorporate into the CMR. Moreover, the DPH provided that the mandate would continue indefinitely, well beyond the three-month time limit provided for an emergency regulation.

For all these reasons, Plaintiffs are highly likely to show that the Flu Shot Mandate cannot be enforced because it was not adopted pursuant to any of the requirements of the MAPA.

C. The Flu Shot Mandate Is Unconstitutional

Even if the DPH had enacted the Flu Shot Mandate pursuant to the rules required by MAPA, and it had the authority to regulate vaccinations for post-secondary students, neither of which it did, the Flu Shot Mandate must still be struck down as unconstitutional under the

[3] https://www.mass.gov/news/flu-vaccine-now-required-for-all-massachusetts-school-students-enrolled-in-child-care-pre.

Massachusetts and United States Constitutions. When the DPH chose to condition the provision of an education on their injection of an influenza vaccine, the agency invalidated Plaintiffs' informed medical decisions, and impinged upon Plaintiffs' fundamental constitutional rights to bodily integrity, informed consent, parental choice, and the substantive due process rights under the United States Constitution and the Massachusetts Constitution.

1. Plaintiffs' Have Valid Constitutionally Protected Reasons to Refuse the Influenza Vaccine

While not necessary to decide that the Flu Shot Mandate is unconstitutional, Plaintiffs' decisions to not receive the influenza vaccine are entirely reasonable and rational. With virtually all pharmaceutical products, there are risks and benefits. Vaccines are no exception. (*See* Expert Affidavit of P. Aaby and C. Stabell Benn, hereinafter "**Aaby and Benn Aff.**" at ¶ 8; *see also* Doshi et al. Aff. at ¶¶ 17-26.) This is why the cornerstone of medical ethics is informed consent, a principle which is also a long recognized fundamental, civil, and human right. (Aaby and Benn Aff. at ¶ 5.) Informed consent requires conveying the risks and benefits of a medical procedure or pharmaceutical product to a patient and obtaining un-coerced consent. *See, e.g., Shine v. Vega*, 429 Mass. 456, 463 (1999) (reiterating the fundamental right to informed consent to "decide whether a particular medical treatment is in [the patient's] best interests"). Nonetheless, in enacting the Flu Shot Mandate, the DPH took away this right to informed consent for the influenza vaccine from all students in the Commonwealth.

It is a well-established fact that influenza vaccines can cause serious injury and death, as well as various harmful unintended consequences. (Doshi et al. Aff. ¶¶ 17-26; Aaby and Benn Aff. at ¶ 8.) Because of the dangers posed by vaccines, Congress enacted the National Childhood Vaccine Injury Act of 1986 (the "**1986 Act**"), which granted vaccine manufacturers (and any medical personnel that administers a vaccine) blanket immunity from liability for injuries caused

by these products.[4] Vaccines are the only medical products in the U.S. with such immunity. This immunity creates a moral hazard for those promoting these products because product liability lawyers, one of the other pillars of how the U.S. ensures the safety of its drug supplies, play no role in the safety of vaccines.

Those injured by the influenza vaccine must file a claim against the U.S. government in the Vaccine Injury Compensation Program, administered in the United States Court of Federal Claims. (Doshi et al. Aff. ¶¶ 20-21.) Over $4 billion has been paid out by this program for vaccine injury claims and influenza vaccines represent over 50% of these claims. (*Id.* at ¶ 21.) Injuries from influenza vaccines for which compensation has been paid include Anaphylaxis (severe allergic reaction), Bell's Palsy, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Complex Regional Pain Syndrome (CRPS), Cardiac Arrest, Death, Fibromyalgia, Guillain-Barre Syndrome (GBS), Multiple Sclerosis (MS), and Transverse Myelitis (TM), among many others. (*Id*.)

Moreover, in the last ten years, the Vaccine Adverse Events Reporting System (VAERS), administered by the CDC and FDA, has received reports of the following serious events following receipt of an influenza vaccine: 1,527 deaths; 3,327 permanent disabilities; 12,692 hospitalizations; and 40,040 emergency room and/or medical office visits. (*Id*. at ¶ 20.) A report from researchers at Harvard Medical School, including the Director of Bioinformatics, funded by an agency within the U.S. Department of Health and Human Services, stated that "fewer than 1% of vaccine adverse events are reported" to VAERS. (*Id.*)

The assumptions and advertised views about influenza vaccine products have stifled the ability for most people – even otherwise intelligent and analytical individuals – to rationally and

[4] *See* https://www.law.cornell.edu/uscode/text/42/300aa-1.

objectively consider these products. This issue is compounded by the fact that many consider it off limits to even request to see the evidence which underpins claims regarding influenza vaccines. In a court, public health officials cannot justify their policies and statements regarding the influenza vaccine without evidence. Plaintiffs, therefore, respectfully ask that all preconceived notions regarding these products be set aside. That only proven statements be considered. And that the Court, if it reaches the constitutional issues in this case, cautiously examine the proof for any claim regarding influenza vaccines made by either party.

2. The DPH Did Not Have A Compelling Interest to Enact the Mandate

Having impinged on these constitutional rights, the DPH has the burden to prove it has a compelling state interest to exclude adults from college and children from K-12 school, and that exclusion is the least restrictive means to achieve the compelling interest.

Courts have recognized that the desire to control the spread of an infection can constitute such a compelling state interest. However, **that compelling interest to control influenza spreading from student-to-student is absent with regard to the influenza vaccine because studies have repeatedly concluded that there is no evidence to support that the influenza vaccine prevents transmission of the influenza virus**. (Doshi et al. Aff. at ¶¶ 11-13.)

As detailed in the accompanying expert report, Cochrane is an independent scientific body that conducts systematic reviews of available scientific studies to assess the current state of knowledge on questions of interest. (*Id*. at ¶ 11.) Its partners and funders include the National Institutes of Health (NIH) and the World Health Organization (WHO). *Id*. The process Cochrane undertakes to conduct a systematic review involves a thorough search and critical assessment of all the published articles on a given clinical topic. *Id*. By reviewing all existing studies, Cochrane's systematic reviews aim to reduce bias when appraising the scientific literature and help

protect against "cherry picking." *Id*. Systematic reviews are widely regarded as the most trustworthy sources of information, sitting atop the Evidence-Based Medicine Pyramid. *Id*.

In 2010, Cochrane published a systematic review entitled "Vaccines for preventing influenza in healthy adults" which, after a review of the published randomized clinical trials and comparative studies for the influenza vaccine, "found no evidence that vaccines prevent viral transmission" of influenza. (*Id*. at ¶12.) In 2014, Cochrane updated this systematic review with 41 new trials and in 2018 it updated it again with 52 additional trials comprising over 80,000 additional individuals. (*Id*.) These updates did not change the conclusion it reached in 2010 that there is no evidence that influenza vaccines prevent viral transmission of influenza. (*Id*.)

In 2018, Cochrane conducted the same systematic review of all published clinical trials and studies with regard to influenza vaccination and children entitled "Vaccines for preventing influenza in healthy children." (*Id*. at ¶ 13.) It concluded that "we could find no convincing evidence that vaccines can reduce … community transmission of influenza." (*Id*.)

Furthermore, Plaintiffs are submitting with this brief expert affidavits from world-renown experts on the influenza vaccines. Those experts affirm that "at present we could find no convincing evidence that vaccines can reduce mortality, hospital admissions, serious complications, or community transmission of influenza." (*Id*. at ¶ 15.)

In addition to preventing transmission in school settings (for which the evidence is lacking, as noted above), the DPH has also asserted that a goal of the Flu Shot Mandate was to "save lives and preserve healthcare resources."[5] And in its press conference, Commonwealth officials cited in support of the Flu Shot Mandate statistics for emergency room visits and deaths associated with the "flu."

[5] https://www.mass.gov/news/flu-vaccine-now-required-for-all-massachusetts-school-students-enrolled-in-child-care-pre.

However, this premise is not supported by the available science. Randomized clinical trials have not demonstrated that administration of influenza vaccines reduces the risk of hospitalization or mortality, a failing clearly set forth in the Cochrane review on this topic. (Doshi et al. Aff. at ¶¶ 14-16.) In 2018, the Cochrane review of influenza vaccines in healthy children reached the conclusion that "at present we could find no convincing evidence that vaccines can reduce mortality, hospital admissions, serious complications, or community transmission of influenza." (*Id.* at ¶15.) As for adults, in 2018 Cochrane concluded that "We found low-certainty evidence that hospitalization rates and time off work may be comparable between vaccinated and unvaccinated adults, although the confidence interval around the effect for hospital admission is wide and there was substantial variation in the direction of effect on time off work." (*Id.*) In other words, there was no compelling evidence of benefit in a reduction in hospital admission or time off work. (*Id.*) Other systematic reviews focusing on randomized controlled trials have reached similar conclusions regarding the lack of a reduction in hospitalization and mortality from influenza vaccines. (*Id.*)

In fact, there are randomized trials which report findings that raise questions about the ability of influenza vaccines to **increase** the risk of non-influenza flu-like symptoms. (*Id.* ¶ 16.) In one such study, conducted by the Centers for Disease Control and Prevention, the authors wrote: "During the 1997-1998 influenza season, vaccine recipients reported significantly more ILI-related [ILI = influenza like illness] sick days, lost workdays, and lost work hours for physician visits than placebo recipients." (*Id.*)

For these reasons, the DPH cannot assert a compelling interest to impinge upon Plaintiffs' constitutional rights. All that remains is a naked infringement on these rights, which is unconstitutional.

3. The DPH Had No Rational Basis for the Flu Shot Mandate

The Flu Shot Mandate cannot survive the strict scrutiny analysis that applies where, as here, fundamental rights are infringed. However, even apart from a strict scrutiny analysis, for the same reasons discussed *supra,* the Flu Shot Mandate cannot even survive the more lenient "rational basis" test. Indeed, the DPH's stated reasons for the Flu Shot Mandate are so inadequate and so scientifically unsound that the Flu Shot Mandate is not even rationally related to a legitimate governmental purpose. It does not, and cannot, meet the policy objectives the DPH has proposed.

The purported purpose of the flu shot mandate is to "reduce flu-related illness and the overall impact of respiratory illness during the COVID-19 pandemic." (Ex. A.) DPH's reasoning that the spread of influenza or hospitalization rates might decrease with an increase in influenza vaccine uptake is not founded in fact or science. *See* Section C.2., *supra*.

III. PLAINTIFFS WILL SUFFER IRREPARABLE HARM, WHICH WILL OUTWEIGH ANY DELAY IN ENFORCING THE FLU SHOT MANDATE

An irreparable harm is one that "`cannot be vindicated" by an award of damages if the moving party prevails in the case. *Doe vs. Yunits*, No. 001060A, 2000 WL 33162199 (Mass. Super. Oct. 11, 2000) (applying the irreparable harm standard in an educational setting) (Ex. C.) Here the plaintiffs, and numerous other students in the Commonwealth, are all facing the prospect of being denied their right to an education, or at the very least being denied the right to receive that education in their chosen schools. By being excluded from school, plaintiffs are not only missing educational opportunities, but are also "being denied the benefits of attending school with [their] peers, learning in an interactive environment, and developing socially." *Id.* In such situations, Massachusetts courts have previously had no problem finding that the student missing school will suffer irreparable harm. *Id.* (finding irreparable harm where a student was being forced to be home schooled because "the doctrine of 'separate but equal' has no place" in education (internal

quotations omitted)); *see also Doe* v. *Worcester Pub. Sch.*, 484 Mass. 598, 604 (2020) (affirming the conclusion that that a student who is suspended from school would suffer irreparable harm). Alternatively, if Plaintiffs do not receive an injunction, and are forced to choose to receive the influenza vaccine against their will, that is not an act that can be undone.

With regard to the relative burdens faced by the parties, Plaintiffs are merely asking that the Court preserve the current status quo, as it has stood for years. As the DPH press release noted, the Flu Shot Mandate is a new requirement, one that neither the Legislature nor the DPH had previously seen fit to require. Even though the state is still experiencing the COVID-19 pandemic, as discussed in the accompanying expert affidavits, there is little support for the idea that the Flu Shot Mandate will reduce either transmission or hospitalizations. (Doshi et al. Aff. ¶¶ 11-16.) And many other states and countries have chosen to *not* enact such a mandate in the face of the pandemic. (*E.g.*, Aaby and Benn Aff. at ¶¶ 7.) As such, the evidence is that the effect on the Commonwealth's pandemic response will be minimal if the proposed injunction is granted. Thus, this is "a case where the status quo should be maintained to minimize the harm that final relief cannot redress ... by creating or preserving, … a state of affairs such that after the full trial, a meaningful decision may be rendered for either party." *Loyal Order of Moose, Inc.*, 439 Mass. at 603.

Lastly, it is unquestionably in the public's interest to prevent a state agency, like the DPH, from acting outside of the authority granted to it by the Legislature, especially whereas here, allowing such actions will irreparably impinge on important constitutional rights. Plaintiffs do not oppose any individual receiving the influenza vaccine, and even with an injunction the DPH will be free to encourage people to receive the influenza vaccine (without forcing them to receive it).

CONCLUSION

Wherefore, Plaintiffs respectfully request the court grant their motion and issue a preliminary injunction prohibiting the DPH from enforcing the Flu Shot Mandate during the pendency of this action.

Dated: December 17, 2020

Respectfully submitted,

SIRI & GLIMSTAD LLP

/s/ Aaron Siri

Aaron Siri (*pro hac vice* motion filed herewith
Elizabeth Brehm (*pro hac vice* motion filed herewith)
200 Park Avenue, Seventeenth Floor
New York, New York 10166
Tel: (212) 532-1091
E: aaron@sirillp.com
E: ebrehm@sirillp.com



Stefan L. Jouret, BBO #656196
JOURET LLC
Two Center Plaza, Suite 610
Boston, MA 02108
(617) 523-0133 (main)
(617) 507-2576 (facsimile)
jouret@jouretLLC.com

Attorneys for Plaintiffs

COMMONWEALTH OF MASSACHUSETTS

SUFFOLK, ss. SUPERIOR COURT
CIVIL ACTION NO. _____

TAMAR MASSOYAN-ARTINIAN, on behalf of her children, and MADISON SCHILTZ,

Plaintiffs,

v.

MONICA BHAREL, in her official capacity as Commissioner of the Massachusetts Department of Public Health and the MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH,

Defendants.

JURY TRIAL DEMANDED

DECLARATION OF ELIZABETH A. BREHM, ESQ.

I, Elizabeth A. Brehm, declare as follows:

1. I am an associate with the law firm of Siri & Glimstad LLP, counsel to Plaintiffs in this action. My *pro hac* application for appearance before this court is filed and pending. I make this declaration in support of Plaintiffs' Motion for Preliminary Injunction in the above-referenced action.

2. Exhibit A, attached hereto, is a true and correct copy of an August 19, 2020 Department of Public Health ("**DPH**") press release titled "*Flu Vaccine Now Required for all Massachusetts School Students Enrolled in Child Care, Pre-School, K-12, and Post-Secondary Institutions*" available at https://www.mass.gov/news/flu-vaccine-now-required-for-all-massachusetts-school-students-enrolled-in-child-care-pre.

3. Exhibit B, attached hereto, is a true and correct copy of an FAQ released by DPH titled "New! Influenza Vaccine Requirement for School Attendance: Kindergarten through Grade 12 available at https://archives.lib.state.ma.us/bitstream/handle/2452/832122/on1187155975.pdf.

4. Exhibit C, attached hereto, is a true and correct copy of *Doe vs. Yunits*, No. 001060A, 2000 WL 33162199 (Mass. Super. Oct. 11, 2000) which is cited on page 21 of Plaintiffs' Memorandum of Law in Support of a Preliminary Injunction.

Pursuant to 28 U.S.C. § 1746, I declare under penalty of perjury the foregoing to be true and correct, to the best of my knowledge, information and belief.

Executed this 17th day of December, 2020.

EA Brehm

Elizabeth A. Brehm, Esq.

EXHIBIT A

OFFERED BY Department of Public Health

PRESS RELEASE

Flu Vaccine Now Required for all Massachusetts School Students Enrolled in Child Care, Pre-School, K-12, and Post-Secondary Institutions

FOR IMMEDIATE RELEASE:

8/19/2020 Department of Public Health

MEDIA CONTACT

Omar Cabrera, Manager of Ethnic Media and Community Outreach

Phone	Online
(617) 624-5006	Omar.Cabrera@State.MA.US

BOSTON — State public health officials today announced that influenza immunization will be required for all children 6 months of age or older who are attending Massachusetts child care, pre-school, kindergarten, K-12, and colleges and universities. The new vaccine requirement is an important step to reduce flu-related illness and the overall impact of respiratory illness during the COVID-19 pandemic.

Students will be expected to have received a flu vaccine by December 31, 2020 for

the 2020-2021 influenza season, unless either a medical or religious exemption is provided. Also exempted are K-12 students who are homeschooled and higher education students who are completely off-campus and engaged in remote learning only. This new flu immunization requirement to enter school in January is in addition to existing vaccine requirements for all those attending child care, preschool, K-12, and colleges and universities in Massachusetts. Elementary and secondary students in districts and schools that are using a remote education model are not exempt.

“Every year, thousands of people of all ages are affected by influenza, leading to many hospitalizations and deaths,” said **Dr. Larry Madoff, Medical Director, DPH’s Bureau of Infectious Disease and Laboratory Sciences**. “It is more important now than ever to get a flu vaccine because flu symptoms are very similar to those of COVID-19 and preventing the flu will save lives and preserve healthcare resources.”

All children at least 6 months old who attend child care or preschool must be immunized in accordance with the ACIP Recommended Immunization Schedule.

All students in K-12 must receive the seasonal influenza vaccine annually by December 31. New students entering between January 1 and March 31 must have received a dose of vaccine for the current flu season before entry.

Depending on the child’s age and flu vaccination history, a second dose of flu vaccine in the same season may be recommended. In these cases, the second dose is not required for school entry.

For older students, the flu vaccine requirement applies to all full-time undergraduate and graduate students under 30 years of age and all full- and part-time health science students. The requirement includes individuals from outside the U.S. attending or visiting classes or educational programs in Massachusetts as part of an academic visitation or exchange program. The only exception is for college and university students who exclusively attend classes online and never visit campus in person. College students who attend any classes or activities on campus, even once, must be vaccinated by December 31.

The updated table of immunization requirements for the upcoming school year can be found at www.mass.gov/doc/immunization-requirements-for-school-entry-0/download.

More information can be found here.

###

Media Contact

Phone

(617) 624-5006

Online

Omar.Cabrera@State.MA.US

Department of Public Health

DPH promotes the health and well-being of all residents by ensuring access to high-quality public health and healthcare services, and by focusing on prevention, wellness, and health equity in all people.

More

Did you find what you were looking for on this webpage? *

◯ Yes ◯ No

Send Feedback

EXHIBIT B

New!
Influenza Vaccine Requirement for Childcare Attendance for Children 6 months of age or older

Beginning in the fall of 2020, influenza vaccine will be required for all children attending childcare who are 6 months of age or older. Influenza vaccine is always important to receive to reduce the risk of getting sick with the influenza, reduce the severity of disease if one does get sick (including the risk of hospitalization) due to influenza, as well as preventing the spread of influenza to others. During the COVID-19 pandemic, influenza vaccine will be especially critical to reduce the overall impact of respiratory illness on the population, protect vulnerable populations from severe illness, and decrease the overall burden on the healthcare system.

Which children need to receive influenza vaccine?
All children attending childcare who are 6 months of age or older will be required to receive influenza vaccine for the current influenza season for childcare attendance unless they have a medical or religious exemption.

When do children need to receive influenza vaccine?
Children must receive influenza vaccine for the current flu season by December 31, 2020.

Are there any exemptions to receiving influenza vaccine?
Medical and religious exemptions are allowable in the state of Massachusetts.

What type of influenza vaccine can children receive?
Any age-appropriate licensed influenza vaccine for the current season fulfills the requirement. Influenza vaccine is not recommended or licensed for children less than 6 months of age.

Should children without a documented dose of seasonal influenza vaccine be excluded from childcare on January 1st?
Address questions about enforcement of immunization requirements with your legal counsel. We encourage childcare providers to work with families and healthcare providers to satisfy the requirements for children who are not compliant on January 1st.

What about children who enroll after December 31?
Newly enrolling children between January 1 and March 31 must have a documented dose of influenza vaccine for the current influenza season (along with all other required vaccinations) when they start childcare.

What about children who enroll later in the spring?
Children enrolling after March 31 are not required to have a dose of influenza vaccine for enrollment.

Will my program have to report the number of children who received influenza vaccine in the preschool/childcare immunization survey?
Yes, there will be a survey to report influenza vaccination rates for children in childcare. The timing and details of the survey are still being developed. More information will be available soon.

Will influenza vaccine be required every year?
Influenza vaccine is now a required vaccine for childcare attendance and will be required as of December 31 for all children 6 months of age or older attending childcare each year.

Are 2 doses of influenza vaccine required for some children, according to ACIP guidelines?
Children younger than 9 may need two doses of influenza vaccine depending on the number of influenza vaccines they've received in the past. Children should be vaccinated according to ACIP recommendations but only one dose of influenza vaccine is required for childcare attendance.

New!
Influenza Vaccine Requirement for School Attendance: Kindergarten through Grade 12

Beginning with the 2020-2021 school year, influenza vaccine will be required for all students. Influenza vaccine is always important to receive to reduce the risk of getting sick with influenza, reduce the severity of disease if one does get sick (including the risk of hospitalization) due to influenza, as well as preventing the spread of influenza to others. During the COVID-19 pandemic, influenza vaccine will be especially critical to reduce the overall impact of respiratory illness on the population, protect vulnerable populations from severe illness, and decrease the overall burden on the healthcare system.

Which students need to receive influenza vaccine?
Students in Kindergarten – Grade 12 will be required to receive influenza vaccine for the current influenza season for school attendance unless they have a medical or religious exemption.

When do students need to receive influenza vaccine?
Students must receive influenza vaccine for the current season by December 31, 2020.

Are there any exemptions to receiving influenza vaccine?
Medical and religious exemptions are allowable in the state of Massachusetts.

What type of influenza vaccine can students receive?
Any age-appropriate licensed influenza vaccine for the current season fulfills the requirement. This includes injectable and nasal spray vaccine types.

Should students without a documented dose of seasonal influenza vaccine be excluded from school on January 1st?
Enforcement of school immunization requirements is determined at the local level. We encourage school communities to work with families and healthcare providers to satisfy the requirements for students who are not compliant on January 1st.

What about students who enroll after December 31?
Newly enrolling students between January 1 and March 31 must have a documented dose of influenza vaccine for the current influenza season (along with all other required

vaccinations) when they start school.

What about students who enroll later in the spring?
Students enrolling after March 31 are not required to have a dose of influenza vaccine for the current school year.

Will my school have to report on influenza vaccine in the Kindergarten and Grade 7 school immunization surveys?
Yes—the surveys will be open as usual during the fall to input information on other vaccines. By January 2021, a new section of the survey may be completed to report influenza vaccination rates for students enrolled in Kindergarten and Grade 7. We anticipate both parts of the survey, the traditional school immunization survey and the influenza component, will be due by the end of January 2021.

Will my school have to report the number of students who received influenza vaccine in the Grade 11 school immunization survey?
Yes—the Grade 11 survey will open in early 2021 and will include the influenza question with the survey. More information on the timeline for the Grade 11 survey will be available in the future.

Will my school have to report the number of students who received influenza vaccine for students in all grades?

While the influenza vaccine requirement exists for every grade, you will be asked to complete school immunization surveys for Kindergarten, Grade 7, and Grade 11.

Will influenza vaccine be required every year or just for the 2020-2021 school year?

Influenza vaccine is now a required vaccine for school attendance and will be required as of December 31 for all students in Kindergarten through Grade 12 each school year.

Do younger students require 2 doses according to ACIP guidelines?

Children younger than 9 may need two doses of influenza vaccine depending on the number of influenza vaccines they have received in the past. Children should be vaccinated according to ACIP recommendations but only one dose of influenza vaccine is required for school attendance.

If my school will be providing instruction remotely, will students still need to meet immunization requirements?

The school immunization requirements, including the requirement for seasonal influenza vaccine, apply to all Massachusetts students enrolled in Kindergarten through Grade 12, regardless of whether the district is providing instruction in-person, or using a hybrid or remote learning model.

Do the flu immunization requirements apply to students that are home schooled?

Immunization requirements, including the flu immunization requirement, do not apply to home schooled students unless the student will ever need to access the school building for sports, after school activities or any other reason.

New!
Influenza Vaccine Requirement for Attendance at Post-Secondary Institutions

Beginning with the 2020-2021 school year, influenza vaccine will be required for all full-time undergraduate and graduate students under 30 years of age and all full- and part-time health science students at post-secondary institutions. Influenza vaccine is always important to receive to reduce the risk of getting sick with influenza, reduce the severity of disease if one does get sick (including the risk of hospitalization) due to influenza, as well as preventing the spread of influenza to others. During the COVID-19 pandemic, influenza vaccine will be especially critical to reduce the overall impact of respiratory illness on the population, protect vulnerable populations from severe illness, and decrease the overall burden on the healthcare system.

Which students need to receive influenza vaccine?
Requirements apply to all full-time undergraduate and graduate students under 30 years of age and all full- and part-time health science students. Student may have a medical or religious exemption.

When do students need to receive influenza vaccine?
Students must receive influenza vaccine for the current season by December 31, 2020.

Are there any exemptions to receiving influenza vaccine?
Medical and religious exemptions are allowable in the state of Massachusetts.

What type of influenza vaccine can students receive?
Any age-appropriate licensed influenza vaccine for the current season fulfills the requirement. This includes injectable and nasal spray vaccine types.

Should students without a documented dose of seasonal influenza vaccine be excluded on January 1st?
Enforcement of immunization requirements is determined at the local level. We encourage post-secondary institutions to work with families and healthcare providers to satisfy the requirements for students who are not compliant on January 1st.

What about students who enroll after December 31?

Newly enrolling students between January 1 and March 31 must have a documented dose of influenza vaccine for the current influenza season (along with all other required vaccinations) when they start school.

What about students who enroll later in the spring?
Students enrolling after March 31 are not required to have a dose of influenza vaccine until they enroll in the Fall 2021 semester.

Will my institution have to report on influenza vaccine in the college immunization survey?
Yes—the surveys will be open as usual during the fall to input information on other required vaccines. There will also be a survey to report influenza vaccination rates for students at post-secondary institutions. The timing and details of the survey are still being developed. More information will be available soon.

Will influenza vaccine be required every year or just for the 2020-2021 school year?
Influenza vaccine is now a required vaccine for attendance at a post-secondary institution in Massachusetts and will be required annually as of December 31 for **all** students who will be on campus for any reason and are subject to immunization requirements.

If my school will be providing instruction remotely, will students still need to meet immunization requirements?

The immunization requirements apply to all students who attend any classes or activities on campus, even once. If all instruction and activities are conducted remotely and the student will never be on campus in person, the requirements would not apply. If the first part of the year will be conducted remotely but later portions may be in person, we recommend collecting immunization records as early as possible to ensure all records are in place prior to students attending classes or activities in person.

EXHIBIT C

Not Reported in N.E.2d, 2000 WL 33162199 (Mass.Super.)
(Cite as: 2000 WL 33162199 (Mass.Super.))

Superior Court of Massachusetts.
Pat DOE,[FN*,FN1]

FN* Editor's Note: A petition for interlocutory relief from the preliminary injunction entered in this opinion was denied by the Appeals Court sub nom *Doe v. Brockton School Committee,* No.2000-J-638 (November 30, 2000) (Jacobs, J.).

FN1. By her next friend, Jane Doe, plaintiff's grandmother and guardian.

v.
John YUNITS, et al.[FN2]

FN2. Maurice Hancock, Wayne Carter, George Allen, Mary Gill, Dennis Eaniri, Kevin Nolan, Ronald Dobrowski. School Committee Members; Joseph Bage, Superintendent; Kenneth Cardone, Principal of South Junior High School; Dr. Kenneth Sennett, Senior Director for Pupil Services, in their individual and official capacities; and Brockton Public Schools.

No. 001060A.
Oct. 11, 2000.

MEMORANDUM OF DECISION AND ORDER ON PLAINTIFF'S MOTION FOR PRELIMINARY INJUNCTION

GILES.

***1** Plaintiff Pat Doe [FN3] ("plaintiff'), a fifteen-year-old student, has brought this action by her next friend, Jane Doe, requesting that this court prohibit defendants from excluding the plaintiff from South Junior High School ("South Junior High"), Brockton, Massachusetts, on the basis of the plaintiff's sex, disability, or gender identity and expression. Plaintiff has been diagnosed with gender identity disorder, which means that, although plaintiff was born biologically male, she has a female gender identity. [FN4] Plaintiff seeks to attend school wearing clothes and fashion accouterments that are consistent with her gender identity. Defendants have informed plaintiff that she could not enroll in school this academic year if she wore girls' clothes or accessories. After a hearing, and for the reasons stated below, plaintiff's motion for preliminary injunction is *ALLOWED.*

FN3. A pseudonym.

FN4. This court will use female pronouns to refer to plaintiff: a practice which is consistent with the plaintiff's gender identity and which is common among mental health and other professionals who work with transgender clients.

BACKGROUND

Plaintiff began attending South Junior High, a Brockton public school, in September 1998, as a 7th grader. In early 1999, plaintiff first began to express her female gender identity by wearing girls' make-up, shirts, and fashion accessories to school. South Junior High has a dress code which prohibits, among other things, "clothing which could be disruptive or distractive to the educational process or which could affect the safety of students." In early 1999, the principal, Kenneth Cardone ("Cardone"), would often send the plaintiff home to change if she arrived at school wearing girls' apparel. On some occasions, plaintiff would change and return to school; other times, she would remain home, too upset to return. In June 1999, after being referred to a therapist by the South Junior High, plaintiff was diagnosed with gender identity disorder. Plaintiff's treating therapist, Judith Havens ("Havens"), determined that it was medically and clinically necessary for plaintiff to wear clothing consistent with the female gender and that failure to do so could cause harm to plaintiff's mental health.

Plaintiff returned to school in September 1999, as an 8th grader, and was instructed by Cardone to come to his office every day so that he could approve the plaintiff's appearance. Some days the plaintiff would be sent home to change, sometimes returning to school dressed differently and sometimes remaining home. During the 1999-2000 school year, plaintiff stopped attending school, citing the hostile environment created by Cardone. Because of plaintiff's

many absences during the 1999-2000 school year, plaintiff was required to repeat the 8th grade this year.

Over the course of the 1998-1999 and 1999-2000 school years, plaintiff sometimes arrived at school wearing such items as skirts and dresses, wigs, high-heeled shoes, and padded bras with tight shirts. The school faculty and administration became concerned because the plaintiff was experiencing trouble with some of her classmates. Defendants cite one occasion when the school adjustment counselor had to restrain a male student because he was threatening to punch the plaintiff for allegedly spreading rumors that the two had engaged in oral sex. Defendants also point to an instance when a school official had to break up a confrontation between the plaintiff and a male student to whom plaintiff persistently blew kisses. At another time, plaintiff grabbed the buttock of a male student in the school cafeteria. Plaintiff also has been known to primp, pose, apply make up, and flirt with other students in class. Defendants also advance that the plaintiff sometimes called attention to herself by yelling and dancing in the halls. Plaintiff has been suspended at least three times for using the ladies' restroom after being warned not to.

***2** On Friday, September 1, 2000, Cardone and Dr. Kenneth Sennett ("Sennett"), Senior Director for Pupil Personnel Services, met with the plaintiff relative to repeating the 8th grade. At that meeting, Cardone and Sennett informed the plaintiff that she would not be allowed to attend South Junior High if she were to wear any outfits disruptive to the educational process, specifically padded bras, skirts or dresses, or wigs. On September 21, 2000, plaintiff's grandmother tried to enroll plaintiff in school and was told by Cardone and Sennett that plaintiff would not be permitted to enroll if she wore any girls' clothing or accessories. Defendants allege that they have not barred the plaintiff from school but have merely provided limits on the type of dress the plaintiff may wear. Defendants claim it is the plaintiff's own choice not to attend school because of the guidelines they have placed on her attire. Plaintiff is not currently attending school, but the school has provided a home tutor for her to allow her to keep pace with her classmates.

On September 26, 2000, the plaintiff filed a complaint in this court claiming a denial of her right to freedom of expression in the public schools in violation of G.L.c. 71, § 82; a denial of her right to personal dress and appearance in violation of G.L. c. 76, § 83; a denial of her right to attend school in violation of G.L. c. 76, § 5; a denial of her right to be free from sex discrimination guaranteed by Articles I and XIV of the Declaration of Rights of the Massachusetts Constitution; a denial of her right to be free from disability discrimination guaranteed by Article CXIV of the said Declaration of Rights; a denial of her due process rights as guaranteed by G.L. c. 71, § 37 and G.L. c. 76, § 17; a denial of her liberty interest in her appearance as guaranteed by the Massachusetts Declaration of Rights, Art. I and X; and a violation of her right to free expression as guaranteed by the said Declaration of Rights, Art. I and X.

DISCUSSION

I. Introduction

In evaluating a request for a preliminary injunction, the court must examine "in combination the moving party's claim of injury and chance of success on the merits." *Packing Industries Group, Inc. v. Cheney,* 380 Mass. 609, 617 (1980). "If the judge is convinced that failure to issue the injunction would subject the moving party to a substantial risk of irreparable harm, the judge must then balance this risk against any similar risk of irreparable harm which granting the injunction would create for the opposing party ... Only where the balance between these risks cuts in favor of the moving party may a preliminary injunction properly issue." *GTE Products Corp. v. Stewart,* 414 Mass. 721, 722-23 (1993), quoting *Packaging Industries Group, Inc. v. Cheney, supra* (footnote omitted). In addition, where the injunction is sought against a public entity, as it is here, the court must consider the risk of injury to the public interest which would flow from the grant of the injunction. *Brookline v. Goldstein,* 388 Mass. 443, 447 (1983); *Biotti v. Board of Selectmen of Manchester,* 25 Mass.App.Ct. 637, 639 (1988).

II. The Likelihood of Plaintiff's Success on the Merits

***3** Plaintiff's complaint asserts eight causes of action based on the Massachusetts Declaration of Rights and the General Laws. They are individually addressed below to evaluate the likelihood of success on the merits.

A. Freedom of Expression, Massachusetts Declaration of Rights, Art. II and X

The Massachusetts Declaration of Rights, Article XVI (as amended by Article 77) provides, "[t]he right of free speech shall not be abridged." The analysis of this article is guided by federal free speech analysis. See *Hosford v. School Committee of Sandwich,* 421 Mass. 708, 712 n. 5 (1996); *Opinion of the Justices to the House of Representatives,* 387 Mass. 1201, 1202 (1982); *Colo. v. Treasurer and Receiver General,* 378 Mass. 550, 558 (1979). According to federal analysis, this court must first determine whether the plaintiff's symbolic acts constitute expressive speech which is protected, in this case, by Article VXI of the Massachusetts Declaration of Rights. See *Texas v. Johnson, supra,* citing *Spence v. Washington, supra.* If the speech is expressive, the court must next determine if the defendants' conduct was impermissible because it was meant to suppress that speech. See *Texas v. Johnson,* 491 U.S. 397, 403 (1989), citing *United States v. O'Brien,* 391 U.S. 367, 377 (1968); see also *Spence v. Washington,* 418 U.S. 405, 414 n. 8 (1974). If the defendants' conduct is not related to the suppression of speech, furthers an important or substantial governmental interest, and is within the constitutional powers of the government, and if the incidental restriction on speech is no greater than necessary, the government's conduct is permissible. See *United States v. O'Brien, supra.* In addition, because this case involves public school students, suppression of speech that "materially and substantially interferes with the work of the school" is permissible. See *Tinker v. Des Moines Community School Dist.,* 393 U.S. 503, 739 (1969).

1. The Plaintiff's Conduct is Expressive Speech Which is Understood by Those Perceiving It

Symbolic acts constitute expression if the actor's intent to convey a particularized message is likely to be understood by those perceiving the message. See *Spence v. Washington,* 418 U.S. 405, 410-11 (1974) (finding that an upside-down flag with a peace symbol attached was protected speech because it was a purposeful message people could understand); see also *Chalifoux v. New Caney Independent School Dist.,* 976 F.Sup. 659 (S.D.Tex.1997) (students wearing rosary beads as a sign of their religious belief was likely to be understood by others and therefore protected).

Plaintiff in this case is likely to establish that, by dressing in clothing and accessories traditionally associated with the female gender, she is expressing her identification with that gender. In addition, plaintiff's ability to express herself and her gender identity through dress is important to her health and well-being, as attested to by her treating therapist. Therefore, plaintiff's expression is not merely a personal preference but a necessary symbol of her very identity. Contrast *Olesen v. Board of Education of School District No. 228,* 676 F.Sup. 820 (N.D.Ill.1987) (school's anti-gang policy of prohibiting males from wearing earrings, passed for safety reasons, was upheld because plaintiff's desire to wear an earring as an expression of his individuality and attractiveness to girls was a message not within the scope of the First Amendment).

***4** This court must next determine if the plaintiff's message was understood by those perceiving it, i.e., the school faculty and plaintiff's fellow students. See *Bivens v. Albuquerque Public Schools,* 899 F.Sup. 556 (D.N.M.1995) (student failed to provide evidence that his wearing of sagging pants to express his identity as a black youth was understood by others and, therefore, such attire was not speech). In the case at bar, defendants contend that junior high school students are too young to understand plaintiff's expression of her female gender identity through dress and that "not every defiant act by a high school student is constitutionally protected speech." *Id.* at 558. However, unlike *Bivens,* here there is strong evidence that plaintiff's message is well understood by faculty and students. The school's vehement response and some students' hostile reactions are proof of the fact that the plaintiff's message clearly has been received. Moreover, plaintiff is likely to establish, through testimony, that her fellow students are well aware of the fact that she is a biological male more comfortable wearing traditionally "female"-type clothing because of her identification with that gender.

2. The Defendants' Conduct Was a Suppression of the Plaintiff's Speech

Plaintiff also will probably prevail on the merits of the second prong of the *Texas v. Johnson* test, that is, the defendants' conduct was meant to suppress plaintiff's speech. Defendants in this case have prohibited the plaintiff from wearing items of clothing that are traditionally labeled girls' clothing, such as dresses and skirts, padded bras, and wigs. This constitutes direct suppression of speech because biological females who wear items such as tight skirts to

school are unlikely to be disciplined by school officials, as admitted by defendants' counsel at oral argument. See *Texas v. Johnson,* 491 U.S. 397, 408-16 (1989). Therefore, the test set out in *United States v. O'Brien,* which permits restrictions on speech where the government motivation is not directly related to the content of the speech, cannot apply here. Further, defendants' argument that the school's policy is a content-neutral regulation of speech is without merit because, as has been discussed, the school is prohibiting the plaintiff from wearing clothes a biological female would be allowed to wear. Therefore, the plaintiff has a likelihood of fulfilling the *Texas v. Johnson* test that her speech conveyed a particularized message understood by others and that the defendants' conduct was meant to suppress that speech.

3. Plaintiff's Conduct is not Disruptive

This court also must consider if the plaintiff's speech "materially and substantially interferes with the work of the school." *Tinker v. Des Moines Community School Dist., supra.* Defendants argue that they are merely preventing disruptive conduct on the part of the plaintiff by restricting her attire at school. Their argument is unpersuasive. Given the state of the record thus far, the plaintiff has demonstrated a likelihood of proving that defendants, rather than attempting to restrict plaintiff's wearing of distracting items of clothing, are seeking to ban her from donning apparel that can be labeled "girls' clothes" and to encourage more conventional, male-oriented attire. Defendants argue that any other student who came to school dressed in distracting clothing would be disciplined as the plaintiff was. However, defendants overlook the fact that, if a female student came to school in a frilly dress or blouse, make-up, or padded bra, she would go, and presumably has gone, unnoticed by school officials. Defendants do not find plaintiff's clothing distracting *per se,* but, essentially, distracting simply because plaintiff is a biological male.

***5** In addition to the expression of her female gender identity through dress, however, plaintiff has engaged in behavior in class and towards other students that can be seen as detrimental to the learning process. This deportment, however, is separate from plaintiff's dress. Defendants vaguely cite instances when the principal became aware of threats by students to beat up the "boy who dressed like a girl" to support the notion that plaintiff's dress alone is disruptive. To rule in defendants' favor in this regard, however, would grant those contentious students a "heckler's veto." See *Fricke v. Lynch,* 491 F.Sup. 381, 387 (D .R.I.1980). The majority of defendants' evidence of plaintiff's disruption is based on plaintiff's actions as distinct from her mode of dress. Some of these acts may be a further expression of gender identity, such as applying make-up in class; but many are instances of misconduct for which any student would be punished. Regardless of plaintiff's gender identity, any student should be punished for engaging in harassing behavior towards classmates. Plaintiff is not immune from such punishment but, by the same token, should not be punished on the basis of dress alone.

Plaintiff has framed this issue narrowly as a question of whether or not it is appropriate for defendants to restrict the manner in which she can dress. Defendants, on the other hand, appear unable to distinguish between instances of conduct connected to plaintiff's expression of her female gender identity, such as the wearing of a wig or padded bra, and separate from it, such as grabbing a male student's buttocks or blowing kisses to a male student. The line between expression and flagrant behavior can blur, thereby rendering this case difficult for the court. It seems, however, that expression of gender identity through dress can be divorced from conduct in school that warrants punishment, regardless of the gender or gender identity of the offender. Therefore, a school should not be allowed to bar or discipline a student because of gender-identified dress but should be permitted to ban clothing that would be inappropriate if worn by any student, such as a theatrical costume, and to punish conduct that would be deemed offensive if committed by any student, such as harassing, threatening, or obscene behavior. See *Bethel v. Fraser,* 478 U.S. 675 (1986).

B. G.L. c. 71, § 82

Defendants argue that G.L. c. 71, § 82 is inapplicable because the statute only applies to secondary school; and South Junior High has been designated a primary school. Therefore, plaintiff will probably fail in this claim if defendants can substantiate their assertion. Nevertheless, the Supreme Court's constitutional analysis in *Tinker,* which was codified by G.L. c. 71, § 82, see *Pyle v. School Committee of South Hadley,* 423 Mass. 283, 286 (1996), remains applicable in this case and implicates the same principles. As

discussed, plaintiff has demonstrated a likelihood of success on the merits in her common law freedom of expression claim.

C. Liberty Interest in Appearance Massachusetts Declaration of Rights Article I and X

***6** Plaintiff is also likely to prevail in this claim. A liberty interest under the First Amendment has been recognized to protect a male student's right to wear his hair as he wishes. See *Richards v. Thurston,* 424 F.2d 1281 (1st Cir.1970), cited with approval *Bd. of Selectmen of Framingharn v. Civil Service Commission,* 366 Mass. 547, 556 (1974). The question in liberty interest cases is whether the government's interest in restricting liberty is strong enough to overcome that liberty interest. Given that plaintiff has a likelihood of success in proving that her attire is not distracting, as discussed above, she is likely to prove that defendants' interests do not overcome the recognized liberty interest in appearance.

D. Sex Discrimination G.L. c. 76, § 5 and Article I and XIV of the Massachusetts Declaration of Rights

G.L. c. 76, § 5 states that "Every person shall have the right to attend the public schools of the town where he actually resides ... No person shall be excluded from or discriminated against in admission to a public school of any town, or in obtaining the advantages, privileges and course of study of such public school on account of race, color, sex, religion, national origin or sexual orientation." G.L. c. 76, § 5 (2000). Federal cases have recognized the impropriety of discriminating against a person for failure to conform with the norms of' their biological gender. See *Price Waterhouse v. Hopkins,* 490 U.S. 228, 250 (1989) (sex stereotyping occurred when members of an accounting firm denied female associate promotion because she failed to walk, talk, and dress femininely); *Rosa v. Park West Bank,* 214 F.3d 213 (1st Cir .2000) (claim of sex discrimination may be sustained when cross-dressing man was denied a loan application until he went home to change clothes). This court finds plaintiff's reliance on such cases persuasive and the cases cited by defendants distinguishable, as discussed below.

Plaintiff contends that defendants' action constitute sex discrimination because defendants prevented plaintiff from attending school in clothing associated with the female gender solely because plaintiff is male. Defendants counter that, since a female student would be disciplined for wearing distracting items of men's clothing, such as a fake beard, the dress code is gender-neutral. Defendants' argument does not frame the issue properly. Since plaintiff identifies with the female gender, the right question is whether a female student would be disciplined for wearing items of clothes plaintiff chooses to wear. If the answer to that question is no, plaintiff is being discriminated against on the basis of her sex, which is biologically male. [FN5] Therefore, defendants' reliance on cases holding that discrimination on the basis of sexual orientation, transsexualism, and transvestism are not controlling in this case because plaintiff is being discriminated against because of her gender. See *Ulane v. Eastern Airlines,* 742 F.2d 1081 (7th Cir.1984).[FN6] Furthermore, such cases have been criticized and distinguished under both Title VII and the First and Fourteenth Amendments. See *Quinn v. Nassau County Police Dept.,* 53 F.Sup.2d 347 (E.D.N.Y.1999); *Blozis v. Mike Raisor Ford, Inc.,* 896 F.Sup. 805 (N.D.Ind.1995); *Schwenk v. Hartford,* 204 F.3d 1187 (9th Cir.2000).

FN5. This case is distinguishable from *Harper v. Edgewood Bd. of Education,* 655 F.Sup. 1353 (S.D.Ohio 1987). In *Harper,* the court granted summary judgment in favor of the defendants, who prevented two students dressed in clothing of the opposite gender from attending the prom against a claim that the plaintiffs' First Amendment rights were violated. The court found the school's action permissible because it fostered community values and maintained discipline. Plaintiff in this case, however, is not merely engaging in rebellious acts to demonstrate a willingness to violate community norms; plaintiff is expressing her personal identity, which cannot be suppressed by the school merely because it departs from community standards.

FN6. *LaFleur v. Bird-Johnson Co.,* 1994 W.L. 878831 (Mass.Super. Nov. 3, 1994) [3 Mass.L.Rptr. 196], is also distinguishable. *LaFleur* was decided after *Price Waterhouse v. Hopkins* but recognized the Supreme Judicial Court's holding in *Macauley v. MCAD,* 379 Mass. 279 (1979), that transsexual discrimination is not within the scope of this state's sexual discrimination law.

> However, the case at hand differs from *LaFleur,* where the plaintiff claimed she was discriminated against in the employment context because she was a transvestite, because the instant plaintiff is likely to establish that defendants have discriminated against her on the basis of sex by applying the dress code against her in a manner in which it would not be applied to female students.

***7** In support of their argument, defendants cite cases in which gender-specific school dress codes have been upheld in the face of challenges based on gender discrimination and equal protection because the codes serve important governmental interests, such as fostering conformity with community standards. See *Jones v. W.T. Henning Elementary School,* 721 So.2d 530 (La.App.3rd Cir1998); *Hines v. Caston School Corp.,* 651 N.E.2d 330, 335 (Ind.App.1995); *Harper v. Edgewood Board of Education.* 655 F.Sup. 1353 (S.D.Ohio 1987). Such cases are not binding on this court. This court cannot allow the stifling of plaintiff's selfhood merely because it causes some members of the community discomfort. "Our constitution ... neither knows nor tolerates classes among citizens." *Plessy v. Ferguson,* 163 U.S. 537, 539 (1896) (dissenting opinion of Harlan, J.). Thus, plaintiff in this case is likely to establish that the dress code of South Junior High, even though it is gender-neutral, is being applied to her in a gender discriminatory manner.

E. Disability Discrimination Article CXIV of the Massachusetts Declaration of Rights

Plaintiff does not have a likelihood of success in proving that the defendants' conduct constituted disability discrimination. Analysis of federal discrimination law is instructive in construing state disability discrimination law. See *Cox v. New England Tel. & Tel. Co.,* 414 Mass. 375 (1993). The federal Americans with Disabilities Act expressly excludes "transvestism, transsexualism ... [and] gender identity disorders not resulting from physical impairments ..." 42 U.S.C. 12211(b) (2000). While noting that the courts of this state can, and often do, provide more protection than its federal counterpart, there is no authority to support the notion that Gender Identity Disorder is a protected disability under the Massachusetts Declaration of Rights of laws of this state.

F. Due Process G.L. c. 76, § 17

Plaintiff does not have a likelihood of success on the merits of this claim because, as defendants correctly point out, the plaintiff has not been expelled from school. Therefore, no process was due the plaintiff.

G. G.L. c. 71, § 83

Defendants again are correct in asserting that this section, which protects a student's right to personal dress, is a local option statute which applies only to jurisdictions that have chosen to adopt it. G.L. c. 71, § 86. Therefore, the plaintiff has not demonstrated a likelihood of success on the merits of this claim.

II. Irreparable Harm

The party seeking an injunction bears the burden of establishing irreparable harm, i.e., that it may suffer a loss of rights that cannot be vindicated should it prevail after a full hearing on the merits. *GTE Products Corp. v. Stewart, supra* at 726. Plaintiff in this case has met the burden of establishing irreparable harm. The plaintiff is currently being home schooled because the defendants will not allow her to attend school in girls' attire. Therefore, plaintiff is being denied the benefits of attending school with her peers, learning in an interactive environment, and developing socially. See *McLaughlin v. Boston School Committee,* 938 F.Sup. 1001, 1011-12 (D.Mass.1994). Such harm is further exacerbated by the fact that the plaintiff has been the subject of much controversy over the past two years and now is noticeably absent from school. Defendants argue that any harm to the plaintiff is self-induced because plaintiff has chosen not to attend school under the conditions the defendants have put on her attire. This contention is without merit. Defendants are essentially prohibiting the plaintiff from expressing her gender identity and, thus, her quintessence, at school. Their actions have forced plaintiff to submit to home schooling. However, "in the field of public education the doctrine of 'separate but equal' has no place." *Brown v. Board of Education of Topeka,* 347 U.S. 483, 495 (1954).

III. The Balance of the Equities

***8** The balance of the equities tips in favor of plaintiff in his case. The plaintiff attended South Junior High School for two academic years; and the school and its students, with the exception of new students entering this year, are accustomed to inter-

acting with plaintiff and, thus, are capable of doing so again. Because the school is empowered to discipline plaintiff for conduct for which any other student would be disciplined, the harm to the school in readmitting plaintiff is minimal. On the other hand, if plaintiff is barred from school, the potential harm to plaintiff's sense of self-worth and social development is irreparable. Defendants cite cases that stand for the proposition that a school's interest in disciplining students by barring them from school outweigh the harm to the student. See *Katchak v. Glasgow Independent School District,* 690 F.Sup. 580, 583 (W.D.Ky.1988). In this case, however, the school is not disciplining the plaintiff for certain conduct. The school is barring her from school on account of the expression of her very identity. Defendants maintain that plaintiff is free to enroll in school as long as she complies with the stated dress code. This is not entirely true because the defendants have placed specific restrictions on plaintiff's dress that may not be placed on other female students. This court does take note of the fact that defendants made efforts to accommodate the plaintiff's desire to dress in girl's clothes for over a year. However, their proscription of the items of clothing that can be worn by plaintiff is likely to be impermissible. Therefore, the harm to plaintiff by the actions of the defendants outweigh the harm to the defendants in granting this injunction.

IV. The Harm to the Public Interest

Defendants have not made a showing that the granting of this injunction will harm the public interest. Although defendants contend that plaintiff's dress is disruptive to the learning process, the workings of the school will not be disrupted if they are permitted to discipline plaintiff according to normal procedures for truly disruptive attire and inappropriate behavior. Furthermore, this court trusts that exposing children to diversity at an early age serves the important social goals of increasing their ability to tolerate such differences and teaching them respect for everyone's unique personal experience in that “Brave New World” out there.

ORDER

For all the foregoing reasons, plaintiff's motion for preliminary injunction is *ALLOWED;* and it is hereby *ORDERED THAT:*

1. Defendants are preliminarily enjoined from preventing plaintiff from wearing any clothing or accessories that any other male or female student could wear to school without being disciplined.

2. Defendants are further preliminarily enjoined from disciplining plaintiff for any reason for which other students would not be disciplined.

3. If defendants do seek to discipline plaintiff in conformance with this order, they must do so according to the school's standing policies and procedures.

Mass.Super.,2000.
Doe ex rel. Doe v. Yunits
Not Reported in N.E.2d, 2000 WL 33162199 (Mass.Super.)

END OF DOCUMENT

COMMONWEALTH OF MASSACHUSETTS

SUFFOLK, ss. SUPERIOR COURT
CIVIL ACTION NO. _____

TAMAR MASSOYAN-ARTINIAN, on behalf of her children, and MADISON SCHILTZ,

Plaintiffs,

v.

MONICA BHAREL, in her official capacity as Commissioner of the Massachusetts Department of Public Health and the MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH,

Defendants.

EXPERT AFFIDAVIT OF P. DOSHI, T. JEFFERSON, P. GOTZSCHE, AND C. HENEGHAN

We, Peter Doshi, Thomas Jefferson, Peter Gøtzsche, and Carl Heneghan, state as follows:

1. We submit this affidavit in support of Plaintiffs' Motion for a preliminary injunction. We have personal knowledge of the facts set forth herein and, if called to testify, each of us could competently testify as to the following:

EXPERIENCE & CREDENTIALS

2. I, Peter Doshi, hold a PhD, and I am an Associate Professor with Tenure in the Pharmaceutical Health Services Research Department at the University of Maryland School of Pharmacy.[1] I teach a required course in the PharmD curriculum, "Medical Evidence," which trains

[1] https://faculty.rx.umaryland.edu/pdoshi/.

students in skills necessary to critically appraise the scientific literature. I research the drug and vaccine approval process, how the risks and benefits of medical products are communicated, and how to improve the credibility and accuracy of evidence synthesis and biomedical publications. At the University of Maryland, I lead the RIAT Support Center which aims to accelerate the correction of the scientific record of clinical trials by making clinical trial publications more accurate and more complete, addressing the problems of publication bias and reporting bias. I have received national recognition for my work on clinical trial data transparency.[2] I am also an associate editor of *The BMJ* (formerly, the British Medical Journal), which is roughly equivalent to the *Journal of the American Medical Association* in the United States.[3] (Attached as Exhibit A is a copy of my CV.) I have studied influenza policy since around 2004. I have many peer reviewed publications on the topic (see Exhibit A), and my PhD dissertation[4] is on the topic of CDC and WHO influenza control policies (primarily vaccines). In 2013, I published a peer-reviewed article entitled "Influenza Vaccines: Time for a Rethink" by invitation of the editor-in-chief of *JAMA Internal Medicine,* a professor of medicine at U.C. San Francisco, based on being considered an "expert in the field."

3. I, Thomas Jefferson, hold an MD degree and am a Fellow of Faculty of Public Health in the United Kingdom and a Member of Royal College of General Practitioners. I am a Senior Clinical Tutor at the University of Oxford. My specialty is analyzing evidence-based medicine and bias in drug and vaccines testing. I am the lead author of Cochrane reviews on influenza vaccines, and have published widely on the topic of influenza vaccines, other vaccines, and public health. (Attached as Exhibit B is a copy of my CV.) I started my health care career as

[2] https://www.nytimes.com/2013/06/30/business/breaking-the-seal-on-drug-research.html.

[3] https://www.bmj.com/about-bmj/editorial-staff/peter-doshi.

[4] http://dspace.mit.edu/handle/1721.1/69811.

a general practitioner (1980–1985 and 1999-2001), trained in public health in 1986 and obtained a MSc and Fellowship of Faculty of Public Health, as well as a diploma in Health Economics. I have been a contributor to The Cochrane Collaboration for over 20 years and am an author and editor for the Cochrane Acute Respiratory Infections (ARI) Group and a member of other Cochrane Groups. I have experience in synthetizing data from both large pharmaceutical and RWE data sets, both within formal studies and raw data. I have worked in vaccines, antivirals, infectious disease agents, neurodegenerative diseases, diabetic drugs, and different devices in classes IIb and III in a variety of designs (such as trials, economic evaluations, meta-analyses and epidemiological studies) and the use of regulatory evidence in Cochrane reviews. My work is cited in the James Lind Library. I am a member of the Italian MoH NITAG (national independent technical advisory group) on vaccines and a founder of the Brighton Collaboration, an international network of researchers developing standardized reporting of potential vaccines' harms.

4. I, Peter Gøtzsche, am a medical doctor and Doctor of Medical Science. I have been involved in medical research and the evaluation of medical research for 45 years. In 1993, I co-founded the Cochrane Collaboration which is a collaborative effort by patients, scientists, and researchers around the world to evaluate medical research to assist patients, health professionals, and policy makers to make better decisions. During the twenty-five years I worked with the Cochrane Collaboration, for which I was the Director of the Nordic Cochrane Centre, the group has published about 10,000 systematic reviews or protocols for upcoming reviews on the benefits and harms of interventions used in healthcare. In 2010, I became Professor of Clinical Research Design and Analysis at the University of Copenhagen. In 2018, I founded the Institute for Scientific Freedom where I continue with the same kind of work that I performed at the Cochrane Collaboration. (A copy of my CV with a list of books, book chapters and publications are attached

as Exhibit C.) I am the author of seven books since 2007, the first of which is *Rational Diagnosis and Treatment: Evidence-based Clinical Decision-making (4th ed.)*. One of my most recent books, published in 2020, and the one which is most relevant to the issues in this case, is titled *Vaccines: Truths, Lies and Controversy*. The book was published by People's Press in Denmark; will be published by Skyhorse in New York in 2021; and will appear in many languages. The book has a chapter on the influenza vaccines, and specifically reviews the evidence of its benefits and harms.

5. I, Carl Heneghan, am a registered medical doctor in the United Kingdom and am on the specialist register as a general practitioner since 2005. I hold a DPhil and I am Professor of Evidence Based Medicine at the University of Oxford. I have 25 years' experience as a clinical epidemiologist with expertise in evidence-based medicine, research methods, and evidence synthesis. I have over 400 peer-reviewed publications (current H index 70); published 95 systematic reviews and am currently Editor in Chief of BMJ Evidence-Based Medicine, contact editor in the Cochrane Acute Respiratory Infection group, and Editor of the Catalogue of Bias. My work includes investigating drugs and devices, advising governments on regulatory evidence, assessing health claims, and research on common presenting conditions in primary care, including work on acute respiratory infections. I am a clinical advisor to two UK All Parliamentary Party Groups on Surgical Mesh and Hormone Pregnancy Tests, an adviser to the WHO clinical trials registry platform and a founder of the AllTrials campaign; three times I have been voted one of the top 100 NHS clinical leaders by the Health Service Journal. In 2018. I was awarded National Institute for Health Research Senior Investigator status (Senior Investigators are among the most prominent and prestigious researchers funded by the NIHR and the most outstanding leaders of patient and people-based research within the NIHR research community). In 2019, I received a lifetime achievement award from Oxford's Medical Science Division for my sustained

commitment to education and teaching. I am Director of the Centre for Evidence-Based Medicine (CEBM), which builds capacity through teaching and training activities. I teach undergraduates, postgraduates, and teachers of EBM, and I am Director of Programs in Evidence-Based Health Care. (Attached as Exhibit D is a copy of my CV.)

6. We have not received any compensation, either directly or in-kind, for this affidavit.

THE "FLU"

7. The Massachusetts Department of Public Health repeatedly refers to influenza vaccines as an approach for dealing with the "flu." However, most cases of the "flu," respiratory infections and illnesses, are not caused by influenza virus but rather by other viruses.[5] Every year, hundreds of thousands of respiratory specimens are tested across the United States and, on average, only 16% are found to be influenza positive.[6] Other viruses, *e.g.*, adenoviruses, respiratory syncytial virus, rhinoviruses, and coronaviruses, cause a clinically indistinguishable disease all known colloquially as "flu." Hence, the influenza vaccine, even if it were a 100% effective product, could only address a small fraction of the "flu" cases in Massachusetts as it does not and cannot address the other viruses.

THE INFLUENZA VACCINE

8. There is no single "influenza vaccine." There are a wide range of distinct products, produced by different manufacturers, each with different ingredients, manufacturing facilities, and safety and efficacy profiles that regulators need to evaluate prior to initial approval and licensing each year.

---

[5] *See* https://onlinelibrary.wiley.com/doi/epdf/10.1111/irv.12789; *see also* https://academic.oup.com/ajcp/article/147/1/43/2697603.

[6] Doshi P. Influenza: marketing vaccine by marketing disease. *BMJ 2013;346:f3037* https://www.bmj.com/content/346/bmj.f3037.

9. Not only is each influenza vaccine a unique product, the process for culturing the influenza virus and creating the vaccines results in variations from year to year, batch to batch, and potentially even from dose to dose. This is because, unlike drugs that are made from a consistent small molecule, these products are biologics produced using biological material. Each brand of influenza vaccine also changes each year to target strains of influenza virus expected to be in circulation in the coming season. The influenza vaccine is therefore not a single, unchanging product over time, but rather differs from year to year, product to product, and batch to batch.

10. One implication of this is that, once a given product is licensed, new formulations of that product (annually produced) are allowed on the market each year without knowing their efficacy or safety profile. Performance in a given season can only be discovered after the fact (*i.e.*, after the season has ended).

NO EVIDENCE THAT INFLUENZA VACCINES PREVENT TRANSMISSION OF INFLUENZA

11. The Cochrane Collaboration, considered an independent scientific body, conducts systematic reviews of all the best available scientific studies to assess the current state of the science on questions of interest. Its partners and funders include the U.S. National Institutes of Health (NIH), the World Health Organization (WHO), national health agencies, and leading medical universities from around the globe.[7] The process of conducting a systematic review involves a systematic, thorough search, and critical assessment of all relevant articles on a given clinical topic. Systematic reviews are a methodology for reducing bias when appraising the scientific literature and help protect against "cherry picking." Systematic reviews are widely

[7] https://www.cochrane.org/about-us/our-funders-and-partners.

regarded as the most trustworthy sources of information, sitting atop the Evidence-Based Medicine pyramid.[8]

12. In 2010, Cochrane published a systematic review entitled "Vaccines for preventing influenza in healthy adults" which, after a review of the published randomized clinical trials and comparative studies for the influenza vaccine, "found no evidence that vaccines prevent viral transmission" of influenza.[9] In 2014, Cochrane updated this systematic review with 41 new trials and in 2018 it updated it again with 52 additional trials comprising over 80,000 additional individuals.[10] These updates did not change the conclusion reached in 2010 that **there is no evidence that influenza vaccines prevent viral transmission of influenza**.

13. In 2018, Cochrane conducted the same systematic review of all published clinical trials and studies with regard to children entitled "Vaccines for preventing influenza in healthy children."[11] It concluded that "**we could find no convincing evidence that vaccines can reduce … community transmission of influenza**."[12]

NO RELIABLE EVIDENCE THAT INFLUENZA VACCINES PREVENT HOSPITALIZATIONS AND DEATH

14. Randomized clinical trials have not demonstrated that administration of influenza vaccines reduces the risk of hospitalization or mortality, something demonstrated clearly by the Cochrane review on this topic.[13] These trials were conducted prospectively and were randomized, hence reducing the potential bias. There have been a number of observational studies (studies that

[8] https://guides.lib.uci.edu/ebm/pyramid.

[9] https://pubmed.ncbi.nlm.nih.gov/20614424/.

[10] https://pubmed.ncbi.nlm.nih.gov/24623315/; https://pubmed.ncbi.nlm.nih.gov/29388196/.

[11] https://pubmed.ncbi.nlm.nih.gov/29388195/.

[12] https://pubmed.ncbi.nlm.nih.gov/29388195/ (emphasis added).

[13] https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD004876.pub4/full.

looked retrospectively at historical data, generally from medical claims databases) that were not randomized, and hence highly susceptible to bias, which indicated influenza vaccines lowered the rate of hospitalization. These observational studies are unreliable and inconsistent with the well-controlled clinical trials which have not demonstrated any such reduction. Many of them have reported a dramatic and totally implausible efficacy of influenza vaccines (one famous one[14] reported influenza vaccines reduced all deaths by half – not just influenza-associated deaths, but all deaths). Such results have long been criticized as plainly implausible,[15] and a variety of studies have been conducted to understand how these analyses could arrive at such unbelievable results.[16]

15. In 2018, the Cochrane review of influenza vaccines in healthy children reached the conclusion that "at present we could find no convincing evidence that vaccines can reduce mortality, hospital admissions, serious complications, or community transmission of influenza."[17] As for adults, in 2018 Cochrane concluded that "We found low-certainty evidence that hospitalisation rates and time off work may be comparable between vaccinated and unvaccinated adults, although the confidence interval around the effect for hospital admission is wide and there was substantial variation in the direction of effect on time off work."[18] In other words, there was no compelling evidence of demonstrating benefit in a reduction in hospital admission or time off work, and Cochrane recommended that a sufficiently large, "publicly funded, high-quality, placebo-controlled trial run over several seasons should be undertaken."[19] Other systematic

[14] https://www.nejm.org/doi/full/10.1056/NEJMoa070844.

[15] https://pubmed.ncbi.nlm.nih.gov/18163274/.

[16] https://pubmed.ncbi.nlm.nih.gov/16368725/ ; https://pubmed.ncbi.nlm.nih.gov/16368724/ ; https://pubmed.ncbi.nlm.nih.gov/18556629/.

[17] https://pubmed.ncbi.nlm.nih.gov/29388195/.

[18] https://pubmed.ncbi.nlm.nih.gov/29388196/.

[19] https://pubmed.ncbi.nlm.nih.gov/29388196/.

reviews focusing on randomized controlled trials have reached similar conclusions regarding the lack of a reduction in hospitalization and mortality from influenza vaccines. For example, a non-Cochrane systematic review published in *The Lancet Infectious Diseases* concluded that the "[e]vidence for protection in adults aged 65 years or older is lacking."[20]

16. In addition to the lack of credible evidence demonstrating any ability to prevent hospitalization and death, there are randomized trials which report findings that raise questions about the ability of influenza vaccines to **increase** risk of non-influenza flu-like symptoms; in one such study, conducted by the Centers for Disease Control and Prevention, the authors write: "During the 1997-1998 influenza season, vaccine recipients reported significantly more ILI-related [ILI = influenza like illness] sick days, lost workdays, and lost work hours for physician visits than placebo recipients."[21] The fact that the vaccine group in a randomized trial fared worse than the placebo group underscores the unpredictability of effects.

INFLUENZA VACCINES CAN CAUSE SERIOUS HARM

17. While influenza vaccines are often portrayed as risk free, no medical intervention is risk free, and serious adverse events linked to influenza vaccine have occurred. In general, the evidence base on harms from influenza vaccines can be characterized as largely inadequate, leaving great uncertainty about the benefit/harms profile, particularly in children.

18. Part of the reason for this lack of certainty is that harms from influenza vaccines are not adequately studied. For example, while Cochrane explained that "influenza vaccines were associated with serious harms such as narcolepsy and febrile convulsions," it surprisingly found:

> …only one safety study of inactivated vaccine in children under 2 years, carried out nearly 30 years ago in 35 children (ab Wright 1976a). The lack of safety data for inactive vaccines in younger

[20] https://pubmed.ncbi.nlm.nih.gov/22032844/.

[21] https://pubmed.ncbi.nlm.nih.gov/11015795/.

> children is particularly surprising given that the inactive vaccine is now recommended for healthy children six months and older in the USA and Canada (AAPCID 2004; Harper 2004; Orr 2004).[22]

The Cochrane report also highlights a number of other issues. For many studies, adverse events are not adequately described or reported. Many important adverse events in part lack a more robust evidence base for lack of standardized ways of measuring adverse events, a point raised in other safety reviews.[23] For some influenza vaccines, manufacturers refused to provide all data regarding harms. Adverse events also tend to be actively monitored for only a short period of time, relying on passive data collection methods for detecting adverse events after a brief initial period.

19. Also consider events that occurred during the last pandemic a decade ago, with two "swine flu" H1N1 vaccines in 2009-10, vaccines for which heightened surveillance was put in place. That influenza season would witness the following, as one of us wrote about in *JAMA Internal Medicine*: "Australia suspended its universal vaccination program for children younger than 5 years because of a surge in febrile convulsions following vaccination (1 in 110 children).[24]

20. In terms of the potential for injury from the influenza vaccine, it is worth noting that in the last ten years, the Vaccine Adverse Events Reporting System (VAERS), administered by the CDC and FDA, has received reports of the following serious events following receipt of an influenza vaccine: 1,527 deaths; 3,327 permanent disabilities; 12,692 hospitalizations; and 40,040 emergency room and/or medical office visits.[25] A report from researchers at Harvard Medical School, including the Director of Bioinformatics, funded by the Agency for Health Research and

---

[22] https://pubmed.ncbi.nlm.nih.gov/29388195/.

[23] https://pubmed.ncbi.nlm.nih.gov/26822822/.

[24] Stokes B. Ministerial review into the public health response into the adverse events to the seasonal influenza vaccine. Department of Health, Government of Western Australia; July 2010. https://ww2.health.wa.gov.au/-/media/Files/Corporate/Reports-and-publications/PDF/Stokes_Report.pdf. Accessed December 7, 2020.

[25] https://wonder.cdc.gov/vaers.html (Query date Nov 25, 2020; covers July 1, 1990 to present.)

Quality, an agency within the United States Department of Health and Human Services, stated that "fewer than 1% of vaccine adverse events are reported" to VAERS.[26]

21. Influenza vaccines represent 50% (3,852) of the 7,705 compensated claims (10/01/1988 through 09/01/2020),[27] for which damages have been paid out by the Vaccine Injury Compensation Program, administered in the United States Court of Federal Claims.[28] The injuries for which this compensation has been paid for claims of injury from the influenza vaccine include: Acute Disseminated Encephalomyelitis (ADEM), Anaphylaxis (severe allergic reaction), Axonal Polyneuropathy, Bell's Palsy, Cellulitis, Chronic Inflammatory Demyelinating Polyneuropathy (CIDP), Clinically Isolated Syndrome (CIS), Complex Regional Pain Syndrome (CRPS), Cardiac Arrest, Death, Fibromyalgia, Guillain-Barre Syndrome (GBS), Insomnia, Multiple Sclerosis (MS), Motor Neuropathy, Optic Neuritis, Parsonage-Turner Syndrome (brachial neuritis), Postural orthostatic tachycardia syndrome (POTS), Sensory Polyneuropathy, Shoulder Injury Related to Vaccine Administration (SIRVA), Small Fiber Neuropathy, Stevens Johnson Syndrome (SJS), Subcutaneous Abscess, Transverse Myelitis (TM), Vasovagal Syncope.[29]

22. We are not drawing conclusions regarding the causal role of the vaccine in the VAERS reports or federal court compensation cases, nor do we know the frequency of each type of adverse event in the population as such conclusions cannot be made without further study. Instead, we highlight them to indicate the scale of such reports and the need for more rigorous study of influenza vaccine safety.

---

[26] https://digital.ahrq.gov/sites/default/files/docs/publication/r18hs017045-lazarus-final-report-2011.pdf.

[27] https://www.hrsa.gov/sites/default/files/hrsa/vaccine-compensation/data/data-statistics-report.pdf.

[28] https://www.uscfc.uscourts.gov/vaccine-programoffice-special-masters.

[29] https://www.uscfc.uscourts.gov/aggregator/sources/7.

UNINTENDED CONSEQUENCES AND NON-SPECIFIC EFFECTS

23. In addition to potential injuries, the influenza vaccine can have other unintended consequences: so-called "off-target" or "nonspecific effects." This section outlines a few of these nonspecific effects.

24. An important nonspecific effect of influenza vaccine is that it may increase susceptibility to other influenza like illnesses. For example, a study from researchers at the University of Hong Kong, Queen Mary Hospital, and Centre for Influenza Research compared children receiving the influenza vaccine with those receiving a saline injection in a prospective randomized double-blind study.[30] Both groups had a statistically similar rate of influenza, but the group receiving the influenza vaccine had a statistically significant 4.4 times increased risk of non-influenza infections. Thus, the influenza vaccine appears to have increased these children's susceptibility to other respiratory viral infections.

25. Rigorous observational studies also suggest that influenza vaccination may increase the risk of non-influenza respiratory viruses or novel influenza viruses, not covered in that year's vaccine.[31]

26. There is also evidence for cohort, or year of birth, effects in influenza mortality, which have in particular been noticed during pandemics.[32] The difference in survival rates depends on the experience individuals have in surviving influenza infection, which generates robust and long-lived immune memory. These individuals, upon reencountering an influenza viral stain in old age for which they previously developed immunity, enjoy immunological memory to

[30] https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3404712/.

[31] https://pubmed.ncbi.nlm.nih.gov/29525279/; https://pubmed.ncbi.nlm.nih.gov/20386731/.

[32] https://pubmed.ncbi.nlm.nih.gov/23717567/; https://pubmed.ncbi.nlm.nih.gov/31502229/; https://pubmed.ncbi.nlm.nih.gov/9652423/.

these strains. In contrast, it is well established that influenza vaccines do not provide long-lived immunity conferred by natural infection and, moreover, influenza vaccines' very modest efficacy is even poorer for the elderly. The combination of these considerations can make a reasonable case that, given what we currently know about the disease and influenza vaccines, arguably the most effective strategy for an individual is to experience some influenza infection as a healthy adult, when the risk of complications is very low, thus generating a better immunity portfolio against influenza in old age, a time when the risk of complications is much higher.

CONCLUSION

27. While the harms from influenza vaccines are typically understated or not properly studied, the benefits of influenza vaccines are exaggerated, often contrary to the scientific findings, or simply asserted without evidence. It is unfortunate that public health officials justify their policies and statements regarding the influenza vaccine through selective citations of the evidence base rather than conclusions reached after systematic and thorough review of the reliable evidence.[33]

28. For the avoidance of doubt, we are not against any individual receiving the influenza vaccine and in this affidavit we have not provided any opinion regarding other vaccines.

29. Rather, it is our collective scientific view that before a product is recommended to a patient, let alone mandated to a patient, there should be clear evidence to support the recommendation. There should be rigorous placebo-controlled, randomized trials that have

[33] As an additional example, the CDC technical document on influenza vaccines expressly states that "Influenza vaccination **might reduce** the frequency of secondary complications and risk for influenza-related hospitalization and death," which reflects the unproven nature of whether influenza vaccines can reduce hospitalization and death. https://www.cdc.gov/mmwr/volumes/65/rr/rr6505a1.htm (emphasis added). Nonetheless, the CDC's website pages designed for public and state health department consumption does not include this qualifier but rather inaccurately presents the evidence as clear cut and definitive. https://www.cdc.gov/flu/about/burden-averted/2019-2020.htm This is another example of the gap between the science and the policy.

demonstrated that influenza vaccines prevent transmission and reduce hospitalizations, ICU admissions, or mortality. Ideally, there should be at least two such trials, publicly funded, and run over multiple influenza seasons with multiple different influenza vaccines. Unfortunately, the reality is that, despite influenza vaccines being recommended since 1960, not a single placebo-controlled randomized trial was ever set up to study whether the vaccine carries any of these potential benefits. The proven benefits should also be large enough that it can be confidently judged that influenza vaccines will bring public health benefits in excess of any harms. The history of influenza vaccines does not support this premise.[34]

SIGNED UNDER THE PAINS AND PENALTIES OF PERJURY,

Peter Doshi

Thomas Jefferson

Peter Gøtzsche

Carl Heneghan

This 17th day of December, 2020.

[34] It is also troubling to mandate a product whose safety and efficacy remain untested due to its reformulation every year and hence is effectively a new product every year, in addition to variations between products and lots of each influenza vaccine product.

EXHIBIT A

Curriculum Vitae of Peter Doshi, PhD

1) Biographical Information

A. Undergraduate Education

Brown University 1999 – 2002
Providence, Rhode Island
Bachelor of Arts
Anthropology

B. Graduate Education

Harvard University 2003 – 2006
Cambridge, Massachusetts
Master of Arts
Regional Studies—East Asia

Massachusetts Institute of Technology 2006 – 2011
Cambridge, Massachusetts
Doctor of Philosophy
History, Anthropology, and Science, Technology and Society

C. Postdoctoral Training

Johns Hopkins University School of Medicine 2011 – 2013
Baltimore, Maryland
Postdoctoral fellowship in Comparative Effectiveness Research
Divisions of General Pediatrics and General Internal Medicine

D. Employment Experience

University of Maryland School of Pharmacy
Assistant Professor of Pharmaceutical Health Services Research 2014 – 2019
Associate Professor of Pharmaceutical Health Services Research 2019 – present

BMJ 2013 – present
Associate Editor

Johns Hopkins University November 2012
Krieger School of Arts and Sciences
Part-time lecturer

2) Scholarly Activity

A. Publications in Refereed/Peer Reviewed Journals
(Note: **Name of the faculty member in bold** and the corresponding author underlined. Students, residents, fellows, or post-docs supervised by the faculty member are indicated with an asterisk*)

1. **Doshi P**, Spence O*, Kuzucan A*, Powers JH 3rd. Communication of Nonefficacy Benefits of New Drugs Approved on the Basis of Noninferiority Trials Alone: Cohort Study of FDA and Sponsor Communication, 2011-2017. JAMA Intern Med. 2019;179(5):719–721. doi:10.1001/jamainternmed.2018.7040
2. Desai B*, Hong K*, Powers JH 3rd, **Doshi P**. Reporting of Drug Benefit in FDA-Approved Prescription Drug Labeling [published online ahead of print, 2019 Oct 28]. J Gen Intern Med. 2019;10.1007/s11606-019-05460-2. doi:10.1007/s11606-019-05460-2
3. Spence O*, Hong K*, Onwuchekwa Uba R*, **Doshi P**. Availability of study protocols for randomized trials published in high-impact medical journals: A cross-sectional analysis [published online ahead of print, 2019 Aug 26]. Clin Trials. 2019;1740774519868310. doi:10.1177/1740774519868310
4. **Doshi P**, Sieluk J*, Hung A*. The possible harms of statins: What do product labels, patient package inserts, and pharmacy leaflets tell us?. J Am Pharm Assoc (2003). 2019;59(2):195–201. doi:10.1016/j.japh.2018.12.003
5. Jefferson T, **Doshi P**, Boutron I, Golder S, Heneghan C, Hodkinson A, Jones M, Lefebvre C, Stewart LA. When to include clinical study reports and regulatory documents in systematic reviews. BMJ Evid Based Med. 2018 Dec;23(6):210-217. doi: 10.1136/bmjebm-2018-110963. Epub 2018 Oct 11. PubMed PMID: 30309870.
6. Jørgensen L, **Doshi P**, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. BMJ. 2018 Sep 24;362:k3694. doi: 10.1136/bmj.k3694. PubMed PMID: 30249615.
7. **Doshi P**. Pandemrix vaccine: why was the public not told of early warning signs? BMJ. 2018 Sep 20;k3948. doi: 10.1136/bmj.k3948.
8. Jørgensen L, **Doshi P**, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines. BMJ. 2018 Sep 24;k3694. doi: 10.1136/bmj.k3694.
9. Hodkinson A, Dietz KC, Lefebvre C, Golder S, Jones M, **Doshi P**, et al. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. Systematic Reviews. 2018 Dec [cited 2018 Oct 2];7(1). doi: 10.1186/s13643-018-0766-x
10. Spence O*, Onwuchekwa Uba R*, Shin S*, **Doshi P**. Patient consent to publication and data sharing in industry and NIH-funded clinical trials. Trials 2018

May 3;19(1):269. doi: 10.1186/s13063-018-2651-2.
0 citations (Scopus), 55 social media mentions (PlumX Metrics), 4 readers on Mendeley (PlumX Metrics)

11. **Doshi P**, Hur P*, Jones M, Albarmawi H*, Jefferson T, Morgan DJ, et al. Informed consent to study purpose in randomized clinical trials of antibiotics, 1991 through 2011. JAMA Intern Med 2017;177(10):1452-1459.
4 citations (Scopus), 53 blog and social media mentions (Altmetric), 13 news outlet mentions (Altmetric), 9 readers on Mendeley (PlumX metrics), 7 full text views in EBSCO databases (PlumX Metrics), 342 PDF downloads from journal website

12. Mayo-Wilson E, Li T, Fusco N, Bertizzolo L, Canner JK, Cowley T, **Doshi P**, Ehmsen J, Gresham G, Guo N, Haythornthwaite JA, Heyward J, Hong H, Pham D, Payne JL, Rosman L, Stuart EA, Suarez-Cuervo C, Tolbert E, Twose C, Vedula S, Dickersin K. Cherry-picking by trialists and meta-analysts can drive conclusions about intervention efficacy. J Clin Epidemiol 2017 Nov;91:95-110.
3 citations (Scopus), 62 blog and social media mentions (PlumX Metrics), 11 readers on Mendeley (PlumX Metrics)

13. **Doshi P.** The unofficial vaccine educators: are CDC funded non-profits sufficiently independent? BMJ 2017 Nov 7;359:j5104.
0 citations (Scopus), 273 social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 1734 full text views on journal website, 205 PDF downloads from journal website

14. Sieluk J*, Palasik B*, dosReis S, **Doshi P**. ADHD medications and cardiovascular adverse events in children and adolescents: cross-national comparison of risk communication in drug labeling. Pharmacoepidemiol Drug Saf 2017 Mar;26(3):274-284.
0 citations (Scopus), 6 social media mentions (Altmetric), 3 readers on Mendeley (Altmetric)

15. Spelsberg A, Prugger C, **Doshi P**, Ostrowski K, Witte T, Husgen D, et al. Contribution of industry funded post-marketing studies to drug safety: survey of notifications submitted to regulatory agencies. BMJ 2017 Feb 7;356:j337.
3 citations (Scopus), 263 blog and social media mentions (Altmetric), 7 news outlet mentions (Altmetric), 21 readers on Mendeley (Altmetric), 18,941 full text views on journal website, 1927 PDF downloads from journal website, 9 user-generated Bitly links to article with a total of 200 link clicks (PlumX Metrics)

16. **Doshi P**, Jefferson T. Open data 5 years on: A case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. Trials 2016;17(1).
9 citations (Scopus), 59 blog and social media mentions (Altmetric), 15 readers on Mendeley (PlumX Metrics), 10 full text views in EBSCO databases (PlumX Metrics), 8 user-generated Bitly links to article with a total of 99 link clicks (PlumX Metrics)

17. **Doshi P**. Is this trial misreported? Truth seeking in the burgeoning age of trial transparency. BMJ 2016 Oct 24;355:i5543.
2 citations (Scopus), 59 blog and social media mentions (Altmetric), 10 readers on Mendeley (Altmetric), 1761 full text views on journal website, 239 PDF downloads from journal website

18. Heneghan CJ, Onakpoya I, Jones MA, **Doshi P**, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Mahtani KR, Nunan D, Howick J, Jefferson T. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technol Assess 2016 May;20(42):1-242.
10 citations (Scopus), 84 blog and social media mentions (Altmetric), 1 news outlet mention (PlumX Metrics) 1 policy document mention (Altmetric), 46 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics)

19. **Doshi P**. Data too important to share: do those who control the data control the message? BMJ 2016 Mar 2;352:i1027.
13 citations (Scopus), 93 blog and social media mentions (Altmetric), 4 news outlet mentions (Altmetric), 20 readers on Mendeley (Altmetric), 9127 full text views on journal website, 1086 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 5 link clicks (PlumX Metrics)

20. Persaud N, **Doshi P**. North American regulatory agencies can and should make clinical trial data publicly available. CMAJ 2016 Feb 2;188(2):96-97.
5 citations (Scopus), 21 blog and social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics)

21. Hung A*, Sieluk J*, **Doshi P**. The Untapped Potential of Pharmacy Leaflets for Informing Patients About Drug Benefits and Risks. JAMA Intern Med 2016 Jan;176(1):11-12.
1 citation (Scopus), 87 blog and social media mentions (Altmetric), 9 readers on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics), 517 PDF downloads from journal website

22. **Doshi P**. Defining antibiotic effectiveness and resistance: how a private party may soon rule judgments over susceptibility testing. BMJ 2016 Jan 6;352:h6849.
0 citations (Scopus), 19 social media mentions (Altmetric), 3 readers on Mendeley (Altmetric), 733 full text views on journal website, 168 PDF downloads from journal website

23. Mayo-Wilson E, Hutfless S, Li T, Gresham G, Fusco N, Ehmsen J, Heyward J, Vedula S, Lock D, Haythornthwaite J, Payne JL, Cowley T, Tolbert E, Rosman L, Twose C, Stuart EA, Hong H, **Doshi P**, Suarez-Cuervo C, Singh S, Dickersin K. Integrating multiple data sources (MUDS) for meta-analysis to improve patient-centered outcomes research: A protocol for a systematic review. Syst Rev 2015;4(1).
2 citations (Scopus), 13 social media mentions (Altmetric), 22 readers on Mendeley (Altmetric)

24. Mayo-Wilson E, **Doshi P**, Dickersin K. Are manufacturers sharing data as promised? BMJ 2015 Sep 25;351:h4169.
6 citations (Scopus), 57 blog and social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 974 full text views on journal website, 211 PDF downloads from journal website

25. **Doshi P**. Speeding new antibiotics to market: a fake fix? BMJ 2015 Mar 25;350:h1453.
14 citations (Scopus), 150 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 25 readers on Mendeley (Altmetric), 6165 full text views on journal website, 811 PDF downloads from journal website, 2 full text views in EBSCO databases (PlumX Metrics), 6 user-generated Bitly links to article with a total of 286 link clicks (PlumX Metrics)

26. Jefferson T, Jones MA, **Doshi P**, Del Mar CB, Hama R, Thompson MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in adults and children. Cochrane Database Syst Rev 2014;2014(4).
128 citations (Scopus), 398 blog and social media mentions (Altmetric), 37 news outlet mentions (Altmetric), 188 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 5 Wikipedia references (Altmetric), 4 YouTube video mentions (Altmetric), 9 user-generated Bitly links to article with a total of 32 link clicks (PlumX Metrics)

27. Jefferson T, Jones MA, **Doshi P,** Del Mar CB, Hama R, Thompson MJ, et al. Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. BMJ Open 2014 Sep 30;4(9):e005253-2014-005253.
8 citations (Scopus), 88 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 23 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 4490 full text views on journal website, 567 PDF downloads from journal website, 9 user-generated Bitly links to article with a total of 18 link clicks (PlumX Metrics)

28. Jefferson T, **Doshi P**. Multisystem failure: the story of anti-influenza drugs. BMJ 2014 Apr 10;348:g2263.
31 citations (Scopus), 26 blog and social media mentions (Altmetric), 33 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics) 5952 full text views on journal website, 1344 PDF downloads from journal website, 5 user-generated Bitly links to article with a total of 3 link clicks (PlumX Metrics)

29. Jefferson T, Jones M, **Doshi P**, Spencer EA, Onakpoya I, Heneghan CJ. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014 Apr 9;348:g2545.
106 citations (Scopus), 776 blog and social media mentions (Altmetric), 32 news outlet mentions (Altmetric), 156 readers on Mendeley (Altmetric), 2 Wikipedia references (PlumX Metrics), 105,987 full text views on journal website, 18,869 PDF downloads from journal website, 1 full text view in EBSCO databases

(PlumX Metrics), 26 user-generated Bitly links to article with a total of 139 link clicks (PlumX Metrics)

30. **Doshi P**, Dickersin K, Healy D, Vedula SS, Jefferson T. Restoring invisible and abandoned trials: A call for people to publish the findings. BMJ 2013;346(7913).
78 citations (Scopus), 336 blog and social media mentions (Altmetric), 47 news outlet mentions (Altmetric), 1 Wikipedia reference (PlumX Metrics), 89 readers on Mendeley (Altmetric), 56,338 full text views on journal website, 5169 PDF downloads from journal website, 19 user-generated Bitly links to article with a total of 134 link clicks (PlumX Metrics)

31. **Doshi P**. Influenza vaccines: time for a rethink. JAMA Intern Med 2013 Jun 10;173(11):1014-1016.
10 citations (Scopus), 95 social media mentions (Altmetric), 1 news outlet mention (PlumX Metrics), 19 readers on Mendeley (Altmetric), 1 full text view in EBSCO databases (PlumX Metrics), 972 PDF downloads from journal website, 4 user-generated Bitly links to article with a total of 2 link clicks (PlumX Metrics)

32. **Doshi P**, Jefferson T. The first 2 years of the European Medicines Agency's policy on access to documents: secret no longer. JAMA Intern Med 2013 Mar 11;173(5):380-382.
19 citations (Scopus), 3 blog mentions (Altmetric), 10 readers on Mendeley (Altmetric), 4 full text views in EBSCO databases, 1079 PDF downloads from journal website, 2 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)

33. **Doshi P**, Jefferson T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open 2013 Feb 26;3(2):10.1136/bmjopen-2012-002496. Print 2013.
38 citations (Scopus), 57 blog and social media mentions (Altmetric), 1 policy document reference (Altmetric), 18 readers on Mendeley (Altmetric), 10,343 full text views on journal website, 1558 PDF downloads from journal website

34. **Doshi P**, Jefferson T, Del Mar C. The imperative to share clinical study reports: recommendations from the Tamiflu experience. PLoS Med 2012;9(4):e1001201.
95 citations (Scopus), 117 blog and social media mentions (journal website), 141 readers on Mendeley (Mendeley.com), 1 Wikipedia reference (PlumX Metrics), 62,915 full text views on journal website, 5459 PDF downloads from journal website and PubMed Central, 1 user-generated Bitly link to article with a total of 3 link clicks (PlumX Metrics)

35. Jefferson T, Jones MA, **Doshi P**, Del Mar CB, Heneghan CJ, Hama R, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database Syst Rev 2012 Jan 18;1:CD008965.
89 citations (Scopus), 66 blog and social media mentions (Altmetric), 7 news outlet mentions (Altmetric), 99 readers on Mendeley (Altmetric), 3 Wikipedia references (PlumX Metrics), 1 YouTube video mentions (Altmetric)

36. **Doshi P**, Jones M, Jefferson T. Rethinking credible evidence synthesis. BMJ 2012 Jan 17;344:d7898.
39 citations (Scopus), 26 blog and social media mentions (Altmetric), 58 readers on Mendeley (Altmetric), 1 policy document reference (Altmetric), 11,133 full text views on journal website, 1832 PDF downloads from journal website

37. **Doshi P**. The elusive definition of pandemic influenza. Bull World Health Organ 2011 Jul 1;89(7):532-538.
40 citations (Scopus), 41 readers on Mendeley (PlumX Metrics), 515 full text views in EBSCO databases (PlumX Metrics)

38. Jefferson T, **Doshi P**, Thompson M, Heneghan C, Cochrane Acute Respiratory Infections Group. Ensuring safe and effective drugs: who can do what it takes? BMJ 2011 Jan 11;342:c7258.
37 citations (Scopus), 12 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 38 readers on Mendeley (Altmetric), 7022 full text views on journal website, 11 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 109 link clicks (PlumX Metrics)

39. Jefferson T, Jones M, **Doshi P**, Del Mar C, Dooley L, Foxlee R. Neuraminidase inhibitors for preventing and treating influenza in healthy adults. Cochrane Database Syst Rev 2010 Feb 17;(2):CD001265. doi(2):CD001265.
60 citations (Scopus), 2 blog and social media mentions (Altmetric), 14 readers on Mendeley (Altmetric)

40. **Doshi P**. Neuraminidase inhibitors--the story behind the Cochrane review. BMJ 2009 Dec 8;339:b5164.
58 citations (Scopus), 47 blog and social media mentions (Altmetric), 4 news outlet mentions (Altmetric), 52 readers on Mendeley (Altmetric), 14,332 full text views on journal website, 7 PDF downloads from journal website

41. Jefferson T, Jones M, **Doshi P**, Del Mar C. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ 2009 Dec 8;339:b5106.
209 citations (Scopus), 45 blog and social media mentions (Altmetric), 5 news outlet mentions (Altmetric), 2 Wikipedia references (Altmetric), 101 readers on Mendeley (Altmetric), 79,183 full text views on journal website, 13,916 PDF downloads from journal website, 7 full text views in EBSCO databases (PlumX Metrics), 2 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)

42. **Doshi P**. Calibrated response to emerging infections. BMJ 2009 Sep 3;339:b3471.
63 citations (Scopus), 2 blog mentions (Altmetric), 1 Wikipedia reference (PlumX Metrics), 8 readers on Mendeley (Altmetric), 9667 full text views on journal website, 30 PDF downloads from journal website

43. **Doshi P**. Trends in recorded influenza mortality: United States, 1900-2004. Am J

Public Health 2008 May;98(5):939-945.
48 citations (Scopus), 11 social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 37 readers on Mendeley (Altmetric), 3466 full text views in EBSCO databases (PlumX Metrics)

B. Presentations at Scientific or Professional Meetings
(Note: **Name of the faculty member in bold**. Students, residents, fellows, or post-docs supervised by the faculty member are indicated with an asterisk*)

1. **Doshi P**. The BMJ Investigative Journalism Conference. “Standards for drug approval: too stringent, too lax, or just right?” Berlin, Germany. November 18, 2019
Presentation; International; Podium

2. **Doshi P.** Friends of the National Library of Medicine conference. "Better clinical trials for new product development" Bethesda, MD. June 14, 2017
Invited presentation; National; Podium

3. **Doshi P.** "The gain to be realized by research transparency." 2016 Consumers United for Evidence-based Health Care annual meeting July 29, 2016, Washington DC
Invited presentation; National; Podium

4. **Doshi P,** Sieluk J*, Hung A***.** "The Possible Harms of Statins: What do Product Labels and Pharmacy Leaflets Tell Us?" AACP Annual Meeting, Anaheim, CA. July 2016;
Invited presentation; National; Poster

5. **Doshi P.** Johns Hopkins School of Public Health. "The Hopkins mandatory flu vaccination policy, the search for truth, and freedom of speech in an academic institution" Baltimore, MD. June 10, 2016
Invited presentation; Local; Podium

6. **Doshi P.** "Adaptive Licensing & Access to Data" webcast presentation to European Public Health Alliance, Brussels, Belgium. April 18, 2016
Invited presentation; International; Webcast

7. **Doshi P.** “Speeding new antibiotics to market: a fake fix?”, National Physicians Alliance annual meeting. Washington, DC.; October 17, 2015
Invited presentation; National; Podium

8. **Doshi P.** “How CUE can engage lay journalists”, 2015 Consumers United for Evidence-based Health Care annual meeting, July 24, 2015. Washington, DC
Invited presentation; National; Podium

9. **Doshi P.** “Good and Bad Reanalysis”, Society for Clinical Trials. May 19, 2015. Washington, DC
Invited presentation; National; Podium

10. **Doshi P.** "How Open Data Can Reduce Reporting Biases and Help Patients Choose Wisely," Global Health & Innovation Conference. March 29, 2015, New Haven, CT
Invited presentation; National; Podium

11. **Doshi P.** "Who wants my data and what are they going to do with it?", Consumers United for Evidence-based Healthcare (CUE) annual meeting, Washington D.C., July 25, 2014
Invited presentation; Non-reviewed; National; Podium

12. **Doshi P.** "Searching for evidence under the waterline", Health Technology Assessment International (HTAi) annual meeting, Washington, DC, June 18, 2014
Invited presentation; International; Podium

13. **Doshi P.** "'Open' access to clinical trials: rhetoric and fine print", Society for Clinical Trials annual meeting, Philadelphia, May 19, 2014
Invited presentation; National; Podium

14. **Doshi P.** "Thoughts on misleading analyses", Presentation at Institute of Medicine consensus study meeting, February 4, 2014
Invited presentation; National; Podium

15. **Doshi P.** "Restoring Invisible and Abandoned Trials: the RIAT concept", presentation at CBI conference on Clinical Data Disclosure and Transparency, January 30, 2014
Invited presentation; National; Podium

16. **Doshi P.** "Restoring Invisible and Abandoned Trials: the RIAT concept", presentation at "The state of contemporary biomedical literature" conference sponsored by age.na.s, Rome, Italy, December 12, 2013
Invited presentation; International; Podium

17. **Doshi P.** "Restoring Invisible and Abandoned Trials: the RIAT concept", presentation at oPen conference, Naples, Italy, December 13, 2013
Invited presentation; International; Podium

18. **Doshi P.** "Credible evaluation of trials: what kind of data do we need?", Presentation at Institute of Medicine workshop on sharing clinical research data, October 5, 2012
Invited presentation; National; Podium

19. **Doshi P,** Bass E. "Do media understand that systematic reviews are not just another 'new study'?" 18th Annual National Research Services Award (NRSA) Conference; June 23, 2012
Presentation; National; Poster

C. Special Lectures (Invited)

1. “Working with regulatory data – a non-regulatory, non-industry perspective” Presentation to closed FDA-Health Canada meeting, Silver Spring, November 13, 2018; Invited lecture.
2. “Better evidence for better health” Presentation to WHO Uppsala Monitoring Centre 40th Anniversary, Uppsala, Sweden; May 17, 2018; Invited lecture
3. “The RIAT Initiative for Tackling Bias in Biomedical Literature” Presentation to National Library of Medicine ClinicalTrials.gov team, March 5, 2018; Invited lecture.
4. “Interim guidance on how to decide whether to include clinical study reports and other regulatory documents into Cochrane reviews” Presentation to Cochrane Scientific Committee, by web, February 28, 2018; Invited lecture
5. "Ensuring Accuracy in Clinical Trial Publications: Weighing Options" Continuing medical education lecture, Food and Drug Administration. Silver Spring, MD. October 25, 2017; Invited lecture
6. Office of Research Integrity conference "Quest for Research Excellence". Washington, DC. August 9, 2017; Panel Participation
7. "Why we need clinical trial data, and how FDA can help reduce abuse of the medical literature" Food and Drug Administration, Silver Spring, MD. June 6, 2017; Invited lecture
8. "Ensuring accuracy in clinical trial publications: weighing options" online webcast through University of Maryland M-CERSI program. April 20, 2017; Invited lecture
9. "Ensuring accuracy in clinical trial publications: weighing options" Food and Drug Administration, Silver Spring, MD. March 14, 2017; Invited lecture
10. "Finding “Big Data” (OK, big detail) under the waterline" Johns Hopkins University, Baltimore, MD. January 27, 2017; Invited lecture
11. “How We Fooled Ourselves into Thinking the Revolution on Data Transparency Was Won,” Johns Hopkins Center for Clinical Trials seminar series January 6, 2016; Invited lecture
12. “The NYAG’s contribution to evidence-based medicine,” New York State Attorney General's Office. New York, NY; November 9, 2015; Invited lecture
13. “Breaking the Seal on Drug Company Research”, presentation at Des Moines University “Leadership series” seminar, Des Moines, Iowa; September 18, 2014; Invited lecture
14. Dean’s Convocation panel on “Big Data.” University of Maryland School of Law; September 22, 2014; Panel participation

D. Other Publications and Related Activities

1. Publications not peer reviewed

1. Lexchin J, Herder M, **Doshi P**. Canada finally opens up data on new drugs and devices. BMJ. 2019;365:l1825. Published 2019 Apr 17. doi:10.1136/bmj.l1825
2. **Doshi P**. EMA scales back transparency initiatives because of workload. BMJ 2018;362:k3513. doi: 10.1136/bmj.k3513.
3. **Doshi P**, Shamseer L*, Jones M, Jefferson T. Restoring biomedical literature with RIAT. BMJ 2018 Apr 26;361:k1742. doi: 10.1136/bmj.k1742.
   0 citations (Scopus), 60 social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 118 PDF downloads from journal website
4. **Doshi P**. EMA recommendation on hydroxyethyl starch solutions obscured controversy. BMJ 2018 Mar 20;360:k1287. doi: 10.1136/bmj.k1287.
   1 citation (Scopus), 22 blog and social media mentions (Altmetric), 1 reader on Mendeley (Altmetric), 161 PDF downloads from journal website
5. **Doshi P**. CDC tightens controls on scientists' communication with news media. BMJ 2018 Feb 14;360:k675.
   0 citations (Scopus), 5 social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 4 readers on Mendeley (Altmetric), 403 full text views on journal website, 63 PDF downloads from journal website
6. **Doshi P**. FDA to begin releasing clinical study reports in pilot programme. BMJ 2018 Jan 23;360:k294.
   0 citations (Scopus), 47 blog and social media mentions (Altmetric), 294 full text views on journal website, 61 PDF downloads from journal website
7. **Doshi P**. "Independent" reanalysis of landmark starch solutions trial was published by original authors. BMJ 2017 Jul 21;358:j3552.
   0 citations (Scopus), 96 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 2 readers on Mendeley (Altmetric), 2536 full text views on journal website, 274 PDF downloads from journal website
8. **Doshi P**. The problem with US website for collecting adverse events after vaccination is resolved. BMJ 2017 Sep 8;358:j4164.
   0 citations (Scopus), 133 social media mentions (Altmetric), 131 full text views on journal website, 46 PDF downloads from journal website
9. **Doshi P**. US government website for collecting adverse events after vaccination is inaccessible to most users. BMJ 2017;357.
   0 citations (Scopus), 325 social media mentions and interactions (PlumX Metrics), 2 news outlet mentions (PlumX Metrics), 550 full text views on journal website, 67 PDF downloads from journal website
10. **Doshi P**, Godlee F. The wider role of regulatory scientists. BMJ 2017 Apr

27;357:j1991.
4 citations (Scopus), 45 blog and social media mentions (Altmetric), 3 readers on Mendeley (Altmetric), 1224 full text views on journal website, 216 PDF downloads from journal website

11. **Doshi P**. FDA unease about faster drug approval. BMJ 2017;357.
2 citations (Scopus), 124 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 3 readers on Mendeley (Altmetric), 908 full text views on journal website, 169 PDF downloads from journal website

12. **Doshi P**. Medical response to Trump requires truth seeking and respect for patients. BMJ 2017 Feb 7;356:j661.
0 citations (Scopus), 188 blog and social media mentions (Altmetric), 2 news outlet mentions (Altmetric), 3 readers on Mendeley (Altmetric), 8710 full text views on journal website, 147 PDF downloads from journal website

13. **Doshi P**. Update: New England journal of medicine publishes correction to 2012 chest trial of hydroxyethyl starch versus colloids. BMJ 2016;352.
3 citations (Scopus), 4 social media mentions (Altmetric), 2 readers on Mendeley (Altmetric), 653 full text views on journal website, 233 PDF downloads from journal website

14. Zito JM, **Doshi P**. For-profit Uses of Real-World Data: What Would Frances Kelsey Do? Med Care 2016 Dec;54(12):1045-1047.
3 citations (Scopus), 1 social media mention (Altmetric), 2 readers on Mendeley (Altmetric)

15. **Doshi P**. FDA drug summaries: a simplification too far? BMJ 2015 Jun 12;350:h3135.
0 citations (Scopus), 14 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 4 readers on Mendeley (Altmetric), 665 full text views on journal website, 181 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 4 link clicks (PlumX Metrics)

16. **Doshi P**. Convicting Zika. BMJ 2016 Apr 7;353:i1847.
4 citations (Scopus), 79 social media mentions (Altmetric), 52 readers on Mendeley (Altmetric), 17,401 full text views on journal website, 1085 PDF downloads from journal website, 4 user-generated Bitly links to article with a total of 39 link clicks (PlumX Metrics)

17. **Doshi P**, Jefferson T. The evidence base for new drugs: New legislation in germany provides another piece of a complex puzzle. BMJ 2015;350.
0 citations (Scopus), 61 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 1 reader on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics), 1118 full text views on journal website, 474 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 1 link click (PlumX Metrics)

18. **Doshi P**, Stahl-Timmins W, Merino JG, Simpkins C. Visualising childhood

vaccination schedules across G8 countries. BMJ 2015;351.
2 citations (Scopus), 17 social media mentions (Altmetric), 6 readers on Mendeley (Altmetric), 1331 full text views on journal website, 272 PDF downloads from journal website, 1 user-generated Bitly link to article with a total of 1 link click (PlumX Metrics)

19. Jones M, Jefferson T, **Doshi P**, Del Mar C, Heneghan C, Onakpoya I. Commentary on Cochrane review of neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Clin Microbiol Infect 2015;21(3):217-221.
5 citations (Scopus), 2 social media mentions (PlumX Metrics)

20. **Doshi P**. No correction, no retraction, no apology, no comment: paroxetine trial reanalysis raises questions about institutional responsibility. BMJ 2015 Sep 16;351:h4629.
16 citations (Scopus), 535 blog and social media mentions (Altmetric), 52 news outlet mentions (Altmetric), 46 readers on Mendeley (Altmetric), 21,165 full text views on journal website, 2473 PDF downloads from journal website, 18 user-generated Bitly links to article with a total of 266 link clicks (PlumX Metrics)

21. **Doshi P**. 21st century cures: is US medicines bill a colossal mistake? BMJ 2015 Jul 23;351:h4013.
3 citations (Scopus), 66 blog and social media mentions (Altmetric), 1 news outlet mention (Altmetric), 6 readers on Mendeley (Altmetric), 1563 full text views on journal website, 127 PDF downloads from journal website, 1 user-generated Bitly link to article with a total of 2 link clicks (PlumX Metrics)

22. **Doshi P**. No vote in US Congress on proposal to create new pathway for approving antibiotics. BMJ 2015 Mar 31;350:h1767.
0 citations (Scopus), 3 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 152 full text views on journal website, 60 PDF downloads from journal website

23. **Doshi P**, Zito J, DosReis S. Digging for data on harms in duloxetine trials: It's time for policy makers to get serious about drug related harms. BMJ 2014;348.
2 citations (Scopus), 6 blog and social media mentions (Altmetric), 16 readers on Mendeley (Altmetric), 1092 full text views on journal website, 363 PDF downloads from journal website

24. Jefferson T, Jones MA, **Doshi P**, Del Mar CB, Hama R, Thompson M, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Sao Paulo Med J 2014;132(4):256-257.
2 citations (Scopus), 2 readers on Mendeley (PlumX Metrics)

25. **Doshi P**. US incentive scheme for neglected diseases: a good idea gone wrong? BMJ 2014 Jul 21;349:g4665.
4 citations (Scopus), 2 blog and social media mentions (Altmetric), 1 policy document reference (Altmetric), 19 readers on Mendeley (PlumX Metrics), 3158

full text views on journal website, 350 PDF downloads from journal website, 6 user-generated Bitly links to article with a total of 2 link clicks (PlumX Metrics)

26. **Doshi P**. EMA policy on transparency is "strikingly" similar to deal struck with drug company, say experts. BMJ 2014 Jun 12;348:g3852.
1 citation (Scopus), 16 blog and social media mentions (Altmetric), 3 readers on Mendeley (PlumX Metrics), 606 full text views on journal website, 98 PDF downloads from journal website, 2 user-generated Bitly links to article with a total of 13 link clicks (PlumX Metrics)

27. Jefferson T, **Doshi P**. Multisystem failure: the story of antinfluenza drugs. Recenti Prog Med 2014 May;105(5):187-190.
2 citations (Scopus), 11 social media mentions and interactions (PlumX Metrics)

28. **Doshi P**. From promises to policies: is big pharma delivering on transparency? BMJ 2014 Feb 26;348:g1615.
6 citations (Scopus), 60 blog and social media mentions (Altmetric), 1 reader on Mendeley (PlumX Metrics), 1510 full text views on journal website, 345 PDF downloads from journal website, 6 user-generated Bitly links to article with a total of 17 link clicks (PlumX Metrics)

29. **Doshi P**, Groves T, Loder E. Clinical trial data: get them while you can. BMJ: British Medical Journal 2014 01/11;348(7940):8-8.
4 citations (Scopus), 19 social media mentions (Altmetric), 4 readers on Mendeley (PlumX Metrics), 1270 full text views on journal website, 262 PDF downloads from journal website

30. **Doshi P**, Vedula SS, Li T. Yoda and truth seeking in medicine: Making sense of the curious case of rhBMP-2. BMJ 2013;347(7915).
2 citations (Scopus), 12 blog and social media mentions (Altmetric), 4 readers on Mendeley (Altmetric), 967 full text views on journal website, 246 PDF downloads from journal website

31. **Doshi P**, Goodman SN, Ioannidis JP. Raw data from clinical trials: within reach? Trends Pharmacol Sci 2013 Dec;34(12):645-647.
29 citations (Scopus), 1 social media mention (PlumX Metrics), 34 readers on Mendeley (Mendeley.com)

32. **Doshi P**. Transparency interrupted: the curtailment of the European Medicines Agency's Policy on access to documents. JAMA Intern Med 2013 Nov 25;173(21):2009-2011.
7 citations (Scopus), 10 blog and social media mentions (Altmetric), 10 readers on Mendeley (PlumX Metrics), 655 PDF downloads from journal website, 3 user-generated Bitly links to article with a total of 89 link clicks (PlumX Metrics)

33. **Doshi P**. Putting GlaxoSmithKline to the test over paroxetine. BMJ 2013 Nov 12;347:f6754.
6 citations (Scopus), 67 blog and social media mentions (Altmetric), 23 readers on Mendeley (Altmetric), 1 Wikipedia reference (PlumX Metrics), 3012 full text views

on journal website, 466 PDF downloads from journal website, 1 full text view in EBSCO databases (PlumX Metrics), 2 user-generated Bitly links to article with a total of 11 link clicks (PlumX Metrics)

34. **Doshi P**. Influenza: marketing vaccine by marketing disease. BMJ 2013 May 16;346:f3037.
17 citations (Scopus), 952 social media mentions (Altmetric), 9 news outlet mentions (PlumX Metrics), 72 readers on Mendeley (Altmetric), 36,002 full text views on journal website, 4488 PDF downloads from journal website, 29 user-generated Bitly links to article with a total of 1535 link clicks (PlumX Metrics)

35. **Doshi P**, Jefferson T. Drug Data Shouldn't Be Secret. New York Times 2012 04/11;161(55738):1.
0 citations (Scopus)

36. **Doshi P**, Akabayashi A. Japanese Childhood Vaccination Policy. Camb Q Healthc Ethics 2010 Jul;19(3):283-289.
5 citations (Scopus), 2 social media mentions (Altmetric), 5 readers on Mendeley (Altmetric), 22 full text views on journal website, 51 PDF downloads from journal website

37. Jefferson T, Jones M, **Doshi P**, Del Mar C. Possible harms of oseltamivir--a call for urgent action. Lancet 2009 Oct 17;374(9698):1312-1313.
30 citations (Scopus), 26 readers on Mendeley (Mendeley.com)

38. **Doshi P**. Science in the Private Interest: Has the Lure of Profits Corrupted Biomedical Research? IEEE Technology & Society Magazine Spring 2006;25(1):10-11.
0 citations (Scopus), 491 full text views on journal website

39. **Doshi P**. Selling 'pandemic flu' through a language of fear. Christian Science Monitor 2006 03/21;98(79):9.
0 citations (Scopus)

40. **Doshi P**. Viral Marketing. Harper's Magazine 2006 03;312(1870):54.
0 citations (Scopus)

41. **Doshi P**. Are US flu death figures more PR than science? BMJ 2005;331(7529):1412.
13 citations (Scopus), 63 blog and social media mentions (Altmetric), 3 news outlet mentions (Altmetric), 11 readers on Mendeley (Altmetric), 1 YouTube video mention (Altmetric), 12,755 full text views on journal website, 1345 PDF downloads from journal website

2. Letters to the editor in refereed journals

1. **Doshi P,** Spence O*, Powers JH. Noninferiority Trials. N Engl J Med 2018 Jan 18;378(3):304. 0 citations (Scopus)

2. Jones M, Del Mar C, **Doshi P**. Findings of an Observational Study of Neuraminidase Inhibitors Highly Sensitive to Decision to Exclude 1652 Treated Patients. Clin Infect Dis 2017 Sep 15;65(6):1050. 1 citation (Scopus), 2 readers on Mendeley (PlumX Metrics), 104 PDF downloads from journal website
3. Kuzucan A*, **Doshi P**, Zito JM. Pharmacists can help to end direct-to-consumer advertising. Am J Health Syst Pharm 2017 May 15;74(10):640-642. 0 citations (Scopus), 58 social media mentions and interactions (PlumX Metrics), 1 reader on Mendeley (Altmetric), 81 full text views in EBSCO databases (PlumX Metrics)
4. **Doshi P**, Jefferson T. Neuraminidase Inhibitors and Influenza Infection. JAMA Intern Med 2016 Mar;176(3):415-416. 0 citations (Scopus), 237 PDF downloads from journal website, 22 readers on Mendeley (PlumX metrics)
5. **Doshi P**, Heneghan C, Jefferson T. Oseltamivir for influenza. Lancet 2015 Sep 19;386(9999):1134-1135. 0 citations (Scopus), 1 social media mention (PlumX Metrics)
6. Collignon P, **Doshi P,** Del Mar C, Jefferson T. Safety and efficacy of inactivated influenza vaccines in children. Clin Infect Dis 2015 Feb 1;60(3):489. 1 citation (Scopus), 2 social media mentions (Altmetric), 10 readers on Mendeley (PlumX Metrics), 2 Wikipedia references (PlumX Metrics), 61 PDF downloads from journal website
7. Del Mar C, **Doshi P,** Hama R, Jones M, Jefferson T, Heneghan C, et al. Neuraminidase inhibitors for influenza complications. Lancet 2014;384(9950):1260-1261. 0 citations (Scopus), 1 social media mention (PlumX Metrics), 20 readers on Mendeley (Mendeley.com)
8. **Doshi P**, Jefferson T. Clinical trials: Tamiflu reviewers respond to critics. Nature 2014 May 15;509(7500):288. 1 citation (Scopus), 2 social media mentions (Altmetric), 10 readers on Mendeley (Altmetric), 107 full text views in EBSCO databases (PlumX Metrics), 1 user-generated Bitly link to article with a total of 2 link clicks (PlumX Metrics)
9. **Doshi P**, Jefferson T. Authors' reply to Dunning. BMJ 2014 Apr 30;348:g3018. 0 citations (Scopus), 1 reader on Mendeley (PlumX Metrics), 295 full text views on journal website, 87 PDF downloads from journal website
10. **Doshi P**. The importance of influenza vaccination-reply. JAMA Intern Med 2014 Apr;174(4):645-646. 0 citations (Scopus), 208 PDF downloads from journal website
11. **Doshi P**, Abi-Jaoude E, Lexchin J, Jefferson T, Thomas RE. Influenza vaccination of health care workers. CMAJ 2013;185(2):150. 2 citations (Scopus), 3 readers on Mendeley (Mendeley.com)
12. **Doshi P**. EFPIA-PhRMA's principles for clinical trial data sharing have been misunderstood. BMJ 2013;347(7922). 2 citations (Scopus), 5 social media mentions (Altmetric), 1 news outlet mention (Altmetric), 2 readers on Mendeley

(Altmetric), 832 full text views on journal website, 170 PDF downloads from journal website

13. **Doshi P**. The 2009 influenza pandemic. Lancet Infect Dis 2013;13(3):193. 1 citation (Scopus), 2 readers on Mendeley (Mendeley.com)
14. Jones M, Hama R, Jefferson T, **Doshi P**. Neuropsychiatric adverse events and oseltamivir for prophylaxis. Drug Saf 2012 Dec 1;35(12):1187-8; author reply 1188-90. 8 citations (Scopus), 2 readers on Mendeley (PlumX Metrics), 47 full text views in EBSCO databases, 122 PDF downloads from journal website
15. Heneghan C, Jefferson T, **Doshi P**. Antivirals for treatment of influenza. Ann Intern Med 2012 Sep 4;157(5):385-6; author reply 386-7. 0 citations (Scopus)
16. Cochrane Neuraminidase Inhibitors Review Team. Does oseltamivir really reduce complications of influenza? Clin Infect Dis 2011 Dec;53(12):1302-3; author reply 1303-4. 0 citations (Scopus), 33 PDF downloads from journal website
17. **Doshi P**, Jefferson T. WHO and pandemic flu. Another question for GSK. BMJ 2010 Jun 29;340:c3455. 2 citations (Scopus), 1 social media mention (PlumX Metrics), 4 readers on Mendeley (PlumX Metrics), 1168 full text views on journal website, 4 PDF downloads from journal website
18. Jefferson T, **Doshi P.** WHO and pandemic flu. Time for change, WHO. BMJ 2010 Jun 29;340:c3461. 5 citations (Scopus), 1 social media mention (PlumX Metrics), 2 readers on Mendeley (PlumX Metrics), 1343 full text views on journal website, 7 PDF downloads from journal website
19. Collignon P, **Doshi P**, Jefferson T. Ramifications of adverse events in children in Australia. BMJ 2010 Jun 9;340:c2994. 7 citations (Scopus), 132 social media mentions (Altmetric), 6 readers on Mendeley (PlumX Metrics), 2885 full text views on journal website, 11 PDF downloads from journal website
20. **Doshi P.** Pandemic influenza: severity must be taken into account. J Infect Dis 2010 May 1;201(9):1444-1445. 4 citations (Scopus), 5 readers on Mendeley (PlumX Metrics), 19 full text views in EBSCO databases (PlumX Metrics), 13 PDF downloads from journal website
21. **Doshi P**. Doshi responds. Am J Public Health 2008;98(11):1928-1930. 0 citations (Scopus), 5 social media mentions (Altmetric)
22. **Doshi P**. Reason for optimism. BMJ 2008;336(7637):172. 0 citations (Scopus), 4 readers on Mendeley (PlumX Metrics), 457 full text views on journal website, 95 PDF downloads from journal website
23. **Doshi P**. Popular and scientific attitudes regarding pandemic influenza. Emerg Infect Dis 2008 Sep;14(9):1501-2; author reply 1502. 1 citation (Scopus), 4 readers on Mendeley (PlumX Metrics), 176 full text views in EBSCO database (PlumX Metrics)

24. **Doshi P**. Estimation of death rates from pandemic influenza. Lancet 2007 Mar 3;369(9563):739; author reply 739-40. 1 citation (Scopus), 12 readers on Mendeley (Mendeley.com)
25. **Doshi P.** Influenza vaccination: policy versus evidence: Policy is in the lead. Br Med J 2006;333(7576):1020-1021. 2 citations (Scopus), 5 readers on Mendeley (PlumX Metrics), 982 full text views on journal website, 298 PDF downloads from journal website

3. Referee for professional or scientific journal

1. AHRQ Effective Health Care Program
2. American Journal of Respiratory and Critical Care Medicine
3. American Journal of Public Health
4. Annals of Internal Medicine
5. BMC Medical Research Methodology
6. BMC Public Health
7. BMJ
8. Canadian Medical Association Journal (CMAJ)
9. CNS Drugs
10. Drug and Therapeutics Bulletin
11. European Journal of Pediatrics
12. European Journal of Public Health
13. Expert Review of Vaccines
14. Health Affairs
15. Health Policy
16. Health Technology Assessment (Italian government)
17. Healthcare Policy
18. Influenza and Other Respiratory Viruses
19. JAMA Internal Medicine
20. Journal of Biomedical Research
21. Journal of Clinical Epidemiology
22. Journal of Medical Ethics
23. New England Journal of Medicine
24. PLOS Medicine
25. PLOS ONE
26. Trials
27. World Medical and Health Policy

4. Editorial positions on professional or scientific journals

Associate Editor **2013 – ongoing**
The BMJ (www.bmj.com)

Guest editorial board member **2017 – 2018**
Scientific Data (www.nature.com/sdata/)

E. Honors and Awards

New Investigator Award **2015**
American Association of Colleges of Pharmacy

The Wired Smart List 2013 (UK) **2013**
http://www.wired.co.uk/magazine/archive/2013/12/features/the-smart-list-2013

Nathan Wolfe/CNN Prize **2013**
Johns Hopkins Bloomberg School of Public Health

Siegel Teaching Prize **2011**
Massachusetts Institute of Technology

MIT-Japan Program intern **2009**
Massachusetts Institute of Technology

Presidential Fellowship **2006 – 2007**
Massachusetts Institute of Technology

Noma-Reischauer Prize in Japanese Studies **2006**
Graduate Student Essay Prize for "The Lost Lessons of SMON [subacute myelo-optico neuropathy]"
Kodansha Ltd., Publishers and the Reischauer Institute, Harvard University

Joseph Fletcher Memorial Prize for excellence in an A.M. thesis **2006**
Harvard University

Summer Foreign Language Assistance Scholarship (FLAS) for Japanese **2004**
Harvard University

Best Socio-Cultural Anthropologist **2002**
Brown University

Perry Gatson Scholarship Award for Outstanding Achievement in Anthropology **2002**
Brown University

3) Service

A. Scientific, Professional and Scholarly Organizations

The BMJ **2013 – indefinite**
The BMJ (formerly the *British Medical Journal*) is an international peer reviewed medical journal. I serve as an associate editor, a paid position, in which capacity I write articles, commission articles, handle manuscripts, and contribute to journal decision making.
International organization; Staff position

Health Canada **2017 – ongoing**
Selected to be on "roster of experts" for Health Canada's Health Products and Food Branch (HPFB) activated related to the implementation of public release of clinical information
International organization; Volunteer position

European Medicines Agency **Jan - Apr 2013**
Participated in two advisory groups (rules of engagement & good analysis practice) regarding EMA's draft Policy 0070, Publication of Clinical Trial Data
International organization; Volunteer position

Committee on Publication Ethics **2015 – ongoing**
International organization; Member; 3 years

American College of Cardiology **2013**
Writing committee member on Data Transparency Health Policy Statement
National organization; Volunteer position

AACP **2014 – 2016**
National organization; Member; 2 years

Rho Chi **2017 – ongoing**
Inducted in 2017
National organization; Member; 1 years

Cochrane **2018 – ongoing**
International organization; Member; 5 years

B. Additional professional service

Reagan-Udall Foundation for the FDA **2016 – ongoing**
Unpaid member of IMEDS Steering Committee

EXHIBIT B

CURRICULUM VITAE Thomas Oliver JEFFERSON
(1 August 2020)

Brief biographies appear in the series "Lifeline" on The Lancet 2003; 361:188. (11 January) and in the Feature Pioneers of Transparency BMJ 2014;350:g7717

H-Index 58

Two most cited papers:

Guidelines for authors and peer reviewers of economic submissions to the BMJ
MF Drummond, TO Jefferson. BMJ 313 (7052), 275-283 (1720 citations)

Vaccines for preventing influenza in healthy adults
V Demicheli, T Jefferson, E Ferroni, A Rivetti, C Di Pietrantonj. Cochrane database of systematic reviews (1558 citations)

Key words: Evidence synthesis, Epidemiology, Health Economics, Regulatory data, Market access

ADDRESS (Home)
Via Adige 28a
00061 Anguillara Sabazia
(Roma)
Italy
Mobile ++39 32 92025051
Email jefferson.tom@gmail.com

MEDALS & DECORATIONS

UNPROFOR Medal (1992)
OFFICER (BROTHER) Order of St John of Jerusalem (1994).
NATO Medal (Former Yugoslavia Clasp) 1996

RELEVANT ACADEMIC & PROFESSIONAL QUALIFICATIONS

Degree in Medicine and Surgery, Pisa University (1979).
Diploma of the Royal College of Obstetrician & Gynaecologists UK (DRCOG, 1982).
Certificate of Vocational Training in General Practice UK (1984).
Membership of the Royal College of General Practitioners UK (MRCGP 1985).
Membership of the Chartered Institute of Linguists UK (1985).
Diploma in Tropical Medicine & Hygiene UK (London School of Hygiene & Tropical Medicine 1987).
MSc Community Medicine UK (London School of Hygiene & Tropical Medicine 1988).
Membership of the Faculty of Public Health Medicine UK (MFPHM 1990).
Accreditation in Public Health Medicine UK (1990).
Accreditation in General Practice UK (1990).
Titolo di Scuola di Guerra (1991)
Certificate in Health Economics, University of Aberdeen UK (1996).
Fellowship of the Faculty of Public Health Medicine UK (FFPHM 1999).

RECENT and PRESENT ACTIVITIES

Unitl November 2019 I provided scientific supervision for the Agenas (Agenzia per i Servizi Sanitari Regionali) HTA programme for non-pharmaceuticals. Agenas is an agency of the Italian MoH. Part of my work entailed supervising a group of 10 researchers and taking responsibility for designing, devising and carrying out HTA and Horizon Scanning assessments. I was scientific lead for the European EUNeHTA Joint Action 2 (Workpackage 4 – devices and diagnostics) project (2012-2015, see below). The EUNeHTA Collaboration is a network of European public agencies producing structured HTA information for national use. In 2021 the Collaboration should become a permanent network funded by the

Commission. I was also scientific coordinator for Workpackage 4 which assessesed non pharmaceutical interventions, such as in vitro tests. This involved coordinating some 70 researchers from 28 agencies from 23 countries (from Estonia to Bulgaria, to Greece and Sweden). The project started in 2012 and was completed in 2015. I carried out the same role for the previous EUNeHTA project (Joint Action 1 or JA1 with the European Commission). Until November 2019 I was a member of two different workpackages and a reviewer for two projects in these workpackages as part of the EUNeHTA JA3.

I co-developed a methodology for synthetising evidence of effectiveness, efficiency, safety and resource utlisation using regulatory information and data from different sources, both regulatory and open source. This activity was initially funded by NIHR UK until mid-2015, then the Cochrane Methods Innovations Fund (MIF), NIHR again and since 2016 the Cochrane Nordic Centre. The MIF project was a collaboration to draft advice of when and how to include regulatory material in Cochrane reviews.
I am developing this work further by streamlining the use of regulatory data and its incorporation into user friendly, timely reviews.

As part of a team in the Nordic Cochrane Centre we carryied out a systematic review of HPV vaccines based on regulatory documents. The evidence set for the review was assembled by us from a variety of sources into an Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies, shortly to be published. At present we are developing the same reviews further with the complete regulatory dataset released by Health Canada after a court case.

Since 2015 I am a Fellow of the Centre for Evidence Based Medicine of the **University of Oxford**, in the UK. I am now Senior Clinical Tutor on the Complex Reviews Module of the MSc in Evidence Based Health course.

I am visiting Professor Visiting Professor Institute of Health & Society at the Faculty of Medicine of Newcastle University (2019-2021).

With the 3 other Cochrane colleagues I am a co-investigator in a John and Laura Arnold Foundation grant for development of a RIAT support centre (2017-2020).

RIAT stands for Restoring Invisible and Abandoned Trials. In short, RIAT is a mechanism that enables researchers to address two long-standing problems in the medical literature: non-publication of trials and misreporting. Our concept was first outlined here: http://www.bmj.com/content/346/bmj.f2865

The RIAT Support Center will help accelerate the correction of the scientific record of clinical trials by making it more accurate and more complete.

Finally, with the help of the Cochrane Central Editorial Unit we stabilised of our three long-standing influenza vaccine reviews. These were released in January 2018.

My activity line of regulatory data started with updating of Cochrane review A159 (Neuraminidase Inhibitors for influenza). A159 is currently based exclusively on regulatory information (essentially clinical study reports - CSRs from EMA and comments by FDA and PMDA - about 150K pages in all).

The story is told in:

David Payne. Tamiflu: the battle for secret drug data. BMJ 2012;345:e7303 doi: 10.1136/bmj.e7303 (Published 29 October 2012).
http://www.bmj.com/content/345/bmj.e7303

http://www.nytimes.com/2013/06/30/business/breaking-the-seal-on-drug-research.html?pagewanted=1&_r=3&smid=tw-share

http://www.newsweek.com/2014/11/21/medical-science-has-data-problem-284066.html
The pioneers of transparency. BMJ 2015;350:g7717 (Published 02 Jan 2015)

I was a member of EMA's Clinical Trials Advisory Group 2 (CTAG2).

I am on the editorial board of BMJ Evidence Based Medicine (BMJ EBM).

I am an unpaid collaborator to the project *Beyond Transparency in Pharmaceutical Research and Regulation* led by Dalhousie University and funded by the Canadian Institutes of Health Research (2018-2022).

I currently teach on the Complex Reviews module of the MSc in Evidence Based Health Care at Oxford University and currently supervising to MSc students. This involves reviews of regulatory data, economic studies, diagnostic studies, qualitative studies and IPI meta-analyses.

I am a member of the WHO Infection Prevention and Control Research and Development Expert Group for COVID-19.

PAST CONSULTANCIES AND OTHER ACTIVITIES

In the past I have carried out research for the **Ministry of Defence UK** (suite of Cochrane reviews on viral and arthropod borne fevers prevention), **NICE** (HTA of zanamivir for influenza), **Roche** (the economics of antivirals neuraminidase inhibitors), **EU** (systematic review of evidence of safety of MMR vaccines and of the economics of pneumococcal vaccines), **WHO** (systematic review of evidence of safety of Hepatitis B vaccines), **Glaxo SmithKline** (systematic review of evidence of safety and effectiveness of DPT vaccines), **Sanofi- Synhtelabo** (Development of Pleconaril), **Istituto Superiore di Sanita'** and **ASSR** (now Agenas), (coordinator of the national clinical guidelines project) (see below), **Netherlands Health Council** (safety of Hepatitis B vaccine update review), **IMS Health**

(Antidiabetic drugs) the **Piemonte Region** of Northern Italy (suite of Cochrane reviews on influenza vaccines), **Agenzia di Sanita' Pubblica Lazio** - Public Health Agency of Lazio Region (guidelines implementation trial project and coordination of a two cluster randomised trials of guidelines implementation, on behalf of the UK's Technology Assessment Programme I updated two reviews on the effects of editorial peer review. I have been involved in a 5 year update and rewrite of his Cochrane review on Neuraminidase Inhibitors exclusively based on regulatory information. (HTA – 10/80/01 Update and amalgamation of two Cochrane Reviews: neuraminidase inhibitors for preventing and treating influenza in healthy adults and children— *http://www.nets.nihr.ac.uk/projects/hta/108001*).

I am a member of the editorial base of the Cochrane Acute Respiratory Infections Group. Reviewer, Cochrane Infectious Diseases, Acute Respiratory Infections, Hepato-biliary, Airways and Colorectal Cancer Groups.

Director, Health Reviews Ltd, my own company.

Member, editorial, board of *Recenti Progressi in Medicina* and *BMC Health Services Research*.

Peer reviewer for BMJ, Lancet, JAMA, JAMA Internal Medicine, CMAJ, New England Journal of Medicine, Vaccine and Canadian Coordinating Office for Health Technology Assessment (CCOHTA) Emerging Technology bulletins.

I am an Academic Editor, PLOS ONE (2013-17) and have been a contributor to Last's Dictionary of Epidemiology (4th edition).

I do anonymous market access consultancy interviews for various pharmaceutical companies.

Between 1996 and 2009 I was the Co-ordinator of the Cochrane Vaccines Field and 1999 and 2012 I was honorary Research Fellow at the UK Cochrane Centre.

In 2011-13, I acted as an expert witness in a litigation case related to the antiviral oseltamivir, in two litigation cases on potential vaccine-related damage and in a labour case on influenza vaccines in healthcare workers in Canada. In 2016-17 I was a member of an independent data monitoring committee for a **Sanofi Pasteur** clinical trial on an influenza vaccine and a member of three advisory boards for **Boerhinger Ingelheim** (on bronchodilator drug), Takeda (cardiovascular drug) and Bayer (blood replacement).

As part of my HTA activity I have interviewed, collaborated and interacted with scores of clinicians in both primary and hospital care both in Italy and the rest of Europe. Over the past thirty years, I have worked in most therapeutic and prevention areas. Also as part of my Italian HTA and scientific activity I have interacted with patient organisations and have considerable knowledge of the regional Italian structure and its workings thanks to my role as consultant to Agenas.

The HTA report output is accessible at: https://www.agenas.gov.it/aree-tematiche/hta-health-technology-assessment/attivita-hta/report-hta
The Horizon scanning output is accessible at: https://www.agenas.gov.it/aree-tematiche/hta-health-technology-assessment/hs-horizon-scanning/report-hs

Since 2017 I am a member of the Italian MoH National Immunisation Technical Advisory Group (NITAG).

GENERAL PERSONAL & PROFESSIONAL BACKGROUND

I was born on 31 March 1954 in Viareggio (near Pisa), Italy. I was educated in Italy and went to UK in 1980 to do my hospital jobs prior to joining the Army. My professional career has spanned two specialties, General Practice (1980-1985) and Public Health (since 1986). I served in the British Army between 1981 and 1999.
My Army service took place in three continents and two conflicts (South Atlantic and Yugoslavia). I held the rank of Lieutenant Colonel. I am married with five children.

GENERAL PRACTICE CAREER

SHO Medicine, Arbroath Infirmary (1980 - 1981).
SHO Casualty, Croydon (1981).
Post Graduate Medical Officers' Course held Royal Military Academy, Sandhurst and the Royal Army Medical College, London (1981).
SHO O&G, British Military Hospital Hong Kong (1982).
Trainee GP and Regimental Medical Officer in several Gurkha units in Hong Kong and Nepal (1982 - 1984).
GP principal at Royal Military Academy Sandhurst, Armoured Regiment in Germany and Gurkha Battalion in UK and South Atlantic (1984 -1986).
Staff officer (various roles, 1987-1999)
Partner (part-time), North Lane Practice, Aldershot, Hampshire (1999-2001).

PUBLIC HEALTH CAREER

Registrar at the Department of Preventive Medicine at the Royal Army Medical College London (1987-1990).
Honorary Lecturer to the Department of Public Health at King's College Hospital, London (Professors Jim McEwen Norman Noah, 1989 - 1996).
Honorary Senior Lecturer to the Department of Public Health at King's College Hospital, London (1997 - current).
Detachment to the London School of Hygiene and Tropical Medicine on the Diploma in Tropical Medicine and Hygiene Course first and then on Master of Science in Community Medicine (1987- 1988).

Senior Registrar at the RAMC Training Centre near Aldershot (1988 - 1990). Student on the Higher Command and Staff Course at the Italian Army Staff College, Rome (1990 - 1991).
Second in Command of a Medical Battalion in Germany consisting of 250 personnel (1991 - 1992).

Assistant Force Medical Officer, United Nations Protection Force in Yugoslavia (UNPROFOR). I set up all medical facilities for the initial deployment in March 1992 and Director of Public Health for UNPROFOR. I was stationed in Sarajevo (Bosnia- Hercegovina), Belgrade (Serbia) and Zagreb (Croatia) for the duration of six months. Deputy Commander Medical (Preventive Medicine) British Army of the Rhine. I was responsible for all Preventive Medicine services for a population of 120.000 souls (1992-93).

Senior Technical Officer on the Health Services Market Test for British Forces Germany (1993-94). Responsible for developing the Statement of Requirement in preparation for the issuing of the Invitation To Tender and the developing of the purchasing function. Staff Officer, Ministry of Defence, Army Medical Directorate (1994-99). Responsible for health surveillance and health policy formulation for the British Army. My department carried out morbidity surveillance for the British Army and for the NATO SFOR mission in the Former Republic of Yugoslavia (FRY).

In February 1994 I was appointed Visiting Professor in Health Services Research at the University of Pavia, Northern Italy.

In June 1997 I was appointed Edmund Parkes Professor of Preventive Medicine at the Royal Defence Medical College. The chair is recognised by the Faculty of Public Health Medicine of the Royal College of Physicians of the United Kingdom. Additional responsibilities included the strategic management of the Army's 90-strong Environmental Health cadre. This lapsed when I left the Army.

Principal in family medicine, Aldershot, UK, 1999-2001.
British Medical Association HC Roscoe Fellow for the study of the prevention and treatment of the common cold (2000-2002).

Adviser the Lazio Region Public Health Agency (IT) and the Istituto Superiore di Sanità (on the development of evidence-based clinical guidelines) 2001-2005

PRIZES

1982 Army Syntex Award for research into obstetric performance in different ethnic groups (see publication 5).

1984 University of Surrey Research Prize for work on haematological indices of pregnant Gurkha women (see publication 6).

1990 Parkes Memorial Prize for work on the selection and training of Army recruits (see publications 17 e 22).

2009 BMJ prize for best use of BMJ archival material (publication 232)

Past grants:

MOD(UK) - systematic reviews of interventions to prevent influenza in healthy adults

Roche UK Ltd - cost of illness study of the burden of influenza.

BMA Roscoe Fellowship - systematic review of the effects of antivirals for the common cold.

UK HTA programme - systematic review of the effects of zanamavir.

EU - systematic review of safety of MMR vaccines.

EU - systematic review of the economics of pneumococcal vaccines.

WHO - systematic review of evidence of safety of Hepatitis B vaccines.

WHO - systematic review of evidence of safety of aluminium in DTP vaccines.

Glaxo SmithKline Ltd - systematic review of evidence of safety and effectiveness of DPT vaccines.

NHS R&D programme - systematic review of the effects of peer review. An update was commissioned in May 2004.

Regione Piemonte, Italy – systematic reviews of the effects of influenza vaccines in children and elderly and quality studies and their publication on high impact factor journals.

Netherlands Health Council (safety of Hepatitis B vaccine update review)

DH (UK)/NIHR Cochrane review update incentive scheme (several awards)

Lazio Public Health Agency – systematic review of the epidemiology of *S.Pneumoniae*

DH (UK) National coordinating Centre for Methodology

WHO - Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review .

UK NIHR – Developing, updating and rewriting the Cochrane review on Neuraminidase Inhibitors exclusively based on regulatory information.

Cochrane - Methods Innovation Fund (MIF) 2014-17 to develop a methodology for summing up evidence of effectiveness, efficiency and safety using regulatory information and data from different sources, both regulatory and open source.

Arnold Foundation – RIAT centre

RECREATIONAL ACTIVITIES

Weight training, skiing.

MEMBERSHIP OF OTHER ORGANISATIONS (past and present)

Health Economics Study Group (HESG)
International Association of Health Economists (listed in the world directory of Health Economists).
Cochrane Airways Collaborative Review Group
LOCKNET (JAMA/BMJ peer-review network).
World Association of Medical Editors (WAME)
Health Technology Assessment International (international society for HTA)

PUBLICATIONS & REPORTS

1. CAROLI G, JEFFERSON T O. Wedding Party with S.Haifa. Annali Sclavo. 1978; 20: 959-962.

2. CAROLI G, JEFFERSON T O. Finding of E.Coli Phage in Urinary Tract Infections. Annali Sclavo. 1980; 22: 857-860.

3. JEFFERSON T O. Personal View. BMJ. 1982; 284: 1328.

4. JEFFERSON T O, COHEN C. Familial Siringomyelia with Mental Impairment. J R Army Med Corps. 1982; 128: 41-42.

5. JEFFERSON T O, REIDY A J. Incidence of Instrumental Deliveries in Primigravidae of 3 Different Ethnic Groups. J R Army Med Corps. 1983; 129: 46-47.

6. REIDY A J, JEFFERSON T O, KENNEDY P M D. Some Haematological Data on Pregnant Gurkha Women. J R Army Med Corps. 1984; 130: 20-21.

7. JEFFERSON T O. Physical Fitness and Smoking Patterns in a Gurkha Battalion. J R. Army Med Corps. 1986; 132: 168-172.

8. JEFFERSON T O, RASOR P A. Non Simulated Casualty Workload in 2 Field Hospital During Exercise "Bold Gannett". Giornale di Medicina Militare. 1985; 135: 265-268.

9. JEFFERSON T O, TAYLOR V M. Perinatal mortality in infants of two different ethnic groups. Family Practice 1985; 2:175-176.

10. JEFFERSON T O. (Anonymous) Mea culpa. Update. 1985; 31: 932.

11. JEFFERSON T O. Patterns of smoking in 2 infantry battalions. British Army Review. 1986; 82: 84.

12. JEFFERSON T O. A Camera in general practice (Ota's Naevus). Update. 1987; 35: 237.

13. KENNEDY P M D, JEFFERSON T O, REIDY A J. Growth in Gurkha Infants. Family Practice. 1986; 3: 54.

14. JEFFERSON T O. Buon Natale (Letter to the Editor). J Royal Coll Gen Pract.1986: 291.

15. OLLIER W, FENSTENSTEIN, JEFFERSON T O. HLA Antigens in Nepalese. Proceedings of the 3rd Asian Oceania Histocompatibility Conference, Sapporo 1986.

16. JEFFERSON T O. The Prevention of AIDS: Some Principles for the Inception and Assessment of a Health Education Campaign. Rivista Italiana d`Igiene 1988; 48: 3-11.

17. JEFFERSON T O. An Investigation of Medical Discharges from the British Army 1979-1986. J R Army Med Corps. 1989; 135: 115-123.

18. JEFFERSON T O, BRAND H, LEVRE` E, CAROLI G. The Personal Prevention of Malaria. Rivista Italiana d`Igiene 1989; 430: 443-450.

19. JEFFERSON T O, CAROLI G, MOLINARI G, PEIRONE A P. Public Health and Community Medicine in England. Rivista Italiana d`Igiene 1989; 49: 226-238.

20. BASNET I, HADYAPANIOTOU C, JEFFERSON T O, MILLS A. Abortion Services in Wandsworth (MSc Field Service Attachment). London School of Hygiene & Tropical Medicine, 1988.

21. TAYLOR L E, JEFFERSON T O, CAROLI G . Water Supply Engineering and Public Health in the United Kingdom. Rivista Italiana d`Igiene 1990; 50: 81-93.

22. JEFFERSON T O. An Investigation into Regular Recruit Wastage from the British Army, 1988. J R Army Med Corps 1990; 136: 138-145.

23. TAYLOR L E, JEFFERSON T O, CAROLI G. The Water Supply of London. Rivista Italiana d`Igiene. 1990; 3-4: 169-177.

24. DEMICHELI V, JEFFERSON T O, AMPOLA M, CAROLI G, PEIRONE A P. Il Lay Belief System. Nota 1: Lo Studio del Comportamento Sanitario. Rivista Italiana d`Igiene 1990; 3-4: 134-150.

25. JEFFERSON T O, DEMICHELI V, CAROLI G. Nesso tra Casi di Leucemia Infantile e Centrale Nucleare di Sellafield (U K): un Puzzle Epidemiologico. Rivista Italiana d`Igiene 1990 3-4: 178-191.

26. DEMICHELI V, JEFFERSON T O. Le Conseguenze Economiche della Salmonellosi. Antibioticoterapia per la pratica. 1991; 2: 73-81.

27. JEFFERSON T O. First Aid Training. An Appraisal. The Soldier's Longest Journey. J R Army Med Corps. 1991; 137: 27-30.

28. JEFFERSON T O. Procedures for the collection and bottling of mineral waters - Guidelines for handlers. Rivista Italiana d`Igiene 1990; 5-6: 496-8.

29. BISOGNI L, JEFFERSON T O, DEMICHELI V, LOMOLINO G, PACELLI G. Studio della prevalenza delle infezioni ospedaliere in un ospedale generale di zona. Rivista Italian di Antibioticoterapia per la pratica 1991; 4: 159-63.

30. DEMICHELI V, LOMOLINO G, JEFFERSON T O. Audit nei servizi di Igiene Pubblica: l`opinione dei cittadini sugli interventi per incovenienti igienici. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 66. Editrice Periodici 1991.

31. DEMICHELI V, LOMOLINO G, JEFFERSON T O. La qualita` delle iniziative di formazione: l`aggiornamento del personale sul problema delle infezioni ospedaliere. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 81. Editrice Periodici 1991.

32. DEMICHELI V, LOMOLINO G, JEFFERSON T O. L`apporto della Economia Sanitaria alla qualita` delle decisioni. La determinazione del costo della sofferenza.Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 106. Editrice Periodici 1991.

33. DEMICHELI V, LOMOLINO G, JEFFERSON T O. Affermazioni di consenso e verifica della qualita`. Atti del IV Congresso Nazionale della Societa` Italiana di VRQ, Pavia 22-25 Settembre 1991, pagina 107. Editrice Periodici 1991.

34. DEMICHELI V, JEFFERSON T O. Cost-benefit analysis of the introduction of mass vaccination against Hepatitis B in Italy. Journal of Public Health Medicine 1992; 4: 367-375. (Paper presented to the third European Health Services Research Meeting - University College London, 13 - 14 December 1991).

35. DEMICHELI V, JEFFERSON T O. Manuale di Programmazione e organizzazione Sanitaria. Quaderni di Epidemiologia 17. La Goliardica Pavese, Pavia 1992.

36. DEMICHELI V, JEFFERSON T O. Criteri di valutazione del nesso causale e loro applicazione alla questione delle relazioni fra le radiazioni ionizzanti e la leucemia infantile. Tecnica Sanitaria 1993 (in press).

37. JEFFERSON T O, DEMICHELI V, LOMOLINO G. Problemi di Valutazione epidemiologica nelle piccole catastrofi ambientali. Il caso di Camelford in Cornovaglia. Tecnica Sanitaria 1993 (in press).

38. JEFFERSON T O. Public Health Aspects of the war in Yugoslavia. Public Health 1993; 107: 75-8.

39. JEFFERSON T O, DEMICHELI V, WRIGHT D A. An economic evaluation of the introduction of vaccination against Hepatitis A in a peace-keeping operation. The case of the United Nations Protection Force in Yugoslavia (UNPROFOR). International Journal of Technology Assessment in Health Care 1994; 10:490-97. Poster presented at the Fifth European Health Services Research Conference at Maastricht, (December 1993).

40. DEMICHELI V, LOMOLINO G, JEFFERSON T O. Audit of an environmental service in Italy. Proceedings of the Summer Conference of the Faculty of Public Health Medicine, 1992, Eastbourne, Sussex, Inghilterra.

41. JEFFERSON T O, DEMICHELI V. The costs of disease - a look at world literature. Presented at the "Meeting Internazionale sui costi delle malattie e della Salmonellosi", Pavia University (5-6 April 1993) (in press).

42. JEFFERSON T O, DEMICHELI V. Is vaccination against Hepatitis A and B cost-effective? A preliminary look at world literature. Presented at the "Meeting Internazionale sui costi delle malattie e della Salmonellosi", Pavia University (5-6 April 1993) (in press).

43. JEFFERSON T O, DEMICHELI V. Is vaccination against Hepatitis B efficient? A review of world literature. Health Economics 1994; 3:25-37. Paper presented at the Fifth European Health Services Research Conference at Maastricht, (December 1993).

44. JEFFERSON T O. Public Health and the war in Yugoslavia. In McKee M (ed): Health for all in a changing Europe. HFA 2000 News 1993; 25:4-5.

45. DEMICHELI V, JEFFERSON T O. Cost-benefit analysis of the introduction of mass vaccination against Hepatitis B in Italy (letter to the Editor). Journal of Public Health Medicine 1993; 14: 289-290.

46. JEFFERSON T O, MUGFORD M, GRAY A, DEMICHELI V.Puchasers and cost-effectiveness of interventions. Are secondary economic evaluations possible? Abstract presented at the Second Cochrane Colloqium, Hamilton, Ontario, October 1994.

47. JEFFERSON T O, BEHRENS R, DEMICHELI V. Should British soldiers be vaccinated against Hepatitis A? An economic analysis. Vaccine 1994; 12:1379-83.

48. JEFFERSON T O, PIERCE B, DEMICHELI V. Economic burden of an outbreak of a communicable disease of unknown aetiology in a military unit. Journal of Epidemiology and Community Health 1994; 48:423. (letter to the Editor).

49. AKEHURST R, GRAY A, BUXTON M, CHALMERS I, DONALDSON C, CHURNSIDE R, FENN P, FORBES J, GRIFFIN J, HOWARD S, JEFFERSON T, MC GUIRE A, MUGFORD M, O'BRIEN B, OXMAN A, TOWSE A. Assembling information in reviews of randomised controlled trials for subsequent cost-effectiveness analysis. Oxford: UK Cochrane Centre, Workshop Report, November 1993.

50. JEFFERSON T O, MACMILLAN A H M. Whither diplomatosis? Whither APHOM? J Royal Army Med Corps 1994 (letter to the editor).

51. JEFFERSON T O, MUGFORD M, DEMICHELI V. QALY league tables. Health Economics 1994; 3:205. (letter to the editor).

52. MUGFORD M, JEFFERSON T O, SOLL R. A Secondary Systematic Review to Assess whether and how results of randomised controlled trials of surfactant treatment for neonatal RDS can be used to inform questions of cost-effectiveness. Abstract presented at the Second Cochrane Colloqium, Hamilton, Ontario, October 1994.

53. MUGFORD M, McGUIRE A, JEFFERSON T O. Results of a survey of health economists on generalising from economic evaluations.

54. JEFFERSON T O, MUGFORD M, GRAY A, DEMICHELI V. An exercise on the feasibility of carrying out secondary economic analyses. Abstract presented at the Second Cochrane Colloqium, Hamilton, Ontario, October 1994.

55. JEFFERSON T O. Environmental problems for workers abroad. In: Berhens R H, Riley W (editors). Caring for expatriates and workers abroad. Health issues and ethical dilemmas. Proceedings of an international meeting organised by the British Postgraduate Medical Federation the Hospital for Tropical Diseases and the London School of Hygiene and Tropical Medicine. British Postgraduate Medical Federation, London 1994.

56. JEFFERSON T O, DEMICHELI V. A panel priority rating exercise for the British Forces Germany Health Services Market Test. J Royal Army Med Corps 1995; 141:29-34.

57. DEMICHELI V, CASADIO G P, LANCIOTTI G, NOVACO F, JEFFERSON T O. The Emilia costing study: valutazione dell'impatto economico della salmonellosi umana. Mecosan 1995; 11:8-15.

58. WILLIAMS C, COYLE D, GRAY A, HUTTON J, JEFFERSON T O, KARLSSON G, KESTELOOT K, UYL-DE-GROOT, WAIT S. European School of Oncology advisory report to the Commission of the European Communities for "Europe Against Cancer Programme" - cost-effectiveness in cancer care. European Journal of Cancer 1995; 31:1410-24.

59. JEFFERSON T O. Book Review - A Literature Review of the Cost-Effectiveness of Nuclear Medicine by Jan Carter. King's Fund Centre. London: 1995. BMJ 1995.

60. JEFFERSON T O. Book Review - The Measures of Medicine: Benefits, Harms and Costs by Richard K Riegelman. Blackwell Science. London: 1995. BMJ 1995.

61. JEFFERSON T O. The Army and the Cochrane Collaboration (editorial). J Royal Army Med Corps 1995; 141:57-58.

62. JEFFERSON T O. Book Review - Outcomes into Clinical Practice by T Delamothe (editor). BMJ Publishing Group. London: 1994. J Royal Army Med Corps 1995; 141:57-58.

63. JEFFERSON T O, DEMICHELI V. Studi economici sulle riviste mediche: e' tempo di pensare a linee guida. Mecosan 1995; 13: 8-12.

64. JEFFERSON T O, DEMICHELI V, ENTWISTLE V. Assessing quality of economic submissions to the BMJ. BMJ 1995; 311:393-94 (letter to the editor).

65. JEFFERSON T O, DEMICHELI V. Are guidelines for peer-reviewing economic evaluations necessary? A survey of current editorial practice. Health Economics 1995; 4:383-88.

66. SASSI F, DEMICHELI V, JEFFERSON T O. Systematic Review and synthesis of economic studies. Paper presented at the Scientific Basis of Health Services conference. London 2-4 October 1995.

67. JEFFERSON T O, DEMICHELI V, MACMILLAN A H M. Epidemiological needs assessment in the British Army. Poster presented at the Scientific Basis of Health Services conference. London 2-4 October 1995.

68. DEMICHELI V, JEFFERSON T O. Le salmonellosi e lo studio dei costi delle

malattie. In De Palma A, Novaco F, Orlandi L (editors). Le salmonellosi: epidemiologia, costo economico e strategie di intervento. Regione Emilia-Romagna, Assessorato alla Sanita', Bologna 1995; 6-12.

69. JEFFERSON T O, DEMICHELI V. The costs of disease - a look at world literature. In
De Palma A, Novaco F, Orlandi L (editors). Le salmonellosi: epidemiologia, costo economico e strategie di intervento. Regione Emilia-Romagna, Assessorato alla Sanita', Bologna 1995; pages 70-74.

70. DEMICHELI V, JEFFERSON T O. Presentazione dello studio sulla valutazione delle conseguenze economiche della salmonellosi umana in Emilia-Romagna. In De Palma A, Novaco F, Orlandi L (editors). Le salmonellosi: epidemiologia, costo economico e strategie di intervento. Regione Emilia-Romagna, Assessorato alla Sanita', Bologna 1995; 90-93.

71. SASSI F, DEMICHELI V, JEFFERSON T O. Pooling cost data from systematic reviews of economic studies. Poster presented at the Third Cochrane Colloquium, Oslo, Norway, 4-8 October 1995.

72. JEFFERSON T O. The quest for trials on the efficacy of human vaccines: results of the handsearch of the Vaccine journal. Poster presented at the Third Cochrane Colloquium, Oslo, Norway, 4-8 October 1995.

73. JEFFERSON T O. Book Review - Chalmers I, Altman DG. Systematic reviews BMJ Publishing Group. London: 1995. J Royal Army Med Corps 1995; 141:179

74. JEFFERSON T O, DEMICHELI V. Economic evaluation of Influenza vaccination and economic modelling. Can results be pooled? Pharmaeconomics 1996; 9 Suppl 3: 67-72.

75. JEFFERSON T O, DEMICHELI V, MACMILLAN A H M. Pilot study of the introduction of the J95 health data collection system. J Royal Army Med Corps 1996**;** **142**:25-29.

76. JEFFERSON T O, JEFFERSON V M. The quest for trials on the efficacy of human vaccines. Results of the handsearch of "*Vaccine*". Vaccine 1996; 14: 461-64.

77. DRUMMOND M F, JEFFERSON T O for the BMJ Working Party on guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal. Buxton M Demicheli V, Donaldson C, Jönsson B, Mugford M, Rennie D, Rovira J, Rutten F, Schulman K, Smith R, Tonks A, Torrance G, Towse A). Guidelines for authors and peer-reviewers of economic submissions to the British Medical Journal. BMJ 1996; 313:275-83 (3 August).

78. JEFFERSON T O, MUGFORD M, GRAY A, DEMICHELI V. An exercise on the

feasibility of carrying out secondary economic analyses. Health Economics 1996;5:155-165.

79. JEFFERSON T O, DEMICHELI V, MUGFORD M. Elementary Economic Evaluation in Health Care. London: BMJ Books 1996.

80. DEMICHELI V, JEFFERSON T O. Economic aspects of vaccination (Editorial). Vaccine 1996;

81. JEFFERSON T O. Economic evaluations as an aid to decisions on whether to carry out trials - Commentary. Lancet 1996; 348: 141 (20 July).

82. JEFFERSON TO, ROMANO G, DEMICHELI V. La valutazione dell'impatto economico di incidenti tossinfettivi alimentari: problemi metodologici e prospettive italiane. L'Igiene Moderna 1996; 105:993-1003.

83. DEMICHELI V, RIVETTI D, JEFFERSON TO. Economic aspects of a small epidemic of Hepatitis A in a religious community in Northern Italy. Journal of Infection 1996; 33:87-90

84. JEFFERSON TO (Book Review). Medical Informatics.....the essentials. By F T de Dombal. Butterworth Heinemann. Oxford: 1996. J Royal Med Corps 1997;143:64.

85. JEFFERSON T O. New and not so new vaccines- Editorial. BMJ 1996;313:768 (28 September 1996).

86. JEFFERSON TO, DEMICHELI V, PRATT M, DEEKS J, SASSI F, MACMILLAN A. The effectiveness of vaccines against Hepatitis B in healthcare workers. In Gluud C, J¢rgensen T, Morabito A, Pagliaro L, Poynard T, Sutton R (eds). Cochrane Database of Systematic Reviews; Issue 4. Update Software 2001.

87. DEMICHELI V, JEFFERSON TO, PRATT M, BEHRENS R, GRAVES P, BOTTASSO F, RIVETTI D, MACMILLAN A, MORRIS C. The effects of Anthrax vaccines. In Garner P, Gelband H, Oliaro P, Salinas R (eds). Cochrane Database of Systematic Reviews; Update Software 2001, Issue 4.

88. MILLER SAStJ, JEFFERSON TO. Military Health Surveillance. J Royal Med Corps 1997; 143:3 (editorial)

89. DEMICHELI V, JEFFERSON TO, PRATT M, BEHRENS R, GRAVES P, BOTTASSO F, RIVETTI D, MACMILLAN A, MORRIS C. The effects of Plague vaccines. In Garner P, Gelband H, Oliaro P, Salinas R (eds). Cochrane Database of Systematic Reviews; Issue 4. Update Software 2001.

90. DEMICHELI V, JEFFERSON TO, PRATT M, BEHRENS R, GRAVES P, BOTTASSO F, RIVETTI D, MACMILLAN A, MORRIS C. The effects of vaccines

against Tick-Borne Encephalitis (TBE). In Garner P, Gelband H, Oliaro P, Salinas R (eds). Cochrane Database of Systematic Reviews; Update Software 2000, issue 4.

91. JEFFERSON TO, DEMICHELI V, PRATT M. Evidence-based vaccinology. The work of the Cochrane Vaccines Field. Journal of Epidemiology and Community Health 1998;52:207-208.

92. JEFFERSON TO, SMITH R, DRUMMOND MF, KALE R, YI Y, PRATT M. Evaluating the BMJ guidelines on economic submissions: prospective audit of economic submissions to the *BMJ* and *Lancet*. Paper presented at the Third International Congress on Peer Review in Biomedical Publication, Prague 18-20 September 1997.

93. JEFFERSON TO, DEMICHELI V, HUTTON J. The use of systematic reviews for peer reviewing. Poster presented at the Third International Congress on Peer Review in Biomedical Publication, Prague 18-20 September 1997.

94. JEFFERSON TO, DEMICHELI V. A systematic review of world literature on the economics of influenza. Information and News on Influenza. European Scientific Working Group on Influenza. 1997; 7:6.

95. JEFFERSON TO Redundant publication in biomedical sciences. Scientific misconduct or necessity? Science and Engineering Ethics 1998; 4:135-40. (See Corrigenda in Science and Engineering Ethics 1998; 4:392).

96. RIVETTI D. DEMICHELI V, DEEKS J, JEFFERSON TO, PRATT M. The effectiveness and safety of vaccines against human anthrax: a systematic review. Vaccine 1998; 16:880-84.

97. GRAVES PM, DEMICHELI V, JEFFERSON TO, DEEKS JJ, PRATT M. The effects of cholera vaccines. In Garner P, Gelband H, Oliaro P, Salinas R (eds). Cochrane Database of Systematic Reviews; Update Software 2000, Issue 4.

98. JEFFERSON TO. Vaccine trial data systematically assembled, pooled and disseminated by the Cochrane Collaboration. Vaccine 1998; 16:1487-95.

99. JEFFERSON TO, DEMICHELI V. No evidence that vaccines cause insulin dependent diabetes mellitus. Journal of Epidemiology and Community Health 1998; 52: 674-675.

100. DEMICHELI V, JEFFERSON T O. An exploratory review of the economics of recombinant vaccines against Hepatitis B (HB). In: Ronchi E (Editor) Biotechnology and Medical innovation: Socio-economic assessment of the technology, the potential and the products. OECD, Paris 1997 pages 105-123.

101. HUTTON J, JEFFERSON TO. Assessing the potential cost-effectiveness of pneumococcal vaccines: methodological issues and current evidence. Abstract 1998.

102. WRIGHT LA, DEMICHELI V, GILLESPIE WJ, JEFFERSON TO. Morbidity surveillance in the British Army - the first 12 months. J R Army Med Corps 1998; 144:11-17.

103. JEFFERSON TO. An introduction to Health Economics. Epidemiology Supercourse on the Web (editor R LaPorte, University of Pittsburgh) 1998. http://www.pitt.edu/~super1/hec02/.

104. JEFFERSON TO, DRUMMOND MF, SMITH R, YI Y, PRATT M, KALE R. Evaluating the *BMJ* guidelines on economic submissions - Prospective audit of economic submissions to the *BMJ* and *Lancet*. JAMA 1998; 280:275-77.

105. JEFFERSON TO. Vaccines and their adverse effects - real or perceived (editorial). *BMJ* 1998; 317:159-60.

106.JEFFERSON TO. Economic evaluation alongside the UK collaborative ECMO trial (commentary). *BMJ* 1998; 317:915-6.

107. JEFFERSON TO, DEMICHELI V. The socioeconomics of influenza. In Nicholson, Hay and Webster (editors): Textbook of Influenza. London: Blackwell 1998 pages 541-47.

108. JEFFERSON TO, DEMICHELI V. Relation between experimental and non-experimental study designs.HB vaccines: a case study. Journal of Epidemiology and Community Health 1999; 53:51-54.

109. DEMICHELI V, RIVETTI D, DEEKS JJ, JEFFERSON TO. Vaccines for preventing influenza in healthy adults (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.

110. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Neuraminidase inhibitors for influenza. Cochrane Database of Systematic Reviews (Acute Respiratory Infections Module); Oxford: Update Software 2003, Issue 1.

111. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Amantadine & rimantadine for influenza. Cochrane Database of Systematic Reviews (Acute Respiratory Infections Module); Oxford: Update Software 2003, Issue 1.

112. JEFFERSON TO, DEMICHELI V. Methodological quality of economic modelling studies: a case study with hepatitis B vaccines. Pharmacoeconomics 1998; 14:251-7.

113. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Cochrane reviews and systematic reviews of economic evaluations: the case of amantadine and rimantadine in

the prevention and treatment of influenza. In: Snacken R, Szucs TD (editors). The socioeconomics of influenza and its control measures. Pharmacoeconomics 1999; 16: S85-S98.

114. JEFFERSON TO, DEMICHELI V. J95-EPINATO based planning parameters for medical support to operations other than war (OOTW). J R Army Med Corps 1998; 144:72-78.

115. HUTTON J, IGLESIAS C, JEFFERSON TO. Assessing the potential cost-effectiveness of pneumococcal vaccines: methodological issues and current evidence. Drugs and Aging 1999 15 Suppl 1:31-36.

116. JEFFERSON TO. What are the costs and benefits of editorials and non-systematic reviews? BMJ 1999; 318:135. (Personal View) (9 January).

117. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18:957-1030.

118. JEFFERSON TO, MEIER CR, WEGMÜLLER Y. The impact of influenza on adults. Poster presented at the 21st International Congress of Chemotherapy, Birmingham, UK, 4-7 July 1999. Journal of Antimicrobial Chemotherapy 1999 4(Suppl): 43. Abstract P10. (Winner of the 21st International Congress of Chemotherapy Young Investigators Award)

119. JEFFERSON TO, WEGMÜLLER Y, BARKER C, WARD P. Influenza in the workplace: effect of Oseltamivir on ability to perform usual activities and attendance at work. Poster presented at the 21st International Congress of Chemotherapy, Birmingham, UK, 4-7 July 1999. Journal of Antimicrobial Chemotherapy 1999 4(Suppl): 46. Abstract P23.

120. JEFFERSON TO, RABINOVICH R, TUOMILEHTO J. Vaccines and their real or perceived adverse effects – authors' conclusions are at odds with investigators'. BMJ 1999; 318:1487 (letter to the editor).

121. JEFFERSON TO. Should the topics of Cochrane Reviews be Prioritised? Abstract presented at the seventh Cochrane Colloquium, Rome 4-7 October 1999.

122. JEFFERSON TO, DEMICHELI V. Should we Review Single Interventions or All Comparators in a Decision-Making Context? Abstract presented at the seventh Cochrane Colloquium, Rome 4-7 October 1999.

123. JEFFERSON TO, MILAN S. How are the topics of Cochrane Reviews decided? Abstract presented at the seventh Cochrane Colloquium, Rome 4-7 October 1999.

124. JEFFERSON TO. Do vaccines make best use of available resources? (In other words are they cost-effective?). In: Furminger I (editor): 4th European Conference on Vaccinology: the societal value of vaccination. Vaccine 1999; 17:S69-73.

125. GODLEE F, JEFFERSON TO (Editors). Peer Review in Health Sciences. London: BMJ Books 1999.

126. JEFFERSON TO. Real or perceived adverse effects of vaccines and the media – a tale of our times (Editorial). Journal of Epidemiology and Community Health 2000; 54:402-3.

127. JEFFERSON TO. Economic and non-economic factors in evaluating prevention versus treatment. Abstract of talk given at the AAAS Annual Meeting and Science Innovation Symposium (Abstract A 51). Washington DC 17-22 February 2000.

128. JEFFERSON TO, DEEKS JJ. The use of systematic reviews for peer reviewing. In: GODLEE F, JEFFERSON TO (Editors). Peer Review in Health Sciences. London: BMJ Books 1999.

129. COLORECTAL CANCER COLLABORATIVE GROUP. Palliative chemotherapy for advanced colorectal cancer: systematic review and meta-analysis. BMJ 2000; 321:531-5.

130. JEFFERSON TO, DEMICHELI V, DEEKS JJ, RIVETTI D. Prevention and early treatment of influenza in healthy adults. Vaccine 2000; 18:957-1030.

131. JEFFERSON T O, DEMICHELI V, MUGFORD M. Elementary Economic Evaluation in Health Care. Second Edition. London: BMJ Books 2000.

132. HEIJBEL H, JEFFERSON TO. Vaccine Safety – Improving monitoring. Vaccine 2001; 19:2457-60.

132. JEFFERSON TO. Comment: Efficacy and safety of the oral neuraminidase inhibitor Oseltamivir in treating acute influenza. A randomised controlled trial. Evidence-based healthcare 2000; 4:94.

133. MEIER CR, NAPALKOV PN, WEGMUELLER Y, JEFFERSON T, JICK H. Population-based study on incidence, risk factors, clinical complications and drug utilisation associated with influenza in the United Kingdom. European Journal of Clinical Microbiology and Infectious Diseases 2000;19(11):834-842.

133. JEFFERSON TO, HEIJBEL H. Demyelinating disease and Hepatitis B vaccination - Is there a link? Drug Safety 2001; 24(4):249-54.

134. JEFFERSON TO. Monitoring the safety of vaccines: methodological challenges. Paper presented at the 8th Annual meeting of the European Society of Pharmacoviglilance. Verona, Italy 21-23 September 2000. Abstract number 45.

135. JEFFERSON TO, DEMICHELI V. The quality of methods of economic evaluations in healthcare: time for action (editorial). BMJ 2002; 324:313-4. (9 February).

136. WAGER E, JEFFERSON TO. Shortcomings of peer review in biomedical journals. Learned Publishing 2001; 14:257-63.

137. JEFFERSON TO, DEMICHELI V, VALE L. The quality of systematic reviews of economic evaluations in healthcare and what they are telling us: it is time for action. JAMA 2002; 287:2809-2812.

138. BURLS A, CLARK W, STEWART T, PRESTON C, BRYAN S, JEFFERSON T, FRY-SMITH A. Zanamivir for the treatment of influenza in adults. NHS HTA Programme, London: 2002; Vol 6: No 9.

139. JEFFERSON TO, TYRRELL D. Antivirals for the Common Cold (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.

140. JEFFERSON TO, ALDERSON P, DAVIDOFF F, WAGER E. Editorial peer review for improving the quality of reports of biomedical studies (Cochrane Methodology Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.

141. JEFFERSON TO, TYRRELL D. Vaccines for the Common Cold (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.

142. SPIER R, JEFFERSON TO, DEMICHELI V. An editorial policy statement. Submission of economic evaluations of vaccines. Vaccine 2002; 20:1693-1695.

143. JEFFERSON TO, ALDERSON P, DAVIDOFF F, WAGER E. Effects of editorial peer review: a systematic review. JAMA 2002; 287:2784-2786.

144. JEFFERSON TO, WAGER E, DAVIDOFF F. Measuring the quality of editorial peer review. JAMA 2002; 287:2786-2790.

145. WAGER E, GODLEE F, JEFFERSON TO. How to survive peer review. London, BMJ Books 2002.

146. JEFFERSON TO. Advances in the diagnosis and management of influenza. Current Infectious Diseases Reports 2002; 4: 206-10.

147 JEFFERSON TO, BIANCO E, DEMICHELI V. Influenza vaccines in adults. Occupational Medicine 2002; 52(5):255-58.

148. JEFFERSON TO, DEMICHELI V, VALE L. Methodological quality of economic evaluations of health care interventions – evidence from systematic reviews. In:

Donalson C, Mugford M, Vale L (editors). Evidence-based Health economics: from effectiveness to efficiency in health care. London BMJ Books 2002. Pages 67-88.

149. DEMICHELI V, JEFFERSON TO, VALE L. Effectiveness estimates in economic evaluation. In: Donalson C, Mugford M, Vale L (editors). Evidence-based Health economics: from effectiveness to efficiency in health care. London BMJ Books 2002. Pages 89-98.

150. JEFFERSON TO, BIANCO E. Quanto protetti? Aretre' Roche 2002; 35:24-5.

151. JEFFERSON T, RUDIN M. 1st International Symposium on the Evaluation of Safety of Human Vaccines. Expert Opin Drug Saf 2002; 1(2):195-98.

152. JEFFERSON TO, TRAVERSA G. Hepatitis B vaccination: risk-benefit profile and role of systematic reviews in the assessment of causality of adverse events following immunisation. Journal of Medical Virology 2002; 67;451-53.

153. JEFFERSON TO, DEMICHELI V. Polysaccharide Pneumococcal Vaccines. Editorial . BMJ 2002 (in press).

154. JEFFERSON T, DEMICHELI V, VALE L. Educating authors and reviewers of economic evaluations of health care. JAMA 2002 Aug 28;288(8):959 (Letter to the Editor).

155. JEFFERSON TO, PRICE D, DEMICHELI V. Unintended Events following immunisation with MMR: a systematic review. Phamacoepidemiology and Drug Safety 2002; 11:S286 (abstract).

156. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. systematic review of the effects of DTP vaccines in children with or without inactivated polio vaccine (IPV). Phamacoepidemiology and Drug Safety 2002; 11:S285 (abstract).

157. MELE A, JEFFERSON T, FRANCO E, SALMASO S. Change from oral poliovirus vaccine to inactivated poliovirus vaccine. The Lancet 2002; 360:1178 (12 October).

156. BONHOEFFER J, KOHL K, CHEN R, DUCLOS P, HEIJBEL H, HEININGER U, JEFFERSON T, LOUPI E and The Brighton Collaboration. The Brighton Collaboration: addressing the need for standardized case definitions of adverse events following immunization (AEFI). Vaccine 2002; 21:298-302.

157. JEFFERSON TO, SHASHOK K. Journals: how to decide what's worth publishing. Nature 2003; 421:209-10.

158. DEMICHELI V, RIVETTI A, DI PIETRANTONJ C, CLEMENTS CJ, JEFFERSON T. Hepatitis B vaccination and multiple sclerosis - Evidence from a systematic review. Journal of Viral Hepatitis 2003; 5:343-4.

159. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. Systematic review of the effects of pertussis vaccines in children. Vaccine 2003 2003; 21(17-18):2012-2023.

160. JEFFERSON TO, DEMICHELI V. Economic Analysis on infleunza vaccination and treatment. Annals of Internal Medicine 2003; 138(7):607 (letter to the Editor).

161. MELE A, JEFFERSON TO. The use of Hepatitis A vaccine in Italy - evidence-based recommendations from an expert panel. Vaccine 2003; 21:2223 (editorial).

162. JEFFERSON TO, DEMICHELI V. Observational data on harm are already included in systematic reviews. BMJ 2003; 327:750.

163. JEFFERSON TO, PRICE D, DEMICHELI V, BIANCO E. Unintended Events following immunisation with MMR: a systematic review. Vaccine 2003; 21(25-26):3954-60.

164. JEFFERSON TO, SHASHOK K, WAGER E. Get Peered! BMJ 2003. (Christmas issue).

165. GODLEE F, JEFFERSON TO (Editors). Peer Review in Health Sciences. Second edition. London: BMJ Books 2003.

166. MATERIA E, BAGLIO G, CANONACO,D, JEFFERSON T, MELE A, MARCHISIO P, DI DOMENICANTONIO R, GUASTICCHI G. Promoting clinical and organizational appropriateness of tonsillectomy in Italy. European J Public Health 2003; 13: 86 (Supplement. Abstracts of the 11th Annual EUPHA Meeting Globalisation and health in Europe: harmonising public health practices, Roma 20-22 November 2003.)

167. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. Adverse events following immunization with aluminium-containing DTP vaccines - systematic review of the evidence. Lancet Infect Dis 2004; 4: 84–90.

168. JEFFERSON T. Informed choice and balance are victims of the MMR-autism saga. *Lancet Infect Dis* 2004; 4**:** 135-36.

169. JEFFERSON T, PRICE D, DEMICHELI V, BIANCO E. Selective quotation of evidence in vaccines research. Lancet 2004; 363: 1738 (letter to the Editor).

170. JEFFERSON TO. The role of editorial peer review in the evaluation of vaccine safety. Vaccine 2004; 22: 2073-75.

171. JEFFERSON TO, Demicheli V. The first international symposium on vaccine safety. Vaccine 2004:22: 2042-43.

172. PERRIA C. For the IMPLEMEG Study Group (Pierluigi Bartoletti, Paolo Billi, Virgilio Calzini, Maurizio D'Amato, Alfonso Fiorillo, Gabriella Guasticchi, Carmelina Guerriera,

Giuseppe Grasso, Tom Jefferson, Sergio Leotta, Donatella Mandolini, Walter Marrocco, Mazzieri Scheggi, Amina Pasquarella, Carla Perria, Concetta Suraci). **Strategies for the introduction and implementation of a guideline for the treatment of type 2 diabetics by general practitioners (GPs) of the Lazio region of Italy (IMPLEMEG study): Protocol for a cluster randomised controlled trial [ISRCTN80116232]**. BMC Health Services Research 2004, 4:13 (14 Jun 2004)
http://www.biomedcentral.com/1472-6963/4/13

173. JEFFERSON TO, RUDIN M, DIPIETRANTONJ C. Reply to the letter to the Editor Vaccine 2004; 22(21-22):2685.

174. JEFFERSON TO. Bioterrorism and compulsory vaccination. Better vaccines are needed if vaccination is to be made compulsory. (Editorial). BMJ 2004; 329: 524-25. (4 September)

174. JEFFERSON TO. What are we to do about influenza? (Editorial). BMJ 2004; 329: 633-4.

175. SMITH S, DEMICHELI V, JEFFERSON T, HARNDEN A, MATHESON N, DI PIETRANTONJ C. Vaccines for preventing influenza in healthy children (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.

176. RIVETTI D, DEMICHELI V, DI PIETRANTONJ C, JEFFERSON TO, THOMAS R. Vaccines for preventing influenza in the elderly (Protocol for a Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd.

177. JEFFERSON TO. How to deal with influenza: Author's reply. BMJ 2004;329:1238, doi:10.1136/bmj.329.7476.1238-b

178. BIANCO E, DE MASI S, MELE A, JEFFERSON T. Effectiveness of imune globulina in preventing infectious hepatitis and hepatitis A: a systematic review. Digestive and Liver Disease 2004; 36: 834-42

179. JEFFERSON TO, Demicheli V, Price D. Informed choice, balance and the MMR-autism saga (authors' reply). The Lancet Infectious Diseases 2005; 5(1):3-4..

180. JEFFERSON TO. Glossary of peer review. Journal of Epidemiology and Community Health 2004; 58:272.

181. JEFFERSON T, SMITH S, DEMICHELI V, HARNDEN A, RIVETTI A, DI PIETRANTONJ C. Assessment of the efficacy and effectiveness of influenza vaccines in healthy children: systematic review. Lancet 2005; 365:773-80 (26th of February).

182. JEFFERSON T. L'applicazione della medicina basata sulle prove alla tomoscintigrafia a emissione di positroni (PET). Decidere in Medicina 2005; 2:34-40.

183. JEFFERSON T, SMITH S, DEMICHELI V, HARNDEN A, RIVETTI A. Influenza vaccines in healthy children – authors' reply. The Lancet 2005; 385:2087.

184. JEFFERSON T. Peer review and publishing: it's time to move the agenda on. The Lancet 2005; 366:283-284. DOI:10.1016/S0140-6736(05)66968-1.

185. JEFFERSON T. Microbial challenge studies of volunteers—a challenge worth accepting. Lancet 2005 (in press) commentary.

186. JEFFERSON T, SMITH S, DEMICHELI V, HARNDEN A, RIVETTI A. Safety of influenza vaccines in children. Lancet 2005; 366:803-04.

187. JEFFERSON T, RIVETTI D, RIVETTI A, RUDIN M, DI PIETRANTONJ C, DEMICHELI V. Efficacy and effectiveness of influenza vaccines in the elderly: systematic review. Lancet 2005 ; 366:1165 -1174.

188. JEFFERSON T. Attenti alle bufale. Roma: Pensiero Scientifico Editore 2005.

189. Jefferson T, Demicheli V, Rivetti D, Jones M, Di Pietrantonj C, Rivetti A. Antivirals for influenza in healthy adults: systematic review. The Lancet 2006; 367: 303-13. Published Online January 19 2006; DOI: 10.1016/S0140-6736(06) 67970-1.

190. THOMAS RE, JEFFERSON TO, DEMICHELI V, RIVETTI D. Influenza vaccination for health care workers who work with the elderly: A systematic review. The Lancet Infectious Diseases 2006; 6:273-79.

191. JEFFERSON T. Alternative models of quality control for scientific research. Nature 2006 (http://www.nature.com/nature/peerreview/debate/index.html).

192. JEFFERSON T. Attenti alle bufale. Roma, Pensiero Scientifico Editore 2005

193. JEFFERSON T, FERRONI E, CURTALE F, GIORGI ROSSI P, BORGIA P. *S. pneumoniae* in Western Europe: serotype distribution and incidence in children less than 2 years old. The Lancet Infectious Diseases 2006; 6:405-10.

194. JEFFERSON T, FRATI D, GRASSO E. Aviaria: influenza dei polli? Roma: Pensiero Scientifico Editore 2006

195. JEFFERSON T, RUDIN M, BRODNEY FOLSE S, DAVIDOFF F. Editorial peer review for improving the quality of reports of biomedical studies. *The Cochrane Database of Methodology Reviews* 2006, Issue 1. Art. No.: MR000016.pub2. DOI: 10.1002/14651858.MR000016.pub2.

196. JEFFERSON T. The prevention of seasonal influenza – policy versus evidence. BMJ 2006; 333:912-15.

197. JEFFERSON T. Influenza. Clinical Evidence 2006.

196. D RIVETTI, T JEFFERSON, R THOMAS, M RUDIN, A RIVETTI, C DI PIETRANTONJ, V DEMICHELI. Vaccines for preventing influenza in the elderly. Cochrane Database of *Systematic Reviews* 2006, Issue 3. Art. No.: CD004876. DOI: 10.1002/14651858.CD004876.pub2.

197. Jefferson T. Look at all the evidence before stockpiling Amantadine. BMJ 2007; 334:439 (letter to the editor).

198. TO Jefferson, D Rivetti, C Di Pietrantonj, A Rivetti, V Demicheli. Vaccines for preventing influenza in healthy adults. *Cochrane Database of Systematic Reviews* 2007, Issue 2. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub3.

199. TOM JEFFERSON, LUCIA ZARRA, AND LIVIU STOICA. Attenti Alle Bufale ('Beware of Red Herrings'), or, How to Make Evidence-Based Medicine Work for You J. R. Soc. Med. 2006 99: 625-627.

200. TOM JEFFERSON AND LUCIA ZARRA. Bufala spotting, part one: assessing research paper**s** J. R. Soc. Med. 2007 100: 38-39.

201. TOM JEFFERSON AND LUCIA ZARRA. Bufale spotting, part two: assessing systematic reviews J. R. Soc. Med. 2007 100: 180-181.

202. TOM JEFFERSON AND LUCIA ZARRA. Bufale spotting, part three: assessing editorials. J. R. Soc. Med. 2007; 100(6): p. 267

203. CARLA PERRIA, DONATELLA MANDOLINI, CARMELINA GUERRERA, THOMAS JEFFERSON, PAOLO BILLI, VIRGILIO CALZINI, ALFONSO FIORILLO, GIUSEPPE GRASSO, SERGIO LEOTTA, WALTER MARROCCO, CONCETTA SURACI AND AMINA PASQUARELLA. Implementing a guideline for the treatment of type 2 diabetics: results of a Cluster- Randomized Controlled Trial (C-RCT) **[ISRCTN80116232]**. BMC Health Services Research 2007, 7:79 (04 Jun 2007). http://www.biomedcentral.com/1472-6963/7/79

204. TOM JEFFERSON AND LUCIA ZARRA. Bufale Spotting, part 5: Assessing a website. J. R. Soc. Med. 2007; 100(8): p. 367 http://www.jrsm.org/cgi/content/full/100/8/367?ct=ct

205. TO JEFFERSON, D RIVETTI, C DI PIETRANTONJ. Inactivated influenza vaccines in the elderly—are you sure? (Comment). The Lancet (Published Ondine Septmber 25, 2007, DOI:10.1016/S0140-6736(07)61389-0).

206. TOM JEFFERSON, RUTH FOXLEE, CHRIS DEL MAR, LIZ DOOLEY, ELIANA FERRONI, BILL HEWAK, ADI PRABHALA, SREE NAIR, AND ALEX RIVETTI.

Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. BMJ. 2008; 336(7635): p. 77-80

207. TOM JEFFERSON AND LUCIA ZARRA. Bufale Spotting, part 7: Assessing an advert. J. R. Soc. Med. 2007; 100(11): p. 502

208. T JEFFERSON. Cattive Acque. Il Pensiero Scientifico Editore. 2007

209. TOM JEFFERSON AND LUCIA ZARRA. Bufale Spotting, part 9: assessing an economic evaluation. J R Soc Med. 2008; 101(4): p. 175-176.

210. T JEFFERSON, A RIVETTI, A HARNDEN, C DI PIETRANTONJ, AND V DEMICHELI. Vaccines for preventing influenza in healthy children. Cochrane Database Syst Rev 1 Jan 2008: p. CD004879

211. C CATES, T JEFFERSON, AND B ROWE. Vaccines for preventing influenza in people with asthma. Cochrane Database Syst Rev 1 Jan 2008: p. CD000364. http://highwire.stanford.edu/cgi/medline/pmid;18425863

212. TOM JEFFERSON. More cases, doctor? Yes please! Cases J 16 Jul 2008 1(1): p. 38. http://highwire.stanford.edu/cgi/medline/pmid;18631383

213. TOM JEFFERSON. Darkness falls. BMJ. 2008; 337(nov12_1): p. a2501

214. FABIO BERNARDINI, MARINA CERBO, TOM JEFFERSON, ALESSANDRA LO SCALZO, MARCO RATTI - Wireless Capsule Endoscopy in the diagnosis of small bowel disease. Age.na.s. HTA Report. Rome, September 2008. *http://www.ministerosalute.it/dispositivi/paginainternasf.jsp?id=1202&menu=hta*

215. ANTONELLA CAVALLO, MARINA CERBO, DARIO FELLA, TOM JEFFERSON, ANTONIO MIGLIORE, MARIA ROSARIA PERRINI. - Prostheses for primary total hip replacement in Italy. Age.na.s. HTA Report, Rome, September 2008. *http://www.ministerosalute.it/dispositivi/paginainternasf.jsp?id=1202&menu=hta*

216. ANNA MARIA VINCENZA AMICOSANTE, MARINA CERBO, TOM JEFFERSON, SIMONA PAONE, LAURA VELARDI. Rapid (bed-side) tests for influenza. Age.na.s. HTA Report - Rome, September 2008.

217. T JEFFERSON, C DI PIETRANTONJ, M G DEBALINI, A RIVETTI, AND V DEMICHELI. Inactivated influenza vaccines: Methods, policies, and politics. J Clin Epidemiol 2008; 1-10. http://highwire.stanford.edu/cgi/medline/pmid;19124222 doi: 10.1016/j.jclinepi.2008.07.001.

218. T JEFFERSON, C DI PIETRANTONJ, MG DEBALINI, A RIVETTI, V DEMICHELI. Study quality, concordance, take home message, funding and impact. Their relationship in influenza vaccines studies. BMJ 2009 338(feb12_2): p. b354

http://www.bmj.com/cgi/content/abstract/338/feb12_2/b354?ct=ct.

221. T JEFFERSON. Ranking antidepressants. Lancet 23 May 2009 373(9677): p. 1759;

219. JEFFERSON T. Influenza. BMJ Clinical Evidence 2009.

223 A LO SCALZO, M RATTI, T JEFFERSON, F BERNARDINI, AND M CERBO. Wireless capsule for endoscopy in Italy: adding context-specific data to the review of the evidence from literature. Int J Technol Assess Health Care 1 Jul 2009 25(3): p. 297. http://highwire.stanford.edu/cgi/medline/pmid;19619348

224 JEFFERSON T. Pneumococcal vaccines: confronting the confounders. The Lancet 2009; 373: 2008-09.

225 TOM JEFFERSON. A brief history of shroud waving through the centuries. BMJ. 2009; 338(jun30_3): p. b2610
http://www.bmj.com/cgi/content/extract/338/jun30_3/b2610?ct=ct

226. JEFFERSON T, DEL MAR C, DOOLEY L, FERRONI E, AL-ANSARY LA, BAWAZEER GA, VAN DRIEL ML, FOXLEE R, RIVETTI A. Physical interventions to interrupt or reduce the spread of respiratory viruses: systematic review. BMJ. 2009 Sep 21;339:b3675. doi: 10.1136/bmj.b3675. Review.

227. HERXHEIMER A, CLARKE M, EDWARDS R, JEFFERSON T, LOKE Y. A/H1N1 flu. Time for case-control studies of NSAIDs and oseltamivir. BMJ. 2009 Jul 28;339:b3048. doi: 10.1136/bmj.b3048. No abstract available.

228. MIGLIORE A, RATTI M, CERBO M, JEFFERSON T. Health Technology Assessment: managing the introduction and use of medical devices in clinical practice in Italy. Expert Rev Med Devices. 2009 May;6(3):251-7. Review. PMID: 19419283 [PubMed - indexed for MEDLINE]

229. T JEFFERSON, M JONES, P DOSHI, AND C DEL MAR. Possible harms of oseltamivir--a call for urgent action. Lancet 17 Oct 2009 374(9698): p. 1312.

230. JEFFERSON, T. Guest Editorial: Mistaken identity: seasonal influenza versus influenza-like illness. Clinical Evidence 5 October, 2009.

231. TOM JEFFERSON, MARK JONES, PETER DOSHI, AND CHRIS DEL MAR. Neuraminidase inhibitors for preventing and treating influenza in healthy adults: systematic review and meta-analysis. BMJ. 2009; 339(dec07_2): p. b5106. http://www.bmj.com/cgi/content/abstract/339/dec07_2/b5106?ct=ct

232. TOM JEFFERSON AND ELIANA FERRONI. The Spanish influenza pandemic seen through the BMJ's eyes: observations and unanswered questions. BMJ. 2009; 339(dec16_3): p. b5313
http://www.bmj.com/cgi/content/extract/339/dec16_3/b5313?ct=ct

233. A MIGLIORE, MR PERRINI, E ROMANINI, D FELLA, A CAVALLO, M CERBO, AND T JEFFERSON. Comparison of the performance of hip implants with data from different arthroplasty registers. J Bone Joint Surg Br 1 Dec 2009 91(12): p. 1545.
http://highwire.stanford.edu/cgi/medline/pmid;19949114

234. TOM JEFFERSON. Neuraminidase inhibitors produce a small reduction in duration of seasonal influenza in children and reduce transmission in affected households, but effects on serious complications unclear. Evid. Based Med. 2010; 15(1): p. 20-21
http://ebm.bmj.com/cgi/content/extract/15/1/20?ct=ct

235. FERRONI E, JEFFERSON T (2011). Angelo Celli and research on the prevention of malaria at the turn of the 20th century. JLL Bulletin: Commentaries on the history of treatment evaluation (www.jameslindlibrary.org)

236 THOMAS RE, JEFFERSON T, LASSERSON TJ. Influenza vaccination for health care workers who work with the elderly: a Cochrane review. *Health Technology Assessment*, *H1N1 and pandemic flu A special themed issue of HTA*, 2010;14(55):493-588.

237. MIGLIORE A, CORIO M, PAONE S, CERBO M AND JEFFERSON T. Accommodating intraocular lenses for patients with cataract: A review. Expert Review of Ophthalmology 2011 6:4 (431-436).

238. Cochrane Neuraminidase Inhibitors Review Team. Does Oseltamivir Really Reduce Complications of Influenza? Clinical Infectious Diseases. 2011 Dec 15;53(12):1302–3.

239. JEFFERSON T. Should journals sell reprints? BMJ 2011;343:d6448 doi: 10.1136/bmj.d6448

240. JEFFERSON T, JONES MA, DOSHI P, DEL MAR CB, HENEGHAN CJ, HAMA R, THOMPSON MJ. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. *Cochrane Database of Systematic Reviews* 2012, Issue 1. Art. No.: CD008965. DOI: 10.1002/14651858.CD008965.pub3.

241. DOSHI P, JONES MA, JEFFERSON T. Rethinking credible evidence synthesis. *BMJ* 2012; 344:d7898 doi: 10.1136/bmj.d7898

242. Drug Data Shouldn't Be Secret. By PETER DOSHI AND TOM JEFFERSON. The New York Times, April 10, 2012
URL: http://www.nytimes.com/2012/04/11/opinion/drug-data-shouldnt-be-secret.html

Shortened URL: http://nyti.ms/Ivgh9c

243. DOSHI P, JEFFERSON T, DEL MAR C (2012) The Imperative to Share Clinical Study Reports: Recommendations from the Tamiflu Experience. PLoS Med 9(4): e1001201. doi:10.1371/journal.pmed.1001201
Short URL: http://bit.ly/HIbwqO PDF for printing: http://bit.ly/HFBYTV

244. JONES M, HAMA R, JEFFERSON T, DOSHI P. Neuropsychiatric Adverse Events and Oseltamivir for Prophylaxis Drug Saf 2012; 35 (12): 1187-1190.

245. DOSHI P, JEFFERSON T. The first 2 years of the European Medicines Agency's policy on access to documents: Secret no Longer. Arch Intern Med. Published online December 19, 2012. doi:
http://dx.doi.org/10.1001/jamainternmed.2013.3838
http://archinte.jamanetwork.com/article.aspx?articleid=1486542

246. DOSHI P, JEFFERSON T. Clinical study reports of randomised controlled trials: an exploratory review of previously confidential industry reports. BMJ Open. 2013 Feb 26;3(2):e002496.
http://bmjopen.bmj.com/content/3/2/e002496.full and
http://dx.doi.org/10.1136/bmjopen-2012-002496

247. DOSHI P, DICKERSIN K, HEALY D, VEDULA SS, JEFFERSON T. Restoring invisible and abandoned trials: a call for people to publish the findings *BMJ* 2013; 346 doi: http://dx.doi.org/10.1136/bmj.f2865 (Published 13 June 2013).

248. CHAN A-W, SONG F, VICKERS A, JEFFERSON T, DICKERSIN K, GØTZSCHE PC et al. Increasing value and reducing waste: addressing inaccessible research. The Lancet, Volume 383, Issue 9913, Pages 257 - 266, 18 January 2014. doi:10.1016/S0140-6736(13)62296-5.
http://www.thelancet.com/journals/lancet/article/PIIS0140-6736%2813%2962296-5/fulltext.

249. JEFFERSON T, JONES MA, DOSHI P, DEL MAR CB, HAMA R, THOMPSON MJ, et al. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Cochrane Database of Systematic Reviews 2014, Issue 4. Art. No.: CD008965 DOI: 10.1002/14651858.CD008965.pub4

250. HENEGHAN CJ, ONAKPOYA I, THOMPSON M, SPENCER EA, JONES M, JEFFERSON T. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. BMJ 2014; 348. DO 10.1136/bmj.g2547. UL http://www.bmj.com/content/348/bmj.g2547

251. JEFFERSON T, DOSHI P. Multisystem failure: the story of anti-influenza drugs. BMJ 2014;348. DOi 10.1136/bmj.g2263
UL http://www.bmj.com/content/348/bmj.g2263

252. JEFFERSON T, DOSHI P. EMA's double U-turn on its Peeping Tom policy for data release. BMJ Blog 2014.

253. JEFFERSON T, DOSHI P, LEMMENS T. EMA's data sharing policy—towards peeping tom based medicine? BMJ Blog 2014. http://blogs.bmj.com/bmj/2014/05/22/tom-jefferson-et-al-emas-data-sharing-policy-towards-peeping-tom-based-medicine/

254. JEFFERSON T, JONES MA, DOSHI P, DEL MAR CB, HAMA R, THOMPSON MJ, ONAKPOYA I, HENEGHAN CJ. Risk of bias in industry-funded oseltamivir trials: comparison of core reports versus full clinical study reports. BMJ Open 2014;4:e005253-e005253 http://bmjopen.bmj.com/cgi/content/full/bmjopen-2014-005253?ijkey=AHfmbBvUum2MicR&keytype=ref

255. Jefferson T. EMA's release of regulatory data—trust but verify BMJ Blogs

256. JEFFERSON T**.** EMA's Release of Regulatory Data: Possible Fall out for Journals and Research Synthesis.

257. TOM JEFFERSON AND PETER DOSHI: Thanksgiving special—menus needed at the EMA's restaurant

258. PETER DOSHI and TOM JEFFERSON. The Evidence Base for New Drugs (editorial). Published: 2 March 2015; BMJ 2015;350:h952. http://www.bmj.com/content/350/bmj.h952

259. TOM JEFFERSON. The EMA revolution gathers pace http://blogs.bmj.com/bmj/2015/06/30/tom-jefferson-the-ema-revolution-gathers-pace/

260. Are we ready for the EMA revolution? http://blogs.bmj.com/bmj/2015/06/30/tom-jefferson-are-we-ready-for-the-ema-revolution/

261. EMA confidential—the EMA continues consultation on its 0070 policy and concerns appear http://blogs.bmj.com/bmj/2015/07/09/tom-jefferson-ema-confidential/

262. KHALED EL EMAM**,** TOM JEFFERSON**,** PETER DOSHI http://blogs.bmj.com/bmj/2015/08/27/maximizing-the-value-of-clinical-study-reports/

263. KHALED EL EMAM**,** TOM JEFFERSON**,** PETER DOSHI. The release of regulatory documents under EMA policy 0070: Now you see them, now you don't.

264. DOSHI P, JEFFERSON T. Open data 5 years on: a case series of 12 freedom of information requests for regulatory data to the European Medicines Agency. Trials (2016) 17:78 DOI 10.1186/s13063-016-1194-7. http://trialsjournal.biomedcentral.com/articles/10.1186/s13063-016-1194-7

265. PETER DOSHI & TOM JEFFERSON. Access to clinical trial data from the European Medicines Agency.

266. JEFFERSON T, DEMICHELI V. Is the timing of recommended childhood vaccines evidence based? BMJ 2016; 352 doi: http://dx.doi.org/10.1136/bmj.i867 (Published 23 February 2016) Cite this as: BMJ 2016;352:i867. http://www.bmj.com/content/352/bmj.i867

267. CARL J HENEGHAN, IGHO ONAKPOYA, MARK A JONES, PETER DOSHI, CHRIS B DEL MAR, ROKURO HAMA, MATTHEW J THOMPSON, ELIZABETH A SPENCER, KAMAL R MAHTANI, DAVID NUNAN, JEREMY HOWICK, TOM JEFFERSON. Neuraminidase inhibitors for influenza: a systematic review and meta-analysis of regulatory and mortality data. Health Technology Assessment . 2016 (in press) http://www.journalslibrary.nihr.ac.uk/hta

268. JEFFERSON T. Facing the unreliability of clinical trials literature. Drug and Therapeutics Bulletin of Navarre, Spain. 2015;23(2). http://www.navarra.es/home_en/Temas/Portal+de+la+Salud/Profesionales/Documentacion+y+publicaciones/Publicaciones+tematicas/Medicamento/BIT/

269. DAVIS C, LEXCHIN J, JEFFERSON T, GØTZSCHE P, MCKEE M. “Adaptive pathways” to drug authorisation: adapting to industry? BMJ 2016;354:i4437 doi: 10.1136/bmj.i4437 (Published 16 August 2016). Download free here

270. Tom Jefferson: The EMA’s policy 0070 is live BMJ blogs

271. DOSHI P, HUR P, JONES M, ALBARMAWI H, JEFFERSON T, MORGAN DJ, SPEARS PA, POWERS JH. Informed consent to study purpose in randomized controlled trials of antibiotics, 1991-2011. JAMA Intern Med. Published online August 21, 2017. doi:10.1001/jamainternmed.2017.3820

272. TOM JEFFERSON. Sticking to principles and anticipating outcomes. Recenti Prog Med 2017; 108: 347-49. https://goo.gl/64jFkp

273 TOM JEFFERSON. The UK turns to Witty, Vallance, and Van Tam for leadership: revolving doors? BMJ blogs.

274. MAHTANI KR, JEFFERSON T, HENEGHAN C. What makes a systematic review “complex”? BMJ blogs.

275. DOSHI P, JEFFERSON T. Disclose Data Publicly, without Restriction. In Davis L, Miller JD, Sharfstein JM, Kesselheim AS. Blueprint for transparency at the US Food and Drug Administration. Winter 2017. Pages 42-45. DOI: 10.1177/1073110517750611.

276. JØRGENSEN L, GØTZSCHE PC, JEFFERSON T. Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. Systematic Reviews 2018 **7**:8. https://doi.org/10.1186/s13643-018-0675-z.

277. DEMICHELI V, JEFFERSON T, FERRONI E, RIVETTI A, DI PIETRANTONJ C. Vaccines for preventing influenza in healthy adults. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD001269. DOI: 10.1002/14651858.CD001269.pub6.

278. JEFFERSON T, RIVETTI A, DI PIETRANTONJ C, DEMICHELI V. Vaccines for preventing influenza in healthy children. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD004879. DOI: 10.1002/14651858.CD004879.pub5.

279. DEMICHELI V, JEFFERSON T, DI PIETRANTONJ C, FERRONI E, THORNING S, THOMAS RE, RIVETTI A. Vaccines for preventing influenza in the elderly. Cochrane Database of Systematic Reviews 2018, Issue 2. Art. No.: CD004876. DOI: 10.1002/14651858.CD004876.pub4.

280. JEFFERSON T, RIVETTI A DEMICHELI V. Why have three long-running Cochrane Reviews on influenza vaccines been stabilised? http://community.cochrane.org/news/why-have-three-long-running-cochrane-reviews-influenza-vaccines-been-stabilised

281. Tom Jefferson and Peter Doshi: RIP PubMed commons
BMJ Blogs

282. Jefferson T, Jørgensen L. Redefening the “E” in EBM. BMJ Evidence Based Medicine. 10.1136/bmjebm-2018-110918.

283. Mahtani K, Jefferson T, Heneghan C, Nunan D, Aaronson J. What is a ’complex systematic review'? Criteria, definition, and examples. 10.1136/bmjebm-2018-110965 http://dx.doi.org/10.1136/bmjebm-2018-110965.

284. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias. BMJ Evidence Based Medicine. Published Online First: 27 July 2018. doi: 10.1136/bmjebm-2018-111012.

285. Jefferson T, Jørgensen L. Human papillomavirus vaccines, complex regional pain syndrome, postural orthostatic tachycardia syndrome, and autonomic dysfunction - a review of the regulatory evidence from the European Medicines Agency. Indian J Med Ethics. Published online on October 17, 2016.

286. Hodkinson A, Dietz KC, Lefebvre C, Golder S, Jones M, Doshi P, Heneghan C, Jefferson T, Boutron I, Stewart L. The use of clinical study reports to enhance the quality of systematic reviews: a survey of systematic review authors. Systematic Reviews 2018. 7:117. https://doi.org/10.1186/s13643-018-0766-x

287. Jefferson T, Demicheli V, Di Pietrantonj C, Rivetti D. Amantadine and rimantadine for influenza A in adults. Cochrane Database of Systematic Reviews 2006 , Issue 2 . Art. No.: CD001169. DOI: 10.1002/14651858.CD001169.pub3.

288. Jørgensen L, Doshi P, Gøtzsche P, Jefferson T. Challenges of independent assessment of potential harms of HPV vaccines BMJ 2018; 362 doi: https://doi.org/10.1136/bmj.k3694

289. Peter Doshi, Tom Jefferson, Mark Jones, John H. Powers III. Baloxavir: Roche's new oseltamivir? https://www.bmj.com/content/363/bmj.k4531/rr

290. Tom Jefferson. How Cochrane is doing pharma a good turn. https://blogs.bmj.com/bmj/2018/11/12/tom-jefferson-cochrane-pharma-good-turn/

291. Doshi P, Jefferson T, Jones M et al. Call to action: RIAT restoration of a previously unpublished methodology in Gardasil vaccine trials. https://www.bmj.com/content/346/bmj.f2865/rr-7
Protocol available at: https://osf.io/234kw/. DOI 10.17605/OSF.IO/234KW

292. Tom Jefferson, Florence Bourgeois, Kyungwan Hong, Mark Jones, Haeyoung Lee, Vinay Prasad, O'Mareen Spence, Peter Doshi. Re-analysis of mortality in HPV vaccine trials: systematic review. PROSPERO 2019 CRD42019122348 Available from: http://www.crd.york.ac.uk/PROSPERO/display_record.php?ID=CRD42019122348

293. Doshi P, Jefferson T, Jones M et al. Additional trials within scope: a follow-up to our "Call to action: RIAT restoration of a previously unpublished methodology in Gardasil vaccine trials". https://www.bmj.com/content/346/bmj.f2865/rr-9

294. Carl Heneghan, Tom Jefferson. Gender-affirming hormone in children and adolescents. https://blogs.bmj.com/bmjebmspotlight/ (Posted on 25th February 2019)

295. Jefferson T (2019). Sponsorship bias in clinical trials – growing menace or dawning realisation? JLL Bulletin: Commentaries on the history of treatment evaluation. (https://www.jameslindlibrary.org/articles/sponsorship-bias-in-clinical-trials-growing-menace-or-dawning-realisation/)

296. Jefferson T, Formoso G, Venturelli F, Vicentini M, Chiarolla E, Ballini L. Hadrontherapy for cancer. An overview of HTA reports and ongoing studies. Recenti Prog Med 2019; 110:566.

297. Doshi et al. Adjuvant-containing control arms in iivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. BMJ Evidence-Based Medicine 2020. https://doi.org/10.1136/bmjebm-2019-111331

298. Jørgensen, L., Gøtzsche, P.C. & Jefferson, T. Benefits and harms of the human papillomavirus (HPV) vaccines: systematic review with meta-analyses of trial data from clinical study reports. *Syst Rev* **9,** 43 (2020). https://doi.org/10.1186/s13643-019-0983-y

299. Jørgensen, L., Gøtzsche, P.C. & Jefferson, T. Benefits and harms of the human papillomavirus (HPV) vaccines: comparison of trial data from clinical study reports with corresponding trial register entries and journal publications. Syst Rev 9, 42 (2020). https://doi.org/10.1186/s13643-020-01300-1.

300. Jefferson T, Demasi M, Doshi P. Statins for primary prevention: what is the regulators role? Evid. Based Med. 2020 0: p. bmjebm-2019-111321v1-bmjebm-2019-111321. http://ebm.bmj.com/cgi/content/full/bmjebm-2019-111321.

301. Jefferson T. Covid 19—many questions, no clear answers. https://blogs.bmj.com/bmj/2020/03/02/tom-jefferson-covid-19-many-questions-no-clear-answers/

302. Jefferson T. Refining the “E” in EBM. BMJ Evidence Based Medicine.

Tom Jefferson: Covid 19—we live in surreal times https://blogs.bmj.com/bmj/2020/03/05/tom-jefferson-covid-19-we-live-in-surreal-times/

Tom Jefferson: Covidair flight 19 from Rome to Oxford and back again. https://blogs.bmj.com/bmj/2020/03/10/tom-jefferson-covidair-flight-19-from-rome-to-oxford-and-back-again/

303. Doshi P, Bourgeois F, Hong K, et al. Adjuvant-containing control arms in pivotal quadrivalent human papillomavirus vaccine trials: restoration of previously unpublished methodology. BMJ Evidence-Based Medicine Published Online First: 17 March 2020. doi: 10.1136/bmjebm-2019-111331 https://doi.org/10.1136/bmjebm-2019-111331

Tom Jefferson: Covid-19—supermarket wisdom https://blogs.bmj.com/bmj/2020/03/20/tom-jefferson-covid-19-supermarket-wisdom/

COVID-19. Can Historical Antivirals Be of Use?

https://www.cebm.net/covid-19/covid-19-can-historical-antivirals-be-of-use/

COVID-19 – The Tipping Point
https://www.cebm.net/covid-19/covid-19-the-tipping-point/

COVID-19: What proportion are asymptomatic?
https://www.cebm.net/covid-19/covid-19-what-proportion-are-asymptomatic/

Problems in identifying the origins of an outbreak
https://www.cebm.net/covid-19/problems-in-identifying-the-origins-of-an-outbreak/

Covid 19 - Modelling the models
https://www.cebm.net/covid-19/modelling-the-models/

https://www.cebm.net/covid-19/sars-cov-2-viral-load-and-the-severity-of-covid-19/

Are COVID-19 patients in hospital or admitted to hospital?
https://www.cebm.net/covid-19/are-covid-19-patients-in-hospital-or-admitted-to-hospital/

303. Jefferson, T. (2020). Sponsorship bias in clinical trials: growing menace or dawning realisation? Journal of the Royal Society of Medicine, 113(4), 148–157. https://doi.org/10.1177/0141076820914242
http://journals.sagepub.com/share/2F3RYZGUQTJTADJT3AJW?target=10.1177/0141076820914242

COVID-19 – The great plague of Lombardy – a not so distant resonance chamber
https://www.cebm.net/covid-19/covid-19-the-great-plague-of-lombardy-a-not-so-distant-resonance-chamber/

Is Lombardy the widow of Hampstead?
https://www.cebm.net/covid-19/covid-19-is-lombardy-the-widow-of-hampstead/

What does RCGP surveillance tell us about COVID-19 in the community
https://www.cebm.net/covid-19/what-does-rcgp-surveillance-tell-us-about-covid-19-in-the-community/

COVID-19 – Tracking European Mortality
https://www.cebm.net/covid-19/covid-19-tracking-european-mortality/

COVID 19 – The Widow of Hampstead Revisited

Effect of Latitude on COVID-19

Six Countries: Three-quarters of the COVID Deaths

COVID-19 Global Charts of Deaths

Covid 19 Epidemic “Waves”
https://www.cebm.net/covid-19/covid-19-epidemic-waves/

COVID 19 – Nova et Vetera: Lazaretts of Venice
https://www.cebm.net/covid-19/covid-19-nova-et-vetera-lazaretts-of-venice/

COVID-19: Unravelling the Uncertainties
https://www.cebm.net/covid-19/covid-19-unravelling-the-uncertainties/

COVID-19: Re-establishing ‘Fever Hospitals’
https://www.cebm.net/covid-19/covid-19-reestablishing-fever-hospitals/

COVID 19 - Understanding the Unknown in Acute Respiratory Infections
https://www.cebm.net/covid-19/covid-19-understanding-the-unknown-in-acute-respiratory-infections/

COVID-19: Have we forgotten our children in all this?
https://www.cebm.net/covid-19/covid-19-have-we-forgotten-our-children-in-all-this/

Let’s bring back Britain’s fever hospitals
https://www.spectator.co.uk/article/Lets-bring-back-Britains-fever-hospitals

Don’t place too much faith in models predicting another coronavirus wave
https://www.telegraph.co.uk/politics/2020/05/16/dont-place-much-faith-models-predicting-another-coronavirus/

Jefferson, T. Refining the E in EBM. Evid. Based Med. 2020 0: p. bmjebm-2020-111348v1-bmjebm-2020-111348
http://ebm.bmjjournals.com/cgi/content/full/bmjebm-2020-111348v1?ct

Could mass testing for Covid-19 do more harm than good?
https://www.spectator.co.uk/article/could-mass-testing-for-covid-19-do-more-harm-than-good-

Rome, 1 August 2020

EXHIBIT C

Curriculum vitae

for

Peter C. Gøtzsche

Updated October 2020

Contents

Personal data

Peter Christian Gøtzsche, Kløvervang 39, 2970 Hørsholm, Denmark
MD, DrMedSci, MSc (biology and chemistry), fil. mag.
Director, Institute for Scientific Freedom, Copenhagen
Visiting Professor, lnstitute of Health & Society, University of Newcastle, England

Email: pcg@scientificfreedom.dk
Mobile: +45 53 64 20 66
Websites: scientificfreedom.dk and deadlymedicines.dk.
Twitter: @PGtzsche1

Date of birth: 26 November 1949
Family relation: Married, 2 children
Citizenship: Danish

Education

1968	Student exam, Næstved Gymnasium. Marks: 9.0.
1970	First part of biology, University of Copenhagen. Marks: ug-.
1970-73	Studies at the universities of Uppsala and Lund.
1973	MSc in biology and chemistry, University of Lund.
1974	MSc in biology and chemistry, University of Copenhagen. Special subject in entomology. Marks: 10.
1984	MD, University of Copenhagen. Marks: 10.0.
1987	Diploma Course in Tropical Medicine, Copenhagen (2 months; passed).
1990	Thesis, University of Copenhagen.
1995	Specialist in internal medicine.

Appointments

Pregraduate

01.02.72 - 31.05.72	Teacher, Norrmalmsskolan, Piteå, Sweden (2 months).
01.09.74 - 31.01.75	Teacher, Falkonergårdens Gymnasium.
01.04.75 - 31.03.77	Drug representative and product manager, Astra Group A/S.
01.04.77 - 31.08.83	Head of medical department, Astra-Syntex A/S.

Postgraduate

01.06.84 - 30.09.84	Registrar, Bispebjerg Hospital, Med Dept C
01.10.84 - 31.12.85	Registrar, Herlev Hospital, Surgical Dept
01.06.85 - 31.08.85	Registrar, Herlev Hospital, Med Dept F
01.01.86 - 31.08.86	Registrar, Rigshospitalet, Dept of Infect Dis
01.09.86 - 30.09.87	Registrar, Hvidovre Hospital, Dept of Hepatology
01.09.87 - 31.05.95	Chief, Nordic coordination office for AIDS trials, Rigshospitalet
01.09.88 - 31.01.90	Junior Lecturer, Theory of Medicine, University of Copenhagen
01.02.89 - 28.02.90	Registrar, Herlev Hospital, Med Dept C
01.03.90 - 28.02.91	Registrar, Rigshospitalet, Med Dept A
01.03.91 - 31.08.91	Registrar, Rigshospitalet, Med Dept L
01.09.91 - 29.02.92	Registrar, Rigshospitalet, Dept of Infect Dis
01.03.92 - 30.06.93	Senior registrar, Hvidovre Hospital, Dept of Rheumatology
01.09.92 - 30.06.93	Lecturer, internal medicine, Hvidovre Hospital
01.07.93 - 31.08.95	Senior registrar, Rigshospitalet, Dept of Infect Dis
01.10.93 - 31.05.97	Senior House Medical Officer, Rigshospitalet

01.03.92 - 31.12.98	Editor, Bibliotek for Læger
01.02.90 - 31.03.10	Lecturer, Theory of Medicine, University of Copenhagen
01.10.93 - 30.04.19	Director, The Nordic Cochrane Centre
01.06.97 - 30.04.19	Chief physician, Rigshospitalet
01.04.10 - 30.04.19	Professor, Clinical Research Design and Analysis, University of Copenhagen

Funding support

1987 Danish Medical Research Council
1988 Danish Medical Research Council
1989 Danish Medical Research Council
1990 Danish Medical Research Council
1990 Danish Arthritis Foundation
1992 Medical Society in Copenhagen
1992 Fund for progress in Medical Science
1992 Danish Arthritis Foundation
1992 Fonden til Lægevidenskabens Fremme
1992 Todelegatet
1993 Rigshospitalet
1993 Research Foundation for Greater Copenhagen, Faroe Islands and Greenland.
1993 Ministry of Health
1994 Rigshospitalet
1994 European Union, BIOMED I
1995 European Union, BIOMED II
1995 Nordic Council of Ministers
1995 Rigshospitalet
1995 Copenhagen Hospital Foundation
1996 Danish Medical Research Council
1996 Nordic Council of Ministers
1996 Apothecary Foundation
1997 Fonden ”En god start i livet”
1997 Nordic Council of Ministers
1997 Sygekassernes Helsefond
1997 Research Fund, Leo Pharmaceuticals
1998 State Institute for Medical Health Technology Assessment
1998 European Union, BIOMED 2
1998 Nordic Council of Ministers
1998 Danish Medical Research Council
1999 Nordic Council of Ministers
1999 Danish Ministry of Health
2000 Nordic Council of Ministers
2000 Ministry of Health
2000 Mindelegat (lrs. Kay Lynæs)
2001 Nordic Council of Ministers
2001 Mindelegat (lrs. Kay Lynæs)
2002 Mindelegat (lrs. Kay Lynæs)
2002 Nordic Council of Ministers
2003 Danish Medical Research Council
2003 Danish Ministry of Health
2003 Rigshospitalet
2003 Nordic Council of Ministers
2004 Nordic Council of Ministers
2005 Nordic Council of Ministers
2006 Nordic Council of Ministers
2006 IMK Charitable Fund
2007 Danish Medical Research Council
2007 The Cancer Foundation
2008 Nordic Council of Ministers
2008 Sygekassernes Helsefond

2008 Rigshospitalet
2008 Danish Medical Research Council
2009 Rigshospitalet
2009 Capital Region of Denmark
2009 Agnes and Poul Friis' Foundation
2010 Augustinus Foundation
2010 Oticon Foundation
2010 Rigshospitalet
2010 Lundbeck Foundation
2010 Kontorchef Gerhard Brønsted's Travel Grant
2010 Tryg Foundation
2010 University of Copenhagen
2010 Sygekassernes Helsefond
2010 Julie von Müllen's Foundation
2010 The Free Research Councils
2011 The Cochrane Collaboration
2011 Rigshospitalet
2012 Rigshospitalet
2012 Tryg Foundation
2012 Sygekassernes Helsefond
2012 The Cochrane Collaboration
2014 Laura and John Arnold Foundation, Houston, Texas, PhD stipend
2014 Laura and John Arnold Foundation, Houston, Texas, PhD stipend
2015 University of Copenhagen, PhD stipend
2020 Laura and John Arnold Foundation, Houston, Texas, research

Awards and other academic honours

1992 Farmer from Stenløse, Peder Laurids Pedersen's donation.
1993 Co-founder of the Cochrane Collaboration
1997 Award of the year from the foundation "A good start in life".
1999 Henrik R. Wulff's prize from Danish Society for Theory in Medicine
2001 Skrabanek Foundation Prize, Trinity College, Dublin.
2001 Niels A. Lassen's prize.
2003 Queen Ingrid's Lecture, Åbenrå Hospital.
2004 Harry Boström Lecture, Swedish Society for Internal Medicine, Annual Meeting.
2006 Top-ten peer reviewer for British Medical Journal for the year 2006.
2007 Winner of the 2007 Society of Medical Writers' Academic Writing Award (for: Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. BMJ 2006;332:538-41).
2009 Michael Berger Award, Düsseldorf.
2012 Winner of the annual Prescrire Prize for medical and pharmaceutical books (for: Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012:1-388).
2014 Winner of the Annual LAP Award (psychiatry award), Denmark.
2014 Co-founder and member of the Board of the Council for Evidence-based Psychiatry, London.
2014 Winner of the British Medical Association's Annual Book Award in the category Basis of Medicine for Deadly Medicines and Organised Crime: How big pharma has corrupted health care.
2014 Award from the International Society of Ethical Psychology and Psychiatry for "intellectual honesty and bravery in tackling the biomedical-industrial complex."
2015 Honourable Award, Consul General Ernst Carlsen's Foundation.
2015 Book of the Year, US Tributaries Radio, for Deadly Psychiatry and Organised Denial.
2015 Top ten finalist for the award "Dane of the year," nominated by psychiatric patients.
2016 HealthWatch Award, London
2016 Protector for Stemmehørernetværket (Hearing Voices Network)
2016 Co-founder and member of the Board, International Institute for Psychiatric Drug Withdrawal.
2017 Elected member of the Cochrane Governing Board, with the most votes of the 11 candidates.
2017 Honored Guests Award in Ethical Human Sciences and Services. Breggin: Psychiatric Drug Facts.
2018 Member of the Advisory Council of International Center for the Study of Patient-Oriented Psychiatry.
2018 Member of the Advisory Council of the Center for the Study of Empathic Therapy, Education & Living.

2020 Award from the Danish Patient Association for being the bravest doctor in the last decade.

Some recent appearences in documentary films and satires

1. The Daily Show, New York. 2014; Sept 16.
2. Frank Wittig Frank.Wittig@swr.de Südwestrundfunk
3. Lægemiddelindustrien, NRK1, 2014.
4. Danmark på piller. Tre dokumentarer i DR TV 2014.
5. TV fra en anden planet, kanal 1, juni 2015. http://kanal-1.dk/tv-fra-en-anden-planet/.
6. Crazywise, 2016.
7. "Lykkepillen". Dokumentarfilm om Silje Marie Strandberg. 2017.
8. Cause of death: unknown. Documentary film about filmmaker's sister, Renate Hoel. 2017.
9. Diagnosing psychiatry. Documentary film about Peter Gøtzsche. 2018.
10. Speed Demons: Dying For Attention. 2018.
11. sera@westernmassrlc.org
12. The drug industry. sejucer@gmail.com. Russia 1
13. Michael Siewierski, New Roots Films. info@foodchoicesmovie.com 2018 launch.
14. Medicating normal. Periscope Moving Pictures. 2019.

Publications

My scientific works have been cited about 50,000 times. My H-index is 67 according to Web of Science, September 2018, which means that 67 papers have been cited at least 67 times.

DrMedSci thesis

Bias in double-blind trials. Dan Med Bull 1990;37:329-36. Defended 10 May 1990 at the University of Copenhagen, Faculty for Health Sciences. Examiners: Professor, DrMedSci Ib Lorenzen and chief physician, DrMedSci Henrik R. Wulff.

Academic books

Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 4. udgave. København: Munksgaard; 1997.

Wulff HR, Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 3rd edition. Oxford: Blackwell Scientific; 2000. Translated into Swedish, Spanish and Polish.

Wulff HR, Gøtzsche PC. Rationel klinik. Evidensbaserede diagnostiske og terapeutiske beslutninger, 5. udgave. København: Munksgaard Danmark; 2006.

Gøtzsche PC. Rational Diagnosis and Treatment. Evidence-Based Clinical Decision-Making, 4th edition. Chichester: Wiley; 2007.

Gøtzsche PC. Mammography screening: truth, lies and controversy. London: Radcliffe Publishing; 2012. Winner of the Prescrire Prize 2012.

Gøtzsche PC. Deadly medicines and organised crime: How big pharma has corrupted health care. London: Radcliffe Publishing; 2013. Winner, British Medical Association's Annual Book Award, Basis of Medicine in 2014. Translated into 15 languages.

Gøtzsche PC. Dødelig medicin og organiseret kriminalitet: Hvordan medicinalindustrien har korrumperet sundhedsvæsenet. København: People's Press; 2013.

Gøtzsche PC. Deadly psychiatry and organised denial. Copenhagen: People's Press; 2015. Translated into many languages.

Gøtzsche PC. Dødelig psykiatri og organiseret fornægtelse. København: People's Press; 2015.

Gøtzsche PC. Overlevelse i en overmedicineret verden: Find selv evidensen. København: People's Press; 2018.

Gøtzsche PC. Survival in an overmedicated world: look up the evidence yourself. Copenhagen: People's Press; 2019

Gøtzsche PC. Death of a whistleblower and Cochrane's moral collapse. Copenhagen: People's Press; 2019.

Gøtzsche PC. Vaccines: truth, lies and controversy. Copenhagen: People's Press; 2020.

Gøtzsche PC. Mental health survival kit and withdrawal from psychiatric drugs. Copenhagen: Institute for Scientific Freedom; 2020.

Gøtzsche PC. Mentalt overlevelseskit og udtrapning af psykofarmaka. København: Institute for Scientific Freedom; 2020.

Travel book

Gøtzsche PC. På safari i Kenya. København: Samlerens forlag; 1985.

Articles in international journals with peer review

Total number of citations: about 50,000; H-index: 67 (Web of Science, September 2018).

1. Andersen LA, Gøtzsche PC. Naproxen and aspirin in acute musculoskeletal disorders: a double-blind, parallel study in sportsmen. Pharmatherapeutica 1984;3:535-41.
2. Sindet-Pedersen S, Petersen JK, Gøtzsche PC. Incidence of pain conditions in dental practice in a Danish county. Community Dent Oral Epidemiol 1985;13:244-6.
3. Geisler C, Gøtzsche PC, Hansen SS, Juul K, Plesner AM, Nissen NI. Naproxen has greater antipyretic effect on fever related to Hodgkin´s disease than to other tumours or to infection. Scand J Haematol 1985;35:325-8.
4. Sindet-Pedersen S, Petersen JK, Gøtzsche PC, Christensen H. A double-blind, randomized study of naproxen and acetylsalicylic acid after surgical removal of impacted lower third molars. Int J Oral Maxillofac Surg 1986;15:389-94.
5. Gøtzsche PC, Hvidberg EF, Juul P. Rational choice of dose: insufficient background knowledge? Ration Drug Ther 1986;20:1-7.
6. Gøtzsche PC. Reference bias in reports of drug trials. BMJ 1987;295:654-6.
7. Fogh S, Schapira A, Bygbjerg IC, Jepsen S, Mordhorst CH, Kuijlen K, Ravn P, Rønn A, Gøtzsche PC. Malaria chemoprophylaxis in travellers to east Africa: a comparative prospective study of chloroquine plus proguanil with chloroquine plus sulfadoxine/pyrimethamine. BMJ 1988;296:820-2.
8. Gøtzsche PC, Hørding M. Condoms to prevent HIV transmission do not imply truly safe sex. Scand J Infect Dis 1988;20:233-4.
9. Gøtzsche PC, Andreasen F, Egsmose C, Lund B. Steady state pharmacokinetics of naproxen in elderly rheumatics compared with young volunteers. Scand J Rheumatol 1988;17:11-6.
10. Gøtzsche PC, Bygbjerg IC, Olesen B, Møller LH, Salim YS, Faber V. Yield of diagnostic tests of opportunistic infections in AIDS: a survey of 33 patients. Scand J Infect Dis 1988;20:395-402.
11. Andersson PG, Hinge HH, Johansen O, Andersen CU, Lademann A, Gøtzsche PC. Double-blind study of naproxen vs placebo in the treatment of acute migraine attacks. Cephalalgia 1989;9:29-32.
12. Gøtzsche PC. Patients' preference in indomethacin trials: an overview. Lancet 1989;i:88-91.
13. Gøtzsche PC. Methodology and overt and hidden bias in reports of 196 double-blind trials of nonsteroidal, antiinflammatory drugs in rheumatoid arthritis. Controlled Clin Trials 1989;10:31-56 (amendment:356).
14. Gøtzsche PC. Multiple publication in reports of drug trials. Eur J Clin Pharmacol 1989;36:429-32.
15. Gøtzsche PC. Review of dose-response studies of NSAIDs in rheumatoid arthritis. Dan Med Bull 1989;36:395-9.
16. Gøtzsche PC. Meta-analysis of grip strength: most common, but superfluous variable in comparative NSAID trials. Dan Med Bull 1989;36:493-5.
17. Hørding M, Gøtzsche PC, Bygbjerg I, Pedersen M, Faber V, Berg K. Lack of immunomodulating effect of disulfiram in HIV positive patients. Internat J Immunopharmacol 1990;12:145-7.
18. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K. Opportunistic infections and malignancies in 231 Danish AIDS patients. AIDS 1990;4:233-8.
19. Jørgensen A, Shao J, Maselle S, Yangi E, Thomsen A, Matunda S, Bygbjerg I, Gøtzsche P, Svendsen J, Skinhøj P, Faber V. Evaluation of simple tests for detection of HIV antibodies: analysis of interobserver variation in Tanzania. Scand J Infect Dis 1990;22:283-5.
20. Jørgensen AF, Mwakyusa D, Cegielski P, Gøtzsche P, Hørding M, Lallinger G, Mbaga I, Pallangyo K, Richter C, Shao J, Bygbjerg I, Skinhøj P, Faber V. The effect of fusidic acid on Tanzanian patients with AIDS. AIDS 1990;4:1037-8.
21. Jørgensen AF, Jensen VG, Shao JF, Maselle S, Mbaga IM, Mwakyusa DH, Gøtzsche PC, Richter C, Pallangyo K, Cegielsky P, Lallinger G, Bygbjerg I, Skinhøj P, Faber V. Beta-2-microglobulin as a prognostic marker for patients with AIDS in Dar es Salaam, Tanzania. AIDS 1990;4:1168-9.
22. Gøtzsche PC. Sensitivity of effect variables in rheumatoid arthritis: a meta-analysis of 130 placebo controlled NSAID trials. J Clin Epidemiol 1990;43:1313-8.
23. Hørding M, Gøtzsche PC, Christensen LD, Bygbjerg IC, Faber V. Double-blind trial of bestatin in HIV-positive patients. Biomed Pharmacother 1990;44:475-8.

24. Pedersen C, Gerstoft J, Tauris P, Lundgren JD, Gøtzsche PC, Buhl M, Salim Y, Schmidt K, Nielsen JO. Trends in survival of Danish AIDS patients from 1981 to 1989. AIDS 1990;4:1111-6.
25. Gøtzsche PC, Kelbæk H, Vissing SF, Nielsen SL, Munck O, Christensen NJ, Lyngsøe J, Mathiesen ER. Acute cardiovascular effects of insulin in hyperglycaemic type I diabetics. Scand J Clin Lab Invest 1991;51:93-7.
26. Gøtzsche PC. Patients' views on the least acceptable increase in survival with zidovudine treatment. Scand J Infect Dis 1991;23:509-10.
27. Gjørup IE, Gøtzsche PC, Baden H, Andersen B. Surgical treatment of morbid obesity: a survey of overall outcome 1968-89. Dan Med Bull 1991;38:405-7.
28. Nielsen C, Nielsen CM, Petersen JL, Gøtzsche PC, Pedersen C, Arendrup M, Vestergaard BF. Isolation of HIV from cultures of purified CD4+ lymphocytes. J Virol Methods 1991;35:15-25.
29. Gøtzsche PC, Lange B. Comparison of search strategies for recalling double-blind trials from MEDLINE. Dan Med Bull 1991;38:476-8.
30. Nordic Medical Research Councils' HIV Therapy Group. Double-blind dose-response study of zidovudine in AIDS and advanced HIV infection. BMJ 1992;304:13-7 (manuscript and scientific coordinator: PC Gøtzsche).
31. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. J Clin Epidemiol 1992;45:587-94.
32. Nielsen C, Gøtzsche PC, Nielsen CM, Gerstoft J, Vestergaard BF. Development of resistance to zidovudine in HIV strains isolated from CD4+ lymphocytes and plasma during therapy. Antiviral Res 1992;18:303-16.
33. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Trend towards decreased survival in patients infected with HIV resistant to zidovudine. Scand J Infect Dis 1992;24:563-5.
34. Gøtzsche PC, Pødenphant J, Olesen M, Halberg P. Critique of meta-analysis of second-line antirheumatic drugs. J Clin Epidemiol 1993;46:319-21.
35. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine suspension as adjuvant to energy restricted diet in treating obesity. BMJ 1993;306:1093-6.
36. Gøtzsche PC. Zidovudine in HIV infection. Ann Med 1993;25:213-4.
37. Rasmussen MH, Andersen T, Breum L, Hilsted J, Gøtzsche PC. Observer variation in measurements of waist-hip ratio and the abdominal sagittal diameter. Int J Obes 1993;17:323-7.
38. Gøtzsche PC. Meta-analysis of NSAIDs: contribution of drugs, doses, trial designs, and meta-analytic techniques. Scand J Rheumatol 1993;22:255-60.
39. Gøtzsche PC. Is there logic in the placebo? Lancet 1994;344:925-6.
40. Gøtzsche PC. Steroids and peptic ulcer: an end to the controversy? J Intern Med 1994;236:599-601.
41. The Standards of Reporting Trials Group. A proposal for structured reporting of randomized controlled trials. JAMA 1994;272:1926-31 (member of writing committee).
42. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Somatostatin v placebo in bleeding oesophageal varices: randomised trial and meta-analysis. BMJ 1995;310:1495-8.
43. Ullum H, Gøtzsche PC, Victor J, Dickmeiss E, Skinhøj P, Pedersen BK. Defective natural immunity: an early manifestation of human immunodeficiency virus infection. J Exp Med 1995;182:789-99.
44. Mulward S, Gøtzsche PC. Sample size of randomized double-blind trials 1976-1991. Dan Med Bull 1996;43:96-8.
45. Gøtzsche PC, Liberati A, Luca P, Torri V. Beware of surrogate outcome measures. Int J Technol Ass Health Care 1996;12:238-46.
46. Gøtzsche PC, Hansen M, Stoltenberg M, Svendsen A, Beier J, Faarvang KL, et al. Randomized, placebo controlled trial of withdrawal of slow-acting antirheumatic drugs and of observer bias in rheumatoid arthritis. Scand J Rheumatol 1996;25:194-9.
47. Ullum H, Diamant M, Victor J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Increased circulating levels of interleukin-6 in HIV seropositive subjects. J AIDS 1996;13:93-9.
48. Gøtzsche PC. Blinding during data analysis and writing of manuscripts. Controlled Clin Trials 1996;17:285-90.
49. Gøtzsche PC, Johansen HK. Antifungal prophylactic or empiric therapy vs placebo or no treatment in cancer patients with neutropenia (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software; 1997. Updated quarterly.
50. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 1997. Updated quarterly.
51. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 1997. Updated quarterly.

52. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of lung cancer: a meta-analysis. Eur J Clin Pharmacol 1997;51:389-93.
53. Gøtzsche PC, Johansen HK. Meta-analysis of prophylactic or empirical antifungal treatment versus placebo or no treatment in patients with cancer complicated by neutropenia. BMJ 1997;314:1238-44.
54. Gerstoft J, Melander H, Bruun JN, Pedersen C, Gøtzsche PC, Berglund O, et al. Alternating treatment with didanosine and zidovudine versus either drug alone for the treatment of advanced HIV infection: the ALTER study. Scand J Infect Dis 1997;29:121-8.
55. Ullum H, Victor J, Katzenstein TL, Gerstoft J, Gøtzsche PC, Bendtzen K, Skinhøj P, Pedersen BK. Decreased short-term production of tumor necrosis factor-□ and interleukin-1□ in human immunodeficiency virus-seropositive subjects. J Infect Dis 1997;175:1507-10.
56. Ullum H, Cozzi-Lepri A, Bendtzen K, Victor J, Gøtzsche PC, Phillips AN, Skinhøj P, Klarlund Pedersen B. Low production of interferon gamma is related to disease progression in HIV infection: evidence from a cohort of 347 HIV-infected individuals. AIDS Res Hum Retroviruses 1997;13:1039-46.
57. Hammarquist C, Burr ML, Gøtzsche PC. House dust mites and control measures in the management of asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 1998. Updated quarterly.
58. Gøtzsche PC. Somatostatin or octreotide vs placebo in bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 1998. Updated quarterly.
59. Gøtzsche PC, Johansen HK. Meta-analysis of short term low dose prednisolone versus placebo and non-steroidal, anti-inflammatory drugs in rheumatoid arthritis. BMJ 1998;316:811-8.
60. Rønn AM, Rønne-Rasmussen J, Gøtzsche PC, Bygbjerg IC. Neuropsychiatric manifestations after mefloquine therapy for Plasmodium falciparum malaria: comparing a retrospective and a prospective study. Trop Med Int Health 1998; 3:83-8.
61. Gøtzsche PC, Hammarquist C, Burr M. House dust mite control measures in the management of asthma: meta-analysis. BMJ 1998;317:1105-10.
62. Hróbjartsson A, Gøtzsche PC, Gluud C. The controlled trial turns 100 years: Fibiger's trial of serum treatment of diphtheria. BMJ 1998;317:1243-5.
63. Christensen PM, Gøtzsche PC, Brøsen K. The sparteine/debrisoquine (CYP2D6) oxidation polymorphism and the risk of Parkinson's disease: a meta-analysis. Pharmacogenetics 1998;8:473-9.
64. Astrup A, Gøtzsche PC, van de Werken K, Ranneries C, Toubro S, Raben A, Buemann B. Meta-analysis of resting metabolic rate in formerly obese subjects. Am J Clin Nutr 1999;69:1117-22.
65. Johansen HK, Gøtzsche PC. Problems in the design and reporting of trials of antifungal agents encountered during meta-analysis. JAMA 1999;282:1752-9.
66. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 1999;2:430-6.
67. Gøtzsche PC, Olsen O. Is screening for breast cancer with mammography justifiable? Lancet 2000;355:129-34.
68. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. BMJ 2000;320:1058-61.
69. Gøtzsche PC. Do patients with osteoarthritis get the clinical research they need? Ann Rheum Dis 2000;59:407-8.
70. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2000;3:521-8 (updated).
71. Gøtzsche PC. Why we need a broad perspective on meta-analysis: It may be crucially important for patients. BMJ 2000;321:585-6.
72. Johansen HK, Gøtzsche PC. Amphotericin B vs fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
73. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
74. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations vs amphotericin B in cancer patients with neutropenia (Cochrane Review). In: The Cochrane Library, Issue 1. Oxford: Update Software; 2000.
75. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: The Cochrane Library, Issue 2. Oxford: Update Software; 2000. (updated).
76. Olesen V, Engell L, Jensen KL, Gøtzsche PC. Randomised clinical trials in the Scandinavian Journal of Rheumatology. Scand J Rheumatol 2000;29:349-51.

77. Gøtzsche PC, Johansen HK. Short-term low-dose corticosteroids vs placebo and nonsteroidal antiinflammatory drugs in rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001. (updated).
78. Gøtzsche PC. Reporting of outcomes in arthritis trials measured on ordinal and interval scales is inadequate in relation to meta-analysis. Ann Rheum Dis 2001;60:349-52.
79. Altman DG, Schulz KF, Moher D, Egger M, Davidoff F, Elbourne D, Gøtzsche PC, Lang T, for the CONSORT Group. The revised CONSORT statement for reporting randomized trials: Explanation and elaboration. Ann Intern Med 2001;134:663-94.
80. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? An analysis of clinical trials comparing placebo with no treatment. N Engl J Med 2001;344:1594-602.
81. Gøtzsche PC, Johansen HK, Burr ML, Hammarquist C. House dust mite control measures for asthma (Cochrane Review). In: The Cochrane Library, Issue 3. Oxford: Update Software; 2001. (updated).
82. Olsen O, Middleton P, Ezzo J, Gøtzsche PC, Hadhazy V, Herxheimer A, et al. Quality of Cochrane reviews: assessment of sample from 1998. BMJ 2001;323:829-32.
83. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;5:800-7 (updated).
84. Hróbjartsson A, Gøtzsche PC. Core belief in powerful effects of placebo interventions is in conflict with no evidence of important effects in a large systematic review. Adv Mind-Body Med 2001;17:312-8.
85. Olsen O, Gøtzsche PC. Cochrane review on screening for breast cancer with mammography. Lancet 2001;358:1340-2.
86. Olsen O, Gøtzsche PC. Systematic review of screening for breast cancer with mammography. Lancet 2001 (http://image.thelancet.com/extras/fullreport.pdf).
87. Olsen O, Gøtzsche PC. Screening for breast cancer with mammography (Cochrane Review). In: The Cochrane Library, Issue 4. Oxford: Update Software, 2001.
88. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2001;6:894-901 (updated).
89. Gøtzsche PC. Somatostatin analogues for acute bleeding oesophageal varices (Cochrane Review). In: The Cochrane Library, Issue 1, 2002. Oxford: Update Software (updated).
90. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
91. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
92. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer (Cochrane Review). In: The Cochrane Library, Issue 2, 2002. Oxford: Update Software. (updated).
93. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;7:1063-70.
94. Mowatt G, Shirran L, Grimshaw JM, Rennie D, Flanagin A, Yank V, MacLennan G, Gøtzsche PC, Bero LA. Prevalence of honorary and ghost authorship in Cochrane reviews. JAMA 2002;287:2769-71.
95. Gøtzsche PC. Medicalisation of risk factors. BMJ 2002;324:890-1.
96. McDonald S, Lefebvre C, Antes G, Galandi D, Gøtzsche P, Hammarquist C, Haugh M, Jensen KL, Kleijnen J, Loep M, Pistotti V, Rüther A. The contribution of handsearching European general health care journals to the Cochrane Controlled Trials Register. Evaluation & The Health Profession 2002;25:65-76.
97. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2002;8:1203-11 (updated).
98. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2003;9:1292-300.
99. Hróbjartsson A, Gøtzsche PC. Placebo treatment versus no treatment (Cochrane Review). In: The Cochrane Library, Issue 1, 2003. Oxford: Update Software.
100. Kösters JP, Gøtzsche PC. Regular self-examination or clinical examination for early detection of breast cancer (Cochrane Review). In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.
101. Gøtzsche PC. The debate on breast cancer screening with mammography is important. J Am Coll Radiol 2004;1:8-14.
102. Wienecke T, Gøtzsche PC. Paracetamol versus nonsteroidal anti-inflammatory drugs for rheumatoid arthritis (Cochrane Review). In: The Cochrane Library, Issue 1, 2004. Chichester: John Wiley & Sons, Ltd.

103. Jørgensen KJ, Gøtzsche PC. Presentation on websites of possible benefits and harms from screening for breast cancer: cross sectional study. BMJ 2004;328:148-51.
104. Gøtzsche PC. On the benefits and harms of screening for breast cancer. Int J Epidemiol 2004;33:56-64.
105. Johansen HK, Nørregaard L, Gøtzsche PC, Pressler T, Koch C, Høiby N. Antibody response to Pseudomonas aeruginosa in cystic fibrosis patients: A marker of therapeutic success?-A 30-year Cohort study of survival in Danish CF patients after onset of chronic P. aeruginosa lung infection. Pediatr Pulmonol 2004;37:427-32.
106. Chan A-W, Hróbjartsson A, Haahr MT, Gøtzsche PC, Altman DG. Empirical evidence for selective reporting of outcomes in randomized trials: comparison of protocols to published articles. JAMA 2004;291:2457-65.
107. Pildal J, Gøtzsche PC. Polyclonal immunoglobulin for treatment of bacterial sepsis: a systematic review. Clin Infect Dis 2004;39:38-46.
108. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;11:1551-9 (updated).
109. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions (Cochrane Review). In: The Cochrane Library, Issue 3, 2004. Chichester, UK: John Wiley & Sons, Ltd (updated).
110. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? Update of a systematic review with 52 new randomized trials comparing placebo with no treatment. J Intern Med 2004;256:91-100.
111. Gøtzsche PC, Johansen HK, Schmidt LM, Burr ML. House dust mite control measures for asthma. The Cochrane Database of Systematic Reviews 2004, Issue 4. Art. No.: CD001187.
112. Ioannidis JPA, Evans SJW, Gøtzsche PC, O'Neill RT, Altman DG, Schulz K, Moher D, for the CONSORT Group. Better reporting of harms in randomized trials: An extension of the CONSORT statement. Ann Intern Med 2004;141:781-8.
113. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2004;12:1702-10 (updated).
114. Schmidt LM, Gøtzsche PC. Of mites and men: reference bias in narrative review articles: a systematic review. J Fam Pract 2005;54:334-8.
115. Pildal J, Chan A-W, Hróbjartsson A, Forfang E, Altman DG, Gøtzsche PC. Comparison of descriptions of allocation concealment in trial protocols and the published reports: cohort study. BMJ 2005;330:1049-52.
116. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;13:1525-32 (updated).
117. Karmisholt K, Gyntelberg F, Gøtzsche PC. Physical activity for primary prevention of disease: systematic reviews of randomised clinical trials. Dan Med Bull 2005;52:86-9.
118. Karmisholt K, Gøtzsche PC. Physical activity for secondary prevention of disease: systematic reviews of randomised clinical trials. Dan Med Bull 2005;52:90-4.
119. Gøtzsche PC. Research integrity and pharmaceutical industry sponsorship: trial registration, transparency and less reliance on industry trials are essential. Med J Aust 2005;182:549-50.
120. Gluud LL, Sørensen TIA, Gøtzsche PC, Gluud C. The journal impact factor as a predictor of trial quality and outcomes: cohort study of hepato-biliary randomized clinical trials. Am J Gastroenterol 2005;100:2431-5.
121. Haug C, Gøtzsche PC, Schroeder TV. Registries and registration of clinical trials. N Engl J Med 2005;353:2811-2.
122. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. London: BMJ Publications, Clinical Evidence, 2005;14:1498-1505 (updated).
123. Jørgensen KJ, Johansen HK, Gøtzsche PC. Voriconazole versus amphotericin B in cancer patients with neutropenia. The Cochrane Database of Systematic Reviews 2006, Issue 1. Art. No.: CD004707.
124. Jørgensen KJ, Johansen HK, Gøtzsche PC. Flaws in design, analysis and interpretation of Pfizer's antifungal trials of voriconazole and uncritical subsequent quotations. Trials 2006,7:3.
125. Jørgensen KJ, Gøtzsche PC. Content of invitations to publicly funded screening mammography. BMJ 2006;332:538-41.
126. Gøtzsche PC. Lessons from and cautions about noninferiority and equivalence randomized trials. JAMA 2006;295:1171-3.
127. Hróbjartsson A, Gøtzsche PC. Unsubstantiated claims of large effects of placebo on pain: serious errors in meta-analysis of placebo analgesia mechanism studies. J Clin Epidemiol 2006;59:336-8.
128. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan A-W. Constraints on publication rights in industry-initiated clinical trials. JAMA 2006;295:1645-6.
129. Johansen HK, Gøtzsche PC, Keogan MT. Vaccines for preventing infection with Pseudomonas aeruginosa in people with cystic fibrosis. The Cochrane Database of Systematic Reviews 2006, Issue 2. Art. No.: CD001399 (updated).

130. Gøtzsche PC. Believability of relative risks and odds ratios in abstracts: cross-sectional study. BMJ 2006;333:231-4.
131. Due AK, Johansen HK, Gøtzsche PC. Fungal infection-related mortality versus total mortality as an outcome in trials of antifungal agents. BMC Medical Research Methodology 2006,6:40.
132. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews compared with industry supported meta-analyses and other meta-analyses of the same drugs: systematic review. BMJ 2006;333:782-5.
133. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD001877.
134. Haedersdal M, Gøtzsche PC. Laser and photoepilation for unwanted hair growth. Cochrane Database of Systematic Reviews 2006, Issue 4. Art. No.: CD004684.
135. Zahl P-H, Gøtzsche PC, Andersen JM, Mæhlen J. Results of the Two-County trial of mammography screening are not compatible with contemporaneous official Swedish breast cancer statistics. Dan Med Bull 2006;53:438-40.
136. Gøtzsche PC, Mæhlen J, Zahl P-H. What is publication? Lancet 2006;368:1854-5.
137. Gøtzsche PC, Hrobjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Ghost authorship in industry-initiated randomised trials. PLoS Med 2007; 4(1):e19.
138. Gøtzsche PC, Hrobjartsson A, Maric K, Tendal B. Data extraction errors in meta-analyses that use standardized mean differences. JAMA 2007; 298(4):430-7.
139. Hrobjartsson A, Gøtzsche PC. Powerful spin in the conclusion of Wampold et al.'s re-analysis of placebo versus no-treatment trials despite similar results as in original review. J Clin Psychol 2007; 63(4):373-7.
140. Jørgensen KJ, Klahn A, Gøtzsche PC. Are benefits and harms in mammography screening given equal attention in scientific articles? A cross-sectional study. BMC Med 2007; 5:12.
141. Pildal J, Hrobjartsson A, Jørgensen KJ, Hilden J, Altman DG, Gøtzsche PC. Impact of allocation concealment on conclusions drawn from meta-analyses of randomized trials. Int J Epidemiol 2007; 36(4):847-57.
142. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Epidemiology 2007; 18(6):805-35.
143. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007; 4(10):e297.
144. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; STROBE Initiative. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Ann Intern Med 2007; 147(8):W163-94.
145. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Lancet 2007; 370(9596):1453-7.
146. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Epidemiology 2007; 18(6):800-4.
147. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Bull World Health Organ 2007; 85(11):867-72.
148. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Prev Med 2007; 45(4):247-51.
149. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. BMJ 2007; 335(7624):806-8.
150. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. PLoS Med 2007; 4(10):e296.
151. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. Ann Intern Med 2007; 147(8):573-7.
152. Welch HG, Woloshin S, Schwartz LM, Gordis L, Gøtzsche PC, Harris R, Kramer BS, Ransohoff DF. Overstating the evidence for lung cancer screening: the International Early Lung Cancer Action Program (I-ELCAP) study. Arch Intern Med 2007; 167(21):2289-95.

153. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma: systematic review. Allergy 2008 Jun;63(6):646-59.
154. Lundh A, Gøtzsche PC. Recommendations by Cochrane Review Groups for assessment of the risk of bias in studies. BMC Med Res Methodol 2008 Apr 21;8:22.
155. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev 2008; (2):CD001187.
156. Gøtzsche PC, Hrobjartsson A. Somatostatin analogues for acute bleeding oesophageal varices. Cochrane Database Syst Rev 2008; (3):CD000193.
157. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2008; (4):CD001399.
158. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; STROBE Initiative. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008 Apr;61(4):344-9.
159. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP; Iniciativa STROBE. [The Strengthening the Reporting of Observational Studies in Epidemiology [STROBE] statement: guidelines for reporting observational studies]. Gac Sanit 2008 Mar-Apr;22(2):144-50.
160. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies]. Rev Esp Salud Publica 2008; 82(3):251-9.
161. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP. [The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting of observational studies]. Internist (Berl) 2008; 49(6):688-93.
162. Zahl PH, Jørgensen KJ, Maehlen J, Gøtzsche PC. Biases in estimates of overdetection due to mammography screening. Lancet Oncol 2008 Mar;9(3):199-201.
163. Jørgensen AW, Maric KL, Tendal B, Faurschou A, Gøtzsche PC. Industry-supported meta-analyses compared with meta-analyses with non-profit or no support: differences in methodological quality and conclusions. BMC Med Res Methodol 2008; 8:60.
164. Chan A-W, Hróbjartsson A, Jørgensen KJ, Gøtzsche PC, Altman DG. Reporting of sample size calculations and data analysis methods in randomized trials: comparison of publications with protocols. BMJ 2008;337:1404-7.
165. Madsen MV, Gøtzsche PC, Hrobjartsson A. Acupuncture treatment for pain: systematic review of randomised clinical trials with acupuncture, placebo acupuncture, and no acupuncture groups. BMJ 2008;338:330-3.
166. Gøtzsche PC. Readers as research detectives. Trials 2009;10:2.
167. Gøtzsche P, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Breast screening: the facts - or maybe not. BMJ 2009;338:446-8.
168. Krogsbøll LT, Hróbjartsson A, Gøtzsche PC. Spontaneous improvement in randomised clinical trials: meta-analysis of three-armed trials comparing no treatment, placebo and active intervention. BMC Medical Research Methodology 2009, 9:1.
169. Gøtzsche PC, Kassirer JP, Woolley KL, Wager E, Jacobs A, Gertel A, Hamilton C. What should be done to tackle ghostwriting in the medical literature? PLoS Med 2009;6(2):e23.
170. Jørgensen KJ, Brodersen J, Hartling OJ, Nielsen M, Gøtzsche PC. Informed choice requires information about both benefits and harms. J Med Ethics 2009;35(4):268-9.
171. Vandenbroucke JP, Von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ, Poole C, Schlesselman JJ, Egger M; Iniciativa STROBE. [Strengthening the reporting of observational studies in epidemiology (STROBE): explanation and elaboration]. Gac Sanit. 2009 Mar-Apr;23(2):158.
172. Jørgensen KJ, Gøtzsche PC. Overdiagnosis in publicly organised mammography screening programmes: systematic review of incidence trends. BMJ 2009;339:b2587.
173. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009 Aug 18;151(4):W65-94.
174. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP,Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. PLoS Med 2009 Jul 21;6(7):e1000100.
175. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. J Clin Epidemiol 2009;62(10):e1-34.

176. Liberati A, Altman DG, Tetzlaff J, Mulrow C, Gøtzsche PC, Ioannidis JP, Clarke M, Devereaux PJ, Kleijnen J, Moher D. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009 Jul 21;339:b2700.
177. Tendal B, Higgins JP, Jüni P, Hróbjartsson A, Trelle S, Nüesch E, Wandel S, Jørgensen AW, Gesser K, Ilsøe-Kristensen S, Gøtzsche PC. Disagreements in meta-analyses using outcomes measured on continuous or rating scales: observer agreement study. BMJ 2009 Aug 13;339:b3128.
178. Hróbjartsson A, Pildal J, Chan AW, Haahr MT, Altman DG, Gøtzsche PC. Reporting on blinding in trial protocols and corresponding publications was often inadequate but rarely contradictory. J Clin Epidemiol. 2009 Sep;62(9):967-73.
179. Gøtzsche PC, Nielsen M. Screening for breast cancer with mammography. Cochrane Database of Systematic Reviews 2009, Issue 4. Art. No.: CD001877.
180. Jørgensen KJ, Hróbjartsson A, Gøtzsche PC. Divine intervention? A Cochrane review on intercessory prayer gone beyond science and reason. J Negat Results Biomed 2009 Jun 10;8:7.
181. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Overdiagnosis in organised mammography screening in Denmark: a comparative study. BMC Women's Health 2009;9:36.
182. Jørgensen KJ, Gøtzsche PC. Who evaluates public health programmes? A review of the NHS Breast Screening Programme. J R Soc Med 2010;103:14-20.
183. Hróbjartsson A, Gøtzsche PC. Placebo interventions for all clinical conditions. Cochrane Database of Systematic Reviews 2010, Issue 1. Art. No.: CD003974.
184. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Breast cancer mortality in organised mammography screening in Denmark: comparative study. BMJ 2010;340:c1241.
185. Brodersen J, Jørgensen KJ, Gøtzsche PC. The benefits and harms of screening for cancer with a focus on breast screening. Pol Arch Med Wewn 2010;120:89-94.
186. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Obstet Gynecol 2010 May;115(5):1063-70.
    a. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. PLoS Med 2010 Mar 24;7(3):e1000251.
187. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010 Aug;63(8):834-40.
188. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomized trials. Ann Intern Med 2010 Jun 1;152(11):726-32.
189. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. BMC Med 2010 Mar 24;8:18.
190. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 Statement: updated guidelines for reporting parallel group randomised trials. Trials 2010 Mar 24;11:32.
191. Schulz KF, Altman DG, Moher D; CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010 Mar 23;340:c332.
192. Gøtzsche PC, Berg S. Sleep apnoea: from person to patient, and back again. BMJ 2010 Mar 30;340:c360.
193. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010 Mar 23;340:c869.
194. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; Consolidated Standards of Reporting Trials Group. CONSORT 2010 Explanation and Elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 2010 Aug;63(8):e1-37.
195. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, et al. [CONSORT 2010 Explanation and Elaboration: updated guidelines for reporting parallel group randomised trials (Chinese version)]. Zhong Xi Yi Jie He Xue Bao 2010;8(8):701-41.
196. Moher D, Liberati A, Tetzlaff J, Altman DG; PRISMA Group. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. Int J Surg 2010;8(5):336-41.
197. Jørgensen AW, Jørgensen KJ, Gøtzsche PC. Unbalanced reporting of benefits and harms in abstracts on rofecoxib. Eur J Clin Pharmacol 2010 Apr;66(4):341-7.
198. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Syst Rev 2010;(7):CD007851.
199. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy: systematic review. Dan Med Bull 2010;57(9):A4175.

200. Lundh A, Barbateskovic M, Hrobjartsson A, Gøtzsche PC. Conflicts of interest at medical journals: the influence of industry-supported randomised trials on journal impact factors and revenue - cohort study. PLoS Med 2010;7(10):e1000354.
201. Gøtzsche PC, Delamothe T, Godlee F, Lundh A. Adequacy of authors' replies to criticism raised in electronic letters to the editor: cohort study. BMJ 2010 Aug 10;341:c3926.
202. Cordoba G, Schwartz L, Woloshin S, Bae H, Gøtzsche PC. Definition, reporting, and interpretation of composite outcomes in clinical trials: systematic review. BMJ 2010;341:c3920.
203. la Cour JL, Brok J, Gøtzsche PC. Inconsistent reporting of surrogate outcomes in randomised clinical trials: cohort study. BMJ 2010;341:c3653.
204. Lundh A, Gøtzsche PC. Sponsorship of medical textbooks by drug or device companies. CMEJ 2011;1:e10-7.
205. Gøtzsche PC. Time to stop mammography screening? CMAJ 2011;183:1957-8.
206. Gøtzsche PC, Jørgensen AW. Opening up data at the European Medicines Agency. BMJ 2011;342:d2686.
207. Gøtzsche PC, Jørgensen KJ. The Breast Screening Programme and misinforming the public. J R Soc Med 2011;104(9):361-9.
208. Gøtzsche PC. Niels Finsen's treatment for lupus vulgaris. J R Soc Med 2011;104(1):41-2.
209. Gøtzsche PC. Relation between breast cancer mortality and screening effectiveness: systematic review of the mammography trials. Dan Med Bull 2011;58(3):A4246.
210. Higgins JP, Altman DG, Gøtzsche PC, Juni P, Moher D, Oxman AD, et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. BMJ 2011;343:d5928.
211. Jørgensen KJ, Keen JD, Gøtzsche PC. Is mammographic screening justifiable considering its substantial overdiagnosis rate and minor effect on mortality? Radiology 2011;260(3):621-7.
212. Lundh A, Krogsbøll LT, Gøtzsche PC. Access to data in industry-sponsored trials. Lancet 2011;378(9808):1995-6.
213. Nielsen M, Gøtzsche P. An analysis of psychotropic drug sales. Increasing sales of selective serotonin reuptake inhibitors are closely related to number of products. Int J Risk Saf Med 2011;23(2):125-32.
214. Schroll JB, Moustgaard R, Gøtzsche PC. Dealing with substantial heterogeneity in Cochrane reviews. Cross-sectional study. BMC Med Res Methodol 2011;11:22.
215. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. BMJ 2011;343:d4692.
216. Tendal B, Nuesch E, Higgins JP, Juni P, Gøtzsche PC. Multiplicity of data in trial reports and the reliability of meta-analyses: empirical study. BMJ 2011;343:d4829.
217. Zahl PH, Gøtzsche PC, Maehlen J. Natural history of breast cancers detected in the Swedish mammography screening programme: a cohort study. Lancet Oncol 2011;12(12):1118-24.
218. Gøtzsche PC. Why we need easy access to all data from all clinical trials and how to accomplish it. Trials 2011;12(1):249.
219. Gøtzsche PC, Jørgensen KJ, Zahl PH, Maehlen J. Why mammography screening has not lived up to expectations from the randomised trials. Cancer Causes Control 2012;23:15-21.
220. Gøtzsche PC. Strengthening and opening up health research by sharing our raw data. Circ Cardiovasc Qual Outcomes 2012;5:236-7.
221. Grønhøj Larsen C, Jørgensen KJ, Gøtzsche PC. Regular health checks: cross-sectional survey. PLoS One 2012;7:e33694.
222. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG; CONSORT. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. Int J Surg 2012;10:28-55.
223. Nielsen M, Hansen EH, Gøtzsche PC. What is the difference between dependence and withdrawal reactions? A comparison of benzodiazepines and selective serotonin re-uptake inhibitors. Addict 2012;107:900-8.
224. Lundh A, Krogsboll LT, Gøtzsche PC. Sponsor's participation in conduct and reporting of industry trials: a descriptive study. Trials 2012;13:146.
225. Schroll JB, Maund E, Gøtzsche PC. Challenges in coding adverse events in clinical trials: a systematic review. PLoS One 2012;7:e41174.
226. Gøtzsche PC. Deficiencies in proposed new EU regulation of clinical trials. BMJ 2012;345:e8522.
227. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Sys Rev 2012;(10):CD009009.
228. Gøtzsche PC, Ioannidis JPA. Content area experts as authors: helpful or harmful for systematic reviews and meta-analyses? BMJ (Online) 2012;345:e7031.

229. Krogsbøll LT, Jørgensen KJ, Grønhøj Larsen C, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease: Cochrane systematic review and meta-analysis. BMJ (Online) 2012;345:e7191.
230. Gøtzsche PC. Big pharma often commits corporate crime, and this must be stopped. BMJ 2012;345:e8462.
231. Chan A-W, Tetzlaff JM, Altman DG, Laupacis A, Gøtzsche PC, Krleža-Jerić K et al. SPIRIT 2013 Statement: Defining Standard Protocol Items for Clinical Trials. Ann Intern Med 2013;158:200-7.
232. Beller EM, Glasziou PP, Altman DG, Hopewell S, Bastian H, Chalmers I et al. PRISMA for Abstracts: reporting systematic reviews in journal and conference abstracts. PLoS Med 2013;10:e1001419.
233. Bindslev JBB, Schroll J, Gøtzsche PC, Lundh A. Underreporting of conflicts of interest in clinical practice guidelines: cross sectional study. BMC Med Ethics 2013;14:19.
234. Chan A-W, Tetzlaff JM, Gøtzsche PC, Altman DG, Mann H, Berlin JA et al. SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ (Online) 2013;346:e7586.
235. Gøtzsche PC, Jørgensen KJ. Screening for breast cancer with mammography. Cochrane Database Sys Rev 2013;(6):CD001877.
236. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. JAMA 2013;309:2489-90.
237. Nielsen M, Hansen EH, Gøtzsche PC. Dependence and withdrawal reactions to benzodiazepines and selective serotonin reuptake inhibitors. How did the health authorities react? Int J Risk Saf Med 2013;25:155-68.
238. Rasmussen K, Jørgensen KJ, Gøtzsche PC. Citations of scientific results and conflicts of interest: the case of mammography screening. Evidence - Based Medicine (English Edition). 2013;18:83-9.
239. Schroll JB, Bero L, Gøtzsche PC. Searching for unpublished data for Cochrane reviews: cross sectional study. BMJ (Online) 2013;346:f2231.
240. Wolfe N, Gøtzsche PC, Bero LA. Strategies for obtaining unpublished drug trial data: a qualitative interview study. Syst Rev 2013;2:31.
241. Zahl P-H, Juhl Jørgensen K, Gøtzsche PC. Overestimated lead times in cancer screening has led to substantial underestimation of overdiagnosis. Br J Cancer 2013;109:2014-9.
242. Chan AW, Song F, Vickers A, Jefferson T, Dickersin K, Gøtzsche PC, Krumholz HM, Ghersi D, van der Worp HB. Increasing value and reducing waste: addressing inaccessible research. Lancet 2014;383:257-66.
243. Smith R, Gøtzsche PC, Groves T. Should journals stop publishing research funded by the drug industry? BMJ 2014 ;348:g171.
244. Maund E, Tendal B, Hróbjartsson A, Lundh A, Gøtzsche PC. Coding of adverse events of suicidality in clinical study reports of duloxetine for the treatment of major depressive disorder: descriptive study. BMJ 2014;348:g3555.
245. Maund E, Tendal B, Hróbjartsson A, Jørgensen KJ, Lundh A, Schroll J, Gøtzsche PC. Benefits and harms in clinical trials of duloxetine for treatment of major depressive disorder: comparison of clinical study reports, trial registries, and publications. BMJ 2014;348:g3510.
246. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. J R Soc Med 2014;107:256-7.
247. Gøtzsche PC. Why I think antidepressants cause more harm than good. Lancet Psychiatry 2014;1:104-6.
248. Gøtzsche PC, Johansen HK. Nystatin prophylaxis and treatment in severely immunodepressed patients. Cochrane Database Syst Rev 2014;(9):CD002033.
249. Gøtzsche PC, Johansen HK. Routine versus selective antifungal administration for control of fungal infections in patients with cancer. Cochrane Database Syst Rev 2014;(9):CD000026.
250. Gøtzsche PC. "Human guinea pig" asks for animal studies. BMJ (Online) 2014;349:g6714.
251. Gøtzsche PC. Our prescription drugs kill us in large numbers. Polskie Archiwum Medycyny Wewnętrznej 2014;124:628-34.
252. Johansen HK, Gøtzsche PC. Amphotericin B versus fluconazole for controlling fungal infections in neutropenic cancer patients. Cochrane Database Syst Rev 2014;(9):CD000239.
253. Johansen HK, Gøtzsche PC. Amphotericin B lipid soluble formulations versus amphotericin B in cancer patients with neutropenia. Cochrane Database Syst Rev 2014;(9):CD000969.
254. Jørgensen KJ, Gøtzsche PC, Dalbøge CS, Johansen HK. Voriconazole versus amphotericin B or fluconazole in cancer patients with neutropenia. Cochrane Database Syst Rev 2014;(2):CD004707.
255. Jørgensen AW, Lundstrøm LH, Wetterslev J, Astrup A, Gøtzsche PC. Comparison of results from different imputation techniques for missing data from an anti-obesity drug trial. PLoS One 2014;9:e111964.

256. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, Mulrow CD, Pocock SJ et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. Int J Surg 2014;12:1500-24.
257. von Elm E, Altman DG, Egger M, Pocock SJ, Gøtzsche PC, Vandenbroucke JP et al. The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) Statement: guidelines for reporting observational studies. IntJ Surg 2014;12:1495-99.
258. Zahl P-H, Jørgensen KJ, Gøtzsche PC. Lead-time models should not be used to estimate overdiagnosis in cancer screening. J Gen Intern Med 2014;29:1283-6.
259. Gøtzsche PC. Does long term use of psychiatric drugs cause more harm than good? BMJ 2015;350:h2435.
260. Gøtzsche PC. Mammography screening is harmful and should be abandoned. J R Soc Med 2015;108:341-5.
261. Hutton B, Salanti G, Caldwell DM, Chaimani A, Schmid CH, Cameron C, et al. The PRISMA extension statement for reporting of systematic reviews incorporating network meta-analyses of health care interventions: checklist and explanations. Ann Intern Med 2015;162:777-84.
262. Johansen HK, Gøtzsche PC. Vaccines for preventing infection with Pseudomonas aeruginosa in cystic fibrosis. Cochrane Database Syst Rev 2015;(8):CD001399.
263. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Screening with urinary dipsticks for reducing morbidity and mortality. Cochrane Database Syst Rev 2015;(1):CD010007.
264. Moher D, Shamseer L, Clarke M, Ghersi D, Liberati A, Petticrew M, et al. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. Syst Rev 2015;4:1.
265. Rasmussen KM, Schroll J, Gøtzsche PC, Lundh A. Under-reporting of conflicts of interest among trialists: a cross-sectional study. J R Soc Med 2015;108:101-7.
266. Gøtzsche PC, Johansen HK. Intravenous alpha-1 antitrypsin augmentation therapy for treating patients with alpha-1 antitrypsin deficiency and lung disease. Cochrane Database Sys Rev 2016;(9):CD007851.
267. Johansson M, Brodersen J, Gøtzsche PC, Juhl Jørgensen K. Screening for reducing morbidity and mortality in malignant melanoma (Protocol). Cochrane Database Sys Rev 2016;(9):CD012352.
268. Bielefeldt AØ, Danborg PB, Gøtzsche PC. Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. J R Soc Med 2016;109:381-92.
269. Davis C, Lexchin J, Jefferson T, Gøtzsche P, McKee M. "Adaptive pathways" to drug authorisation: adapting to industry? BMJ 2016;354:i4437.
270. Jørgensen KJ, Gøtzsche PC. Breast cancer: Updated screening guidelines - much ado about small improvements. Nat Rev Clin Oncol 2016;13:139-40.
271. Schroll JB, Penninga EI, Gøtzsche PC. Assessment of adverse events in protocols, clinical study reports, and published papers of trials of orlistat: a document analysis. PLoS Med 2016;13:e1002101.
272. Sharma T, Guski LS, Freund N, Gøtzsche PC. Suicidality and aggression during antidepressant treatment: systematic review and meta-analyses based on clinical study reports. BMJ 2016;352:i65.
273. Simonsen AL, Danborg PB, Gøtzsche PC. Persistent sexual dysfunction after early exposure to SSRIs: Systematic review of animal studies. Int J Risk Saf Med 2016;28:1-12.
274. Maund E, Guski LS, Gøtzsche PC. Considering benefits and harms of duloxetine for treatment of stress urinary incontinence: a meta-analysis of clinical study reports. CMAJ 2017;189:E194-203.
275. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl PH. Breast cancer screening in Denmark: a cohort study of tumor size and overdiagnosis. Ann Intern Med 2017;166:313-23.
276. Danborg PB, Simonsen AL, Gøtzsche PC. Impaired reproduction after exposure to ADHD drugs: Systematic review of animal studies. Int J Risk Saf Med 2017;29(1-2):107-24.
277. Sharma T, Gøtzsche PC, Kuss O. The Yusuf-Peto method was not a robust method for meta-analyses of rare events data from antidepressant trials. J Clin Epidemiol 2017;91:129-36.
278. Boesen K, Saiz LC, Erviti J, Storebø OJ, Gluud C, Gøtzsche PC, Jørgensen KJ. The Cochrane Collaboration withdraws a review on methylphenidate for adults with attention deficit hyperactivity disorder. Evid Based Med 2017;22:143-7.
279. Gøtzsche PC, Gøtzsche PK. Cognitive behavioural therapy halves the risk of repeated suicide attempts: systematic review. J R Soc Med 2017;110:404-10.
280. Rasmussen K, Bero L, Redberg R, Gøtzsche PC, Lundh A. Collaboration between academics and industry in clinical trials: cross sectional study of publications and survey of lead academic authors. BMJ 2018;363:k3654.
281. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias. BMJ Evid Based Med 2018;23:165-8.
282. Marquardsen M, Ogden M, Gøtzsche PC. Redactions in protocols for drug trials: what industry sponsors concealed. J R Soc Med 2018;111:136-41.

283. Jørgensen L, Gøtzsche PC, Jefferson T. Index of the human papillomavirus (HPV) vaccine industry clinical study programmes and non-industry funded studies: a necessary basis to address reporting bias in a systematic review. Syst Rev 2018;7:8.
284. Gøtzsche PC. Patients not patents: Drug research and development as a public enterprise. Eur J Clin Invest 2018;48(2):e12875.
285. Gøtzsche PC. A totally new system is needed for drug research and development. Eur J Clin Invest 2018;48(2):e12883.
286. Jørgensen L, Doshi P, Gøtzsche PC, Jefferson T Challenges of independent assessment of potential harms of HPV vaccines. BMJ 2018;362;k3694.
287. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. General health checks in adults for reducing morbidity and mortality from disease. Cochrane Database Syst Rev 2019;1:CD009009.
288. Börjesson J, Gøtzsche PC. Effect of lithium on suicide and mortality in mood disorders: A systematic review. Int J Risk Saf Med 2019;30(3):155-166.
289. Danborg PB, Gøtzsche PC. Benefits and harms of antipsychotic drugs in drug-naïve patients with psychosis: A systematic review. Int J Risk Saf Med 2019 Sep 14. doi: 10.3233/JRS-195063. [Epub ahead of print].
290. Danborg PB, Valdersdorf M, Gøtzsche PC. Long-term harms from previous use of selective serotonin reuptake inhibitors: A systematic review. Int J Risk Saf Med 2019;30(2):59-71.
291. Gøtzsche PC. What is the moral collapse in the Cochrane Collaboration about? Ind J Med Ethics 2019 Oct-Dec;4(4) NS:303-9.
292. Gøtzsche PC. Cochrane authors on drug industry payroll should not be allowed. BMJ Evid Based Med 2019 Apr 11.
293. Gøtzsche PC. Institute for Scientific Freedom. BMJ Evid Based Med 2019 Aug;24(4):123-4.
294. Johansson M, Brodersen J, Gøtzsche PC, Jørgensen KJ. Screening for reducing morbidity and mortality in malignant melanoma. Cochrane Database Syst Rev 2019 Jun 3;6:CD012352.
295. Jørgensen L, Gøtzsche PC, Jefferson T. Increased incidence of cervical cancer in Sweden: an unlikely link with human papillomavirus (HPV) vaccination. BMJ Sex Reprod Health 2019 Sep 18. pii: bmjsrh-2018-200245. doi: 10.1136/bmjsrh-2018-200245. [Epub ahead of print].
296. Paludan-Müller AS, Ogden MC, Marquardsen M, Vive J, Jørgensen KJ, Gøtzsche PC. Do protocols for new randomised trials take previous similar trials into account? Cohort study of contemporary trial protocols. BMJ Open 2019;9:e026661.
297. Gøtzsche PC, Vinther S, Sørensen A. Forced medication in psychiatry: Patients' rights and the law not respected by Appeals Board in Denmark. Clin Neuropsychiatry 2019;16:229-33.
298. Sharma T, Guski LS, Freund N, Meng DM, Gøtzsche PC. Drop-out rates in placebo-controlled trials of antidepressant drugs: A systematic review and meta-analysis based on clinical study reports. Int J Risk Saf Med 2019;30:217-32.
299. Gøtzsche PC, Dinnage O. What have antidepressants been tested for? A systematic review. Int J Risk Saf Med 2020;31:157-163.
300. Paludan-Müller AS, Sharma T, Rasmussen K, Gøtzsche PC. Extensive selective reporting of quality of life in clinical study reports and publications of placebocontrolled trials of antidepressants. Int J Risk Saf Med 2020 (in press).
301. Gøtzsche PC. Long-term use of antipsychotics and antidepressants is not evidence-based. Int J Risk Saf Med 2020;31:37-42.
302. Gøtzsche PC. Long-term use of benzodiazepines, stimulants and lithium is not evidence-based. Clin Neuropsychiatry 2020;17:281-3.

Articles without peer review

1. Gøtzsche PC. Vandtægers respirationsforhold (Heteroptera, Hydrocorisae). Special subject, University of Copenhagen, Faculty for Natural Sciences, 1974, 83 pp.
2. Gøtzsche PC, Marinelli K, Gylding-Sabroe JP, Larsen N-E, Sørensen K. Bioavailability of naproxen tablets and suppositories in steady state. Scand J Rheumatol 1983;suppl 50:1-9.
3. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. Ugeskr Læger 1983;145:3902-4.
4. Gøtzsche PC, Karlsen FØ, Andersen B. Dosis-respons bias. Nord Med 1986;101:24-5.
5. Jørgensen FR, Gøtzsche PC, Hein P, Jensen CM, Nielsen BM, Nielsen FM, Rønholt EB, Tranberg FH. Naproxen (Naprosyn) og mobilisering ved behandling af akut ankeldistorsion. Ugeskr Læger 1986;148:1266-8.
6. Gøtzsche PC. Vurdering af kliniske lægemiddelundersøgelser. Ugeskr Læger 1986;148:2417-20.
7. Ørnskov F, Gøtzsche PC. Lodtrækningsprincippet. Et forsøg på en medicinsk-etisk analyse. Ugeskr Læger 1988;150:897-900.

8. Gøtzsche PC. Oversigtsartikler og meta-analyser (leder). Ugeskr Læger 1988;150:1765-6.
9. Olesen B, Gøtzsche PC, Bygbjerg IC, Møller LH, Faber V. Hospitalsomkostninger ved diagnostik og behandling af AIDS-patienter. De første 33 patienter på Rigshospitalet. Ugeskr Læger 1988;150:2250-2.
10. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. Videnskabelige artikler i Ugeskrift for Læger gennem 25 år. Artikeltype og forsøgsdesign. Ugeskr Læger 1989;151:218-20.
11. Gøtzsche PC, Forrest M, Hermann GG, Jørgensen PE, Andersen B. Videnskabelige artikler i Ugeskrift for Læger gennem 25 år. Analyse og tolkning af forsøgsresultater. Ugeskr Læger 1989;151:220-2.
12. Gøtzsche PC. Medicinske studenters holdning til lodtrækning og selvvalg ved brystkræftkirurgi og forslag om et nyt design. Ugeskr Læger 1989;151:2719-21.
13. Mandrup-Poulsen T, Gøtzsche PC, Ott P, Pedersen BK, Sørensen JB. Dansk intern medicin i en brydningstid på tærsklen til det 21. århundrede. Bibliotek for Læger 1991;183:69-82.
14. Gøtzsche PC. Biasproblemer i kort- og langtidsdobbeltblindforsøg og forslag til forbedringer. Månedsskr Prakt Lægegern 1992;70:159-64.
15. Gøtzsche PC. Metaanalyser: metodologiske og forskningsetiske overvejelser. Bibliotek for Læger 1993;185:17-29.
16. Gøtzsche PC. Det Nordiske Cochrane Center: samarbejde om systematiske oversigter over behandlingers effekter. Nord Med 1994;109:244-5.
17. Gøtzsche PC. Meta-analyser og kvalitetssikring. Journal 1994;2:16-7.
18. Gøtzsche PC. Er placebobegrebet logisk? Bibl Læger 1995;187:71-8.
19. Rigshospitalets Forskningspolitik, 1994, 16 pp.
20. Gøtzsche PC. Supplement til Rigshospitalets Forskningspolitik, 1994, 40 pp.
21. Gøtzsche PC. Kontrollerede kliniske forsøgs troværdighed - randomiseringsproblemet. Ugeskr Læger 1995;157:597-8.
22. Gøtzsche PC, Krog JW, Moustgaard R. Bibliometrisk analyse af dansk sundhedsvidenskabelig forskning 1988-1992. Ugeskr Læger 1995;157:5075-81.
23. Gøtzsche PC. Patientbehandling og sikkerhed - Cochrane-databasernes betydning. Ugeskr Læger 1995;157:6247.
24. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. København: Det Etiske Råd; 1996:1-32.
25. Gøtzsche PC. Det Nordiske Cochrane Center og Netværk: Nordisk samarbejde om systematiske oversigter over behandlingers effekter. Social- och Hälsovårdsnytt i Norden 1996;13:10-11.
26. Gøtzsche PC. Anvendte procedurer skal være videnskabeligt dokumenterede. Lægen 1996;14:10-2.
27. Hallas J, Gøtzsche PC. Det Nordiske Cochrane Center og Netværk - et samarbejde om systematiske oversigter over behandlingseffekter. Farmakoepi-Nyt 1996;nov:4-5.
28. Olsen O, Gøtzsche PC. Nødvendigheden af elektronisk opdaterede metaanalyser: Doppler-ultralyd i obstetrikken som eksempel. Ugeskr Læger 1997;159:27-8.
29. Gøtzsche PC. Fibigers forsøg om serumbehandling af difteri. Bibl Læger 1997;189:143-6.
30. Gøtzsche PC, Jensen KL, Hammarquist C. Randomiserede kliniske forsøg i Ugeskrift for Læger 1948-1995. Ugeskr Læger 1997;159:4762-5.
31. Gøtzsche PC. Cochrane-samarbejdets betydning for evidensbaseret medicin. Ugeskr Læger 1997;159:6721-4.
32. Gøtzsche PC. Hjælp til et evidensbaseret sundhedsvæsen. Social- & Hälsovårdsnytt i Norden 1998;2:12-13 og www.shn.dk/2-98/cochrane.htm.
33. Gøtzsche PC. Randomisering og blinding i sundhedsvidenskabelig forskning. Bibl Læger 1998;190:369-80.
34. Gøtzsche PC. Lus i skindpelsen. Ugeskr Læger 1998;160:7610-1.
35. Gøtzsche PC. Det Nordiske Cochrane Center: Status efter 5 år og fremtidsperspektiver. Ugeskr Læger 1999;161:932-4.
36. Olsen O, Gøtzsche PC. Der er noget galt i mammografistudierne! Ingen støtte til konklusionen at brystkræftscreening har gavnlig effekt. Läkartidningen 2000;97:286-7.
37. Gøtzsche PC. Cochranesamarbetets betydelse för evidensbaserad medicin. Läkartidningen 2000:97:3180-2.
38. Wille-Jørgensen PA, Gøtzsche PC. Evidensbaseret kirurgi. Ugeskr Læger 2001;163:737-40.
39. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? Ugeskr Læger 2001;163:1576.
40. Pedersen T, Gluud CN, Gøtzsche PC, Matzen P, Wille-Jørgensen P. Hvad er evidensbaseret medicin? Ugeskr Læger 2001;163:3769-72.
41. Gøtzsche PC, Olsen O. Screening for mammacancer - to år efter. Ugeskr Læger 2002;164:204-6.

42. Gøtzsche PC, Jørgensen KJ. Screening for brystkræft - et tveægget sværd. Ugeskr Læger 2005;167:1312-4.
43. Gøtzsche PC. Uafhængig klinisk interventionsforskning er meget påkrævet. Ugeskr Læger 2005;167:1491-4.
44. Gøtzsche PC. COX-2-hæmmere og andre nonsteroide antiinflammatoriske stoffer - hvad er fremtiden? Ugeskr Læger 2006;168:1972-3.
45. Gøtzsche PC. Paracetamol har samme effekt som nonsteroide antiinflammatoriske stoffer ved akutte skader i bevægeapparatet. Ugeskr Læger 2006;168:1981-2.
46. Gøtzsche PC. [Freedom of expression and editorial independence: Four firings and a Kafkanian process]. Ugeskr Laeger 2008 Apr 28;170(18):1537-8.
47. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. Månedsskr Prakt Lægegern 2008;86 (maj):551-7.
48. Gøtzsche PC. Kasuistiske meddelelser: fortsat en hovedkilde til forvirring, men nu på patientgruppeniveau. Bibl Læger 2009;201:87-91.
49. Gøtzsche PC, Johansen HK, Haahr MT, Altman DG, Chan A-W. Videnskabelig uredelighed. Ugeskr Læger 2009;171:1206-9.
50. Gøtzsche PC. Atter fri adgang til Cochrane-biblioteket for alle danskere. Ugeskr Læger 2009;171:932-3.
51. Gøtzsche PC, Hartling O, Nielsen M, Jørgensen KJ, Brodersen J. Invitation til brystkræftscreening: propaganda eller information? Ugeskr Læger 2009;171:1963.
52. Gøtzsche PC, Lundh A. Industrisponsoreret efteruddannelse hører ikke hjemme i et evidensbaseret sundhedsvæsen. Ugeskr Læger 2009;171:2228-9.
53. Gøtzsche PC, Jørgensen KJ. [Honest information about mammography screening, please!]. Lakartidningen. 2009;106(44):2860-1.
54. Gøtzsche PC. Evidensbaseret medicin: Ankestyrelsen mod Sundhedsstyrelsen om husstøvmider. Ugeskr Læger 2009;171:3727.
55. Jørgensen AW, Gøtzsche PC. [Insufficient access to research data not acceptable]. Ugeskr Laeger 2010 May 24;172(21):1585.
56. Gøtzsche PC. Lovforslaget om kliniske forsøg viger uden om de allerstørste problemer. Ugeskr Laeger 2011;173(11):840.
57. Gøtzsche PC. Hvorfor fejlinformerer Sundhedsstyrelsen om mammografiscreening? Videnskab.dk 2011; http://videnskab.dk/krop-sundhed/hvorfor-fejlinformerer-sundhedsstyrelsen-om-mammografiscreening.
58. Gøtzsche PC. Medicinalindustriens forskningsfusk og de købte læger. 2011; http://videnskab.dk/kultur-samfund/medicinalindustriens-forskningsfusk-og-de-kobte-laeger.
59. Gøtzsche PC. Åbent brev til Lundbeck om antidepressiva og selvmord. Videnskab dk 2011;http://videnskab.dk/krop-sundhed/abent-brev-til-lundbeck-om-antidepressiva-og-selvmord.
60. Gøtzsche PC, Tendal B, Clarke M. Review production in The Cochrane Collaboration - where is it happening and why? Cochrane Database Syst Rev 2011;Suppl 1:16-9.
61. Gøtzsche PC. We need access to all data from all clinical trials. Cochrane Database Syst Rev 2011;12:ED000035.
62. Gøtzsche PC. Hvorfor så snævre grænser for omfang i Ugeskriftet? Ugeskr Læger 2012;174:297.
63. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for breast cancer with mammography. The Nordic Cochrane Centre 2012. Available from: http://nordic.cochrane.org/
64. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J. Screening for brystkræft med mammografi. The Nordic Cochrane Centre 2012. Available from: http://nordic.cochrane.org/
65. Jørgensen KJ, Gøtzsche PC. [Mortality in breast cancer is decreasing - but not because of screening. Time to abolish the mammography screening]. Läkartidningen 2012;109:690-2.
66. Jørgensen KJ, Gøtzsche PC. Rintasyöpäkuolleisuus vähenee, muttei seulonnan ansiosta. Suomen Lääkärilehti 2012;11:856-8.
67. Gøtzsche PC. Mammografiscreening gør raske kvinder syge. Fokus på Kræft og sygepleje 2012;2:18-20.
68. Gøtzsche PC. Lægers råd om medicin er ikke sunde. Politikens kronik 2012 Nov 29.
69. Gøtzsche PC. Vores lykkepille-epidemi er dybt skadelig. Berlingskes kronik 2012 Dec 16.
70. Gøtzsche PC. Overdiagnostik og overmedicinering i børnepsykiatrien. Pædagogisk Psykologisk Tidsskrift 2013;50:95-100.
71. Gøtzsche PC. Bør bekendtgørelsen om videnskabelig uredelighed revideres endnu en gang? Ugeskr Læger 2013;175:2512-3.
72. Gøtzsche PC. Alvorlige skadevirkninger af HPV-vaccinen. HPV-magasinet 2016;1:18-9.

73. Gøtzsche PC. De mange usynlige medicindødsfald: Et chokerende højt antal mennesker dør på grund af den medicin, de tager. Men ofte er de dødsfald usynlige før lægen. Løsningen er at bruge mindre medicin. Ugeskr Læger 2016;10:990-1.
74. Gøtzsche PC, Lund K. Tvangsmedisinering må forbys. Kritisk Juss 2016;2:118-57.
75. Gøtzsche PC. What do we know about the safety of the HPV vaccines? Tidsskr Nor Laegeforen 2017;137:11-2.
76. Gøtzsche PC. Hvad er der kommet ud af kræftindsatserne? Dagens Medicin 2017;2:8-9.
77. Gøtzsche PC. Chemical or Psychological Psychotherapy? 2017; Jan 29. www.madinamerica.com/.
78. Gøtzsche PC. Editorial Misconduct: Finnish Medical Journal Rejects Paper on Suicide Risk. 2017; Feb 22. www.madinamerica.com/.
79. Gøtzsche PC. Vi kan og bør undvære antidepressiv medicin: kritik af Sundhedsstyrelsen. www.deadlymedicines.dk.
80. Gøtzsche PC. DSAM-formand på afveje om antidepressiva. Dagens Medicin 2017; 3. marts.
81. Gøtzsche PC. Svar til: DepressionsForeningen: Medicin bliver ofte det eneste mulige valg. http://videnskab.dk/ 2017; 8. marts.
82. Gøtzsche PC. Medikamentfri behandling. Dagens Medisin 2017; 10. marts.
83. Gøtzsche PC. Antidepressiva bör inte användas till barn och ungdomar. Läkartidningen 2017; 12. marts.
84. Gøtzsche PC. Antidepressiva skader mere end de gavner. Dagens Medicin 2017;15. marts.
85. Gøtzsche PC. Norske Renate Hoel døde pludseligt og uventet i juli 2005, 34 år gammel. Ugeskr Læger 2017; 23. marts.
86. Toft B, Gøtzsche PC. Psykofarmakaepidemien kan bekæmpes. Information 2017; 3. april.
87. Jørgensen KJ, Gøtzsche PC, Jørgensen T. Tilstrækkelig evidens til at undlade tjek. Dagens Medicin 2017;7:23.
88. Gøtzsche PC. Private virksomheder skal også kunne undersøges for videnskabelig uredelighed. Ugeskr Læger 2017;179:633.
89. Gøtzsche PC. Røgfrit Danmark. 2017; 28. april. www.deadlymedicines.dk.
90. Gøtzsche PC. Kræftens Bekæmpelse vildleder. Dagens Medicin 2017; 17. marts.
91. Gøtzsche PC. Ingen pålitlig evidens visar att läkemedel kan förebygga självmord. Läkartidningen 2017; 1. maj.
92. Gøtzsche PC. Medicin mod Alzheimer virker ikke. Ugeskr Læger 2017; 8. maj.
93. Gøtzsche PC. Måske kan du blive medicinfri. Kronik. Jyllands-Posten 2017; 13. maj.
94. Gøtzsche PC. Skal angst behandles med piller? Angstavisen 2017; nr. 57, juni:4-6.
95. Gøtzsche PC. Depressionspiller gør større skade end gavn. Politiken 2017; 25. juni.
96. Gøtzsche PC. Hun fik den sidste kemo på vej til kapellet. Kronik. Politiken 2017; 2. juli.
97. Gøtzsche PC. Antidepressants increase the risk of suicide, violence and homicide at all ages. BMJ 2017; Sept 3. http://www.bmj.com/content/358/bmj.j3697/rr-4.
98. Gøtzsche PC. Psychiatry Ignores an Elephant in the Room. 2017; Sept 21. www.madinamerica.com/.
99. Gøtzsche PC. Din overvægt er en selvskabt plage - derfor skal du selv betale. Berlingske 2017; 12. aug.
100. Gøtzsche PC. What is it like being on the Governing Board? 2017; Sept 27. http://community.cochrane.org/news/what-it-being-governing-board.
101. Gøtzsche P. Medicinfri psykiatri. http://tidsskriftet.no/comment-view/11179. 2017 (ingen dato).
102. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Hvordan skal man trappe ud af psykofarmaka? Kronik. Jyllands-Posten 2017; 10. okt.
103. Danborg PB, Simonsen AL, Hróbjartsson A, Gøtzsche PC. Long-term changes in observed behaviour after exposure to psychiatric drugs: a systematic review of animal studies. Nordic Cochrane Centre 2017; Nov 14. http://nordic.cochrane.org/.
104. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Learning About Psychiatric Drug Withdrawal. 2017; Nov 16. https://www.madinamerica.com/.
105. Gøtzsche PC. Psychiatrists Roadblock Psychiatric Drug Withdrawal Initiatives: Part 1. 2017; Dec 4. https://breggin.com/.
106. Gøtzsche PC, Toft B, Rüdinger B, Kortegaard L, Runciman O, Sørensen A. Udtrapning af psykofarmaka: En opfordring til de praktiserende læger. Practicus 2017; 17. dec:48-50.
107. Jørgensen KJ, Gøtzsche PC. Lægemiddelstyrelsen og lægemiddelindustrien ligner et lukket kredsløb. Ugeskr Læger 2017;179:2336-7.
108. Gøtzsche PC. What do we know about the safety of the HPV vaccines? Tidsskr Nor Laegeforen 2017;137:11-2.
109. Jørgensen KJ, Gøtzsche PC. Lægemiddelstyrelsen og lægemiddelindustrien ligner et lukket kredsløb. Ugeskr Læger 2017;179:2336-7.
110. Jørgensen KJ, Gøtzsche PC. Lægemiddelstyrelsens nonchalante holdning til kræftmedicin og interessekonflikter. Ugeskr Læger 2018;180:170-1.

111. Jørgensen KJ, Gøtzsche PC. Uhæderlighed og interessekonflikter er to forskellige ting, Henrik Ullum. Ugeskr Læger 2018;180:172.
112. Jørgensen KJ, Gøtzsche PC. Arbejder Lægemiddelstyrelsen for patienterne? Politikens Kronik 2018; 5 febr.
113. Jørgensen KJ, Gøtzsche PC. Interessekonflikter er allerede diskvalificerende. Heldigvis. Ugeskr Læger 2018;180:268.
114. Boesen K, Simonsen AL, Danborg PB, Jørgensen KJ, Gøtzsche PC. Lægemiddelannoncer i Ugeskrift for Læger bør ikke forekomme. Ugeskr Læger 2018;180:1596-7.
115. Jørgensen L, Gøtzsche PC, Jefferson T. The Cochrane HPV vaccine review was incomplete and ignored important evidence of bias: Response to the Cochrane editors. BMJ Evidence-Based Medicine. 2018; 17 September.
116. Gøtzsche PC. Moralsk ledelseskrise i Cochrane-samarbejdet. Politikens Kronik 2018; 27. sept.
117. Gøtzsche PC. Cochrane—no longer a Collaboration. https://blogs.bmj.com/bmj/2018/11/08/peter-c-gotzsche-cochrane-no-longer-a-collaboration/. 2018; 8 Nov.
118. Gøtzsche PC. It's Unlikely That 'Antidepressants' Have a True Effect on Depression. https://www.madinamerica.com/2018/01/antidepressants-effect-depression/. 2018; 8 Jan.
119. Gøtzsche PC. Psychiatrists Roadblock Psychiatric Drug Withdrawal Initiatives: Part 2.
120. Gøtzsche PC. https://breggin.com/psychiatrists-roadblock-psychiatric-drug-withdrawal-initiatives-part-2/. 2018 (not dated).
121. Gøtzsche PC. Endnu et tragisk selvmord på depressionspiller. Jyllands-Postens Kronik 2018; 3. feb.
122. Gøtzsche PC. Rewarding the Companies That Cheated the Most in Antidepressant Trials. March 7, 2018 https://www.madinamerica.com/2018/03/rewarding-companies-cheated-most-antidepressant-trials/. 2018; 7 March.
123. Gøtzsche PC. Forbruget af depressionspiller er næsten halveret hos børn og unge i Danmark. http://www.deadlymedicines.dk/forbruget-af-depressionspiller-er-naesten-halveret-hos-born-og-unge-i-danmark/. 2018; 1 maj.
124. Gøtzsche PC. Usage of depression pills almost halved among children in Denmark. https://www.madinamerica.com/2018/05/usage-depression-pills-almost-halved-among-children-denmark/. 2018; 4 May.
125. Davies J, Read J, Hengartner MP, Cosci F, Fava G, Chouinard G, van Os J, Nardi A, Gøtzsche P, Groot P, Offidani E, Timimi S, Moncrieff J, Spada M, Guy A. Clinical guidelines on antidepressant withdrawal urgently need updating. BMJ 2019 May 20;365:l2238.
126. Gøtzsche PC. The harmful myth about the chemical imbalance causing psychiatric disorders. CrossFit 2019 June 28.
127. Gøtzsche PC. "Trust me, I'm a doctor". CrossFit 2019 June 16.
128. Gøtzsche PC. Expert Report. Effect of DTP Vaccines on Mortality in Children in Low-Income Countries. 2019 June 19.
129. Gøtzsche PC. Forced drugging with antipsychotics is against the law: decision in Norway. Mad in America 2019 May 4. https://www.madinamerica.com/2019/05/forced-drugging-antipsychotics-against-law/
130. Gøtzsche PC. Institutional corruption in the Cochrane Collaboration. Mad in America 2019 Feb 14.
131. Gøtzsche PC. Norsk ombudsmand har afgjort, at tvangsmedicinering ikke kan begrundes. Psykiatriavisen 2019 Jan 27.
132. Gøtzsche PC. The depression pill epidemic. CrossFit 2019 June 4.
133. Gøtzsche PC. Why we're establishing an Institute for Scientific Freedom. Mad in America 2018 Dec 30.
134. Gøtzsche PC, Runcimann O, Bækgaard J, Sørensen A, Toft BS. Fem læger, psykologer og farmaceuter: Skru ned for psykofarmaka. Piller er ikke løsningen. Politikens kronik 2019 Sept 8.
135. Gøtzsche PC, Runcimann O, Bækgaard J, Sørensen A, Toft BS. The epidemic of psychiatric drug usage – taper off the pills. Deadly Medicines 2019 Oct 22.
136. Gøtzsche PC. Surviving psychiatry: a typical case of serious psychiatric drug harms. Mad in America 2020 Jan 7.

Book chapters

1. Gøtzsche PC. Problemer og muligheder ved lægemiddelundersøgelser ved reumatoid artrit. I: Jarner D, Friis J, eds. Dansk Reumatologisk Selskab: postgraduat kursus om arthritis rheumatoides. København: Astra, 1992:18-30.
2. The Cochrane Collaboration Handbook. Sackett D, Chalmers I, Silagy C, Gøtzsche PC, Dickersin K, Oxman A, eds. 1994.

3. Gøtzsche PC. Clinical practice should reflect clinical science. In: Gordon C, Christensen JP, eds. Health Telematics for Clinical Guidelines and Protocols. Amsterdam: IOS Press, 1995:17-25.
4. Gøtzsche PC. Meta-analyses: assets and limitations. In: Rose C, Larsen S, Hansen O, Bergh J, Andersen J, eds. Recent advances in breast cancer. Colloquium, Scandinavian Breast Group, Hindsgavl, Oct 11-14. Bristol-Myers Squibb, 1996:139-45.
5. Kleijnen J, Gøtzsche PC, Kunz RH, Oxman A, Chalmers I. So what's so special about randomisation? In: Maynard A, Chalmers I, eds. Non-random reflections on health services research: on the 25 anniversary of Archie Cochrane's Effectiveness and Efficiency. London: BMJ Books, 1997:231-49.
6. Gøtzsche PC. Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? I: Evidensbaseret sundhedsvæsen. Rapport fra II symposium om evidensbaseret sundhedsvæsen. København: Institut for Sundhedsvæsen, DSI rapport 98.04, 1998:119-25.
7. Gøtzsche PC. Metaanalyse - begreber og metoder. I: Andersen D, Almind G, Bock E, Havsteen B, Hørder M, Riis P. Sundhedsvidenskabelig forskning, 5. udg. København: FADL's Forlag, 1999:303-14.
8. Gøtzsche PC. Eettisiä näkökulmia systemaattisiin kirjallisuuskatsauksiin. Helsinki: Stakes, FinOHTAn raportti 11, 1999:19-24.
9. Gøtzsche PC, red. Introduktion til forskning. http://www.dadlnet.dk/dok?/2videnskab/bibliotekforlaeger/frz_forskning.htm, april 2000.
10. Gøtzsche PC. Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. I: MTV, sundhedstjenesteforskning og klinisk praksis. Rapport fra et symposium om evidensbaseret sundhedsvæsen. København: Statens Institut for Medicinsk Teknologivurdering, 2000. p. 38-44.
11. Johansen HK, Gøtzsche PC Lægemiddelindustrien og ytringsfriheden. I: Høiby (red): Råb op og sig stop. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
12. Gøtzsche PC. Screeningsindustrien og ytringsfriheden. I: Høiby (red): Råb op og sig stop. http://www.laegersytringsfrihed.dk/pdf/Yderligere_indlaeg.pdf. 2005.
13. Gøtzsche PC. Assessment bias. In: Kotz S, Balakrishnan N, Read CB, Vidakovic B, eds. Encyclopedia of statistical sciences, 2nd ed. Hoboken, New Jersey: John Wiley & Sons, 2006;vol 1:237-40.
14. Also published in: Wiley Encyclopedia of Clinical Trials, 2007. DOI: 10.1002/9780471462422.eoct062.
15. Gøtzsche PC. Commercial interests versus common goods. In: Lötjönen S, von Troil H, eds. Bioethics, Politics and Business. Copenhagen: Nordic Council of Ministers, TemaNord 2008:125-32. ISBN 978-92-893-1728-3.
16. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. Medicinsk Kompendium, 17. udg. København: Nyt Nordisk Forlag, 2009, kap. 75. ISBN 978-87-17-03933-9.
17. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Informerat samtycke vid mammografiscreening. I: Brodersen J, Hovelius B, Hvas L, eds. Skapar vården ohälsa? Allmänmedicinske reflektioner. Lund: Studentlitteratur AB, 2009:167-75.
18. Brodersen J, Hartling O, Nielsen M, Gøtzsche P. Det informerede samtykke ved screening for brystkræft. I: Brodersen J, Hovelius B, Hvas L, eds. Kan sundhedsvæsenet skabe usundhed? Refleksioner fra almen praksis. København: Månedsskrift for Praktisk Lægegerning, 2009:153-162.
19. Gøtzsche PC. Alternativ behandling. I: Ove B. Schaffalitzky de Muckadell, Stig Haunsø og Hendrik Vilstrup, red. Medicinsk Kompendium. 18. udg. København: Nyt Nordisk Forlag; 2013, kap. 73.
20. Gøtzsche PC. Overdiagnostik og overbehandling i psykiatrien. I: Brinkmann S and Petersen, eds. Diagnoser. Aarhus: Klim; 2015:kapitel 7.
21. Gøtzsche PC. Psychopharmacology is not evidence-based medicine. In: Davies J, ed. The sedated Society. London: Palgrave Macmillan; 2017:23-50.
22. Gøtzsche PC, Lund K. Intet kunnskapsgrunnlag for tvangsmedisinering. In: Kolstad A, Kogstad R, eds. Medikalisering av psykososciale problemer. Oslo: Abstrakt Forlag; 2019: 175-210.

Correspondence, book reviews and similar

1. Gøtzsche PC, Gjørup IE. Virkninger af moderat lakridsindtagelse. Ugeskr Læger 1984;146:207.
2. Gøtzsche PC. Turnusordningen - eller hvordan tre måneder bliver til ingenting. Ugeskr Læger 1984;146:2765.
3. Gøtzsche PC, Karlsen FØ. Buprenorfin og morfin. Ugeskr Læger 1985;147:1786.
4. Gøtzsche PC, Bygbjerg IC. Leverbiopsi ved AIDS? Ugeskr Læger 1988;150:173-4.
5. Gøtzsche PC. Enalapril, atenolol, and hydrochlorothiazide in hypertension. Lancet 1986;iii:38-9.

6. Gøtzsche PC, Karlsen FØ. Lodtrækningsprincippet. Ugeskr Læger 1988;150:1899-1990.
7. Gøtzsche PC, Hørding M. Kondomers sikkerhed. Ugeskr Læger 1988;150:1000.
8. Gøtzsche PC, Hørding M. Kondomers sikkerhed. Ugeskr Læger 1988;150:1697.
9. Gøtzsche PC. Ditiocarb in HIV infection. Lancet 1988;Oct 29:1024.
10. Jørgensen PE, Forrest M, Hermann GG, Gøtzsche PC, Andersen B. (U)videnskabeligt bogholderi. Ugeskr Læger 1989;151:901.
11. Gøtzsche PC. Forskningsmetodologisk lærestykke 2. Ugeskr Læger 1989;151:319.
12. Gøtzsche PC. Forskningsmetodologiske lærestykker 4. Vurdering af korrelationer. Ugeskr Læger 1989;151:456-7.
13. Gøtzsche PC (book review). Duodenal ulcer. Analyses of 293 randomized trials. Stat Med 1990;9:1225-6.
14. Rosenberg R, Gøtzsche PC. Urigtig påstand om naturmedicin. Ugeskr Læger 1991;153:3027.
15. Gøtzsche PC (boganmeldelse). Schou I, ed. Good clinical practice. Kvalitetskrav til klinisk undersøgelse. Ugeskr Læger 1991;153:3636.
16. Gøtzsche PC. P-piller giver ikke brystkræft. Ugeskr Læger 1992;154:1437.
17. Gøtzsche PC. Kommentar (til artikel om placebo). Ugeskr Læger 1992;154:2452.
18. Gøtzsche PC. Placeboeffekt? Ugeskr Læger 1992;154:3006.
19. Rasmussen MH, Andersen T, Breum L, Gøtzsche PC, Hilsted J. Cimetidine and weight loss. BMJ 1993;307:446-7.
20. Gøtzsche PC. Trials of homeopathy. Lancet 1993;June 12:1533.
21. Gøtzsche PC. Zidovudine dosage. BMJ 1993;307:682-3.
22. Gøtzsche PC. Randomiseret undersøgelse af oxytocin? Ugeskr Læger 1994;156:201.
23. Gøtzsche PC (boganmeldelse). Skrabanek P, McCormick J. Follies and fallacies in medicine, anden udgave. Ugeskr Læger 1994;156:7386.
24. Gøtzsche PC. Metaanalyse af magnesiumbehandling af myokardieinfarkt. Ugeskr Læger 1995;157:2727-8.
25. Gøtzsche PC (book review). Xenotransplantation. J Med Ethics 1995:190-1.
26. Gøtzsche PC (boganmeldelse). Chalmers I, Altman DG, eds. Systematic reviews. Ugeskr Læger 1995;157:4364-5.
27. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering? Ugeskr Læger 1996;158:6291-2.
28. Gøtzsche PC. Det sundhedsvidenskabelige grundlag for medicinsk teknologivurdering. Ugeskr Læger 1997;159:68-9.
29. Gøtzsche PC. Ekspertviden eller medicinsk teknologivurdering II. Ugeskr Læger 1997;159:70-1.
30. Gøtzsche PC, Johansen HK. Prophylactic and empirical antifungal treatment in cancer complicated by neutropenia. BMJ 1997;315:489.
31. Johansen HK, Gøtzsche PC. Meta-analysis of prophylactic or empirical antifungal therapy in cancer with neutropenia. Topics Supp Care Oncol 1997;26:9-10.
32. Johansen HK, Gøtzsche PC. Use of odds ratio in calculation of number needed to treat was inappropriate. BMJ 1997;315:879.
33. Gøtzsche PC. Screening for colorectal cancer. Lancet 1997;349:356.
34. Gøtzsche PC. Greenhalgh T: How to read a paper: the basics of evidence based medicine (boganmeldelse). Ugeskr Læger 1998;160:305-6.
35. Gøtzsche PC. Løgn, forbandet løgn og ... metaanalyse (svar). Ugeskr Læger 1998;160:896-7.
36. Gøtzsche PC. Somatostatin for acute oesophageal variceal bleeding. Lancet 1998;351:911.
37. Gøtzsche PC, Johansen HK. Intermittent low dose prednisolone is safe in rheumatoid arthritis. BMJ 1998;316:1606-7.
38. Gøtzsche PC. Statusartikel om antibiotikas effekt ved halsbetændelse. Ugeskr Læger 1998;160:5376.
39. Gøtzsche PC. Hvad er relationen mellem randomiserede forsøg og evidensbaseret medicin? Ugeskr Læger 1999;161:624.
40. Gøtzsche PC. Probability without equations (book review). Stat Med 1999;18:622-3.
41. Gøtzsche PC, Hammarquist C, Burr M. Control of house dust mite in managing asthma. BMJ 1999;318:871.
42. Gøtzsche PC. Var zoneterapiforsøget randomiseret? Ugeskr Læger 1999;161:2224.

43. Gøtzsche PC. Cochranologiens vokseværk. Ugeskr Læger 1999;161:2690-1.
44. Gøtzsche PC. Om Cochrane og brugen af albumin. Ugeskr Læger 1999;161:5552-4.
45. Gøtzsche PC. Skal radikal prostatektomi indføres? Ugeskr Læger 1999;161:3472-3.
46. Gøtzsche PC. Radikal prostatektomi er udokumenteret. Ugeskr Læger 1999;161:5691-2.
47. Gøtzsche PC, Olsen O. Screening mammography re-evaluated. Lancet 2000;355:752.
48. Johansen HK, Gøtzsche PC. Improving the conduct and reporting of clinical trials. JAMA 2000;283:2789.
49. Gøtzsche PC. "Skarp kritik af mammografiscreening"(svar). Ugeskr Læger 2000;162:817.
50. Gøtzsche PC. Openness about the Swedish breast cancer screening trials is needed. Läkartidningen 2000;97:3105-6.
51. Gøtzsche PC, Olsen O. God begrundelse for mammografiscreening. Ugeskr Læger 2000;162:4166-7.
52. Gøtzsche PC. Non-steroidal anti-inflammatory drugs. BMJ 2000;321:568-9.
53. Gøtzsche PC.Openness about the Swedish breast cancer screening trials is needed (author's reply). Läkartidningen 2000;97:3105.
54. Gøtzsche PC, Olsen O. More on mammography. Lancet 2000;356:1276.
55. Gøtzsche PC. Albumin: et vigtigt princip i behandlingen af dekompenseret leversygdom (svar). Ugeskr Læger 2001;163:63-4.
56. Olsen O, Gøtzsche PC. Mister flere kvinder brystet efter screening - og hvornår må vi diskutere det? Ugeskr Læger 2001;163:1576.
57. Gøtzsche PC. Er evidensbaseret medicin evidensbaseret? (svar). Ugeskr Læger 2001;163:182.
58. Gøtzsche PC, Olsen O. Postoperativ strålebehandling øger mortaliteten hos kvinder, der får diagnosticeret brystkræft ved screening. Läkartidningen 2001;98:347.
59. Wille-Jørgensen PA, Gøtzsche PC. Angående evidensbaseret kirurgi (svar). Ugeskr Læger 2001;163:1450.
60. Pedersen T, Møller AM, Gøtzsche PC. Albumin, evidens og metaanalyse: kan dommen appelleres (svar)? Ugeskr Læger 2001;163:1719-20.
61. Gøtzsche PC. Mortalitet efter humant albumin. Ugeskr Læger 2001;163:2260-1.
62. Gøtzsche PC. Debate on screening for breast cancer is not over. BMJ 2001;323:693.
63. Hróbjartsson A, Gøtzsche PC. Is the placebo powerless? N Engl J Med 2001;345:1278-9.
64. Gøtzsche PC. Office of NHS cancer screening programme misrespresents Nordic work in breast screening row. BMJ 2001;323:1131.
65. Gøtzsche PC. Cochrane-rapport om mammografiscreening. Ugeskr Læger 2001;163:6768.
66. Pildal, Gøtzsche PC. Kritikken er berettiget. Läkartidningen 2001;98:5625.
67. Gøtzsche PC. Screening for breast cancer with mammography. Lancet 2001;358:2167-8.
68. Gøtzsche PC. Kritik af Cochrane-oversigt om screening med mammografi er uberettiget. Ugeskr Læger 2002;164:653-4.
69. Gøtzsche PC. Trends in breast-conserving surgery in the Southeast Netherlands: Comment on article by Ernst and colleagues Eur J Cancer 2001, 37, 2435-2440. Eur J Cancer 2002;38:1288.
70. Gøtzsche PC. Update on effects of screening mammography. Lancet 2002;360:338-9.
71. Gøtzsche PC. Terlipressin for acute esophageal variceal hemorrhage. Comment on Cochrane Review. In: The Cochrane Library, Issue 3. Oxford: Update Software; 2002.
72. Gøtzsche PC. Beyond randomized controlled trials. Cancer 2002;94:578.
73. Gøtzsche PC. Mammographic screening: no reliable supporting evidence? Lancet 2002;359:706.
74. Gøtzsche PC. Alarmerande att screeningsförsöken inte ger minskad cancerdödlighet. Läkartidningen 2002;99:945.
75. Hróbjartsson A, Gøtzsche PC. Placebo og bevisbyrde. Ugeskr Læger 2002;164:1525-6.
76. Gøtzsche PC. Misvisende fremstilling af vort arbejde om screening med mammografi. Läkartidningen 2002;99:75-6.
77. Gøtzsche PC. Albumin ved dekompenseret levercirrose. Ugeskr Læger 2002;164:1203-4.
78. Gøtzsche PC. Screening mammography: setting the record straight. Lancet 2002;359:440-1.
79. Gøtzsche PC. Misleading paper on mastectomy rates in a screening programme. http://bmj.com/cgi/eletters/325/7361/418#24972, 26 Aug 2002.

80. Gøtzsche PC. How to swallow one's words with a standard deviation. http://bmj.com/cgi/eletters/325/7366/682#26186, 11 Oct 2002.
81. Gøtzsche PC. Grønt lys for udokumenteret behandling. Ugeskr Læger 2002;164:3568-9.
82. Gøtzsche PC. WHO og The Lancet: ja til mammografiscreening (svar). Ugeskr Læger 2002;164:3082-3.
83. Gøtzsche PC. Invited reponse to "The mammographic screening trials: commentary on the recent work by Olsen and Gøtzsche". J Surg Oncol 2002;81:162-3.
84. Gøtzsche PC. Placebokirurgi: artroskopisk lavage og débridement ved slidgigt. Ugeskr Læger 2002;164:5151.
85. Gøtzsche PC. Kræftens Bekæmpelse, screening og troværdigheden. Ugeskr Læger 2003;165:611-2.
86. Gøtzsche PC. Screening mammography and mortality. Med J Aust 2003;178:189-90.
87. Gøtzsche PC, Hartling O. Er oplysninger om brystkræftscreening troværdige? Ugeskr Læger 2003;165:1068-70.
88. Gøtzsche PC. Uærlighed i lægemiddelafprøvninger koster samfundet dyrt. Ugeskr Læger 2003;165:1691-2.
89. Gøtzsche PC. Breast cancer screening. International Agency for Research on Cancer (IARC) Handbooks of Cancer Prevention (book review). Int J Epidemiol 2003;32:472.
90. Gøtzsche PC. Screening for breast cancer. Ann Intern Med 2003;138:769-70.
91. Gøtzsche PC, Hartling O. Svar på debatindlæg "Mister kvinder unødigt brystet, hvor der screenes for brystkræft?". Ugeskr Læger 2003;165:2586-7.
92. Gøtzsche PC. Uærlighed i lægemiddelafprøvninger koster samfundet dyrt (svar). Ugeskr Læger 2003;165:2673-4.
93. Gøtzsche PC, Hartling O. Svar på "Ingen evidens for at mammografiscreening fører til overbehandling". Ugeskr Læger 2003;165:3026-7.
94. Gøtzsche PC. Uærlighed i lægemiddelforskning og Cochrane Centeret (svar). Ugeskr Læger 2003;165:3098-9.
95. Gøtzsche PC. Skadelig screening for kræft. Politiken 2003; 1. juni, 3. sektion, s. 9.
96. Gøtzsche PC. Mammographic screening for breast cancer. N Engl J Med 2003;349:611.
97. Gøtzsche PC. Mortality reduction by breast-cancer screening. Lancet 2003;362:246.
98. Gøtzsche PC. Mammographic service screening and mortality. Lancet 2003;362:329-30.
99. Gøtzsche PC. Hvornår er noget skadeligt? Politiken 2003; 31. august, 3. sektion, s. 9.
100. Hróbjartsson A, Gøtzsche PC. Unreliable analysis of placebo analgesia in trials of placebo pain mechanisms. Pain 2003;104:714-5.
101. Gøtzsche PC. "Behandlingen er veldokumenteret". Politiken 2003; 5. oktober, 3. sektion, s. 9.
102. Gøtzsche PC. Medicinalindustrien har alt for let spil. Politiken 2003; 23. november, 3. sektion, s. 9.
103. Gøtzsche PC. Ikke-evidensbaseret kommentar om nytten af madrasbetræk ved astma med husstøvmideallergi. Ugeskr Læger 2003;165:4234-5.
104. Gøtzsche PC, Johansen HK, Burr M. Are encasings effective in asthma caused by house dust mite allergens (letter)? J Allergy Clin Immunol 2003;112:220.
105. Gøtzsche PC. Martin Bland and Janet Peacock, Statistical questions in evidence-based medicine (book review). Stat Med 2003;22:2817-20.
106. Gøtzsche PC. Hendes Majestæt Dronning Ingrids XI Festforelæsning, 2003. SØLK 2003;27(9):16-20.
107. Gøtzsche PC. Ondt i ryggen og muskelrelaksantia (reply). Ugeskr Læger 2004;166:1034.
108. Jørgensen KJ, Gøtzsche PC. Websites on screening for breast cancer (authors' reply). BMJ 2004;328:769-70.
109. Gøtzsche PC. Vær forsigtig med videnskabelig uredelighed. Politiken 2004; 25. januar, 3. sektion, s. 9.
110. Gøtzsche PC, Vestergård B. Åbent bibliotek om virkninger og bivirkninger. Politiken 2004; 9. maj, 3. sektion, s. 9.
111. Gøtzsche PC. What to conclude when treatments are harmful. CoRect News, Newsletter, The Cochrane Colorectal Cancer Group 2004;8:2-4.
112. Hróbjartsson A, Gøtzsche PC. Tesen om the powerless placebo. Ugeskr Læger 2004;166:2693-4.
113. Jørgensen KJ, Gøtzsche PC. Overfortolkning af inkonklusivt populationsstudie om brystkræft. Ugeskr Læger 2004;166:2822.
114. Gøtzsche PC. Kreativ markedsføring af margarine og medicin. Politiken 2004; 15. aug., 3. sektion, s. 9.

115. Gøtzsche P. Niels Finsen's treatment for lupus vulgaris. James Lind Library (www.jameslindlibrary.org). © Peter Gøtzsche, 2004.
116. Gøtzsche PC. Re: Trends in the treatment of ductal carcinoma *in situ* of the breast. J Natl Cancer Inst 2004;96:1257.
117. Gøtzsche PC, Jørgensen KJ. Mammografiscreening uden overdiagnostik (reply). Ugeskr Læger 2004;166:3737-8.
118. Gøtzsche PC, Møller A, Pedersen T. Albumin eller fysiologisk saltvand til volumendepleterede intensivpatienter? Ugeskr Læger 2004;166:3835.
119. Gøtzsche PC, Hróbjartsson A. Undocumented editorial on placebos. http://bmj.bmjjournals.com/cgi/eletters/329/7472/927, 2004.
120. Gøtzsche PC. Reply: What to conclude when treatments are harmful (reply). CoRect News, Newsletter, The Cochrane Colorectal Cancer Group 2004;8(2):4.
121. Gøtzsche PC. Misleading quotations and other errors persist in rejoinder on breast cancer screening. Int J Epidemiol 2004;33:1404.
122. Gøtzsche PC. Does exercise training lower mortality in patients with chronic heart failure? http://bmj.bmjjournals.com/cgi/eletters/328/7433/189, 2005.
123. Gøtzsche PC, Jørgensen KJ, Thornton H. Benefits and harms of breast cancer screening. http://bmj.bmjjournals.com/cgi/eletters/330/7485/220, 2005.
124. Gøtzsche PC, Jørgensen KJ, Hartling O. Mammografiscreening - igen. Ugeskr Læger 2005;167:783-4.
125. Gøtzsche PC, Wille-Jørgensen P. Ghost authorship in evidence-based medicine. http://bmj.bmjjournals.com/cgi/eletters/330/7484/163, 2005.
126. Gøtzsche PC, Jørgensen KJ. Outcomes of screening mammography: information to support informed choices. http://bmj.bmjjournals.com/cgi/eletters/bmj.38398.469479.8Fv1, 2005.
127. Gøtzsche PC. Reporting bias: any consequences for Methods and Results sections in Cochrane Reviews? Cochrane News 2005;33:1+8. Also published in: The Cochrane Collaboration Methods Groups Newsletter 2005;9:5.
128. Gøtzsche PC. Screening for brystkræft. Ugeskr Læger 2005;167:1871.
129. Gøtzsche PC, Jørgensen KJ, Thornton H. Presentation of benefits and harms needs to be balanced. BMJ 2005;330:1024.
130. Pedersen T, Møller AM, Gøtzsche PC. Human albumin in critically ill patients. Crit Care Med 2005;33:1183.
131. Gøtzsche PC. Klinisk interventionsforskning: to ledere og et indlæg. Ugeskr Læger 2005;167:2308-9.
132. Gøtzsche PC, Jørgensen KJ. Information needs to support informed choices. BMJ 2005;331:350-1.
133. Gøtzsche PC. Uafhængig klinisk interventionsforskning - eller evidence biased medicine? Ugeskr Læger 2005;167:2916-7.
134. Gøtzsche PC. ALLHAT - epokegørende? Ugeskr Læger 2005;167:3422-3.
135. Gøtzsche PC. The mammography controversy (book review). Lancet 2005;366:1519-20.
136. Gøtzsche PC, Johansen HK. Misleading statements in industry-sponsored meta-analysis of itraconazole. J Clin Oncol 2005;23:9428-9.
137. Gøtzsche PC. Increased incidence of invasive breast cancer after the introduction of service screening with mammography in Sweden. Int J Cancer 2005; 15 Oct: DOI 10.1002/ijc.21632 (and 2006;118:2648).
138. Gøtzsche PC. Screening and breast cancer. N Engl J Med 2006;354:768.
139. Gøtzsche PC. Ramifications of screening for breast cancer: overdiagnosis in the Malmö trial was considerably underestimated. BMJ 2006;332:727.
140. Haug C, Gøtzsche PC, Schroeder TV. Clinical trials report card (reply). N Engl J Med 2006;354:1429.
141. Gøtzsche PC, Jørgensen KJ. Estimate of harm/benefit ratio of mammography screening was five times too optimistic. http://bmj.bmjjournals.com/cgi/eletters/332/7543/691, 2006.
142. Hróbjartsson A, Gøtzsche PC. Follow-up commentary. J Clin Epidemiol 2006;59:340-1.
143. Gøtzsche PC. Disclosures should not be delayed. WHO International Clinical Trials Registry Platform (ICTRP) 2006, March 31 (http://www.who.int/ictrp/006-Peter_Gøtzsche_31March06.pdf)
144. Gøtzsche PC. No double standards in research, please. http://bmj.bmjjournals.com/cgi/eletters/333/7564/374, 2006.

145. Gøtzsche PC, Jørgensen KJ. Mammografiscreening - ideologi kontra videnskab (svar). Ugeskr Læger 2006;168:2263-5.
146. Gøtzsche PC. Tvivlsom dokumentation for effekten af akupunktur. Ugeskr Læger 2006;168:3635.
147. Gøtzsche PC.Tvivlsom dokumentation for effekten af akupunktur 2. Ugeskr Læger 2006;168:4331-2.
148. Hróbjartsson A, Gøtzsche PC. Were patients with unfavorable outcomes deleted in a covert duplicate publication reporting effect of placebo on hypertension? Am J Hypertens 2006;19:655.
149. Gøtzsche PC, Hróbjartsson, Marić K, Tendal B. Comment on Cochrane review CD004878. Cochrane Database of Systematic Reviews 2007.
150. Jørgensen AW, Hilden J, Gøtzsche PC. Cochrane reviews and other meta-analyses, authors' reply. http://bmj.bmjjournals.com/cgi/eletters/333/7572/782, 2006.
151. Gøtzsche PC. Mammography screening leads to an increase in mastectomies, not a decrease. http://www.annals.org/cgi/eletters/146/7/511, 2007.
152. Gøtzsche PC. Comment on: A Martí-Carvajal, G Salanti, AF Cardona. Human recombinant activated protein C for severe sepsis. Cochrane Database of Systematic Reviews 2007, Issue 3. Art. No.: CD004388.
153. Gøtzsche P, Hróbjartsson A, Johansen HK, Altman DG, Chan AW. Criticism is unwarranted: Please read our paper again. September 12, 2007. http://medicine.plosjournals.org/perlserv/?request=read-response&doi=10.1371/journal.pmed.0040019#r1759, 2007.
154. Gøtzsche PC. Asthma guidelines on house dust mites are not evidence-based. Lancet 2008; 370(9605):2100-1.
155. Gøtzsche PC. Mammographic screening from age 40 years. Lancet 2007; 369(9563):737-8.
156. Gøtzsche PC, Bjarnason NH. COX-2 inhibitor. Rheumatology (Oxford) 2007; 46(10):1623-4.
157. Gøtzsche PC, Maehlen J, Zahl PH. Undeclared motives in withdrawing a publication. Lancet 2007; 369(9574):1690.
158. Gøtzsche PC. Covert duplicate publication and misleading sample size calculation: commentary on Lee et al. (2008). Int J Nurs Stud 2008; 45(9):1398.
159. Gøtzsche PC. [Non-useful cancer survival statistics following the Danish Cancer Control Plan]. Ugeskr Laeger 2008; 170(43):3442.
160. Gøtzsche PC. Osteoarthritis of the knee: Topical NSAIDs have unknown effectiveness. BMJ 2008; 336(7640):344.
161. Jørgensen KJ, Hrobjartsson A, Gøtzsche PC. Comment on review of intercessory prayer for the alleviation of ill health (Roberts L, Ahmed I, Hall S. Intercessory prayer for the alleviation of ill health). Cochrane Database of Systematic Reviews 2009, Issue 2. Art. No.: CD000368.
162. Gøtzsche PC, Hartling OJ, Nielsen M, Brodersen J, Jørgensen KJ. Estimate of breast screening benefit was 6 times too large. http://www.bmj.com/cgi/eletters/338/jan27_2/b86. 2009.
163. Gøtzsche PC, Jørgensen KJ. Stephen Duffy's claims on the benefits and harms of breast screening are seriously wrong. http://www.bmj.com/cgi/eletters/338/jan27_2/b86#212985. 2009.
164. Gøtzsche P. Are new drugs for schizophrenia better than old ones? Lancet 2009;373:1248.
165. Gøtzsche PC, Jørgensen KJ, Maehlen J, Zahl PH. Estimation of lead time and overdiagnosis in breast cancer screening. Br J Cancer 2009;100(1):219.
166. Berry DA, Baines CJ, Baum M, Dickersin K, Fletcher SW, Gøtzsche PC, Jørgensen KJ, Junod B, Maehlen J, Schwartz LM, Welch HG, Woloshin S, Thornton H, Zahl PH. Flawed inferences about screening mammography's benefit based on observational data. J Clin Oncol 2009;27(4):639-40.
167. Gøtzsche PC. Quackery, chiropractic and alternative medicine. BMJ 2009: http://www.bmj.com/cgi/eletters/339/jul08_4/b2766.
168. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Svar til Lif. Ugeskr Læger 2009;171:1308.
169. Hróbjartsson A, Gøtzsche PC. Acupuncture for pain: our result is robust to trial selection, and our threshold for minimal clinically effect is low. BMJ rapid responses (17 March); 2009.
170. Hróbjartsson A, Gøtzsche PC. Authors' reply: The quality of the acupuncture interventions was considered in our systematic review. BMJ rapid responses (5 October); 2009.
171. Hróbjartsson A, Gøtzsche PC. Effect of acupuncture and placebo acupuncture. BMJ rapid responses (3 March); 2009.
172. Hróbjartsson A, Gøtzsche PC. Reply to Linde. FACT 2009;14:105.

173. Gøtzsche PC, Johansen HK. Authors' reply on 'House dust mite control measures for asthma'. Allergy 2009;64:190.
174. Jørgensen KJ, Brodersen J, Nielsen M, Hartling OJ, Gøtzsche PC. Fall in breast cancer deaths. A cause for celebration, and caution. BMJ. 2009 May 27;338:b2126.
175. Jørgensen KJ, Gøtzsche PC. Fundamental mistakes in estimate of lives saved by breast screening. BMJ 2009: http://www.bmj.com/cgi/eletters/339/jul21_2/b2922.
176. Jørgensen KJ, Gøtzsche PC. Fundamental errors in estimate of lives saved by screening. BMJ 2009 Aug 25;339:b3359.
177. Jørgensen KJ, Gøtzsche PC. It is time for a new paradigm for overdiagnosis with screening mammography. http://www.bmj.com/cgi/eletters/339/jul09_1/b2587.
178. Jørgensen KJ, Gøtzsche PC. Wald et al.'s estimate of the effect of breast screening is about 10 times higher than the most reliable evidence shows. http://www.bmj.com/cgi/eletters/339/aug25_1/b3359#220390.
179. Jørgensen KJ, Gøtzsche PC. Overdiagnosis with breast screening was seriously underestimated. http://www.annals.org/content/151/10/727.full/reply#annintmed_el_120127. 2009, 20 Nov.
180. Gøtzsche PC, Johansen HK. Alpha1-antitrypsin deficiency. N Engl J Med. 2009;361(21):2101-2.
181. Gøtzsche PC, Jørgensen KJ. [Overdiagnosis with mammography screening is a serious problem]. Lakartidningen. 2009;106(47):3180.
182. Jørgensen KJ, Gøtzsche PC. No visible effect of mammography screening in Denmark. http://www.bmj.com/cgi/eletters/340/mar23_1/c1241.
183. Jørgensen KJ, Gøtzsche PC. Mammography screening hasn't lived up to expectations. http://www.bmj.com/cgi/eletters/340/mar23_1/c1241.
184. Gøtzsche PC. Overdiagnosis with mammography screening is around 25-50%, not 10%. http://www.bmj.com/cgi/eletters/340/jun24_1/c3106.
185. Gøtzsche P. Depression severity and effect of antidepressant medications. JAMA 2010 Apr 28;303(16):1597.
186. Gøtzsche PC. [When one doesn't WANT to see the evidence?]. Ugeskr Laeger 2010 Mar 1;172(9):733.
187. Jørgensen KJ, Gøtzsche PC. The background review for the USPSTF recommendation on screening for breast cancer. Ann Intern Med 2010 Apr 20;152(8):538-9.
188. Jørgensen KJ, Gøtzsche PC. Where is the effect of mammography screening? BMJ 2010. http://www.bmj.com/cgi/eletters/341/aug11_1/c3620.
189. Baum M, Thornton H, Gøtzsche PC, Bewley S, Jørgensen KJ, Barratt A, et al. Breast cancer awareness month. Still awaiting screening facts. BMJ 2010;341:c6152.
190. Gøtzsche PC, Lundh A. [The rheumatologists' conflict of interest and biological medicines]. Ugeskr Laeger 2010;172(45):3126.
191. Gøtzsche PC, Jørgensen KJ, Zahl PH. Breast screening: why estimates differ by a factor of 20-25. J Med Screen 2010;17(3):158-9.
192. Gøtzsche PC. Lessons from the mammography wars. N Engl J Med 2010;363(26):2569.
193. Gøtzsche PC, Jørgensen KJ. Kopans, Smith and Duffy Misrepresent Facts about Mammographic Screening. Radiology 2011; http://pubs.rsna.org/doi/suppl/10.1148/radiol.11110716/suppl_file/110716supp.pdf.
194. Gøtzsche PC, Lundh A. Vigtig deklarering af interessekonflikter. Dagens Medicin 2011;13:27.
195. Gøtzsche PC. [Control should be counteracted]. Ugeskr Laeger 2011;173(33):1991.
196. Gøtzsche PC. Mammography screening ten years on: reflections on a decade since the 2001 review. The Cochrane Collaboration 2011;http://www.cochrane.org/news/blog/mammography-screening-ten-years-reflections-decade-2001-review.
197. Gøtzsche PC. Stop medicinudgifternes himmelflugt. Politiken 5 marts 2011. http://politiken.dk/debat/kroniker/ECE1214179/stop-medicinudgifternes-himmelflugt/
198. Gøtzsche PC. UK drug regulator destroys all evidence after 15 years. BMJ 2011;343:d4203.
199. Gøtzsche PC. Unreliable studies are quoted instead of reliable ones. CMAJ 2011;183:1957-8.
200. Jørgensen KJ, Gøtzsche PC. Elementary flaws in the FH01 study. Lancet Oncol 2011;12(3):215-6.
201. Jørgensen KJ, Gøtzsche PC. The proposed review will not be independent without NICE. BMJ 2011;343:d7533.

202. Jørgensen KJ, Hrobjartsson A, Gøtzsche PC. Leibovici's non-study must be excluded from the Cochrane review. http://www cochranefeedback com/cf/cda/citation do?id=10133#10133 2011;
203. Jørgensen KJ, Zahl PH, Gøtzsche PC. More on screening mammography. N Engl J Med 2011;364(3):284-6.
204. Krogsboll LT, Jørgensen KJ, Gøtzsche PC. [Should the population be offered general health screenings?]. Ugeskr Laeger 2011;173(23):1671.
205. Lunde IM, Gøtzsche PC. [Transparency, reliability and conflict of interest]. Ugeskr Laeger 2011;173(33):1989.
206. Gøtzsche PC. Psykiaterne har ukritisk accepteret ssri-præparaterne. Dagens Medicin 2011;http://www.dagensmedicin.dk/opinion/debat/psykiaterne-har-ukritisk-accepteret-ssri-praparaterne/.
207. Gøtzsche PC. RE: Peter Gøtzsche burde anerkende det vigtige forskningssamarbejde, der foregår mellem læger og medicinalindustrien. Ugeskr Laeger 2011;173(8):599-600.
208. Gøtzsche PC. Selektiv rapportering er et stort problem. Ugeskr Laeger 2011;173(15):1154.
209. Gøtzsche PC. Vigtig debat om gavnlige og skadelige virkninger. Dagens Medicin 2011;14:29.
210. Gøtzsche PC, Jørgensen KJ. RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ 2011;343:d7017.
211. Gøtzsche PC, Jørgensen KJ. RE: RE: Overdiagnosis from non-progressive cancer detected by screening mammography: stochastic simulation study with calibration to population based registry data. BMJ 2011;343:d7017.
212. Gøtzsche PC. Cancer specific mortality is biased in breast screening trials. BMJ 2011;343:d6395.
213. Gøtzsche PC. Total mortality should be the primary outcome in cancer screening trials. BMJ 2011;(343):d6397.
214. Suhrke P, Maehlen J, Schlichting E, Jørgensen KJ, Gøtzsche PC, Zahl PH. RE: Effect of mammography screening on surgical treatment for breast cancer in Norway: comparative analysis of cancer registry data. BMJ 2011;343:d4692.
215. Gøtzsche PC. Kopans' arguments are untruthful. 2011 Aug 18. Available at: www.auntminnie.com/index.aspx?sec=log&URL=http%3a%2f%2fwww.auntminnie.com%2findex.aspx%3fsec%3dsup%26sub%3dwom%26pag%3ddis%26ItemID%3d96204 (accessed 1 Sept).
216. Gøtzsche PCRE: Etisk analyse på automatpilot. Dagens Medicin 2012;http://www.dagensmedicin.dk/blog/kristians-blog/blog-etisk-analyse-pa-automatpilot/.
217. Jørgensen KJ, Gøtzsche PG. Breast Cancer Screening. An independent review is under way. BMJ 2012; 24 April. http://www.bmj.com/content/343/bmj.d6843?tab=responses http://www.bmj.com/content/343/bmj.d6843/rapid-responses.
218. Jørgensen KJ, Keen JD, Zahl PH, Gøtzsche PC. The Two-County breast screening trial cannot provide a reliable estimate of the effect of breast cancer screening. Radiology 2012;262:729-30.
219. Gøtzsche PC. Why does the BMJ support donations of pulse oximeters when they have no effect? BMJ 2012;344:e409.
220. Gøtzsche PC, Jørgensen KJ. Effect of population-based screening on breast cancer mortality. Lancet 2012;379:1297.
221. Jørgensen KJ, Gøtzsche PC. Mammografiscreening redder ikke liv. Dagens Medicin 2012;28 Sept.
222. Gøtzsche PC. Screening for tvangstanker, depression og ADHD?. Ugeskr Læger 2013;175:77.
223. Gøtzsche PC. Developing a new drug costs less than $100m, not $900m. BMJ 2013;346:f398.
224. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. N Engl J Med 2013;368:677-8.
225. Gøtzsche PC. The EMA should continue its new openness policy despite current lawsuits. http://www.bmj.com/content/346/bmj.f2961?tab=responses 2013;21 June.
226. Gøtzsche PC, Maund E. Re: Restoring invisible and abandoned trials: a call for people to publish the findings. http://www.bmj.com/content/346/bmj.f2865/rr/650915 2013;21 June.
227. Gøtzsche PC. AbbVie considers harms to be commercially confidential information: sign a petition. BMJ (Online) 2013;347:f7569.
228. Gøtzsche PC. Developing a new drug costs less than $100m, not $900m. BMJ 2013;346:f398.
229. Gøtzsche PC. Roche continues to drag its feet on access to Tamiflu data. BMJ (Online) 2013;346:f3001.

230. Jørgensen KJ, Gøtzsche PC. Effect of screening mammography on breast cancer incidence. N Engl J Med 2013;368:677-8.
231. Jørgensen KJ, Brodersen J, Gøtzsche PC. Thirteen years of breast screening had no measurable effect on breast cancer mortality in Norway. Int J Cancer 2013;132:1725-6.
232. Krogsbøll L, Juhl Jørgensen K, Gøtzsche PC. Social ulighed i sundhed. Ugeskr Læger 2013;175:74-5.
233. Zahl P-H, Suhrke P, Jørgensen KJ. Overdiagnosis of breast cancer in Norway: what have the authors adjusted for? Int J Cancer 2013;133:2754-5.
234. Gøtzsche PC. Nye cancermidler er ikke bedre end gamle. Ugeskr Læger 2013;175:2138.
235. Gøtzsche PC. Screening for tvangstanker, depression og ADHD? Ugeskr Læger 2013;175:77.
236. Gøtzsche PC. Tvivlsomt om lokalt appliceret NSAID har nogen effekt. Ugeskr Læger 2013;175:377-8.
237. Gøtzsche PC. Vildledning fra Kræftens Bekæmpelse om mammografiscreening. Ugeskr Læger 2013;175:1056.
238. Gøtzsche PC. Vores forskning om lægemiddelindustrien er veldokumenteret. Ugeskr Læger 2013;175:3048.
239. Gøtzsche PC. Der er ikke effekt af drotrecogin alfa ved svær sepsis. Ugeskr Læger 2013;175:903-4.
240. Gøtzsche PC, Jørgensen KJ. The benefits and harms of breast cancer screening. Lancet 2013;381:799.
241. Krogsbøll LT, Jørgensen KJ. Helbredstjek - igen. Ugeskr Læger 2013;175:532.
242. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Universal health checks should be abandoned. BMJ (Online) 2013;347:f5227.
243. Gøtzsche PC. Mammography screening increases non-breast cancer mortality. Trials 2013;14:368.
244. Gøtzsche PC. The drug industry is similary harmful as the tobacco industry. BMJ 2013;347:f5193.
245. Gøtzsche PC. Treatment of urinary incontinence with antimuscarinic drugs is pointless. BMJ 2013;347:f5170.
246. Gøtzsche PC. "I don't want the truth, I want something I can tell Parliament!" BMJ 2013;347:f5222.
247. Krogsbøll LT, Jørgensen KJ, Gøtzsche PC. Health check check. The Times 2013;Aug 20:25.
248. Gøtzsche PC. Incorrect statements by Novo Nordisk. BMJ 2013;347:f4386.
249. Gøtzsche PC. SSRI kan føre til selvmord. Dagens Medicin 2013;3Maj .
250. Gøtzsche PC. Whistleblowere skal beskyttes. Berlingske 2013;5Aug:21.
251. Gøtzsche PC. GlaxoSmithKline and Roche won't disclose their results. BMJ 2013;346:f819.
252. Gøtzsche PC. Comment on risk of bias tool. www.thecochranelibrary.com/details/editorial/5655441. 2014;10 Jan.
253. Gøtzsche PC. Medicinalindustriens mange løgne. Jyllands-Postens kronik 2014;4 Jan..
254. Gøtzsche PC. Psykiatri på afveje. Politiken, kronik, 2014;6 Jan.
255. Gøtzsche PC. Lykkepille-epidemien: skyd ikke budbringeren, men se budskabet. www.epracticus.dk/flx/debat/?FID=2&MID=30 ?. 2014;13 Jan.
256. Gøtzsche PC. Toneangivende psykiatere er fortsat på afveje. Politiken, kronik, 2014;21 Jan .
257. Gøtzsche PC. Brug psykofarmaka mindre og bedre. Weekendavisen 2014;31 Jan.
258. Gøtzsche PC. Vi skal bruge mindre psykofarmaka. Ugeskriftet.dk 2014;6 Feb .
259. Gøtzsche PC. Om statistik og bias. Ugeskr Læger 2014;176:273.
260. Gøtzsche PC. Unwarranted criticism of "Psychiatry Gone Astray". davidhealy.org/get-real-peter-gotzsche-responds/ 2014;17 Feb .
261. Gøtzsche PC. Vildledende forskning og markedsføring. Ugeskr Læger 2014;176:373.
262. Gøtzsche PC. Fejlciteringer om psykiatri. Berlingske 2014;23 Feb.
263. Gøtzsche PC. Fup eller fakta om dødelig medicin. Dagens Medicin 2014;28 Feb .
264. Gøtzsche PC. Screening virker ikke. Jyllands-Posten 2014;8 Mar.
265. Gøtzsche PC. Screening af gravide for depression. Månedsskr Almen Praksis 2014;326-8.
266. Auken M, Gøtzsche PC. Kun via EU sikrer vi åbenhed i medicinalindustrien. Information 2014;5 April.
267. Auken M, Gøtzsche PC. Hyklerisk medicinalindustri. Information 2014;9 April.
268. Gøtzsche PC. Misvisende oplysninger om Cochrane. Altinget 2014;8 April.
269. Gøtzsche PC. Lægger ikke luft til mig. Politiken 2014;9 April.

270. Gøtzsche PC. Cochrane-fjeren, der blev til fem høns. Dagens Medicin 2014;11 April.
271. Gøtzsche PC. Antidepressiv medicin bør undgås til børn og unge. OCD-nyt 2014;1-14:7.
272. Gøtzsche PC. Nyhed om Cochrane var misvisende. http://ugeskriftet.dk/nyhed/cochrane-laegger-afstand-til-goetzsche#comment-354. 2014;8 Apr.
273. Gøtzsche PC. Adverse effects of statins are very common. 2014;21 May . www.bmj.com/content/348/bmj.g3306/rr/698864.
274. Gøtzsche PC. Sundhedstjek: Den politiserende Sundhedsstyrelse. Dagens Medicin 2014;10 Okt.
275. Bewley S, Rose L, Gøtzsche P, Blennerhassett M, Colquhoun D, Pryke M, et al. Time to halt an out of control trial with ineffective oversight. B M J (Online) 2014;349:g5601.
276. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. Authors' reply to Lauritzen and colleagues, Newton and colleagues, and Mangin. B M J (Online) 2014;349:g4790.
277. Gøtzsche PC. Muscular adverse effects are common with statins. BMJ (Online) 2014;348:g3724.
278. Gøtzsche PC, Jørgensen KJ, Krogsbøll LT. General health checks don't work. BMJ (Online) 2014;348:g3680.
279. Gøtzsche PC. Questionable research and marketing of a combination drug for smoker's lungs. J R Soc Med 2014;107:256-7.
280. Gøtzsche PC. Study of study of changes in antidepressant use after FDA warnings is not reliable. BMJ (Online) 2014;349:g5623.
281. Gøtzsche PC, Jørgensen KJ, Zahl P-H. Lead-Time Models Produce Far Too Low Estimates of Overdiagnosis With Mammographic Screening. JACR 2014;11:1098.
282. Gøtzsche PC. Przepisywane leki przyczyną zgonu rzeszy pacjentów. Pol Arch Med Wewn 2014;124:750-6.
283. Gøtzsche PC. Antidepressiva bør ikke bruges til børn og unge. Ugeskr Læger 2015;18 Maj.
284. Gøtzsche PC. Atomoxetin til ADHD er værre end sit rygte. Ugeskr Læger 2015;177:1301-2.
285. Gøtzsche PC. Author's reply to Tovey and colleagues. BMJ 2015;350:h2955.
286. Gøtzsche PC. Comment on "Our prescription drugs kill us in large numbers". Author's reply. Pol Arch Med Wewn 2015;125:106-7.
287. Gøtzsche PC. Correction to "Author's reply to Tovey and colleagues". BMJ 2015;350:h3138.
288. Gøtzsche PC. Days tomme postulater om psykiatrien. Berlingske Tidende 2015;12 Sep;16.
289. Gøtzsche PC. Gøtzsche melder psykiater til Lægeetisk Nævn. Dagens Medicin 2015;9 Okt;16:1.
290. Gøtzsche PC. Hvor stor en rolle spiller antipsykotika i overdødeligheden ved skizofreni? Ugeskr Læger 2015;177:895-6.
291. Gøtzsche PC. Psychiatric drugs should not be used in demented people. BMJ 2015;350:h369.
292. Gøtzsche PC. Psykiateren prøver at skyde budbringeren. Dagens Medicin 2015;9 Okt;16:1.
293. Gøtzsche PC. RE: Comparative benefits and harms of second generation antidepressants and cognitive behavioral therapies in initial treatment of major depressive disorder: systematic review and meta-analysis. BMJ 2015;351:h6019.
294. Gøtzsche PC. Re: Suicide risk assessment and intervention in people with mental illness. BMJ 2015;351:h4978.
295. Gøtzsche PC. Re; Does long term use of psychiatric drugs cause more harm than good?: Maudsley debate and guild interests. BMJ 2015;351:h2435.
296. Gøtzsche PC. Screening doesn't reduce the occurrence of advanced cancers. BMJ 2015;350:h867.
297. Gøtzsche PC. Svar: Børn behandlet med stimulanser udvikler ofte hjerneatrofi. Ugeskr Læger 2015;4 Nov .
298. Gøtzsche PC. Svar: Dokumentationen for, at antidepressiva forårsager selvmord. Ugeskr Læger 2015;177:1649.
299. Gøtzsche PC. Svar: Selvmord forårsaget af antidepressiva skal frem i lyset. Ugeskr Læger 2015;177:1303.
300. Gøtzsche PC. Svar: Tavshedspligt, akademisk dannelse, lægelig pli. Ugeskr Læger 2015;18 Jun.
301. Gøtzsche PC. Tre psykiatriprofessorer på afveje. Politiken 2015;4 Sep.
302. Gøtzsche PC. Tvang i psykiatrien bør forbydes. Politiken 2015;5 Aug.
303. Gøtzsche PC. Usandheder i psykiaterformands boganmeldelse. Ugeskr Læger 2015;7 Okt 7.
304. Jørgensen KL, Gøtzsche PC. Helbredstjek til lavtuddannede er skadeligt. Ugeskr Læger 2015;11 Feb.

305. Jørgensen KJ, Zahl P-H, Gøtzsche PC. Influence of mammography screening on use of mastectomies in Denmark. Acta Oncol 2015;133:54.
306. Gøtzsche PC. SVAR: Begrebet interessekonflikter bør ikke udvandes (svar på Kronik: Interessekonflikter – mere end ussel mammon). Ugeskr Læger 2016:19:1840.
307. Boesen K, Gøtzsche PC, Juhl Jørgensen K. Re: Immediate-release methylphenidate for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Sys Rev 2016;(1):CD005041.
308. Boesen K, Gøtzsche PC. Quality of life of adult patients with attention-deficit/hyperactivity disorder taking methylphenidate. Arch Gen Psychiatry 2016;73:533-4.
309. Gøtzsche PC. Abolishing forced treatment in psychiatry is an ethical imperative [Online] 2016 [Citeret 2016 jun. 17] https://www.madinamerica.com/2016/06/abolishing-forced-treatment-in-psychiatry-is-an-ethical-imperative/
310. Gøtzsche PC. Antidepressants are addictive and increase the risk of relapse. BMJ 2016;352:i574.
311. Gøtzsche PC. Antidepressants increase the risk of suicide and violence at all ages [Online] 2016 [Citeret 2016 nov. 16] https://www.madinamerica.com/2016/11/antidepressants-increase-risk-suicide-violence-ages/
312. Gøtzsche PC. Author's reply to Dubicka and colleagues and Stone. BMJ 2016;352:i915.
313. Gøtzsche PC. Bliv hjemme, næste gang du får en invitation til brystkræftscreening. Politiken 2016;31 Maj:1.
314. Gøtzsche PC. Bred afvisning af mere tvang på bosteder. Ugeskr Læger 2016;13 Sep:9.
315. Gøtzsche PC. Fakta om sundhedstjek er mørkelagt (kronik). Politiken 2016;14 Jan.
316. Gøtzsche PC. Forced admission and treatment in psychiatry are violations of basic human rights and must be abolished. Lecture in Anchorage 2 June 2016. http://psychrights.org/education/GoetzscheJune2016/160602PeterGoetzscheAnchorageTalkTranscript.htm.
317. Gøtzsche PC. Forårsager benzodiazepiner demens? Ugeskr Læger 2016;178:693.
318. Gøtzsche PC. Hvad er der kommet ud af vore indsatser mod kræft?: Hvad har fremskridtet på kræftområdet så været i virkeligheden? Med enkelte undtagelser ikke ret meget. Dagens Medicin 2016;6 Dec .
319. Gøtzsche PC. Medicin og screening mod demens virker ikke: Sundhedsministeren ønsker tidlig opsporing af demens. Men det kan gøre mere skade end gavn. Ugeskr Læger 2016;178:1291.
320. Gøtzsche PC. Polyfarmaci med antipsykotika øger dødeligheden: Studier, der viser, at antipsykotika med polyfarmaci ikke medfører øget dødelighed, er fejlbehæftede, mener Peter Gøtzsche. Ugeskr Læger 2016;178:397.
321. Gøtzsche PC. Praktiserende læger er guld værd (kronik). Jyllands-Posten 2016;9 Nov .
322. Gøtzsche PC Prescription drugs are the third leading cause of death [Online] 2016 [Citeret 2016 jun. 16] http://blogs.bmj.com/bmj/2016/06/16/peter-c-gotzsche-prescription-drugs-are-the-third-leading-cause-of-death/
323. Gøtzsche PC. Psykofarmaka øger risikoen for vold: Noget bør laves om i retspsykiatrien. Ugeskr Læger 2016;178:2039.
324. Gøtzsche PC. Seks ting der er værd at vide om masseskyderier. Videnskab.dk 2016;1 Jun.
325. Gøtzsche PC. Tvangslovene i psykiatrien skal afskaffes. Psykologernes Fagmagasin 2016;17 Mar.
326. Gøtzsche PC Tvangsbehandling med elektrochok bør forbydes [Online] 2016 [Citeret 2016 mar. 12] Tilgængelig fra: URL:http://www.deadlymedicines.dk/tvangsbehandling-med-elektrochok-bor-forbydes/
327. Gøtzsche PC. Unblinding in SSRI trials due to side effects is an important source of bias. Br J Psychiatry 2016;208.
328. Jørgensen KJ, Gøtzsche PC. Breast Cancer Screening: Benefit or Harm? JAMA 2016;315:1402.
329. Gøtzsche PC. Antidepressiva øger risikoen for selvmord og vold i alle aldre. Medicinsk Tidsskrift 2016; 20 Nov:506.
330. Gøtzsche PC. Patients should have free and immediate access to all information related to clinical trials. BMJ 2017;356:j1221.
331. Jørgensen KJ, Gøtzsche PC, Kalager M, Zahl P-H. Breast Cancer Screening in Denmark. Ann Inter Med 2017;167:524.
332. Gøtzsche PC. Hyllning till en enastående psykiatriker. Forord til: Breggin PR. Att sluta med psykofarmaka. Stockholm: Karneval Förlag, 2018.
333. Gøtzsche PC. What is it like being on the Governing Board? http://community.cochrane.org/news/what-it-being-governing-board. 2017; 27 Sept.

334. Gøtzsche PC. Akupunktur virker ikke. Det er ikke dokumenteret, at akupunktur har nogen klinisk relevant effekt på noget som helst. Dagens Medicin 2018; 7 feb.
335. Gøtzsche PC. Nej, jeg står ikke bag 'uhyrlige påstande'. Politiken 2018; 30. april.
336. Gøtzsche PC. Psychiatry is a disaster area in healthcare that we need to focus on. http://www.bmj.com/content/360/bmj.k9/rr-15. 2018; 10 Jan.
337. Gøtzsche PC. Skærpet tilsyn med psykiatere kan være nødvendigt. Dagens Medicin 2018; 9. feb.
338. Gøtzsche PC. Selvmordene forårsaget af depressionspiller vil fortsætte – man bør simpelthen undgå dem. Jyllands-Posten 2018; 11. feb.
339. Gøtzsche PC. Om depression, videnskabelig debat og Cochrane. Jyllands-Posten 2018; 20. feb.
340. Gøtzsche PC. Cipriani review does not add anything. Council for Evidence-based Psychiatry. 2018; 22 Feb.
341. Gøtzsche PC. Learning to live with hearing voices – an authoritative statement lacks documentation. BMJ 2018;361:k2018.
342. Gøtzsche PC. Comment on: "My OCD story: evidence-based medicine to the rescue!" Evidently Cochrane 2019 May 29.
343. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Esketamine for depression? No thanks, please. BMJ 2019 Oct 3.
344. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Re: Esketamine for treatment resistant depression. BMJ 2019 Oct 11.
345. Gøtzsche PC, Hengartner MP, Davies J, Read J, Guy A, Timimi S, Kinderman P. Re: Esketamine for treatment resistant depression. BMJ 2019 Oct 22.
346. Jørgensen KJ, Gøtzsche PC, Krogsbøll LT. Ønskedrømme til en høj pris. Dagens Medicin 2019 June 25.
347. Urato AC, Abi-Jaoude E, Abramson J, et al. National Partnership for Maternal Safety: consensus bundle on venous thromboembolism. Obstet Gynecol 2019;134:1115-7.

Secondary publications in Danish

1. Gøtzsche PC. Reference-bias. Ugeskr Læger 1988;150:228-9.
2. Nordic Medical Research Councils' HIV Therapy Group. Dobbeltblind dosis-responsundersøgelse af zidovudin ved AIDS og fremskreden HIV-infektion. Ugeskr Læger 1993;155:104-7.
3. Gøtzsche PC, Nielsen C, Gerstoft J, Nielsen CM, Vestergaard BF. Patientoverlevelse ved zidovudinresistent HIV. Ugeskr Læger 1994;156:185-6.
4. Gøtzsche PC, Gjørup I, Bonnén H, Brahe NEB, Becker U, Burcharth F. Randomiseret undersøgelse og metaanalyse af somatostatin overfor placebo ved blødende øsofagusvaricer. Ugeskr Læger 1996;158:2393-6.
5. Gøtzsche PC. Vigtigheden af et bredt perspektiv på metaanalyse: kan have afgørende betydning for patienterne. Ugeskr Læger 2000;162:5601.
6. Gøtzsche PC. Bredt perspektiv på metaanalyse af afgørende betydning for patienten. Läkartidningen 2000;97:5882-3.
7. Gøtzsche PC. Bredt perspektiv på metaanalyse - kan have afgørende betydning for patienterne. Tidsskr Nor Lægeforen 2000;120:2810-1.
8. Hróbjartsson A, Gøtzsche PC. Hvad er effekten af placebobehandling? Ugeskr Læger 2002;164:329-33.
9. Jørgensen KJ, Gøtzsche PC. Information om brystkræftscreening på internetsider er ensidig og mangelfuld - sekundærpublikation. Ugeskr Læger 2005;167:174-8.
10. Gøtzsche PC. Forbedret raportering af skadevirkninger i randomiserede forsøg: udvidelse af CONSORT-vejledningen. Ugeskr Læger 2005;167:1520-2.
11. Hróbjartsson A, Chan A-W, Haahr MT, Gøtzsche PC, Altman DG. Selektiv rapportering af effektmål i randomiserede forsøg. Sekundærpublikation. Ugeskr Læger 2005;167:3189-91.
12. Haug C, Gøtzsche PC, Schroeder T. Registre og registrering af kliniske forsøg. Sekundærpublikation. Ugeskr Læger 2006;168:457-8.
13. Gøtzsche PC, Hróbjartsson A, Johansen HK, Haahr MT, Altman DG, Chan AW. Begrænsninger i publikationsrettighederne i industriinitierede kliniske forsøg - sekundærpublikation. Ugeskr Læger 2006;168:2467-9.
14. Jørgensen KJ, Gøtzsche PC. Er invitationer til mammografiscreening et rimeligt udgangspunkt for det informerede samtykke? Sekundærpublikation. Ugeskr Læger 2006;168:1658-60.

15. Gøtzsche PC. Er relative risici og oddsratioer i resumeer troværdige? Sekundærpublikation. Ugeskr Læger 2006;168:2678-80.

Teaching

Pregraduate courses

1988-89	Junior lecturer, Theory of Science, University of Copenhagen.
1990-2012	Lecturer, Theory of Science, University of Copenhagen.
1992-93	Lecturer, internal medicine, Hvidovre Hospital.
1993, 13 May	Course in research methodology, human biology, University of Copenhagen.
1994, 2-3 Feb	Course in research methodology, human biology, University of Copenhagen.
2003, 2 Sept	When is one drug better than another? Denmark's Pharmaceutical University.
2003, 20 Oct	Meta-analyses and their role in systematic reviews. Students in Public Health, Copenhagen.
2015, 15 April	Lectures on Theory of Science for pharmacy students.
2016, 8 Dec	Vore lægemidler er den 3. hyppigste dødsårsag. Farmaceutstuderende, København.
2017, 7 Dec	Kliniske forsøg. Farmaceutstuderende, København.
2018, 30 Apr	Psykiatriske diagnoser og depressionsmedicin. Psykogistuderende, København.
2018, 11 Oct	Kliniske forsøg. Farmaceutstuderende, København.

See also Lectures below, which include many for students.

Postgraduate courses

C: course manager.

1.	Controlled clinical trials of drugs, Rigshospitalet, 3-5 Nov 1986.
2. C	Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 28 Oct 1987.
3.	A-course in research methodology. National Board of Health, 15 Nov 1988.
4.	A-course in clinical decision theory. National Board of Health, 17 Apr 1989.
5. C	Statistics and epidemiology. Scandinavian Diploma Course in Tropical Medicine, University of Copenhagen, 2 Nov 1989.
6. C	Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1989.
7. C	Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 29 Apr 1990.
8.	Course on meta-analyses. Medicom, Copenhagen, 21 May 1990.
9. C	Transdisciplinary course in medical ethics. Danish Society for Theory in Medicine, Copenhagen, 10 Nov 1990.
10.	PhD course in medical ethics. University of Southern Denmark, 17 May 1991.
11.	Course on rheumatoid arthritis. Danish Rheumatological Society, 27 Okt 1991.
12.	Course in clinical trials. Apothecary Society, Hillerød, 5 Nov 1991.
13. C	Litterature evaluation for pharmacists, Hillerød, 2-4 Dec 1991.
14.	Bias. Course in pharmacodynamics. Danish Society for Clinical Pharmacology, 6 Dec 1991.
15. C	Rigshospitalet's course in clinical trials. Hillerød, 2-6 Mar 1992.
16.	A-course in clinical pharmacology. National Board of Health, 3 Mar 1992.
17.	Research methodology for back diseases. Back research group, Copenhagen, 2 Apr 1992.
18.	A-course in clinical pharmacology. National Board of Health, 5 May 1992.

19. PhD course in medical ethics. University of Southern Denmark, 8 May 1992.
20. A-course in clinical pharmacology. National Board of Health, 6 Oct 1992.
21. C Rigshospitalet's course in clinical trials. Hillerød, 19-23 Oct 1992.
22. A-course in rheumatology. National Board of Health, 24 Nov 1992.
23. A-course in clinical pharmacology. National Board of Health, 8 Dec 1992.
24. A-course in rheumatology. National Board of Health, 9 Feb 1993.
25. A-course in clinical pharmacology. National Board of Health, 2 Mar 1993.
26. PhD course in medical ethics. University of Southern Denmark, 26 Mar 1993.
27. C Rigshospitalet's course in clinical trials. Hillerød, 31 Mar-2 Apr 1993.
28. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 19-20 Oct 1993.
29. A-course in clinical pharmacology. National Board of Health, 1 Mar 1994.
30. C PhD course in systematic reviews. Panum Institute, 11-12 Apr 1994.
31. C PhD course in systematic reviews. Panum Institute, 13-14 Apr 1994.
32. C Rigshospitalet's course in clinical trials. Hillerød, 18-22 Apr 1994.
33. Rigshospitalet's research policy. Rigshospitalet, 18 Aug 1994.
34. Course in biological psychiatric research. Bispebjerg Hospital, 17 Jan 1995.
35. Scientific dishonesty. University hospitals' Centre for Nursing Research. Rigshospitalet, 23 Feb 1995.
36. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Copenhagen, 27-29 Mar 1995.
37. Post Conference Course in Evidence-based Health Care: critical appraisal of evidence. International Society for Technology Assessment in Health Care, Dalarna, Sweden, 7-10 June 1995.
38. Use of research results. Rigshospitalet's course in quality development, 15 June 1995.
39. Course on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 29-31 Oct 1995.
40. Course in quality development. Rigshospitalet, 13 Dec 1995.
41. C Course on systematic reviews. Panum Institute, 14-15 Dec 1995.
42. Meta-analyses and evaluation of the quality of research. Danish Society for Internal Medicine. Sundby Hospital, 27 Mar 1996.
43. C Workshop on Handsearching. Nordic Cochrane Centre, 16 Apr 1996.
44. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 17 Apr 1996.
45. C Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 18 Apr 1996.
46. Workshop on Systematic Reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 12-14 May 1996.
47. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 12 Sept 1996.
48. C Workshop on Systematic Reviews for Cochrane Reviewers. Getting a review into Review Manager. Nordic Cochrane Centre, 13 Sept 1996.
49. Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Stockholm, 4-6 Dec 1996.
50. C Course on systematic reviews. Swedish Council for Technology Assessment in Health Care, Göteborg, 17 Dec 1996.
51. The controlled clinical trial and meta-analysis. Danish Society for Internal Medicine. Sundby Hospital, 10 Mar 1997.
52. Meta-analyses and the international Cochrane Collaboration. PhD course in clinical intervention research. MEDIF/MEFA, 13 Mar 1997.
53. Second Nordic Course in Evidence-based Medicine. Oslo, 1-5 June 1997.
54. Minicourse in evidence-based medicine and the Cochrane Library. Rigshospitalet, 5 Nov 1997.
55. C Workshop on Handsearching. Nordic Cochrane Centre, 12 Nov 1997.

56. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 13 Nov 1997.
57. Course in evidence-based medicine. Rigshospitalet, 30 Apr-2 May 1998.
58. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 May 1998.
59. C Workshop on Handsearching. Nordic Cochrane Centre, 9 July 1998.
60. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Helsinki, 21 Sept 1998.
61. Course in evidence-based medicine. Rigshospitalet, 9-12 Nov 1998.
62. C Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 1 Mar 1999.
63. C Workshop on Handsearching. Nordic Cochrane Centre, 3 Mar 1999.
64. Course in evidence-based medicine. Panum, 14-17 June 1999.
65. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 21 Mar 2000.
66. Workshop on Handsearching. Nordic Cochrane Centre, 22 Mar 2000.
67. C Evidence-based medicine. Ringe Back Centre, 14 Apr 2000.
68. C Evidence-based cardiology. Society for Younger Cardiologists, 15 Apr 2000.
69. Workshop on controversial issues related to clinical trials and systematic reviews. Barcelona, 30 June 2000.
70. Workshop on Handsearching. Nordic Cochrane Centre, 11 Sept 2000.
71. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, 31 Jan 2001.
72. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 27 Mar 2001.
73. Meta-analyses - use and misuse. Danish Drug Industry Association, 30 May 2001.
74. C Workshop on Cochrane editing. Hotel Marina, 6-8 Sept 2001.
75. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Karrebæksminde, 6 Feb 2002.
76. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 23 Apr 2002.
77. Course in evidence-based medicine. Rigshospitalet, 3-4 og 17-18 June 2002.
78. C Workshop on Cochrane editing. Hotel Marina, 12-14 Sept 2002.
79. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 7 Oct 2002.
80. Meta-analysis and potential and limitations of evidence-based medicine. 6. Lübecker course, Lübeck, 9-10 Oct 2002.
81. PhD course, Panum Institute, 12 Dec 2002.
82. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, Tune Landbrugsskole, 29 Jan 2003.
83. Prioritisation and evidence-based medicine. Nordjyllands Amtsråd, Ålborg, 13 Feb 2003.
84. C Workshop on Cochrane editing. Nordic Cochrane Centre, 18-19 Sept 2003.
85. Workshop on Systematic Reviews for Cochrane Reviewers. Protocol development. Nordic Cochrane Centre, 6 Oct 2003.
86. C Quality of allocation concealment. 11th Cochrane Colloquium, Barcelona, 28 Oct 2003.
87. PhD course, Panum Institute, 24 Nov 2003.
88. Workshop on research in alternative medicine, Rigshospitalet, 30-31 Mar 2004.
89. Course in evidence-based medicine. Panum Institute, 1-2 og 14-15 June 2004.
90. C PhD course in systematic reviews and meta-analyses. Rolighed, 8-11 Nov 2004.
91. PhD course, Panum Institute, 1 Dec 2004.

92. Quantitative epidemiology: perspectives and limitations. Research School for Animal Reproduction and Health, KVL, 24 Aug 2005.
93. Course in infection pathogenesis. Rigshospitalet, 5 Sept 2005.
94. Doctors' Annual Gathering (Lægedage). Copenhagen, 18 Nov 2005.
95. PhD course in planning clinical research. Panum Institute, 21 Feb 2006.
96. PhD course in epidemiology. Køge, 30 Mar 2006.
97. Reporting of harms. GCP units in Denmark, Nyborg, 31 Mar 2006.
98. PhD course. Pharmaceutical University, 13 June 2006.
99. Doctors' Annual Gathering (Lægedage). Copenhagen, 11 Nov 2006.
100. Systematic reviews. Advanced seminar, Madrid, 16-17 Nov 2006.
101. Seminar on peer review and scientific misconduct. Karolinska Institute, Stockholm, 30 Nov 2006.
102. PhD course, Research ethics. Copenhagen Business School, 19 Mar 2007.
103. Course in clinical decision theory. National Board of Health, Copenhagen, 8 May 2007.
104. PhD course, Ethics in science. Faculty of life sciences, Copenhagen, 13 Aug 2007.
105. Evidence-based medicine. WHO, delegation from Uzbekistan, Hillerød, 21 Sept 2007.
106. Course for clinical microbiologists. National Board of Health, Copenhagen, 24 Sept 2007.
107. PhD course, Research ethics. Copenhagen Business School, 31 Oct 2007.
108. PhD course, Research ethics. Copenhagen Business School, 31 Mar 2008.
109. Course in Clinical Pharmacology, National Board of Health, 17 April 2008.
110. PhD course in planning clinical research. University of Copenhagen, 31 May 2008.
111. Workshop: Clinical trials registration & results reporting: The CONSORT guidelines and beyond. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
112. Course in clinical decision theory. National Board of Health, Copenhagen, 7 and 20 May 2007.
113. PhD course in clinical epidemiology. Køge, 9 Oct 2008.
114. Course in clinical decision theory. National Board of Health, Copenhagen, 19 Nov 2008.
115. Course in clinical decision theory. National Board of Health, Copenhagen, 24 Nov 2009.
116. PhD course in planning clinical research. University of Copenhagen, 21 Jan 2010.
117. Course in clinical decision theory. National Board of Health, Copenhagen, 18 May 2010.
118. Course in clinical pharmacology. National Board of Health, Copenhagen, 1 Apr 2011.
119. Forskeruddannelsesnetværket. Korsør, 17 May 2011.
120. PhD course. Herlev, 16 June 2011.
121. Highlights i reumatologien. Korsør, 1 Sept 2011.
122. PhD course, systematic reviews. University of Copenhagen, 26-29 Sept 2011.
123. Lægemiddelinformation – fup eller fakta? DULM-kursus, 20 April 2012.
124. PhD course, Good scientific practice and reporting, University of Copenhagen, 26-28 Sept 2012.
125. Screening. Speciallægeuddannelsen, Sundhedsstyrelsen, Rigshospitalet, 12 May 2016.
126. Screening. Speciallægeuddannelsen, Sundhedsstyrelsen, Bispebjerg, 10 Nov 2016.
127.C Myter, misforståelser og skader i psykiatrien. Heldagsseminar, Sydhavnen, 15 Dec 2016.
128.C Myter, misforståelser og skader i psykiatrien. Heldagsseminar, Fredericia, 25 April 2017.
129.C Udtrapning af psykofarmaka. Heldagskursus, København, 12 June 2017.
130. Withdrawal of psychiatric drugs, Göteborg, 18-20 Oct 2017.
131. Varför SSRI & liknande antidepressiva bör utgå. Swedish Psychiatrists, Göteborg, 25 Jan 2018.
132.C Seminar om udtrapning af psykofarmaka. Nyborg, 16 March.
133.C Seminar om udtrapning af psykofarmaka. Nyborg, 16 March. (seminar held twice the same day).
134.C Research seminar about depression pills. Copenhagen, 14 June.
135. Power versus rationality: fighting conflicts of interest. Oxford, 19 June 2019.
136.C Vejen ud af medicinens fængslende greb. Heldagsseminar, Kolding, 9 June 2020.

Lectures

IS: invited speaker; more recent titles have been translated into English, for convenience.

1. IS Steady state pharmacokinetics of naproxen in rheumatoid arthritis. XV congrès international de rheumatologie, Paris, 21-27 June 1981.
2. Dosis-respons forhold ved rheumatoid artrit. Ribe amts lægekredsforening, 5 nov 1982.
3. Klinisk farmakologi af naproxen (Naprosyn). Aftenmøder den 7, 11, 12, 19, 25 og 26 april 1983 på hhv. Store Kro, Fredensborg, Hotel H. C. Andersen, Odense, Hotel Impala, Silkeborg, Mogenstrup kro, Hotel Sheraton, København og Rold Storkro.
4. Månedens forskningsproblem: bedre end sig selv. Staff-meeting, amtssygehuset i Herlev, 24 okt 1985.
5. IS Reference bias. En undersøgelse af litteraturreferencemønstret i offentliggjorte lægemiddelundersøgelser. Dansk Selskab for Klinisk Farmakologi, 27 jan 1987.
6. IS Værdien af mikrobiologiske undersøgelser hos HIV-inficerede patienter. Dansk Selskab for Klinisk Mikrobiologi, 7 dec 1987.
7. Yield of diagnostic investigations of opportunistic infections in 33 AIDS patients. European Conference on Clinical Aspects of HIV Infection, Bruxelles, 10-11 Dec 1987.
8. IS Bias i dobbeltblinde undersøgelser af NSAID's med perspektiver for meta-analyser. Dansk Selskab for Medicinsk Reumatologi, 17 feb 1989.
9. IS Meta-analyse af antirheumatica behandling. Møde om den kontrollerede kliniske undersøgelses metodologi: status og perspektiver. Rigshospitalet, 28 apr 1989.
10. IS Meta-analyse af non-steroide antiinflammatoriske stoffer. Dansk Selskab for Intern Medicin, amtssygehuset i Herlev, 13 okt 1989.
11. IS Hvordan stiller man forsøg op, og hvordan analyserer man resultaterne? Årsmøde i Den Danske Klub for Centralsterilisering og Sygehushygiejne, Hotel Frederik II, Slagelse, 10 nov 1989.
12. IS Valg af NSAID ud fra kliniske studier. Specialistmøde for reumatologer, Novo Nordisk, København, 3 maj 1990.
13. IS Meta-analysis of second-line antirheumatic drugs: sample size bias and uncertain benefit. 23rd Nordic Congress of Rheumatology, Tampere, 15 June 1990.
14. IS Bias. Fællesundervisning for den medicinske blok, Hvidovre Hospital, 19 sept 1990.
15. IS Bias in NSAID trials. Italian Meeting on Meta-analysis within Hepatology. Erice, Sicilien, 3-5 Dec 1990.
16. IS Meta-analysis of multiple clinical trials: biases revealed by analysis of trials on first- and secondline antirheumatic drugs. 75th Anniversary of the Danish Association for Internal Medicine, København, 24 Jan 1991.
17. IS Muligheder og farer ved meta-analyser. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 13 feb 1991.
18. IS Hvilket NSAID er bedst? Møde arrangeret af medicinsk afdeling C med de praktiserende læger, amtssygehuset i Herlev, 9 apr 1991.
19. IS Præliminære resultater fra AIDSDOSE studiet. Dansk Selskab for Infektionsmedicin, Rigshospitalet, 30 apr 1991.
20. IS Detection of bias problems through the use of meta-analysis with examples from drug trials in rheumatology. Society for Clinical Drug Trials and Society for Medical Statistics, Stockholm, 22 May 1991.
21. IS Meta-analysis of DMARD's: are they effective? DAK's Rheuma Meeting in Tivoli, 23 Aug 1991.
22. IS Dobbelt-blind dosis responsundersøgelse af zidovudin ved AIDS og fremskreden HIV infektion, Statens Sundhedsvidenskabelige Forskningsråd, 12 nov 1991.
23. IS Internationella och nordiska erfarenheter av zidovudinbehandling. XLVIII Läkaresällskapets Riksstämma, Stockholm, 27 nov 1991.
24. Clinimetric problems in arthritis. Seminar on Bias and Controversies in Clinical Research, Rigshospitalet, 28 Feb 1992.
25. IS Problems and opportunities in drug trials with DMARDs. 24th Scandinavian Congress of Rheumatology, Malmö, 1 June 1992.

26. Meta-analysis is more than a combination of odds ratios. 13th International Meeting of International Society for Clinical Biostatistics, København, 18 Aug 1992.
27. IS Faldgruber i den klinisk kontrollerede undersøgelse. Medicinsk Selskab for Fyns Stift, Odense, 2 nov 1992.
28. IS Statistiske og filosofiske aspekter ved score systemer. Reumatologisk symposium, Nyborg, 12 mar 1993.
29. IS Good Clinical Practice. Ph.d.-studerende på Hvidovre Hospital, 30 sept 1993.
30. The Scandinavian Cochrane Centre. Dansk Selskab for Medicinsk Filosofi, Etik og Metode og Dansk Selskab for Medicinsk Prioritering, København, 13 okt 1993.
31. Det etiske grundlag for det danske sundhedsvæsen. Folkeuniversitetet, 9 november 1993.
32. IS NSAID og gastrointestinal tractus. Metodologiske problemer: er der forskelle mellem midlerne af klinisk relevans? Dansk Gastroenterologisk Selskabs E-kursus, København, 11 jan 1994.
33. IS Clinical practice should reflect clinical science. EU meeting, AIMCOM, Bruxelles, 24 Apr 1994.
34. IS Systematic reviews of clinical trials in policy making and health planning. Nordisk konference om kritiske valg i sundhedssektoren, Dansk Sygehus Institut, 26 Apr 1994.
35. IS Bias in statistical reporting: should the data analyst be blinded? Society for Clinical Trials, 15th annual meeting, Houston, Texas, 9 May 1994.
36. IS Meta-analyses in rheumatology. 25th Scandinavian Congress of Rheumatology, Lillehammer, 2 June 1994.
37. IS Cochrane Center på Rigshospitalet - meta-analyser i klinikken. Dansk Medicinsk Selskabs 75-års jubilæumsmøde, København, 26 aug 1994.
38. IS Orientering om Det Nordiske Cochrane Center. GCP-selskabet, Gentofte, 2 feb 1995.
39. IS Forskningen som prioriteringsgrundlag. Dansk Selskab for Medicinsk Prioritering, Svendborg, 28 apr 1995.
40. IS Meta-analysis of continuous data - NSAIDs as an example. Dansk Epidemiologisk Selskab, København, 2 June 1995.
41. IS Philosophy of sciences - in meta-analysis. 4th Nordic Conference for Medical Libraries, København, 24 Aug 1995.
42. IS Det internationale Cochrane-samarbejde. Nordisk medicinaldirektørmøde, Hornbæk, 1 sept 1995.
43. IS Cochrane Collaboration: implementering i *evidence based medicine*. Prioritering i sundhedsvæsenet, Ringkøbing amtskommune, 27 sept 1995.
44. Cochrane centres. 3rd Annual Cochrane Colloquium, Oslo, 6 Oct 1995.
45. IS Meta-analyses: assets and limitations. Recent Advances in Breast Cancer, Scandinavian Breast Cancer Group, Hindsgavl, 13 Oct 1995.
46. IS A randomized trial of withdrawal of slow acting antirheumatic drugs. Dansk Reumatologisk Selskab, København, 20 okt 1995.
47. IS Forskning som grundlag for indførelse af nye behandlingsmetoder. Temadag om prioritering i sundhedsvæsenet. Nordjyllands amt, Rebild, 1 nov 1995.
48. IS What is sound evidence for decision making? Medicine 96, Finnish Medical Association (Duodecim), Helsinki, 10 Jan 1996.
49. IS Cochrane Collaboration and the health care technology assessment. Medicine 96, Finnish Office for Health Care Technology Assessment, Helsinki, 11 Jan 1996.
50. IS Metaanalyse og kvalitetssikring. Dansk Selskab for Medicinsk Onkologi, Helsingør, 19 jan 1996.
51. Cochrane Centret, Rigshospitalet. Staff-meeting, Sundby Hospital, 23 jan 1996.
52. IS Nordic Cochrane Centre. H:S Forskningsråd, København, 12 mar 1996.
53. Cochrane-samarbejdet. Staff-meeting, Sankt Elisabeths Hospital, 9 apr 1996.
54. IS Bibliometrisk analyse af publikationer udgået fra danske intern medicinske afdelinger 1988-92. Dansk Selskab for Intern Medicins konference om forskningens vilkår i intern medicin, Hillerød, 12 apr 1996.
55. IS Hvad ved vi, og hvad gør vi? Temadag om tværfaglige specialeråd, Rigshospitalet, 2 maj 1996.
56. IS The Cochrane Collaboration. Cochrane Hepato-Biliary Group Meeting, Genève, 25 Aug 1996.
57. IS Medicinsk teknologivurdering og lægemidler. MEDIF's direktørseminarium, Hornbæk, 4 sept 1996.
58. Cochrane-samarbejdet. Staff-meeting, Hvidovre Hospital, 17 sept 1996.

59. IS Meta-analyser. Det Medicinske Selskab i København, Domus Medica, 24 sept 1996.
60. IS Debate: Within ten years, all health decisions will be evidence-based. 4th Annual Cochrane Colloquium, Adelaide, 24 Oct 1996.
61. IS Hvad skal diagnosen bruges til? Dansk Selskab for Klinisk Mikrobiologi, Kolding, 8 nov 1996.
62. Omsorg som effektiv behandling? Næstekærlighed, placebo og alternativ medicin. Dansk Selskab for Medicinsk Filosofi, Etik og Metode, Domus Medica, 14 nov 1996.
63. IS MTV - en nødvendighed i sundhedsvæsenet. Dansk Selskab for Sygehusledelse, Kolding, 28 nov 1996.
64. IS Is the Norwegian Minister of Health correct in saying that the Cochrane Collaboration has made a fetish of the randomised controlled trial? Annual Meeting for The Nordic Cochrane Centre and Network, Oslo, 17 Jan 1997.
65. IS Det Nordiske Cochrane Center. H:S Bestyrelse, København, 29 jan 1997.
66. IS Cochrane centeret. Sundhedsministeriet, København, 30 jan 1997.
67. IS Evidensbaseret medicin. Foreningen af Læger i Erhvervslivet, København, 19 mar 1997.
68. IS The Cochrane Collaboration. Svensk Internmedicinsk förenings vårmöte, Umeå, 20 mar 1997.
69. IS Hvilken sundhedsforskning har vi brug for? (paneloplæg). Forskningsudvalgets og Sundhedsudvalgets høring om sundhedsforskning, Folketinget, 2 apr 1997.
70. IS Nordiska Cochrane-centrat i Köpenhamn. Karolinska Institutet och Stockholm läns landsting, 3 apr 1997.
71. IS Beware of surrogate outcome measures. Dansk hypertensionsselskabs årsmøde, Svendborg, 11 Apr 1997.
72. IS The Cochrane Collaboration. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
73. IS Systematic review: somatostatin and octreotide in bleeding oesophageal varices. 3rd Cochrane Hepato-Biliary Group meeting, 32nd annual EASL meeting, London, 12 Apr 1997.
74. IS Quality and relevance of clinical trials. European Headache Federation 5th Summer School. Rungsted, 25 Apr 1997.
75. IS Sammenfattende vurderinger af behandlingsmetoders værdi - metaanalyser. Møde mellem medlemmerne af de regionale videnskabsetiske komiteer og Den Centrale Videnskabsetiske Komité. Kolding, 21 aug 1997.
76. IS "Evidence Based Medicine". Overlægeforeningens Årsmøde. Nyborg Strand, 29 Aug 1997.
77. The Cochrane Collaboration. WHO's European Office, Programme Manager's Meeting. København, 3 Sept 1997.
78. Cochrane-samarbejdet. Lægemidddelstyrelsen. København, 16 sept 1997.
79. IS Rigshospitalets forskningsproduktion i 1994-96. Temadag om budgettering af forsknings- og udviklingsmidler, Rigshospitalet, 23 sept 1997.
80. IS Scopes and topic lists of Review Groups. 5th Annual Cochrane Colloquium, Amsterdam, 9 Oct 1997.
81. IS Hjælp til selvhjælp: Hvad kan Cochrane-samarbejdet tilbyde sundhedsvæsenet, og hvad kan sundhedsvæsenet tilbyde Cochrane-samarbejdet? Institut for Sundhedsvæsen, Symposium, Køge, 24 okt 1997.
82. IS Evidence based medicine - oplæg og diskussion. H:S Sundhedsfaglige råd, Rigshospitalet, 28 okt 1997.
83. IS Vad är - och hur arbetar - Cochrane Collaboration? Regiondag om Evidence Based Medicine, Södra sjukvårdsregionen, Malmö, 21 nov 1997.
84. Cochrane-samarbetet. Läkemedelsverket, Uppsala, 5 dec 1997.
85. IS Evidence-based medicine: the present and the future. Duodecim, 10th Anniversary Seminar of the Physician's Desk Reference and Database, Helsinki, 28 Jan 1998.
86. IS Ethical aspects in the use of systematic reviews in health care. Workshop on systematic reviews, Stakes & FinOHTA, Helsinki, 30 Jan 1998.
87. IS Præsentation af Cochrane-projektet. Nordisk Ministerråd, Hellerup, 25 mar 1998.
88. IS Getting the message across. 7th European Stroke Conference, Edinburgh, 29 May 1998.
89. IS RCT, status og visioner. Dansk Selskab for Medicinsk Filosofi, Etik og Metode. Festmøde, København, 17 sept 1998.
90. IS Evidensbaseret medicin. Farmaciens Dag, Danmarks Farmaceutiske Selskab, København, 2 okt 1998.

91. IS Demonstrating evidence in action: a case study. 6th Annual Cochrane Colloquium, Baltimore, 25 Oct 1998.
92. IS Bias i randomiserade försök och meta-analyser. Svenska Läkarsällskapets Riksstämma, Göteborg, 24 nov 1998.
93. IS Det Nordiske Cochrane Center og dets samarbejde med klinisk praksis. Statens Sundhedsvidenskabelige Forskningsråd og Statens Institut for Medicinsk Teknologivurdering, Middelfart, 11 feb 1999.
94. IS Evidens fra systematiske reviews. Dansk Endokrinologisk Selskab, Domus Medica, 22 feb 1999.
95. IS Overall status of the Cochrane Collaboration. Cochrane Colorectal Cancer Group meeting, København, 19 Mar 1999.
96. Det Nordiske Cochrane Center og evidensbaseret medicin. Folketingets Sundhedsudvalg, 24 mar 1999.
97. IS Evidensbaseret klinisk praksis. Områdeledelsens Stab og Sekretariat, Odense Universitetshospital, 8 apr 1999.
98. IS Hvad kan Cochrane-databasen bruges til? Dansk Kirurgisk Selskabs Forårsmøde, Herlev, 15 apr 1999.
99. Presentation of The Cochrane Collaboration. Exploratory meeting to consider establishing a Russian Branch of The Nordic Cochrane Centre. Hotel Akademicheskaya, Moskva, 7-8 June 1999.
100. IS Mega-trials or meta-analysis? European Society for Paediatric Research, Panum Instituttet, 28 June 1999.
101. IS Hvad er rationel farmakoterapi? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 22 okt 1999.
102. IS The Cochrane Collaboration i Norden. SBU, Evidensbaseret sjukvård. Stockholm, 27 jan 2000.
103. IS Hvad vil det sige, at behandlingen er evidensbaseret? Jydsk Medicinsk Selskab, Århus, 5 apr 2000.
104. IS Meta-analyser, systematiske reviews. Kursus i evidensbaseret klinik. Frederiksberg hospital, 9 juni 2000.
105. IS Systematic review of breast cancer screening. Meeting with local minister of health and specialist societies. Barcelona, 29 June 2000.
106. IS History of The Cochrane Collaboration. 8th Cochrane Colloquium, Cape Town, 25 Oct 2000.
107. IS Er det alvorlige mangler ved det vitenskapelige grunnlaget for mammografi-screeningen? Årsmøde i Norsk Patologforening, Oslo, 10 nov 2000.
108. IS Är mammografiscreening värdefull? Svensk förening för radiologisk bröstdiagnostik, Rigshospitalet, 16 nov 2000.
109. IS Systematic review of mass screening for breast cancer with mammography. Dansk Selskab for Medicinsk Onkologi, Panum, 20 Nov 2000.
110. IS Hvornår er ændret klinisk praksis nødvendig? Dansk Selskab for Medicinsk Filosofi, Etik og Metode, København, 23 nov 2000.
111. IS Evidensbaseret medicin. KAS Herlev, 28 nov 2000.
112. IS Fallstudie Mammographie Screening. Bern's Universität, 6 Dec 2000.
113. IS Cochrane Collaboration. SBU, Stockholm, 7 feb 2001.
114. IS Utility of mammographic screening for detection of breast cancer and the measurement of the placebo effect. São Paulo, 23 Feb 2001.
115. IS Screening for breast cancer with mammography: a systematic review. Breast and Cervical Cancer Screening Conference, Bielefeld, 6 Apr 2001.
116. IS Concept and methods in Cochrane reviews. Dansk Selskab for Psykiatrisk Epidemiologi, 20 apr 2001.
117. IS Putting the evidence into breast cancer care - challenges and controversies for the future. National Breast Cancer Coalition's Annual Meeting, Washington, 6 May 2001.
118. IS Ankelligament-metaanalyse. Dansk Fod- og Ankelkirurgisk Selskab, Gjern, 18 aug 2001.
119. Misleading publications of major mammography screening trials in major medical journals. Fourth International Congress on Peer Review in Biomedical Publication, Barcelona, 14 Sept 2001.
120. IS Cochrane reviews - the clinical application of evidence. Skandinavisk Forening af Oral og Maxillofacial Kirurger, 21 Sept 2001.
121. IS Hvilke problemer ved screeningsmetoder er politikere ikke blevet informeret om? Dansk Selskab for Medicinsk Prioritering og Dansk Selskab for Almen Medicin, København, 30 okt 2001.

122. IS Mammografiscreening - undersøgt i en metaanalyse. Dansk Selskab for Almen Medicins Risikogruppe, Silkeborg, 23 nov 2001.

123. IS Metaanalyse. Foredrag efter modtagelse af Niels A Lassen prisen, Bispebjerg Hospital, 7 dec 2001.

124. IS Metaanalyse, styrke og svaghed, metodologiske betragtninger. Gruppen af Yngre Gastroenterologer På Vej, København, 12 dec 2001.

125. IS Metaanalyser - hvad kan og skal de bruges til? Selskabet for Teoretisk og Anvendt Terapi, København, 7 feb 2002.

126. IS The old vs the new review. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.

127. IS The importance of the published, peer reviewed protocol. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 9 Apr 2002.

128. IS Problemer ved vurderingen af lægemiddelundersøgelser. Dansk Reumatologisk Selskab, Horsens, 19 apr 2002.

129. IS Conflict of interest. Cochrane Colorectal Cancer Group's Status Meeting, København, 19 Apr 2002.

130. IS Lægers videnskabelige ytringsfrihed, interkollegiale problemer. Dansk Selskab til Sikring af Lægers Ytringsfrihed, København, 3 juni 2002.

131. IS Things to be cautious about when making policy recommendations based on systematic reviews, randomised trials, cohort studies, and expert opinion. Delegates from The Ministry of Health, China, Rigshospitalet, 20 Aug 2002.

132. IS Forskning er ikke fuldstændig objektiv - den kan drejes og vendes, så den passer politisk. Kursus for journalister, København, okt 2002.

133 IS Mammascreening: a critical analysis. Wenckebach Symposium, Groningen, 5 Nov 2002.

134. IS Dissemination experiences in the Cochrane Collaboration. Nordic Campbell Center inauguration seminar, Helsingør, 13 Nov 2002.

135. IS Hva kan epidemiologer bidra med i deatten om mammografiscreening? Den tiende norske epidemiologikonferansen, Trondheim, 14 nov 2002.

136. IS Unambiguous and comparable results as quality measures in health related research. Is randomisation a necessity to obtain reliable knowledge? How are self-selection and self-conscious efforts handled? Konference arrangeret af Videns- og Forskningscenter for Alternativ Behandling, Århus, 27 Nov 2002.

137. IS Ten years of the Cochrane Collaboration. Seminar for Finnish doctors, Biomedicum, Helsinki, 23 Jan 2003.

138. IS Dronning Ingrid's Festforelæsning. Hvad er vore behandlinger værd? Åbenrå Sygehus, 8 maj 2003.

139. IS Temaeftermiddag. Evidensbaseret forebyggelse og behandling. Ålborg Sygehus, 9 sept 2003.

140. IS Plenary lecture. Pitfalls in evidence based medicine. 4th Congress, European Federation of Internal Medicine, Berlin, 11 Sept 2003.

141. IS Debate. Population based breast cancer screening. ECCO 12, Federation of European Cancer Societies, København, 25 Sept 2003.

141. Evidensbaseret forbrugeroplysning. Konference arrangeret af Forbrugerrådet og Det Nordiske Cochrane Center, Christiansborg, København, 22 okt 2003.

142. IS Plenary lecture. Conflicts of interest. XIth Cochrane Colloquium, Barcelona, 27 Oct 2003.

143. IS Evidensbaseret medicin: eksempler og betydning. Møde om medicinforsøg, arrangeret af Institut for Rationel Farmakoterapi, København, 19 nov 2003.

144. Discrepancies between protocols and publications: Evidence of outcome reporting bias in randomised trials. De Videnskabsetiske komitéer for Københavns og Frederiksbergs kommuner, 11 dec 2003.

145. IS Experiences within the Cochrane Collaboration. WHO workshop on grading of evidence, København, 16 Dec 2003.

146. IS Evidensbaseret medicin. Sosial- og helsedirektoratet, Oslo, 15 jan 2004.

147. IS Why is the practice of evidence-based medicine more difficult than it seems? Læknadager 2004, Reykjavik, 23 Jan 2004.

148. IS Doctor, should I have a mammography? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.

149. IS The management of hypertension, should we rely on the good old drugs? (debate). Læknadager 2004, Reykjavik, 23 Jan 2004.

150. IS Evidence-based microbiology. Dansk Selskab for Klinisk Mikrobiologi, uddeling af Wyeth-prisen for 2003, København, 27 jan 2004.
151. IS Mammografi-screening, contra. Foreningen af Yngre Gynækologer og Obstetrikeres Forårsmøde, Odense, 18 marts 2004.
152. IS Evidensgrundlag. Institut for Rationel Farmakoterapi, møde om kriterier for rationelt valg af lægemidler, Kolding, 30 april 2004.
153. IS Hvad er vore behandlinger værd? Gentofte-Vangede Rotary Klub, 26 aug 2004.
154. IS Empirical evidence for selective reporting of outcomes in randomised trials. Den Centrale Videnskabsetiske Komité, København, 27 aug 2004.
155. IS Risikovurdering og formidling omkring screening, og industrisponsoreret forskning. Det Etiske Råd, København, 16 sept 2004.
156. IS Fortsat udbredelse af mammografiscreening. Nordjyllands amtsråd, Ålborg, 19 nov 2004.
157. IS Harry Boström föreläsningen: Cochrane-samarbetet och evidensbaserad medicin. Riksstämman, Svensk Internmedicinsk Förening, Göteborg 25 nov 2004.
158. IS Nutidens og fremtidens krav om evidens for det lægelige arbejde. Nordjyllands Lægekredsforenings 150 års jubilæum, Ålborg, 26 nov 2004.
159. IS Blinding. Expert Discussion Workshop. Institute of Public Health, Cambridge, 17 maj 2005.
160. Sponsorship, bias and methodology: Cochrane Reviews compared with industry-sponsored meta-analyses of the same drugs. 5th International congress on peer review and biomedical publication, Chicago, 17 Sept 2005.
161. Are relative risks and odds ratios in abstracts believable? 5th International congress on peer review and biomedical publication, Chicago, 18 Sept 2005.
162. IS Medical statistics in practice: Dr Jekyll and Mr Hyde. 10 year celebration, Centre for Statistics in Medicine, Oxford, 20 Sept 2005.
163. IS Introduction to key concepts and principles of evidence-based medicine. Moscow Medical Academy, 13 Oct 2005.
164. Constraints on academic freedom in industry-initiated clinical trials. XIII Cochrane Colloquium, Melbourne, 22-26 Oct 2005.
165. IS Should we believe in epidemiology? Scientific seminar, Royal Veterinary and Agricultural University, Copenhagen, 14 Nov 2005.
166. IS Evidence in health care. Health Administration, Copenhagen County, 28 April 2006.
167. IS Commercial interests versus common goods. Nordic Committee on Bioethics, Malmö, 16 Oct 2006.
168. Far too many excluded studies listed in Cochrane Reviews. XIV Cochrane Colloquium, Dublin, 23-26 Oct 2006.
169. IS Cochrane Library. Ministry of Health, Warszawa, 18 Dec 2006.
170. IS Editorial misconduct. Finnish Medical Association, Helsinki, 25 Jan 2007.
171. IS Evidence-based health care. Institute for Competence Development, Copenhagen, 27 Feb 2007.
172. IS Commercial interests. Institute of Technology, Copenhagen, 14 Mar 2007.
173. IS Screening. Danish Society for Pathology, Copenhagen, 23 Mar 2007.
174. IS Selective reporting. Dutch Cochrane Centre's 12.5-year anniversary, Amsterdam, 18 April 2007.
175. IS Evidence-based health care. Aalborg University Hospital, 26 Sept 2007.
176. IS Bias in drug trials. Eur Assoc Clin Pharmacol, Amsterdam, 29 Aug 2007.
177. IS Commercial influence on clinical research. University of Southern Denmark, 15 Nov 2007.
178. IS Evidence-based medicine. Clinical microbiologists, Copenhagen, 21 Nov 2007.
179. IS Evidence for prevention. National Board of Health, Nyborg, 26 Nov 2007.
180. IS Can we trust clinical research results? Medical Society of Copenhagen, 27 Nov 2007.
181. IS Tainted evidence: drug companies and the power of marketing. 2nd South Asian Regional Symposium on Evidence Informed Health Care. Vellore, India, 9 April 2008.
182. IS Research collaboration. Danish Society for Theory in Medicine, Panum, 21 Apr 2008.
183. IS Mammography screening. Dept of Obstetrics, Rigshospitalet, 15 May 2008.
184. IS The corruption of drug research. Swiss Soc Intern Med, Lausanne, 21 May 2008.

185. IS Credibility of clinical research. Central Ethics Committee, Copenhagen, 13 June 2008.
186. IS The burdens of screening. Euroscience Open Forum, Barcelona, 21 July 2008.
187. IS Unhealthy health care. Distinguished scholar lecture, University of Minneapolis, 9 Sept 2008.
188. IS Unhealthy health care. Visiting scientist, University of Dartmouth, 11 Sept 2008.
189. IS Off-label use of drugs. Danish Pharmaceutical Society, Copenhagen, 29 Oct 2008.
190. IS Bias in drug trials. Danish Society for Psychiatric Epidemiology, Copenhagen, 6 Nov 2008.
191. IS Screening for lung cancer. Symposium, Focus on Lung Cancer, Copenhagen, 17 Nov 2008.
192. IS Screening for lung cancer. Danish Society for Pulmonary Medicine, Kolding, 28 Nov 2008.
193. IS Commercial interests. Institute of Technology, Copenhagen, 17 Dec 2008.
194. IS Screening and ethics. Clinical Ethics Committee, Frederiksberg Hospital, 2 Apr 2009.
195. IS Reflexions on screening. Region Middle Jutland, 15 Apr 2009.
196. IS Is the university trustworthy? LIFE, The Bioscientific Faculty, 6 May 2009.
196. IS Mammography screening. Nordic Congress in General Medicine, Copenhagen, 15 May 2009.
197. IS Opening lecture, Evidence-Based Medicine. 8th Congress of European Federation of Internal Medicine, Istanbul, 27 May 2009.
198. IS Cancer screening. Heinrich-Heine University, Düsseldorf, 17 June 2009.
199. IS Overdiagnosis of breast cancer. Cancer Intervention and Surveillance Modelling Network (CISNET), Rotterdam, 24 June 2009.
200. IS Good quality of drug trials. GCP meeting, Gentofte Hospital, 21 Sept 2009.
201. IS Forskningspolitisk debat, cancer screening. Forskningens dag, Herlev Hospital, 28 Okt 2009.
202. IS Breast screening. Norwegian-Danish Seminar, Oslobåden, 2 Nov 2009.
203. IS Breast screening - the facts. Royal College of Obstetricians, London, 9 Nov 2009.
204. IS Er det dyreste det bedste? Region Sjælland, Sørup Heregård, 1 Dec 2009.
205. IS Randomisering i praksis. Trygfondens Forebyggelsescenter, 14 Jan 2010.
206. IS Mammographie-Screening. Berlin, German Cancer Society, 25 Feb 2010.
207. IS Klinisk relevans, hvad er det? Danish Society for Clinical Pharmacology, 2 Mar 2010.
208. IS Evidence: conflict of interest. Auckland, 22 Mar 2010.
209. IS Lægers interaktioner med medicinalindustrien. Region Nordjylland, 4 May 2010.
210. IS Fungal infections. Rigshospitalet, 12 May 2010.
211. IS Arguments for RCTs. Nordic Gastroenterology Congress, Copenhagen, 11 June 2010.
212. IS Ghostwriting is scientific misconduct. Polish Academy of Sciences, 8 Oct 2010.
213. IS Conflicts of interest. Danish University Antidepressant Group, Nyborg, 5 Nov 2010.
214. IS Bioethics: access to data and mammography screening. EU Parliament, Strassbourg, 24 Nov 2010.
215. IS Hvem har mest gavn af lægens medicinudskrivning? Patientforeningen Danmark, 18 Jan 2011.
216. IS Ethical aspects of public vs private research. Nordic Committee on Bioethics, Helsinki, 1 Nov 2011.
217. IS Strengthening and opening up EU's health research. EU Parliament, Brussels, 30 Nov 2011.
218. IS Medicinalindustrien. EU Parliament, Brussels, Social democrats, 1 Feb 2012.
219. IS Access to data from regulatory authorities. Paris, 19 April 2012.
220. IS European Drug Regulators' meeting. Why we need easy access to all data from all clinical trials and how to accomplish it. Copenhagen, 26 April 2012.
221. IS Why we need to open up health research by sharing our raw data. EU Parliament, Brussels, 6 June 2012.
222. IS Access to medical research data in the EU. HAI Europe, Amsterdam, 12 Oct 2012.
223. IS Rethinking clinical practice. Danish University Antidepressant Group, Nyborg, 9 Nov 2012.
224. IS Open access to all data is a moral obligation towards the patients. EU Parliament, Brussels, 13 Nov 2012.
225. IS Introductory statement. European Medicines Agency, London, 22 Nov 2012.
226. IS Time to stop mammography screening. Selling sickness, Washington DC, 21 Feb 2013.
227. IS Transparency saves lives. EU Parliament, Brussels, 10 Apr 2013.

228. IS Medical data tranparency. Ombudsman meeting, EU Parliament, Brussels, 23 Apr 2013.
229. IS Overblik over børn med psykisk sygdom/diagnoser. Sundhedsudvalget, Folketinget, 27 May 2013.
230. IS Gavnlige og skadelige virkninger ved medicinering af børn med psykisk sygdom. Sundhedsudvalget, Folketinget, 27 May 2013.
231. IS Mammografiscreening er skadelig og bør stoppes. Dagens Medicin, Folketinget, 31 May 2013.
232. IS What will we do about overdiagnosis? Dartmouth Institute for Health Policy & Clinical Practice, 12 Sept 2013.
233. IS Deadly medicines and organised crime. Johns Hopkins School of Public Health, Baltimore, 13 Sept 2013.
234. IS Deadly medicines and organised crime. Georgetown University, Washington DC, 16 Sept 2013.
235. IS Why drugs are the third leading cause of death. University College, London, 2 Oct 2013.
236. IS Early diagnosis. University College, London, 2 Oct 2013.
237. IS Psykiatri: medicinalindustriens paradis. Dispuk, Helsingør, 3 Oct 2013.
238. IS Working with evidence. Dansk Selskab for Obstetrik og Gynækologi, Roskilde, 7 Oct 2013.
239. IS 12 usandheder om depression til skade for patienterne. Psykovision, København, 7 Nov 2013.
240. IS Deadly medicines and organised crime. Harvard University, Safra Center for Ethics, 5 Dec 2013.
241. IS Deadly medicines and organised crime. McGill University, Montreal, 6 Dec 2013.
242. IS Deadly medicines and organised crime. Quebec University, Quebec, 9 Dec 2013.
241. IS Deadly medicines and organised crime. Ottawa Hospital, 10 Dec 2013.
243. IS Deadly medicines and organised crime. Women's College Hospital, Toronto, 11 Dec 2013.
244. IS Deadly medicines and organised crime. Toronto University, 12 Dec 2013.
245 IS Dødelig medicin og organiseret kriminalitet. Patientforeningen Danmark, Rigshospitalet, 14 Jan 2014.
246 IS Myter og facts om antidepressiva. Plastikkirurgisk afd, , 16 Jan 2014.
247 IS Lægers samarbejde med industrien, Overlægeforeningen, Hvidovre Hospital, 23 Jan 2014.
248 IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 25 Feb 2014.
249 IS Dødelig medicin og organiseret kriminalitet. Ølstykke Bibliotek, 27 Feb 2014.
250 IS Dødelig medicin og organiseret kriminalitet. JP Læserarrangement, 4 Mar 2014.
251 IS Psykofarmaka. Psykologisk Studenterforum, Århus Universitet, 4 Mar 2014.
252 IS Dødelig medicin og organiseret kriminalitet. Enhedslisten, Region Hovedstaden, 6 Mar 2014.
253 IS Psykofarmaka og andre lægemidler. Plan & Handling, Socialt-Lægeligt Seminar, Valby, 10 Mar 2014.
254 IS General health checks in adults. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
255 IS Why mammography screening should be stopped. Deutsche EBM Netzwerk, Halle, 14 Mar 2014.
256 IS Dødelig medicin og organiseret kriminalitet. Gentofte Bibliotek, 18 Mar 2014.
257 IS Why are prescription drugs the third leading cause of death? Panama City, 2 Apr 2014.
258 Health checks, what were the reactions? Nordic Cochrane Centre, 8 Apr 2014.
259 IS Set all data free. Young Investigators Network, Faculty Club, Panum, 10 Apr 2014.
260 IS Receptpligtig medicin – den tredjehyppigste dødsårsag. FoF København, 22 Apr 2014.
261 IS Why the use of psychiatric drugs may be doing more harm than good. House of Lords, UK, 30 Apr 2014.
262 IS This is not a symptom. South London Gallery, 30 Apr 2014.
263 IS Hvorfor er lægemidler den 3. hyppigste dødsårsag? Studenterforeningen, København, 2 May 2014.
264 IS Good scientific practice. Institute for Public Health, Copenhagen, 7 May 2014.
265 IS Dødelig medicin og organiseret kriminalitet. Praktiserende læger, Hotel Hesselet, 9 May 2014.
266 IS Psykiatri. Sundhedspolitisk Netværk, Ingeniørforeningen, 12 May 2014.
267 IS Psykiatri på afveje. Psykovision, Bethesda, København, 14 May 2014.
268 IS Interessekonflikter i lægeverdenen. Panum Instituttet, 19 May 2014.
269 IS Lægers relation til medicinalindustrien. Roskilde Sygehus, 21 May 2014.
270 IS Psychiatric drugs: does the way we use them cause more harm than good? Distinguished seminars in neuroscience and pharmacology. Panum Institute, 28 May 2014.

271 IS Håndtering af kommercielle interesser. Københavns Universitet, 10 June 2014.

272 IS Psychiatric drugs: does the way we use them cause more harm than good? Amsterdam, 13 June 2014.

273 IS Psykiatri på afveje. Stemmehørernetværket, Christiansborg, 17 June 2014.

274 IS Academia and industry. Annual Nobel Laureate meeting, Lindau, 3 July 2014.

275 IS Overdiagnosis and overtreatment in psychiatry. Finnish Psychological Association, Helsinki, 1 Sept 2014.

276 IS Deadly medicines and organised crime. Helsinki University, 2 Sept 2014.

277 IS Medicamentos que matan y crimen organizado. Barcelona, Institut d'Estudis Catalans, 8 Sept 2014.

278 IS Medicamentos que matan y crimen organizado. Madrid, Organización de Consumidores y Usarios (OCU), 9 Sept 2014.

279 IS Psykofarmaka-debat. Århus Universitet, 11 Sept 2014.

280 IS What are the true benefits and harms of our drugs? Jagiellonian University, Krakow, 7 Oct 2014.

281 IS Cochrane reviews and their importance for evidence-based medicine. Jagiellonian University, Krakow, 7 Oct 2014.

282 IS Deadly medicines and organised crime. Maynooth University, Dublin, 8 Oct 2014.

283 IS Deadly medicines and organised crime. Stillorgan Park Hotel, Dublin, 8 Oct 2014.

284 IS Danmark på lykkepiller. Herstedøster Forsamlingshus, 21 Oct 2014.

285 IS Kan kræft forsvinde af sig selv? Mølholm Forsikring, Carlsberg, 23 Oct 2014.

286 IS Danskernes mentale sundhed. Folkeuniversitetet, Panum, 3 Nov 2014.

287 IS Kliniske forsøg. Pharmaschool, Copenhagen, 5 Nov 2014.

288 IS Dødelig medicin og organiseret kriminalitet. Lægeforeningen Syddanmark, Kolding, 5 Nov 2014.

289 IS Kan kræft forsvinde af sig selv? Mølholm Forsikring, Århus, 5 Nov 2014.

290 IS Mammography screening: why it hasn't lived up to expectations. Santa Rosa, California, 8 Nov 2014.

291 IS Why very few patients benefit from the drugs they take and why many are killed by them. Santa Rosa, California, 9 Nov 2014.

292 IS Why very few patients benefit from the drugs they take and why many are killed by them. Stanford Medical School, 11 Nov 2014.

293 IS Why very few patients benefit from the drugs they take and why many are killed by them. University of British Columbia, Vancouver, 11 Nov 2014.

294 IS Mammography screening: why it hasn't lived up to expectations. University of British Columbia, Vancouver, 12 Nov 2014.

295 IS How to reduce big pharma's influence on guidelines. Kaiser Permanente, Los Angeles, 13 Nov 2014.

296 IS Transforming mad science, reimagining mental health care. International Society of Ethical Psychology and Psychiatry, Los Angeles, 15 Nov 2014.

297 IS Medisinering av psyken – mer skade enn gagn? Cinemateket, Oslo, 25 Nov 2014.

298 IS Global Health. Univ. of Copenhagen, 6 Jan 2015.

299 IS Depression. Young Psychiatrists, Rigshospitalet, 19 Jan 2015.

300 IS Psychiatry. Nurses, Silkeborg 20 Jan 2015.

301 IS Selective publication. Joanna Briggs Institute, Adelaide, 9 Feb 2015.

302 IS Drugs. Grand round. Royal Adelaide Hospital, Adelaide, 10 Feb 2015.

303 IS Psychiatry. Univ. of Adelaide, Adelaide, 10 Feb 2015.

304 IS Drug crimes. Alfred Hospital, Melbourne, 11 Feb 2015.

305 IS Psychiatry. State Library of Victoria, Melbourne, 11 Feb 2015.

306 IS Mammography screening. Alfred Hospital, Melbourne, 12 Feb 2015.

307 IS Drug crimes. Grand round. Royal Melbourne Hospital, Melbourne, 12 Feb 2015.

308 IS Antidepressants. Garvan Institute, Sydney, 12 Feb 2015.

309 IS Drug crimes. Concord Hospital Clinical School, Sydney, 13 Feb 2015.

310 IS Mammography screening. Dougherty Community Centre, Sydney, 13 Feb 2015.

311 IS Psychiatric drugs. University of Sydney Law School, Sydney, 14 Feb 2015.

312 IS Drug crimes. Grand round. Princess Alexandra Hospital, Brisbane, 16 Feb 2015.

313 IS Drug crimes. RACGP College House, Brisbane, 16 Feb 2015.
314 IS Drug crimes. Univ. of Queensland Medical School, Brisbane, 17 Feb 2015.
315 IS Psychiatry. Lady Cilento Children's Hospital, Brisbane, 18 Feb 2015.
316 IS Psychiatry. Adina Apartment Hotel, Brisbane, 18 Feb 2015.
317 IS Drug crimes. Grand round. Gold Coast University Hospital, 19 Feb 2015.
318 IS Lægemidler. Medicinsk Studenterforskning, Nyborg, 12 Mar 2015.
319 IS Depression. Rigshospitalet, 16 Apr 2015.
320 IS Psychiatric drugs. Lansing, Michigan, 17 Apr 2015.
321 IS Antidepressiva. Ålborg Sygehus, 21 Apr 2015.
322 IS Drugs. Danish National Board of Health, 27 Apr 2015.
323 IS The Maudsley Debate. London, 13 May 2015.
324 IS Drugs. Robert-Bosch-Stiftung, Berlin 22 May 2015.
325 IS Psychiatry. General Practitioners Annual Meeting, Bergen 27 May 2015.
326 IS Lægemidler. Læger fra Lolland, 29 May 2015.
327 IS Regulatory data. Int Soc Drug Bull, Pamplona, 29 June 2015.
328 IS Overdiagnosis and overtreatment. Int Soc Drug Bull, Pamplona, 30 June 2015.
329 IS Psykofarmaka. Dansk Psykologforening, København, 12 Sep 2015.
330 IS Antidepressants. Int Meeting, Copenhagen, 16 Sep 2015.
331 IS Forced treatment. Int Meeting, Copenhagen, 16 Sep 2015.
332 IS Antidepressants. Univ. of Roehampton, London, 18 Sept 2015.
333 IS Drugs. Katowice, 19 Sept 2015.
334 IS Mammography screening. Cochrane Colloquium, Wien, 3 Oct 2015.
335 IS Drugs. Oslo 20 years Anniversary Seminar, 19 Oct 2015.
336 IS Tvangsmedicinering. Litteraturhuset, Oslo, 19 Oct 2015.
337 IS Lægemidler. Guldborgsund Bibliotekerne, Nykøbing F, 21 Oct 2015.
338 IS Psykofarmaka. Benzorådgivningen, Middelfart, 23 Oct 2015.
339 IS Psykofarmaka. Enhedslisten, København, 23 Oct 2015.
340 IS Lægemidler. Norsk Studenterforening, Tromsø, 30 Oct 2015.
341 IS Psykofarmaka. Dansk Psykologforening, København, 7 Nov 2015.
342 IS Drugs. Medical Centre in Leiden, 11 Nov 2015.
342 IS Drugs. Arminius, Rotterdam, 12 Nov 2015.
343 IS Lægemidler. FOF Hvalsø, 23 Nov 2015.
344 IS Cancer screening. Gemeinschaftskrankenhaus Havehöhe, Berlin, 25 Nov 2015.
345 IS Psykofarmaka. Dansk Socialrådgiverforening, Fredericia, 30 Nov 2015.
346 IS Deadly medicines. Roma, Italy, 1 Dec 2015.
347 IS Deadly medicines. Univ. of Verona, 2 Dec 2015.
348 IS Deadly medicines. Gruppo Abele, Torino, 3 Dec 2015.
349 IS Deadly medicines. Alba, 3 Dec 2015.
350 IS Psykofarmaka. LAP, København, 18 Dec 2015.
351 IS Global Health. Univ. of Copenhagen, 6 Jan 2016.
352 IS Psykofarmaka. Hvidovre og Glostrup Psykiatri, 7 Jan 2016.
353 IS Psykofarmaka. Bedre Psykiatri, Odense, 14 Jan 2016.
354 IS Läkemedel. Stockholm läns landstings läkemedelskomité, 20 Jan 2016.
355 IS Psykofarmaka. Socialmedicinsk Enhed, Frederiksberg Hospital, 22 Jan 2016.
356 IS Vore overmedicinerede ældre. Assens Ældreråd, 26 Jan 2016.
357 IS Vore overmedicinerede ældre. School of Culture and Society, Karup, 11 Feb 2016.
358 IS Dødelig medicin og organiseret kriminalitet, LOF Slagelse, 29 Feb 2016.
359 IS Receptpligtig medicin – den tredjehyppigste dødsårsag, Tåstrup Bibliotek, 29 Feb 2016.

360 IS Antidepressants Do More Harm Than Good, Tampa, Florida, Adlerian Society, 4 March 2016.
361 IS Mammography screening, European Breast Cancer Meeting, Amsterdam, 9 March 2016.
362 IS Hvorfor gør psykofarmaka større skade end gavn? FOF Gladsaxe, 15 March 2016.
363 IS Drugs: the Dutch Medicines vision. Dutch Parliament, 29 March 2016.
364 IS Medicinsk behandling af psykiske sygdomme. Danske Regioner, Aarhus, 6 April 2016.
365 IS Psykofarmaka gør langt større skade end gavn. Aarhus Universitet, Aarhus, 6 April 2016.
366 IS Fup og fakta om antidepressiv medicin. Folkeuniversitetet i Aalborg, 7 April 2016.
367 IS Dødelig psykiatri. Sind på Frederiksberg, 10 May 2016.
368 IS Hvorfor gør psykofarmaka større skade end gavn? FOF Gladsaxe, 17 May 2016.
369 IS Without data sharing, there is no science, only marketing. Krakow University, 20 May 2016.
370 IS Den psykiatriske epidemi. National Neurokonference, Middelfart, 26 May 2016.
371 IS Dødelig biologisk psykiatri. Dansk Retspsykologisk Selskab, 30 May 2016.
372 IS Forced Psychiatric Treatment Must Be Abolished. Anchorage, 2 June 2016.
373 IS Prescription drugs are the third leading cause of death. Evidence Live, Oxford, 21 June 2016.
374 IS Mortality and drugs (top-3). 50th Anniversary of the Geneesmiddelenbulletin, Leiden, 30 June 2016.
375 IS What is wrong with research and treatment in psychiatry? 50th Anniversary, Leiden, 30 June 2016.
376 IS Hvorfor så få har gavn af psykofarmaka? Social- og Sunhedsskolen. Middelfart, 30 Aug 2016.
377 IS Varning för psykofarmaka! Stockholm, ABF-huset, 5 Sept 2016.
378 IS Deadly psychiatry. Spanish Association for Mental Health, Madrid, 19 Sept 2016.
379 IS Deadly psychiatry. Alibri Llibreria, Barcelona, 20 Sept 2016.
380 IS Varning för psykofarmaka! Bokmässan, Göteborg, 23 Sept 2016.
381 IS Why is it controversial to tell the truth about health care? HealthWatch Award, London, 20 Oct 2016.
382 IS Mammography screening. Cochrane Colloquium, Seoul, 25 Oct 2016.
383 IS Why so few patients benefit from the drugs they take. 21th WONCA, Rio de Janeiro, 3 Nov 2016.
384 IS Varning för psykofarmaka! Stockholm, ABF-huset, 22 Nov 2016.
385 IS Hvorfor er udtrapning af psykofarmaka så vigtigt? Høring i Folketinget, 13 Dec 2016.
386 IS Deadly psychiatry. De Balie, Amsterdam, 19 Dec 2016.
387 IS Myter, misforståelser og skader i psykiatrien. Pædagogisk Psykiatrisk Vejledning, Greve, 4 Jan 2017.
388 IS Psychiatric drugs. Sherbrooke, education for doctors, 20 Jan 2017.
389 IS Myten om den biologiske psykiatri. Christiansborg, 3 March 2017.
390 IS Prescription drugs are the third leading cause of death. University of Helsinki, 9 March 2017.
391 IS Forskning; med eller uden industri. Medicinsk Studenterforskning, Nyborg, 17 March 2017.
392 IS Psykofarmaka. Diplomuddannelsen for socialarbejdere, Faxe Ladeplads, 23 March 2017.
392 IS Dödlig psykiatri och organiserad förnekelse. ISPS, Stockholm, 31 March 2017.
393 IS Vi kan leve uden antipsykotika. Stemmehørernetværket, Odense Rådhus, 27 April 2017.
394 IS Psykofarmaka slår mange ihjel og forkrøbler langt flere. Slagelse Kommune, 3 May 2017.
395 IS Psykofarmaka, psykoterapi og udtrapning. Psykoterapeuter, København, 22 Aug 2017.
396 IS Psykofarmaka, psykoterapi og udtrapning. Psykoterapeuter, Vejle, 28 Aug 2017.
397 IS Overdiagnostik og overbehandling i psykiatrien. Bedre Psykiatri, Odense, 31 Aug 2017.
398 IS Myter om psykofarmaka? København, 26 Sept 2017.
399 IS Myter, misforståelser og skader i psykiatrien. Socialpædagoger, Kolding, 2 Oct 2017.
400 IS Den biologiske psykiatri bygger på en række misforståelser og myter. SIND, Aalborg, 10 Oct 2017.
401 IS International Institute for Psychiatric Drug Withdrawal. World Congress in Psychiatry, Berlin, 11 Oct.
402 IS Psychiatric drugs are the third leading cause of death. World Congress in Psychiatry, Berlin, 11 Oct.
403 IS Psykofarmaka. Neurologisk afd., Herlev Sygehus, 1 Oct.
404 IS How to survive in an over-medicated world. Columbus, Ohio, 11 Nov.
405 IS Harmful drugs you should know about. Columbus, Ohio, 12 Nov.
406 IS Afhængighed af og udtrapning af psykofarmaka. BBH, Klinisk Farmakologisk afd., 1 Dec.

407 IS Mental health in crisis. Sydney, 24 Feb 2018.
408 IS Mental health in crisis. Christchurch, 26 Feb 2018.
409 IS Mental health in crisis. Wellington, 27 Feb 2018.
410 IS Mental health in crisis. Hamilton, 28 Feb 2018.
411 IS Mental health in crisis. Auckland, 2 March 2018.
412 IS Psykofarmaka bør undgås, især til børn og unge. FADD, Slangerup, 7 March.
413 IS How to survive in an overtreated world. Public health course, Madrid, 10 March.
414 IS Why you should usually avoid cancer screening. Cambridge University, 5 April.
415 IS Depressionspiller gör mer skada än nytta. Stockholm, 13 April.
416 IS Complaint to the European Ombudsman and maladministration at EMA. Dublin 21 April via Skype.
417 IS Benefits and harms of depression pills. Copenhagen, 14 June.
418 IS Heroes of Science: Survival of a Whistleblower. Berlin, Max Planck Institute, 27 June.
419 IS Why the current usage of psychiatric drugs does far more harm than good. Berlin, Charité, 28 June.
420 IS Why systematic reviews of published drug trials lead to too much medicine. Helsinki, 17 Aug.
421 IS Overlevelse i en overmedicineret verden. Hillerød, 27 Sept.
422 IS Hvordan overlever man i en overmedicineret verden? Odense, Seniorhøjskolen, 3 Oct.
423 IS Why did we get a Cochrane Collaboration and what is it like today? Rigshospitalet, 12 Oct.
424 IS Chemical and physical interventions for house dust mites: why not? Rigshospitalet, 12 Oct.
425 IS Survival in an overtreated world: Look up the evidence yourself. Univ. of Groningen, 22 Oct.
426 IS Survival in an overtreated world: Look up the evidence yourself. Patiëntenfederatie, Utrecht, 23 Oct.
427 IS Survival in an overtreated world: Look up the evidence yourself. De Balie, Amsterdam, 23 Oct.
428 IS Survival in an overtreated world: Look up the evidence yourself. Ministry of Health, den Haag, 24 Oct.
429 IS Psykofarmaka gør større skade end gavn. Thisted, 31 Oct.
430 IS We need a revolution in psychiatry, the only medical specialty that does more harm than good. Berlin, Charité Hospital, 27 Nov.
431 IS Open science for better health-care for all. Bruxelles, EU Parliament, 29 Nov.
432 Death of a whistleblower: scientific censorship in action. Copenhagen, 9 Mar 2019.
433 IS Evidensbasert medisin. Trondheim, 20 Mar.
434 IS Myter, misforståelser og skader i psykiatrien. København, 13 May.
435 IS Death of a whistleblower and Cochrane's moral collapse. Santa Cruz, California, 9 June.
436 IS Mammography screening should be stopped. Barcelona, 15 June.
437 IS Death of a whistleblower and Cochrane's moral collapse. Madison, Wisconsin, 30 July.
438 IS Critical thinking about psychiatric drugs. Tromsø, 5 Sept.
439 IS Myter, misforståelser og skader i psykiatrien. Århus, 3 Oct.
440 IS The Cochrane affair and conflicts of interest. Paris, 11 Oct.
441 IS Hvordan overlever man i en overmedicineret verden? Esbjerg, 30 Oct.
442 IS Breast cancer screening: state of the art. Porto, 4 Nov.
443 IS General health checks: state of the art. Porto, 5 Nov.
444 IS Forskning og interessekonflikter. Udvalget til Beskyttelse af Videnskabeligt Arbejde. København, 7 Nov.
445 IS Sundhedsvæsen og politik. Helsingør, 21 Nov.
446 IS Does long term use of psychiatric drugs cause more harm than good? Newcastle University, 22 Jan 2020.
447 IS Vacciner, sandhed, løgn og kontroverser. Patientforeningen Danmark, 6 Feb.
448 IS Why prescription drugs are the third leading cause of death. Teleseminar, Madrid, 7 June.
449 IS Hvordan overlever man i en overmedicineret verden? Egmonthøjskolen, Odder, 14 July.
450 IS Uddeling af diagnoser og overmedicinering. Mariehjemmene, København, 4 Sept.
451 IS Science and Society in the Pandemia war. Teleconference, Athens Medical Association, 19 Sept.
452 IS Mental health survival kit. Stanford, METRICS, telelecture, 1 Oct.

453 IS Hvordan overlever man i en overmedicineret verden? Favrskov aftenskole, 26 okt.

Research mentorships

PhD and other degrees

1992 - 1994 Pia Therkildsen. Clinical research behaviour in Danmark. Main tutor. PhD not finished.
1993 - 1994 Flemming Ørnskov. Drug treatment. Main tutor. PhD not finished (emigration).
1996 - 2001 Asbjørn Hróbjartsson. The placebo concept. Main tutor. PhD defended 8 June 2001 at the University of Copenhagen.
2001 - 2004 Jan Peter Kösters (German doctor). Breast cancer screening. Main tutor. Doktors der Medizin defended 17 Sept 2004 at the University of Hamburg.
2000 - 2004 Lise Lotte Kjærgaard. The randomised clinical trial. PhD, changed to DrMedSci, defended 19 Aug 2005 at the University of Copenhagen.
2001 - 2005 Bodil Als-Nielsen. Hepatic encephalopaty. PhD defended 13 May 2005 at the University of Copenhagen.
2001 - 2005 Julie Pildal. Bias in systematic reviews. Main tutor. PhD defended 6 Sept 2005 at the University of Copenhagen.
2004 - 2013 Karsten Juhl Jørgensen. Screening for breast cancer. Main tutor. PhD changed to DrMedSci, defended 11 Jan 2013 at the University of Copenhagen.
2008 - 2009 Marija Barbateskovic. Impact factors and sponsorship. Main tutor. Candidate in science. Marks 12 (top on new scale)
2007 - 2010 Britta Tendal. Standardised mean difference in meta-analysis. Main tutor. PhD defended 26 Aug 2010 at the University of Copenhagen.
2007 - 2011 Anders W. Jørgensen. Robustness of results and conclusions in systematic reviews, trials and abstracts. Main tutor. PhD defended 16 Nov 2011 at the University of Copenhagen.
2007 - 2013 Margrethe Nielsen. Selective serotonin reuptake inhibitors. Main tutor. PhD defended 19 April 2013 at the University of Copenhagen.
2008 - 2013 Andreas Lundh. Conflicts of interest in biomedical publishing. Main tutor. PhD defended 25 April 2013 at the University of Copenhagen.
2010 - 2015 Lasse Teis Krogsbøll. Health checks. Main tutor. PhD defended.
2011 - 2015 Jeppe Schroll. Coding of harms in randomised trials. Main tutor. PhD defended.
2011 - 2016 Emma Maund. Harms of Selective serotonin reuptake inhibitors. Main tutor. PhD defended.
2012 - 2016 Michelle Ogden. Are randomised trials ethical? Main tutor. Stopped 2016.
2012 - 2018 Tarang Sharma. Suicidality and violence on SSRIs. Main tutor. PhD defended.
2016 - 2018 Kristine Rasmussen. Conflicts of interest. Main tutor. PhD defended.
2014 - 2018 Pia Danborg. Psychiatric animal studies. Main tutor.
2016 - 2018 Camilla Hansen. Conflicts of interest. Tutor.
2016 - 2019 Lars Jørgensen. HPV vaccines. Main tutor. PhD defended.
2016 - Anders Sørensen. Psychiatry. Main tutor.
2016 - Marie Bohlbro. Psychiatry. Main tutor.
2017- Kim Boesen. ADHD drugs. Main tutor.

Training students in research

2003 Troels Wienecke. OSVAL II, marks 9, ref. 153 in reference list above.
2003 Karsten Juhl Jørgensen. OSVAL II, marks 10, ref. 154 in reference list above.
2003 Mette Haahr, scholar student, ref. 157 in reference list above.
2003 Lasse Schmidt. OSVAL II, marks 10, ref. 169 in reference list above.
2003 Katrine Karmisholt, scholar student, ref. 172 og 173 in reference list above.
2004 Anne Due, OSVAL II, marks 10, ref. 189 in reference list above.
2004 Anders Jørgensen, OSVAL II, marks 10, ref. 190 in reference list above.
2005 Anders Klahn, OSVAL II, marks 10, ref. 198 in reference list above.
2006 Britta Tendal, scholar student, ref. 196 in reference list above.
2006 Katja Maric, scholar student, ref. 196 in reference list above.
2007 Matias Vested Madsen, OSVAL II, marks 9, ref. 215 in reference list above.
2007 Lasse Krogsbøll, OSVAL II, marks 10, ref. 221 in reference list above.
2007 Jørgen Jacob Eschen, OSVAL II, marks 11. No journal manuscript.
2009 Marija Barbateskovic, manuscript under preparation.

2009 Jeppe Lerche Hansen, manuscript under revision.
2009 Jeppe Schroll, manuscript under revision.
2010 Ann-Sofia Skou Thomsen, OSVAL II, marks 12
2010 Frida Samuelsson, OSVAL II, marks 12
2010 Christian Grønhøj Larsen, OSVAL II, marks 12
2010 Nino Ortner, OSVAL II, marks 12 (Hróbjartsson tutor)
2011 Kristine Rasmussen, special subject, marks 12
2011 Anine Skibsted, special subject, marks 12
2011 Jon Egelund Jensen, special subject, marks 10
2012 Julie Bindslev, special subject, marks 12
2012 Marie Damkjær Hansen, special subject, marks 10 (Hróbjartsson tutor)
2014 Mikkel Marquardsen, special subject, marks 12
2014 Andreas Bielefeldt, special subject, marks 12
2014 Jakob Jensen, special subject, marks 7
2014 Louise Jensen
2014 Nana Freund, no special subject
2014 Asmus Mortensen, special subject, marks 10
2015 Asger Paludan-Müller, bachelor subject, marks 12
2015 Kim Boesen, special subject, marks 12
2015 Anders Simonsen, special subject, marks 12

Expert, Medical Research Council's Statistical Aid Service

1991 Nick Rasmussen. Randomised trial, steroids in periarthrosis.
1991 Holger Sørensen. Randomised trial, haloperidol vs. oxazepam.
1991 Arne Gam. Meta-analysis, soft laser treatment.
1992 Søren Eiskjær. Meta-analysis, osteosynthesis methods in collum fracture.
1993 Arne Gam. Meta-analysis, ultrasound in musculoskeletal disorders.
1993 Hanne Olesen. Meta-analysis, oxygen deficit by anaerobic training.
1993 Kim Brøsen. Meta-analysis, genetic polymorphism and disease risk.
1993 Anita Rønn. Randomised trial, Maloprim vs. placebo in malaria.
1993 Mette Bitsch-Christensen. Immune therapy of children with allergy.
1993 Anne-Lise Christensen. Comparison of methods to diagnose pneumonia.
1993 Anne-Cathrine Halvorsen. Diagnostic methods in bleeding disorders.
1993 Michael Hansen. Biochemical markers for bone formation and resorption.
1994 Robin Bohen. Treatment of fibromyalgia based on psychomotoric theory.
1994 Helle Rask. Randomised trial, volume expansion in surgery.
1995 Allan Ibsen Sørensen. Meta-analysis of endoscopic carpal tunnel dissection.
1996 Hanne Sørensen. Randomised trial, physioterapy in back pain.
1997 Judith Kongsted. Healing in breast cancer.
1998 Poul Sindberg Eriksen. Risks after laser conisation of cervix uteri.
1998 Niels Petri. Orthodontic treatment of sleep apnoea.
2000 Hanne Sørensen. Training for back pain.
2002 Lars Højgaard-Rasmussen. Asthma and osteopathy.
2002 Mette Pedersen. Vocal cord nodules: non-surgery vs. surgery.
2004 Thorkil Christensen. Randomised trial, herbal cream for pain.

Scientific assignments

General

1988 - 1990 Secretary, Danish Society for Theory in Medicine.
1990 Examiner, prize report in medicine, University of Copenhagen.
1990 Member of WHO's expert group in Bukarest, evaluation of AIDS trial in children.
1991 Member of drug committee's quality group, Rigshospitalet.
1992 Member of Ministry of Education's group in Latvia, research evaluation.
1991 - 1998 Expert, Medical Research Council's Statistical Aid Service.
1992 - 1996 Chairman, Danish Society for Theory in Medicine.

1993 - 2005	Examiner, PhD applications, Rigshospitalet.
1993 - 2005	Member of Research Council, Rigshospitalet.
1993 - 2010	Member of Drug Committee, Rigshospitalet.
1995	Member of HS´s working group on clinical databases.
1998	Examiner, PhD thesis (Rasmus Licht).
1998	Chairman and examiner, PhD thesis (Palle Valentiner-Brandt).
1998	Member of ad hoc committee, Office for Scientific Integrity.
1998 - 2005	Expert, Medical Research Council's Statistical Aid Service for East Denmark.
1999	Member of ad hoc committee, Office for Scientific Integrity.
2001	Member of ad hoc committee, Office for Scientific Integrity.
2008	Examiner of case of suspected scientific misconduct in Iran for The Oxford Health Alliance.
2008	Examiner of case of suspected scientific misconduct in Norway.
2011	Examiner, PhD thesis (Bendt Johansen), University of Southern Denmark
2013	Chairman, assessment of candidates for a professorship, University of Copenhagen
2014	Chairman and examiner, PhD thesis (Robert Eriksson), University of Copenhagen
2015	Chairman and examiner, PhD thesis (Bruno Heleno), University of Copenhagen
1993 -	Member CONSORT (Consolidated Standards of Reporting Trials), see www.consort-statement.org.
2004 -	Member of STROBE (Developing Standards of Reporting for Observational Studies in Epidemiology), see www.strobe-statement.org.
2005 -	Member of PRISMA (Quality of reporting of meta-analyses), see http://www.prisma-statement.org/.
2005 -	Member of SPIRIT (Standard Protocol Items for Randomised Trials), see www.spirit-statement.org/.

Editorial work

1992 - 1998	Editor, Bibliotek for Læger.
1995 - 2002	Member of Editorial Board, British Medical Journal.
1995 -	Member of Editorial Advisory Board, Scandinavian Journal of Rheumatology.
1995 -	Member of Editorial Advisory Board, The Cochrane Collaboration.
1997 - 2014	Editor, Cochrane Methodology Review Group
1997 -	Member of Advisory Board, Clinical Evidence, BMJ Publishing.
2000 -	Editorial advisor, BioMedCentral (supports PubMedCentral, USA).
2000 - 2010	Member of Scientific Board, Ugeskrift for Læger
2004 -	Member of Editorial Board, BioMedCentral Medical Research Methodology
2004 -	Member of BMJ Knowledge Advisory Board
2007 -	Academic editor, PLoS Medicine

Performed peer reviews for:

Acta Neuropsychiatrica
Annals of Internal Medicine
BioMed Central Medical Research Methodology
BioMed Central Family Practice
BioMed Central Infectious Diseases
Bibliotek for Læger
BMJ
BMJ Open
Breast Cancer Research and Treatment
Canadian Medical Association Journal
Cancers
Clinical Evidence
Clinical Trials
Clinical Trials and Meta-analysis
Cochrane Airways Group
Cochrane Anaesthesia Group
Cochrane Gynaecological Cancer Group
Cochrane Hepato-Biliary Group
Cochrane Infectious Diseases Group

Cochrane Musculoskeletal Group
Cochrane Musculoskeletal Injuries Group
Cochrane Oral Health Group
Controlled Clinical Trials
Danish Medical Bulletin
European Journal of Neurology
Hong Kong Government Research Council
International Journal of Cancer
International Journal of Epidemiology
International Journal of Risk and Safety in Medicine
International Journal of Technology Assessment in Health Care
JAMA
Journal of Clinical Epidemiology
Journal of Medical Ethics
Lancet
La revue Préscrire
Medical Journal of Australia
Medical Research Council, UK
Medicine, Philosophy and Health Care
Nature Reviews Nephrology
New England Journal of Medicine
PLoS Medicine
Politik
Pharmacogenetics
PharmacoEconomics
Radiotherapy and Oncology
Scandinavian Journal of Gastroenterology
Scandinavian Journal of Medicine and Science in Sports
Scandinavian Journal of Rheumatology
Scandinavian Journal of Social Medicine
Science
Statens beredning för medicinsk utvärdering
Statistics in Medicine
Tobacco Control
Ugeskrift for Læger
Vetenskapsrådet, Sverige
Women's Health

Chairman at congresses and meetings

1. Seminar on Bias and Controversies in Clinical Research. Rigshospitalet, 28 Feb 1992.
2. Pharmacotherapy I - methodological aspects. 25th Scand Congr Rheumatol, Lillehammer, 2 June 1994.
3. Reviews of data on continuous scales. Workshop, 2nd Cochrane Colloq, Hamilton, Canada, 1 Oct 1994.
4. Reviews and Syntheses. 11th Meeting, International Society of Technology Assessment in Health Care, Stockholm, 6 June 1995.
5. Cochrane Hepato-biliary Review Group Meeting. European Association for the Study of the Liver, København, 19 Aug 1995.
6. Cochrane Tuberculosis Review Group Meeting. International Union against Tuberculosis and Lung Disease, Paris, 9 Sept 1995.
7. Scientific presentations. 3rd Annual Cochrane Colloquium, Oslo, 4-8 Oct 1995.
8. Cochrane Depression/Neurosis Review Group Meeting. 3rd Annual Cochrane Colloq, Oslo, 8 Oct 1995.
9. Cochrane Placebo Methods Working Group Meeting. 4th Annual Cochrane Colloq, Adelaide, 21 Oct 1996.
10. Cochrane Colorectal Cancer Group Pre-exploratory Meeting. Cochrane Cancer Network Meeting, Bruxelles, 1 Feb 1997.
11. Cochrane Colorectal Cancer Group Exploratory Meeting. København, 12-13 Sept 1997.
12. 50 years of clinical trials: past, present and future. BMA/BMJ, London, 29-30 Oct 1998. Conference chair and chair of session: Quality and relevance of randomised controlled trials.
13. Evidence based medicine: How do we implement research results effectively? Annual meeting for the Nordic Cochrane Centre and Network, Rigshospitalet, 28 Jan 1999.

14. Exploratory meeting for the Cochrane Anaesthesia Group. 7th Annual Meeting of the European Society of Anaesthesiologists, Amsterdam, 29-30 May 1999.
15. Medical Editors. Second Asian-Pacific Conference on Evidence Based Medicine, Chengdu, China, 8-10 Apr 2002.
16. Scientific presentations. 15th Annual Cochrane Colloquium, São Paulo, 23-27 Oct 2007.
17. Influenza symposium. Rigshospitalet, 23 Sept 2008.
18. Scientific presentations. 16th Annual Cochrane Colloquium, Freiburg, 3-7 Oct 2008.
19. International Cochrane Symposium: EBM and Cochrane reviews. Rigshospitalet, 22 April 2009.
20. Investigating bias. 19th Cochrane Colloquium, Madrid, 21 Oct 2011.
21. Nordic Cochrane Centre's 25th Anniversary Research Symposium. Rigshospitalet, 12 Oct 2018.
22. Institute for Scientific Freedom, inaugural symposium. Copenhagen, 9 March 2019.

Advisory Board member at international congresses

2nd Cochrane Colloquium, Hamilton, Ontario, 1-4 Oct 1994.
3rd Cochrane Colloquium, Oslo, 4-8 Oct 1995.
4th Cochrane Colloquium, Adelaide, Australia, 20-24 Oct 1996.
7th Cochrane Colloquium, Rome, Italien, 5-9 Oct 1999.
8th Cochrane Colloquium, Cape Town, Sydafrika, 25-29 Oct 2000.
9th Cochrane Colloquium, Lyon, 9-13 Oct 2001.
11th Cochrane Colloquium, Barcelona, 26-31 Oct 2003.
12th Cochrane Colloquium, Ottawa, 2-6 Oct 2004.
5th Congress on Peer Review and Biomedical Publication, Chicago, 15-17 Sept 2005.
15th Cochrane Colloquium, São Paulo, 23-27 Oct, 2007, Scientific Program Committee.
6th Congress on Peer Review and Biomedical Publication, Vancouver, 10-12 Sept 2009.
7th Congress on Peer Review and Biomedical Publication, Chicago, 8-10 Sept 2013.
Psychiatric drugs do more harm than good. Copenhagen, 16 Sept 2015.
8th Congress on Peer Review and Biomedical Publication, Chicago, 10-12 Sept 2017.

Expert witness in court cases

2014 Danish High Court, double homicide attempt on methylphenidate.
2014 Norwegian High Court, forced treatment with olanzapine.
2015 Norwegian High Court, Patient Harms Council, oseltamivir for influenza.
2016 Dutch High Court, double homicide case on paroxetine.
2016 Alaska High Court, forced retention and medication of a psychiatric patient.
2019 New York, effects of the DTP vaccine on mortality.
2019 Canada, harms caused by psychiatric drugs.
2019 California, harms of an HPV vaccine.
2020 Australia, harms after psychiatric drugs.
2020 California, forced influenza vaccination
2020 California, harms of an HPV vaccine

Management experience

1967	Co-founder, local fraction of a political party, cashier 1967-68.
1975 - 1977	Cashier, Frederiksberg Atlethics Association.
1977 - 1983	Founder and head, medical department, Astra-Syntex.
1987 - 1995	Founder and head, Nordic coordination office for AIDS trials, Rigshospitalet.
1993	Co-founder of the Cochrane Collaboration
1993 - 2019	Founder and head, The Nordic Cochrane Centre (39 people employed in 2014, incl. those in Copenhagen Trial Unit).
1993 - 1996	Member of the Steering Group, the Cochrane Collaboration.
1996 - 2001	Founder and head, Cochrane Placebo Methods Group.
2002	SHL leadership course.
2008 - 2009	Cashier and board member, Hørsholm Swimming Club.
2018 - 2019	Member of the Cochrane Governing Board.

EXHIBIT D

CURRICULUM VITAE

Carl J Heneghan

Title: Professor
Surname: Heneghan
Forename(s): Carl James

Email: carl.heneghan@phc.ox.ac.uk
Dob: 23/01/1968
Tel: +44 (0)1865 289299
GMC: 4731643

Current Positions:

- Professor of Evidence-Based Medicine, Nuffield Dept. of Primary Care University of Oxford
- Director, Centre for Evidence-Based Medicine
- Honorary Senior Academic General Practitioner, NHS England
- General Practitioner (MRCGP)
- NHS Urgent Care GP Oxford NHS Foundation Trust
- Director Evidence Based Healthcare Programs, University of Oxford (Masters and DPhil)
- NIHR Senior Investigator

Education and Qualifications:

- DPhil, New College, University of Oxford 2009: Incidence, prevention and treatment of acute coronary events in a population study: The Oxford Vascular Study (OXVASC)
- MA (Hons), New College, University of Oxford 2007
- MRCGP (Merit) Royal College of General Practice 2004
- BM, BCH, Medicine and Surgery, New College, University of Oxford 2000
- BA (Hons) 2:1 Physiological Sciences, New College, University of Oxford 1997

Research Fellowships

- NCCRD Research Development Fellowship: NIHR Department of Health 2005-2008
- Clinical Research Fellow, University of Oxford 2003–2005

Past posts:

- Clinical Reader, Clinical Lecturer, Department of Primary Care University of Oxford 2008-2013
- Senior Clinical Research Fellow, Department of Primary Care University of Oxford 2005-2008
- Deputy Director Clinical Fellow CEBM, University of Oxford 2005-10
- General Practice Registrar Thames Valley Primary Care Agency 2003 – 2005
- Senior House Officer 2001– 2003, House Officer Oxford Radcliffe NHS Trust, 2000- 2001

Further positions:

- Director WHO Collaboration Centre
- Chair of Examiner MSc in Evidence-Based healthcare, University of Oxford, External examiner MSc in Primary Care University of Birmingham
- Advisor to WHO International Clinical Trials Registry Platform
- Editor in Chief BMJ Evidence-Based Medicine

Professional memberships

- British Medical Association (BMA)
- Member of the Royal College of General Practice (MRCGP) Specialist register 2005
- Medical Defence Union of Scotland (MDDUS)
- General Medical Council (GMC 4731463) registered 2000

Awards

- University of Oxford, Medical Sciences Division, Lifetime Achievement Award 2019
- NIHR Senior Investigator Award 2017
- ACCEA consultant clinical excellence awards – SILVER Award, April 2017
- HSJ- top 100 NHS clinical leaders 2013 and 2015
- Brisbane Initiative Fellowship July 2007.

- Department of Health Research Development Award 2005-8
- Royal College of General Practitioners: Scientific Foundation Board Award 2004
- Goldsmiths Scholarship Award 2000

---

20 impact Publications (full list of over 400 publications available on request H index 70, I 10 index 232; 23415 citations)

1. Zanamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. Heneghan CJ, Onakpoya I, Thompson M, Spencer EA, Jones M, Jefferson T.BMJ. 2014 Apr 9;348:g2547.
2. Oseltamivir for influenza in adults and children: systematic review of clinical study reports and summary of regulatory comments. Jefferson T, Jones M, Doshi P, Spencer EA, Onakpoya I, Heneghan CJ. BMJ. 2014 Apr 9;348:g2545.
3. Neuraminidase inhibitors for preventing and treating influenza in healthy adults and children. Jefferson T, Jones MA, Doshi P, Del Mar CB, Hama R, Thompson MJ, Spencer EA, Onakpoya I, Mahtani KR, Nunan D, Howick J, **Heneghan CJ**. Cochrane Database Syst Rev. 2014 Apr 10;4:CD008965.
4. Evidence for non-communicable diseases: analysis of Cochrane reviews and randomised trials by World Bank classification. Heneghan C, Blacklock C, Perera R et al. BMJ Open. 2013 Jul 6;3(7). pii: e003298. doi: 10.1136/bmjopen-2013-003298. Print 2013.
5. Hayward G, Thompson MJ, Perera R, Glasziou PP, Del Mar CB, **Heneghan CJ**. Corticosteroids as standalone or add-on treatment for sore throat. Cochrane Database Syst Rev. 2012 Oct 17;10:CD008268. doi: 10.1002/14651858.CD008268.pub2. PMID: 23076943
6. Friedemann C, **Heneghan C,** Mahtani K, et al. Cardiovascular disease risk in healthy children and its association with body mass index: systematic review and meta-analysis. BMJ. 2012 Sep 25;345:e4759. doi: 10.1136/bmj.e4759. PMID: 23015032
7. Blacklock C, **Heneghan C**, Mant D, Ward AM. Effect of UK policy on medical migration: a time series analysis of physician registration data. Hum Resour Health. 2012 Sep 25;10(1):35. PMID: 23009665
8. Balla J, **Heneghan C,** Goyder C, Thompson M. Identifying early warning signs for diagnostic errors in primary care: a qualitative study. BMJ Open. 2012 Sep 13;2(5). Print 2012. PMID: 22983786
9. Heneghan C, Jefferson T, Doshi P. Antivirals for treatment of influenza. Ann Intern Med. 2012 Sep 4;157(5):385-6. PMID: 22944882
10. Hayward G, Thompson MJ, Perera R, Del Mar CB, Glasziou PP, **Heneghan CJ**. Corticosteroids for the common cold. Cochrane Database Syst Rev. 2012 Aug 15;8:CD008116. PMID: 22895973
11. **Heneghan C,** Thompson M, Perera-Salazar R, Gill P, O'Neill B, Nunan D, Howick J, Lasserson D, Mahtani K. Authors' reply to Betts, Stokes, and Kleiner. BMJ. 2012 Aug 14;345:e5431. PMID: 22893647
12. **Heneghan C,** Howick J, O'Neill B, Gill PJ, Lasserson DS, Cohen D, Davis R, Ward A, Smith A, Jones G, Thompson M. The evidence underpinning sports performance products: a systematic assessment. BMJ Open. 2012 Jul 18;2(4). pii: e001702. doi: 10.1136/bmjopen-2012-001702. PMID: 22815461
13. **Heneghan C**, Gill P, O'Neill B, Lasserson D, Thake M, Thompson M. Mythbusting sports and exercise products. BMJ. 2012 Jul 18;345:e4848. doi: 10.1136/bmj.e4848. PMID: 22810389
14. **Heneghan C,** Perera R, Nunan D, Mahtani K, Gill P. Forty years of sports performance research and little insight gained. BMJ. 2012 Jul 18;345:e4797. doi: 10.1136/bmj.e4797. PMID: 22810388
15. Thompson M, **Heneghan C,** Cohen D. How valid is the European Food Safety Authority's assessment of sports drinks? BMJ. 2012 Jul 18;345:e4753. doi: 10.1136/bmj.e4753. PMID: 22810387
16. Nunan D, Wassertheurer S, Lasserson D, Hametner B, Fleming S, Ward A, **Heneghan C.** Assessment of central haemomodynamics from a brachial cuff in a community setting. BMC Cardiovasc Disord. 2012 Jun 26;12(1):48.
17. **Heneghan C,** Thompson M. Rethinking medical device regulation. J R Soc Med. 2012 May;105(5):186-8.
18. Bettiol S, Wang K, Thompson MJ, Roberts NW, Perera R, **Heneghan CJ**, Harnden A. Symptomatic treatment of the cough in whooping cough. Cochrane Database Syst Rev. 2012 May 16;5:CD003257.
19. Hayward G, **Heneghan C**, Perera R, Thompson M. Ann Fam Med. Intranasal corticosteroids in management of acute sinusitis: a systematic review and meta-analysis.2012 May;10(3):241-9.
20. Banerjee A, Newman DR, Van den Bruel A, **Heneghan C**. Diagnostic accuracy of exercise stress testing for coronary artery disease: a systematic review and meta-analysis of prospective studies. Int J Clin Pract. 2012 May;66(5):477-92.

COMMONWEALTH OF MASSACHUSETTS

SUFFOLK, ss. SUPERIOR COURT
CIVIL ACTION NO. _____

TAMAR MASSOYAN-ARTINIAN, on behalf of her children, and MADISON SCHILTZ,

Plaintiffs,

v.

MONICA BHAREL, in her official capacity as Commissioner of the Massachusetts Department of Public Health and the MASSACHUSETTS DEPARTMENT OF PUBLIC HEALTH,

Defendants.

EXPERT AFFIDAVIT OF P. AABY AND C. STABELL BENN

We, Peter Aaby and Christine Stabell Benn, state as follows:

1. We submit this affidavit in support of Plaintiffs' Motion for a preliminary injunction. We have personal knowledge of the facts set forth herein and if called to testify, each of us could competently testify as to the following:

EXPERIENCE & CREDENTIALS

2. I, Christine Stabell Benn, am a medical doctor (1996), PhD (2003), and DMSc (2011), Professor in Global Health at University of Southern Denmark (since 2013), Chair at the Danish Institute for Advanced Study (since 2017), and member of the *Academia Europaea* (since 2020). My research focuses on how vaccines affect the immune system in more general ways than

previously thought. I have published 293 articles, mainly about vaccines, in peer-reviewed journals. My CV is attached in Exhibit A.

3. I, Peter Aaby, an anthropologist, who has studied vaccination policy in West Africa for more than 40 years, am a PhD (1974), DMSc (1988), Professor (1995), Doctor Honoris Causa (Universidade Nova de Lisboa), and member of the *Academia Europaea*. I showed in 1980-1990 that WHO's new high-titer measles vaccine (HTMV) was associated with two-fold increased female mortality in spite of being fully protective against measles infection. This conundrum led to the discovery that vaccines have nonspecific effects, unrelated to protection against the vaccine-targeted infection. WHO had to withdraw the HTMV (1992). My CV is attached in Exhibit B.

4. We have not received any compensation, either directly or in-kind, for this affidavit.

UNIVERSAL DECLARATION ON BIOETHICS AND HUMAN RIGHTS

5. UNESCO's Universal Declaration on Bioethics and Human Rights[1] aims to provide a universal framework of principles and procedures to guide States in the formulation of their legislation, policies or other instruments in the field of bioethics. Article 6.1 of the Declaration states: "*Any preventive, diagnostic and therapeutic medical intervention is only to be carried out with the prior, free and informed consent of the person concerned, based on adequate information. The consent should, where appropriate, be express and may be withdrawn by the person concerned at any time and for any reason without disadvantage or prejudice. Any preventive, diagnostic and therapeutic medical intervention is only to be carried out with the prior, free and informed consent of the person concerned, based on adequate information. The consent should, where appropriate, be express and may be withdrawn by the person concerned at any time and for any reason without disadvantage or prejudice.*" ***Accordingly, vaccines cannot be forced upon anybody***, directly or

[1] http://portal.unesco.org/en/ev.php-URL_ID=31058&URL_DO=DO_TOPIC&URL_SECTION=201.html.

indirectly through deprivation of privileges the individual would otherwise have had (*e.g.*, the right to go to school, to have a job, or to earn a living), all of which can be equated with coercion.

COMPARISON WITH DENMARK

6. Denmark has never recommended an influenza vaccine for all ages. Currently, influenza vaccine is only recommended to the elderly above 65 years of age, people with chronic diseases, people working with vulnerable people, and pregnant women. The Danish Health Authority has evaluated the need for other groups to receive influenza vaccine. The report is currently in public hearing.[2] It establishes that it may be cost-beneficial to offer (but not mandate; no vaccines are mandated in Denmark) influenza vaccine to children aged 0-6 years and to health care workers, but there is no reason to vaccinate older children or adults below 65. ***Thus, The Danish Health Authority does not find it indicated to recommend influenza vaccine to healthy people aged 6 to 65 years.***

7. Denmark is praised for its COVID-19 response, the mortality rate by 13 December being 16/100,000,[3] yet has not changed its recommendations with respect to influenza vaccine as a way of fighting COVID-19.

VACCINES HAVE NON-SPECIFIC EFFECTS THAT MAY BE HARMFUL

8. Following the studies showing that new measles vaccine (HTMV) was associated with increased all-cause mortality for females, numerous studies have documented that all the commonly used vaccines have nonspecific effects.[4] Sometimes the effects are beneficial, reducing susceptibility to unrelated infections. However, sometimes the vaccine effects are deleterious,

[2] https://prodstoragehoeringspo.blob.core.windows.net/c161d76d-572e-4fa5-8b85-a380b9acc084/H%C3%B8ringsversion%20-%20MTV%20for%20influenzavaccination.pdf.

[3] https://covid19.who.int/region/euro/country/dk.

[4] Benn et al, Lancet Infect Dis 2020: https://www.thelancet.com/journals/laninf/article/PIIS1473-3099(19)30742-X/fulltext.

enhancing susceptibility to unrelated infections and increasing mortality. The general pattern seems to be that live vaccines (Measles vaccine, Measles-mumps-rubella vaccine, oral polio vaccine, BCG, smallpox vaccine) have beneficial effects. However in contrast, six non-live vaccines (DTP, HBV, IPV, pentavalent vaccine, H1N1 influenza vaccine, and RTS,S malaria vaccine) have negative effects, particularly for females.[5]

CONCLUSION

9. Mandating vaccines goes against UNESCO's Universal Declaration on Bioethics and Human Rights. Other countries like Denmark, with free universal health care, high average mean age and good population health, are not recommending universal influenza vaccines. Vaccines may have negative nonspecific effects; however, these have not been thoroughly investigated for influenza vaccine.

SIGNED UNDER THE PAINS AND PENALTIES OF PERJURY,

Christine Stabell Benn

Peter Aaby

Signed this 16th day, December 2020.

[5] *Id*.

EXHIBIT A

PERSONAL INFORMATION

Christine Stabell Benn

Bandim Health Project, OPEN, Institute of Clinical Research, University of Southern Denmark/Odense University Hospital, Studiestræde 6, 1455 Copenhagen K

45 25883964

cbenn@health.sdu.dk

www.bandim.org @StabellBenn

Date of birth 15/06/1968 | Nationality Danish | ORCID 0000-0001-6102-3810

WORK EXPERIENCE

2013->	**Professor, OPEN, University of Southern Denmark (USD)/Odense University Hospital**
2012->	**Center leader, Research Center for Vitamins and Vaccines (CVIVA)**
2012->	**Head, Bandim Health Project Copenhagen Division** (hosted at SDU from 2020)
2008-2015	External associate professor, University of Copenhagen, Denmark (UCD)
2007-2011	Senior researcher, Bandim Health Project (BHP), Statens Serum Institut (SSI)
2005-2007	Post-doc, Bandim Health Project, SSI, and Dept. of Infectious Diseases, Rigshospitalet
2003-2004	Post-doc, Dept. of Epidemiology Research, SSI
1999-2003	PhD-student, Dept. of Epidemiology Research, SSI
1998	Maternity leave (March 1998-December 1998)
1996-98	Residence in Surgery, Internal Medicine and GP, Copenhagen
1995	Maternity leave (September 1995-February 1995)
1993	12 months' scholarship, Institute of Epidemiology and Social Science, University of Aarhus, Denmark (UAD) and BHP, Guinea-Bissau

EDUCATION AND TRAINING

2014	Advanced course in responsible research conduct, SSI
2011	**Doctor of Medical Science, UCD**
2006	One month at Pediatric Immunology Department, Stanford University, US
2003	PhD, UCD
1996	MD, UCD
1994	Diploma in Medical Research, UAD
1987-96	Medical Student, UAD and UCD

HONOURS AND AWARDS

2019	**University of Southern Denmark's "Innovation Prize"**
2018	Selected to give a TEDx talk (https://www.youtube.com/watch?v=_d8PNlXHJ48)
2017	**Chair, Danish Institute for Avanced Studies**
2015	Prize for Best Publications, Department of Clinical Research, USD
2014	Nominated for "Best Danish research result of the year"
2011	**Selected by the Danish National Research Foundation for a "Center of Excellence"**
2010	**Received an ERC Starting Grant**
2009+2011	2nd prize: "Best Danish research result of the year"
2009	**Received a Female Research Leader Grant** (Danish Council for Independent Research)
2005	**Awarded Young Research Leader Grant** (Strategic Research Council) as one among the 19 most talented young Danish Researchers
2004	**Nominated for EURYI award as one among the 9 most talented Danish Researchers**

ORGANISATIONAL SKILLS/ MENTORING

- **Responsible for a team of ~15 people at SDU, Denmark**
- **One of seven member of the Steering Board of the Bandim Health Project, Guinea-Bissau**
- **The principal investigator/co-investigator for many large-scale randomised trials in Guinea-Bissau, e.g.:**
  1993-1995: The effect of vitamin A supplementation on the antibody-response to measles vaccine (*Lancet* 1997, *Lancet* 2002)
  2002-2004 : The effect on mortality of 50,000 IU vitamin A given with BCG at birth to normal-birth-weight neonates (*BMJ* 2008)
  2005-2008: The effect on mortality of 25,000 IU vitamin A given with or without BCG to low-birth-weight-neonates (*BMJ* 2010)
  2007-2011: An evaluation of the WHO vitamin A policy: Vitamin A given with vaccines after 6 months of age (*Pediatrics* 2014)
  2008-2012 : The effect on mortality of providing oral polio vaccine at birth (*Clin Inf Dis* 2015)
  2008-2014: The effect on mortality of providing early BCG vaccine to children with low weight (*Clin Inf Dis* 2017)
- **The previous or current supervisor of 26 PhD students and >40 Research year/Masters students.**

OTHER QUALIFICATIONS

- **Member of the Scientific Advisory Committee for EDCTP 2019->**
- **Member of the Life Science assessment panel of ERC Starting Grants 2019**
- PI for a Nordic project "Childhood morbidity and potential non-specific effects of the childhood vaccination programmes", involving the National Immunization Programs in Denmark, Norway, Sweden and Finland (with funding from "NordForsk"), 2017-2022
- Participant, EDCTP Stakeholder Meeting on Co-infections and Co-morbidities, Den Haag 2017
- Member of the PhD grant assessment committee, Odense University Hospital, 2014-2016
- **Technical Advisor, WHO** (Neonatal vitamin A policy), 2008, 2014-16
- **Member of WHO/SAGE working group** on non-specific effects of vaccines 2013-2014 (www.who.int/immunization/sage/sage_wg_non_specific_effects_vaccines_march2013/)
- **Expert member of working group, NIH** (INSPIRE), USA, 2012-2014
- Co-funder of "OPTIMMUNIZE", a consortium which aims to investigate the immunological mechanisms behind the non-specific and sex-differential effects of health interventions, 2010->

SCIENTIFIC INTERESTS

My research focusses on **epidemiological studies** of **health interventions** and their **effect on overall health** in real life. We have observed that that vitamins and vaccines affect **the immune system** in much more general ways than previously thought. Vitamins and vaccines have so-called **non-specific effects.** Based to a large extent on work done in one of the world's poorest countries, Guinea-Bissau, I have formulated the hypothesis that these **health interventions interact,** the interventions and the interactions are **sex-differential**, and the effect of a given intervention may depend more on these interactions than on the specific effects of the interventions.

My main contribution has been to take the observations on non-specific effects forward to **randomised controlled trials.** I have also bridged to **immunological studies**, and explored the **biological mechanisms** underlying the non-specific effects of vitamins and vaccines. Furthermore, we have taken the observations back to Denmark, to test in randomised trials and observational **register-based studies** whether non-specific effects of vaccines are important in high-income settings. Most recently, we are testing whether non-specific effects of BCG vaccine and oral polio vaccine can provide partial protection against COVID-19. I am the **author of 293 scientific articles for peer-reviewed journals.**

Total number of publications in peer reviewed journals (not abstracts): 293. H-index=43 (Web of Science)

1. **Stabell C**, Balé C, da Silva AP, Olsen J, Aaby P. No evidence of fontanelle-bulging episodes after vitamin A supplementation of 6- and 9-months old infants in Guinea-Bissau. ***Eur J Clin Nutr*** 1995; 49: 73-74
2. **Benn CS**, Whittle H, Aaby P, Balé C, Michaelsen KF, Olsen J. Vitamin A and measles. ***Lancet*** 1995; 346: 503-504
3. **Benn CS**, Aaby P, Balé C, Olsen J, Michaelsen KF, George E, Whittle H. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, West Africa. ***Lancet*** 1997; 350: 101-105
4. **Benn CS**, Lisse IM, Balé C, Michaelsen KF, Olsen J, Hedegaard K, Aaby P. No strong long-term effect of vitamin A supplementation in infancy on CD4 and CD8 T-cell subsets. A community study from Guinea-Bissau, West Africa. ***Ann Trop Paediatr*** 2000; 20: 259-264.
5. **Benn CS**, Jeppesen DL, Hasselbalch H, Olesen AB, Nielsen J, Björkstén B, Lisse IL, Aaby P. Thymus size and head circumference at birth and development of allergic diseases. ***Clin Exp Allergy*** 2001; 31: 1862-1866.
6. **Benn CS**, Bager P, Jensen H, Lisse I, Aaby P. Measles and atopy – rash on rash? ***Allergy*** 2001; 56: 800-801.
7. **Benn CS**, Balde A, George E, Kidd M, Whittle H, Lisse IM, Aaby P. Long-term effect of vitamin A supplementation with measles vaccine in infancy on measles-specific antibody levels in Guinea-Bissau, West Africa. ***Lancet*** 2002; 359: 1313-14.
8. **Benn CS**, Bendixen M, Krause TG, Olesen, AB. Questionable coexistence of Th1 and Th2-related diseases. ***J Allergy Clin Immunol*** 2002; 110: 328-29.
9. **Benn CS**, Thorsen P, Jensen JS, Kjær BB, Bisgaard H, Andersen M, Rostgaard K, Björkstén B, Melbye M. Maternal vaginal microflora during pregnancy and risk of asthma hospitalization and anti-asthma medication in early childhood. ***J Allergy Clin Immunol*** 2002; 110: 72-77.
10. Bager P, Westergaard T, Rostgaard K, **Benn CS**, Melbye M. Mode of delivery and risk of allergic rhinitis and asthma. ***J Allergy Clin Immunol*** 2003; 111: 51-6.
11. Westergaard T, Begtrup K, Rostgaard K, Krause TG, **Benn CS**, Melbye M. Reproductive history and allergic rhinitis among 31,145 Danish Women. ***Clin Exp Allergy*** 2003; 33:301-5.
12. **Benn CS**, Benfeldt E, Andersen PK, Olesen AB, Melbye M, Björkstén B. Atopic Dermatitis in Young Children: Diagnostic criteria for Use in Epidemiological Studies Based on Telephone Interviews. ***Acta Derm Venereol*** 2003; 83: 347-350.
13. **Benn CS**, Balé C, Sommerfelt H, Friis H, Aaby P. Vitamin A supplementation and childhood mortality: Amplification of the non-specific effects of vaccines? ***Int J Epidemiol*** 2003; 32:822-8.
14. Aaby P, Jensen H, Rodrigues A, Garly ML, **Benn CS**, Lisse IM, Simondon F. Divergent female-male mortality ratios associated with different routine vaccinations among female-male twin pairs. ***Int J Epidemiol*** 2004; 33:367-73.
15. **Benn CS**, Böttcher MF, Pedersen BV, Filteau SM, Duchén K. Mammary epithelial paracellular permeability in atopic and non-atopic mothers versus childhood atopy. ***Pediatr Allergy Immunol*** 2004; 15:123-6.
16. **Benn CS**, Melbye M, Wohlfahrt J, Björkstén B, Aaby P. The sibling effect, infectious diseases, and risk of atopic dermatitis before 18 months of age. ***BMJ*** 2004; 328:1223-8.
17. Aaby P, Rodrigues A, Biai S, Martins C, Veirum JE, **Benn CS**, Jensen H. Oral polio vaccine and low case fatality at the paediatric ward in Bissau. ***Vaccine*** 2004; 22: 3014-7.
18. **Benn CS**, Wohlfahrt J, Aaby P, Westergaard T, Benfeldt E, Michaelsen KF, Björkstén B, Melbye M. Breastfeeding and Risk of Atopic Dermatitis During The First 18 Months of Life by Parental History of Allergy. ***Am J Epidemiol*** 2004; 160:217-23.
19. Linneberg A, Petersen J, Grønbæk M, **Benn CS**. Alcohol during pregnancy and atopic dermatitis in the offspring. ***Clin Exp Allergy*** 2004; 34: 1678-1683.
20. Nielsen J, **Benn CS**, Bale C, Martins C, Aaby P. Vitamin A supplementation during war-emergency in Guinea-Bissau 1998-1999. ***Acta Trop*** 2005; 93: 275-82.
21. Aaby P, Rodrigues A, Biai S, Martins C, Veirum JE, **Benn CB**, Jensen H. Vaccines and unexpected observations: Flaws or cause for concern? ***Vaccine*** 2005; 23: 2407-8.
22. **Benn CS**, Melbye M, Wohlfahrt J, Björkstén B, Aaby P. [Kohortestudie af effekten af søskende og infektionssygdomme på udvikling af atopisk dermatitis]. ***Ugeskr Laeger*** 2005;167 :1754-7
23. Aaby P, Jensen H, **Benn CS**, Lisse IM. Non-specific effects of vaccination: survival bias may explain findings. ***BMJ*** 2005; 330:844-5.
24. Jensen H, **Benn CS**, Aaby P. Diphtheria-tetanus-pertussis vaccination in low-income countries: improved child survival or survival bias? ***BMJ*** 2005; 330:845-6.
25. Olesen AB, Andersen G, Jeppesen DL, **Benn CS**, Juul S, Thestrup-Pedersen K. Thymus is enlarged in children with current atopic dermatitis. A cross-sectional study. Acta Dem Venereol 2005; 85: 240-243.

26. **Benn CS**, Michaelsen KF. Does the effect of breast-feeding on atopic dermatitis depend on family history of allergy? ***J Pediatr*** 2005;147(1):128-9.
27. **Benn CS**, Martins C, Rodrigues A, Jensen H, Lisse IM, Aaby P. Randomised study of the impact of different doses of vitamin A on childhood morbidity and mortality. ***BMJ*** 2005; 331:1428-32.
28. Linneberg A, Simonsen JB, Petersen J, Stensballe LG, **Benn CS**. Differential effects of risk factors on infant wheeze and atopic dermatitis emphasize a different etiology. ***J Allergy Clin Immunol*** 2006; 117(1):184-9.
29. Kamper-Jørgensen M, Wohlhahrt J, Simonsen J, Thrane N, **Benn CS**. Temporal trends in paediatric infections in Denmark. ***Arch Dis Child*** 2006; 91:401-4.
30. **Benn CS**, Diness B, Fisker AB, Christoffersen D, Friis H. [Høj-dosis vitamin A tilskud sænker børnedødeligheden i lavindkomstlande – kan det blive bedre?]. ***Ugeskr Laeger*** 2006; 168: 2442- 2445.
31. Aaby, P. Gustafson, P, Roth, A, Rodrigues, A, Fernandes, M, Sodemann, M, Holmgren, B, **Benn CS**, Garly, ML, Lisse, IM, and Jensen, H. Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau. ***Vaccine*** 2006; 24:5718-25.
32. Aaby P, Vessari H, Nielsen J, Maleta K, **Benn CS**, Jensen H, Ashorn P. Non-specific and sex-differential effects of routine immunizations in rural Malawi. ***Ped Inf Dis J*** 2006; 25:721-727.
33. **Benn CS**, Fisker AB, Diness BR, Aaby P. Sex-differential effects of neonatal vitamin A supplementation on mortality? ***J Infect Dis*** 2006; 194: 719.
34. Kamper-Jørgensen M, Wohlfahrt J, Simonsen J, Grønbæk M, **Benn CS**. Population-based study of the impact of childcare attendance on hospitalizations for acute respiratory infections. ***Pediatrics*** 2006; 118: 1439-46.
35. Stensballe LG, Kristensen K, Simoes EAF, Jensen H, Nielsen J, **Benn CS**, Aaby P. Atopic Disposition, Wheezing, and Subsequent Respiratory Syncytial Virus Hospitalization in Danish Children Younger Than 18 Months: A Nested Case-Control Study. ***Pediatrics*** 2006;118: 1360-8.
36. **Benn CS**, Aaby P. [Kønsforskelle i respons på præventive sundhedsprogrammer]. ***Ugeskr Laeger*** 2006; 168: 3045-3046.
37. Poulsen A, Stensballe LG, Nielsen J, **Benn CS**, Balde A, Roth A, Lisse IM, Aaby P. Long-term consequences of respiratory syncytial virus acute lower respiratory tract infection in early childhood in Guinea-Bissau. ***Ped Inf Dis J*** 2006: 25: 1025-1031.
38. Rodrigues A, Schellenberg JA, Roth A, **Benn CS**, Aaby P, Greenwood B. Revaccination with Bacillus Calmette-Guerin (BCG) vaccine does not reduce morbidity from malaria in African children. ***Trop Med Int Health*** 2007;12:224-9.
39. Aaby P, **Benn CS**, Nielsen J, Lisse IM, Rodrigues A, Jensen H. Estimating the effect of DTP vaccination on mortality in observational studies with incomplete vaccination data. ***Trop Med Int Health*** 2007;12:15-24.
40. Jensen H, **Benn CS**, Nielsen J, Lisse IM, Rodrigues A, Andersen PK, Aaby P. Survival bias in observational studies of the impact of routine immunisations on childhood survival. ***Trop Med Int Health*** 2007; 12:5-14.
41. **Benn CS**, Fisker AB, Jørgensen MJ, Aaby P. Why worry: Vitamin A with DTP vaccine? ***Vaccine*** 2007; 25: 777-779.
42. Aaby P, Biai S, Veirum JE, Sodeman M, Lisse I, Garly ML, Jensen H, **Benn CS**, Rodrigues A. DTP with or after measles vaccination is associated with increased in-hospital mortality in Guinea-Bissau. ***Vaccine*** 2007; 25: 1265-69.
43. Kamper-Jørgensen M, Wohlfahrt J, Simonsen JB, **Benn CS**. The Childcare Database: a valuable register-linkage. ***Scand J Public Health*** 2007; 35: 323-9.
44. Jensen ML, Dave S, van der Loeff MS, da Costa C, Vincent T, Leligdowicz A, **Benn CS**, Roth A, Ravn H, Lisse IM, Whittle H, Aaby P. Vaccinia Scars Associated with Improved Survival among Adults in Rural Guinea-Bissau. ***PloS ONE*** 2006; 1: e101.
45. Larsen JM, **Benn CS**, Fillie Y, van der Kleij D, Aaby P, Yazdanbakhsh M. BCG stimulated dendritic cells induce an IL-10 producing T-cell population with no Th1/Th2 bias in vitro. ***Immunology*** 2007; 121: 276-82
46. Aaby P, Garly ML, Jensen H, Martins C, Balé C, **Benn CS**, Rodrigues A, Lisse IM. Inactivated polio and diphtheria-tetanus-pertussis vaccines associated with increased female mortality prior to measles vaccination: Observations from vaccination trials in Guinea-Bissau. ***Ped Inf Dis J*** 2007; 26: 247-52.
47. Nante E, Diness BR, Ravn H, Roth A, Aaby P, **Benn CS**. No adverse events associated with simultaneous vitamin A supplementation and Baccille Calmette-Guerin vaccination in normal-birth-weight infants in Guinea-Bissau. ***Eur J Clin Nutr*** 2007 May 30;
48. **Benn CS**, Aaby P. Sex-differential responses to preventive health interventions. ***Dan Med Bull*** 2007; 54: 153-4.

49. Fisker AB, Lisse IM, Aaby P, Erhardt J, Rodrigues A, Bibby B, **Benn CS**. Impact of neonatal vitamin A supplementation with BCG vaccine on vitamin A status at 6 weeks and 4 months of age. ***Am J Clin Nutr*** 2007; 86:1032-9.
50. Diness BR, Fisker AB, Roth A, Yazdanbakhsh M, Sartono E, Whittle H, Nante JE, Lisse IM, Ravn H, Rodrigues A, Aaby P, **Benn CS**. The effect of high-dose vitamin A supplementation on the immune response to Bacille Calmette-Guerin vaccination. ***Am J Clin Nutr*** 2007; 86:1152-9.
51. Kamper-Jørgensen M, Woodward A, Wohlfahrt J, **Benn CS**, Simonsen J, Hjalgrim H, Schmiegelow K. Childcare in the first two years of life reduces the risk of childhood acute lymphoblastic leukaemia. ***Leukaemia*** 2008; 22 :189-93.
52. Eriksson M, Sartono E, Martins CL, Balé C, Garly ML, Whittle H, Aaby P, Pedersen BK, Yazdanbakhsh M, Erikstrup C, **Benn CS**. A comparison of ex vivo cytokine production in venous and capillary blood. ***Clin Exp Immunol*** 2007; 150 :469-76.
53. **Benn CS**, Friis H, Wejse C. Should micronutrient supplementation be integrated in the case management of tuberculosis [Editorial]? ***J Infect Dis*** 2008;197(11):1487-1489.
54. Aaby P, **Benn CS**, Nielsen J, Ravn H. Sex-differential non-specific effects of BCG and DTP in Cebu, The Philippines. ***Int J Epidemiol*** 2008; 38:320-3
55. **Benn CS,** Fisker AB, Jørgensen MJ, Aaby P. Conflicting evidence for neonatal vitamin A supplementation. ***Vaccine*** 2008; 26:4111-2.
56. Hersoug L-G, **Benn CS**, Simonsen JB, Kamper-Jørgensen M, Linneberg A. Maternal employment in childcare institutions and the risk of infant wheeze and atopic dermatitis in the offspring. ***Ped All Immunol*** 2008; 19(8):688-95
57. **Benn CS**, Diness BR, Roth A, Nante E, Fisker AB, Lisse IM, Whittle H, Rodrigues A, Yazdanbakhsh M, Aaby P. Randomised trial of the effect on mortality of 50,000 IU vitamin A given with BCG vaccine to infants in Guinea-Bissau, West-Africa ***BMJ*** 2008; 336:1416-20.
58. **Benn CS,** Whittle H, Fisker A, Aaby P. Neonatal vitamin A supplementation in South Asia: Rapid implementation or understanding the variation? ***BMJ*** Rapid responses 2008;July 11
59. **Benn CS,** Fisker AB, Rodrigues A, Ravn H, Sartono E, Whittle H, Yazdanbakhsh M, Aaby P. Sex-differential effect on infant mortality of oral polio vaccine administered with BCG at birth in Guinea-Bissau. A natural experiment***. PLoS ONE*** 2008; 3(12):e4056.
60. **Benn CS**, Martins C, Rodrigues A, Ravn H, Fisker AB, Christoffersen D, Aaby P. The effect of vitamin A supplementation administered with missing vaccines during national immunisation days in Guinea-Bissau ***Int J Epidemiol*** 2009; 38:304-11.
61. **Benn CS**, Lund S, Fisker A, Jørgensen MJ, Aaby P. Should infant girls receive micronutrient supplementation? ***Int J Epidemiol*** 2009; 38:586-90.
62. Erikstrup E, Mortensen OH, Rinnow A, Fischer CP, Pedersen AM, Krogh-Madsen R, Lindegaard B, Erhardt J, Ullum H, **Benn CS**, Pedersen BK. RBP4-to-retinol ratio, but not total RBP4, is elevated in patients with type 2 diabetes. ***Diabetes Obes Metab*** 2009;11:204-12.
63. **Benn CS**, Rodrigues A, Yazdanbakhsh M, Fisker AB, Ravn H, Whittle H, Aaby P. The effect of high-dose vitamin A supplementation administered with BCG vaccine at birth may be modified by subsequent DTP vaccination. ***Vaccine*** 2009; 27: 2891-98
64. Aaby P, Ravn H, **Benn CS**. Poor control vaccines in two randomised trials of malaria vaccine***? Vaccine*** 2009; 27(22):2914-5.
65. Aaby P, **Benn CS**. Assessment of childhood immunisation coverage. ***Lancet*** 2009; 373:1428.
66. Fine PEM, Williams TN, Aaby P, Källander K, Moulton LH, Flanagan KL, Smith PG, **Benn CS**. Epidemiological studies of the “non-specific effects” of vaccines: I - data collection in observational studies. ***Trop Med Int Health*** 2009;14(9):969-76. Review.
67. Farrington CP, Firth MJ, Moulton LH, Ravn H, Andersen PK, Evans S; Working Group on Non-specific Effects of Vaccines. Epidemiological studies of the non-specific effects of vaccines: II--methodological issues in the design and analysis of cohort studies. ***Trop Med Int Health*** 2009; 14(9):977-85. Review.
68. **Benn CS**, Aaby P, Nielsen J, Binka FN, Ross DA. Does vitamin A supplementation interact with routine vaccinations? An analysis of the Ghana Vitamin A Supplementation Trial. ***Am J Clin Nutr*** 2009; 90(3):629-39, Jul 29.
69. Martins C, Bale C, Garly ML, Rodrigues A, Lisse IM, Ravn H, Eriksson M, **Benn CS**, Whittle H, Aaby P. Girls may have lower levels of maternal measles antibodies and higher risk of subclinical measles infection before the age of measles vaccination. ***Vaccine*** 2009; 27:5220-5.
70. Villumsen M, Sørup S, Jess T, Ravn H, Relander T, Baker JL, **Benn CS**, Sørensen TIAS, Aaby P, Roth A. Risk of Lymphoma and Leukaemia after Bacille Calmette-Guérin and Smallpox Vaccination: A Danish Case-Cohort Study. ***Vaccine*** 2009; 27(49):6950-8.

71. Agergaard J, Lemvik G, Nante E, Helleberg M, Nielsen J, **Benn CS**, Aaby P, Østergaard L Serological evidence for *Chlamydia pneumoniae* infection during the diphtheria-tetanus-pertussis booster vaccination. ***J Infect Dis Immun*** 2010; 2(1): 1 – 14.
72. Aaby P, Martins C, Bale C, Garly ML, Rodrigues A, Biai S, Lisse IM, Whittle H, **Benn CS.** Sex differences in the effect of vaccines on the risk of hospitalisation due to measles in Guinea-Bissau. ***Pediatr Infect Dis J*** 2010;29:324-8
73. Kamper-Jørgensen M, **Benn CS**, Simonsen J, Thrane N, Wohlfahrt J. Clustering of acute respiratory infection hospitalizations in childcare facilities. ***Acta Paediatrica*** 2010; 99:877-82
74. Nielsen J, Sodemann M, Jakobsen M, Gustafson P, **Benn C**, Aaby P. [Health consequences of armed conflict in Guinea-Bissau]. ***Ugeskr Laeger*** 2010; 172(2):132-6.
75. **Benn CS**, Fisker AB, Napirna BM, Roth A, Diness BR, Lausch KR, Ravn H, Yazdanbakhsh M, Rodrigues A, Whittle H, Aaby P. Vitamin A supplementation and BCG vaccination at birth in low birthweight neonates: two by two factorial randomized controlled trial. ***BMJ*** 2010; 340:c1101. doi: 10.1136/bmj.c1101.
76. Roth A, **Benn CS**, Ravn H, Rodrigues A, Lisse IM, Yazdanbakhsh M, Whittle H, Aaby P. A randomized trial of the effect of revaccination with BCG in early childhood and mortality. ***BMJ*** 2010 Mar;107(5):615-20 2010;340:c671
77. Diness BR, Christoffersen D, Pedersen UB, Rodrigues A, Fischer TK, Andersen A, Whittle H, Yazdanbakhsh M, Aaby P, **Benn CS**. The effect of high-dose vitamin A supplementation with BCG vaccine at birth on infant rotavirus colonization and diarrhea. A randomized prospective study from Guinea-Bissau. ***J Infect Dis*** 2010;202:S243-S251
78. Sartono E, Lisse IM, Terveer EM, van de Sande PJM, Whittle H, Fisker AB, Roth A, Aaby P, Yazdanbakhsh M, **Benn CS**. Oral polio vaccine influences the immune response to BCG vaccination. A natural experiment. ***PLoS ONE*** 2010;5: e10328.
79. Shann F, Nohynek H, Scott JA, Hesseling A, Flanagan KL; Working Group on Nonspecific Effects of Vaccines. Randomized trials to study the nonspecific effects of vaccines in children in low-income countries. ***Pediatr Infect Dis J*** 2010;29:457-61.
80. Hein-Kristensen L, Jørgensen MJ, Ravn H, Wiese L, Kurtzhals J, **Benn CS**. Simultaneous Administration of Vitamin A and DTP Vaccine Modulates the Immune Response in a Murine Cerebral Malaria Model. ***Scand J Immunol*** 2010;72:302-8.
81. Aaby P, Martins CL, Garly ML, Balé C, Andersen A, Rodrigues A, Ravn H, Lisse IM, **Benn CS**, Whittle HC. Randomized trial to test the non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality. ***BMJ*** 2010;341:c6495. doi: 10.1136/bmj.c6495
82. Jørgensen M, Hein-Kristensen L, Hempel C, Ravn H, Wiese L, Kurtzhals JAL, **Benn CS**. The effect of vitamin A supplementation and DTP vaccination on parasitemia in an experimental murine malaria model. ***Scand J Inf Dis*** 2010 Nov 25.
83. Sachdev HS, Kirkwood B, **Benn CS**. Neonatal Vitamin A supplementation and infant mortality. ***Bull WHO*** 2010;88:875A–875B | doi:10.2471/BLT.10.0803030
84. Agergaard J, Nante E, Poulstrup G, Nielsen J, Flanagan KL, Østergaard L, **Benn CS**, Aaby P. Diphtheria-tetanus-pertussis vaccine administered simultaneously with measles vaccine is associated with increased morbidity and poor growth in girls. A randomized trial from Guinea-Bissau. ***Vaccine*** 2011; 29: 487-500.
85. Andersen GS, Friis H, Michaelsen KF, Rodrigues A, **Benn CS**, Aaby P, Kæstel P. Effect of Maternal Micronutrient Supplementation on Fetal Loss and Under Two Child Mortality: Long Term Follow-Up of a Randomized Controlled Trial from Guinea Bissau. ***Afr J Reprod Health*** 2010; 14 (2): 17-26
86. Aaby P, **Benn CS**. Non-specific and sex-differential effects of routine vaccines: What evidence is needed to take these effects into consideration in low-income countries? ***Hum Vaccin*** 2011; 7 (1)
87. Diness B, Martins CL, Bale C, Garly ML, Ravn H, Rodrigues A, Whittle H, Aaby P, **Benn CS**. The effect of high-dose vitamin A supplementation at birth on measles incidence during the first 12 months of life in boys and girls. An unplanned study within a randomized trial. ***Br J Nutr*** 2011; 4:1-4
88. Kamper-Jørgensen M, **Benn CS**, Wohlfahrt J. Childcare and health: a review of using linked national registers. ***Scand J Public Health*** 2011;39(7 Suppl):126-30
89. Flanagan KL, Klein SL, Skakkebaek NE, Marriott I, Marchant A, Selin L, Fish EN, Prentice AM, Whittle H, **Benn CS**, Aaby P. Sex differences in the vaccine-specific and non-targeted effects of vaccines. ***Vaccine*** 2011;29(13):2349-54.
90. **Benn CS**, Fisker A, Aaby P. Heterogeneous effects on child survival in neonatal vitamin A supplementation trials. ***Lancet*** 2011;377(9774):1314-5
91. Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, Stensballe L, Diness BR, Lausch KR, Lund N, Biering-Sørensen S, Whittle H, **Benn CS**. Randomized trial of BCG vaccination at birth to low-birth-weight children: Beneficial non-specific effects in the neonatal period? ***J Inf Dis*** 2011;204(2):245-52.

92. Sorup S, Villumsen M, Ravn H, **Benn CS**, Sørensen TIA, Aaby P, Jess T, Roth A. Smallpox Vaccination Reduces the Risk of Infectious Disease Hospitalisation. ***Int J Epidemiol*** 2011 May 4.
93. Jørgensen MJ, Fisker AB, Erikstrup C, Claesson MH, **Benn CS**. SNP may modify the effect of vitamin A supplementation at birth on cytokine production in a whole blood culture assay. ***Br J Nutr*** 2012 Mar;107(5):615-20.
94. Fisker AB, **Benn CS**, Diness BR, Martins C, Rodrigues A, Aaby P, Bibby BM. The effect of 50,000 IU vitamin A with BCG vaccine at birth on growth in the first year of life. ***J Trop Med*** 2011: 570170.
95. Fisker AB, Aaby P, Rodrigues A, Frydenberg M, Bibby BM, **Benn CS**. Vitamin A supplementation at birth might prime the response to subsequent vitamin A supplements in girls. Three year follow-up of a randomized trial. ***PLoS ONE*** 2011;6(8):e23265
96. Yakymenko D, **Benn CS**, Martins C, Diness BR, Fisker AB, Rodrigues A, Aaby P. The impact on different doses of vitamin A supplementation on male and female mortality. A randomised trial from Guinea-Bissau. ***BMC Pediatr*** 2011;11:77.
97. Aaby P, Martins C, **Benn CS**, Whittle H. The new decade of vaccines: getting the evidence right. ***Lancet*** 2012;379(9810):25-6
98. **Benn CS**, Fisker AB, Aaby P. With heterogeneous and potentially harmful effects in existing trials it would be unethical not to conduct further studies of the effect of vitamin A supplementation. ***BMJ*** 2011; rapid responses to *BMJ* 2011;343:doi:10.1136/bmj.d5094
99. Aaby P, Roth A, Biering-Sørensen S, Ravn H, Rodrigues A, Whittle H, **Benn CS**. No evidence of bias in trial showing BCG reduces neonatal mortality. ***J Infect Dis*** 2012 Feb;205(3):515-7.
100. Biering-Sørensen S, Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Whittle H, **Benn CS**. Small randomised trial among low-birth-weight children of Bacillus Calmette-Guérin vaccination at first health center contact. ***Pediatr Inf Dis J*** 2012;31(3):306-8.
101. **Benn CS**. Combining Vitamin A and Vaccines: Convenience or Conflict? ***Dan Med J*** 2012 Jan;59(1):B4378.
102. Fisker AB, Aaby P, Bale C, Balde I, Biering-Sørensen S, Agergaard J, Martins C, Bibby BM, **Benn CS**. Does the effect of vitamin A supplements depend on vaccination status: Observational study from Guinea-Bissau. ***BMJ Open*** 2012;2(1):e000448
103. Aaby P, Ravn H, Roth A, Rodrigues A, Lisse IM, Diness BR, Lausch KR, Lund N, Rasmussen J, Biering-Sørensen S, Whittle H, **Benn CS**. Early diphtheria-tetanus-pertussis vaccination associated with higher female mortality and no difference in male mortality in a cohort of low birthweight children: an observational study within a randomised trial. ***Arch Dis Child*** 2012 Feb 13.
104. Jørgensen MJ, Fisker AB, Sartono E, Andersen A, Erikstrup C, Lisse IM, Yazdanbakhsh M, Aaby P, **Benn CS**. The effect of at-birth vitamin A supplementation on differential white blood cell counts and in-vitro cytokine production - an immunological study nested within a randomised trial in Guinea-Bissau. ***Br J Nutr*** 2012; DOI: 10.1017/S0007114512001304,
105. Aaby P, **Benn CS**, Nielsen J, Lisse IM, Rodrigues A, Ravn H. Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. ***BMJ Open*** 2012;2(3). pii: e000707. doi: 10.1136/bmjopen-2011-000707.
106. Aaby P, Martins C, **Benn CS**, Whittle H. The new decade of vaccines. ***Lancet*** 2012; 379(9810):25-6.
107. Aaby P, Whittle HC, **Benn CS**. Vaccine programmes must consider their effect on general resistance. ***BMJ*** 2012;344:e3769. doi: 10.1136/bmj.e3769.
108. Fisker AB, Aaby P, **Benn CS**. RE: There is no need for further placebo-controlled trials. ***BMJ Open*** 2012:2:e000448
109. **Benn CS**, Aaby P. Diphtheria-Tetanus-Pertussis Vaccination Administered After Measles Vaccine: Increased Female Mortality? ***Pediatr Infect Dis J*** 2012 Jun 7.
110. Aaby P, Martins CL, Garly ML, Rodrigues A, **Benn CS**, Whittle H. The optimal age of measles immunization in low-income countries: A secondary analysis of the assumptions underlying the current policy. ***BMJ Open*** 2012; 2:e000761
111. **Benn CS**, Aaby P. Does IPTi decrease malaria morbidity but not mortality? ***Lancet*** 2012; 380(9846):958-60
112. Rasmussen J, Andersen A, Fisker AB, Ravn H, Sodemann M, Rodrigues A, **Benn CS**, Aaby P. Mid-upper-arm-circumference and mid-upper-arm circumference z-score: The best predictor of mortality. ***Eur J Clin Nutr*** 2012; DOI: EJCN.2012.95
113. Hirve S, Bavdekar A, Juvekar S, **Benn CS**, Nielsen J, Aaby P. Non-specific and sex-differential effects of vaccinations on child survival in rural western India. ***Vaccine*** 2012 Sep 26. pii: S0264-410X(12)01346-1. doi: 10.1016/j.vaccine.2012.09.035.
114. Lund N, Andersen A, Monteiro I, Aaby P, **Benn CS**. No Effect of Oral Polio Vaccine administered at Birth on Mortality and Immune Response to BCG. A Natural Experiment. ***Vaccine*** 2012 Oct 19;30(47):6694-9. doi: 10.1016/j.vaccine.2012.08.055.

115. Welega P, Nielsen J, Adjuik M, Debpuur C, Ross DA, Ravn H, **Benn CS**, Aaby P. Non-specific effects of routine vaccinations: Testing the hypothesis with data from Navrongo, Ghana. ***Trop Med Int Health*** 2012 Sep 24. doi: 10.1111/j.1365-3156.2012.03093.x.
116. Harpsoe MC, Basit S, Bager P, Wohlfahrt J, **Benn CS**, Nohr EA, Linneberg A, Jess T. Maternal obesity, gestational weight gain, and risk of asthma and atopic disease in offspring: A study within the Danish National Birth Cohort. ***J All Clin Imm*** 2012; Nov 1. doi:pii: S0091-6749(12)01502-3. 10.1016/j.jaci.2012.09.008.
117. Bjerregaard-Andersen M, Gomes MA, Joaquím LC, Rodrigues A, Jensen DM, Christensen K, **Benn CS,** Aaby P, Beck-Nielsen H, Sodemann M. Establishing a Twin Registry in Guinea-Bissau. ***Twin Res Hum Genet*** 2012; Oct 22:1-6.
118. Aaby P and **Benn CS.** Saving lives by training innate immunity with BCG vaccine. ***Proc Natl Acad Sci USA*** 2012 Oct 23;109(43):17317-8. doi: 10.1073/pnas.1215761109
119. Bjerregaard-Andersen M, Lund N, Jepsen FS, Camala L, Gomes MA, Christensen K, Christiansen L, Jensen DM, Aaby P, Beck-Nielsen H, **Benn CS**, Sodemann M. A prospective study of twinning and perinatal mortality in urban Guinea-Bissau. ***BMC Pregnancy Childbirth*** 2012 Dec 5;12(1):140.
120. Andersen A, **Benn CS**, Jørgensen MJ, Ravn H. Censored correlated cytokine concentrations: multivariate Tobit regression using clustered variance estimation. ***Stat Med*** 2012 Dec 5. doi: 10.1002/sim.5696.
121. Danneskiold-Samsøe N, Fisker AB, Jørgensen MJ, Ravn H, Andersen A, Balde ID, Leo-Hansen C, Rodrigues A, Aaby P, **Benn CS**. Determinants of vitamin A deficiency in children between 6 months and 2 years of age in Guinea-Bissau. ***BMC Public Health*** 2013;13:172. doi: 10.1186/1471-2458-13-172.
122. Andersen A, Roth A, Jensen KJ, Erikstrup C, Lisse IM, Whittle H, Sartono E, Yazdanbakhsh M, Aaby P, **Benn CS**. The immunological effect of revaccination with Bacille Calmette-Guérin vaccine at 19 months of age. ***Vaccine*** 2013 Mar 6. doi:pii: S0264-410X(13)00239-9.
123. Ørntoft NW, Thorsen K, **Benn CS**, Lemvik G, Nanque JR, Aaby P, Ostergaard L, Agergaard J. Leukocyte transcript alterations in West-African girls following a booster vaccination with diphtheria-tetanus-pertussis vaccine. ***Scand J Clin Lab Invest*** 2013 May 13
124. Villumsen M, Jess T, Sørup S, Ravn H, Sturegård E, **Benn CS**, Aaby P, Roth A.Risk of Inflammatory Bowel Disease following Bacille Calmette-Guérin and Smallpox Vaccination: A Population-based Danish Case-Cohort Study. ***Inflamm Bowel Dis*** 2013 Apr 24.
125. **Benn CS**, Netea MG, Selin LK, Aaby P. A small jab – a big effect: nonspecific immunomodulation by vaccines. ***Trends Immunol*** 2013 May 13. doi:pii: S1471-4906(13)00058-6.10.1016/j.it.2013.04.004.
126. Biering-Sørensen S, Fisker AB, Ravn H, Camala L, Monteiro I, Aaby P, **Benn CS**. The effect of neonatal vitamin A supplementation on growth in the first year of life among low-birth-weight infants in Guinea-Bissau: two by two factorial randomised controlled trial. ***BMC Pediatr*** 2013;13(1):87.
127. Fisker AB, Bale C, Jørgensen MJ, Balde I, Hornshøj L, Bibby BM, Aaby P, **Benn CS**. High-dose vitamin A supplementation administered with vaccinations after 6 months of age: Sex-differential adverse reactions and morbidity. ***Vaccine*** 2013;31(31):3191-8. doi: 10.1016/j.vaccine.2013.04.072.
128. **Benn CS**, Fisker AB, Aaby P. Vitamin A supplementation in Indian children. ***Lancet*** 2013;382(9892):593. oi: 10.1016/S0140-6736(13)61737-7.
129. Martins C, Garly ML, Bale C, Rodrigues A, **Benn CS**, Whittle H, Aaby P. Measles antibody levels after vaccination with Edmonston-Zagreb and Schwarz measles vaccine at 9 months or at 9 and 18 months of age: A serological study within a randomised trial of different measles vaccines. ***Vaccine*** 2013 Aug 27. doi:pii: S0264-410X(13)01135-3. 10.1016/j.vaccine.2013.08.044.
130. Kiraly N, **Benn CS**, Biering-Sørensen S, Rodrigues A, Jensen KJ, Ravn H, Allen KJ, Aaby P. Vitamin A supplementation and BCG vaccination at birth may affect atopy in childhood: long-term follow-up of a randomized controlled trial. ***Allergy*** 2013 Aug 31. doi: 10.1111/all.12216.
131. Bjerregaard-Andersen M, Hansen L, da Silva LI, Joaquím LC, Hennild DE, Christiansen L, Aaby P, **Benn CS**, Christensen K, Sodemann M, Jensen DM, Beck-Nielsen H. Risk of Metabolic Syndrome and Diabetes Mellitus Among Young Twins and Singletons in Guinea-Bissau. ***Diabetes Care*** 2013 Aug 15.
132. Kiraly N, Balde A, Lisse IM, Eriksen HB, Aaby P, **Benn CS**. Vitamin A supplementation and risk of atopy: long-term follow-up of a randomized trial of vitamin A supplementation at six and nine months of age. ***BMC Pediatr*** 2013; 13:190. doi: 10.1186/1471-2431-13-190.
133. Martins CL, **Benn CS,** Andersen A, Balé C, Schaltz-Buchholzer F, Do VA, Rodrigues A, Aaby P, Ravn H, Whittle H, Garly ML. A randomized trial of a standard dose of EZ measles vaccine given at 4.5 months of age: Effect on total hospital admissions. ***J Infect Dis*** 2014; 209(11):1731-8. doi: 10.1093/infdis/jit804.
134. Christensen LD, Eriksen HB, Biering-Sørensen S, Balé C, Do VA, Andersen A, Martins CL, Sodemann M, Aaby P, **Benn CS**. The effect of early measles vaccination on thymic size. A randomized study from Guinea-Bissau. ***Vaccine*** 2014. pii: S0264-410X(14)00066-8. doi: 10.1016/j.vaccine.2014.01.034.
135. Martins C, Garly ML, Bale C, Rodrigues A, Njie-Jobe J, **Benn CS**, Whittle H, Aaby P. Measles virus antibody responses in children randomly assigned to receive standard-titer edmonston-zagreb measles vaccine at 4.5 and

9 months of age, 9 months of age, or 9 and 18 months of age. ***J Infect Dis*** 2014;210(5):693-700. doi: 10.1093/infdis/jiu117.

136. Sørup S, **Benn CS**, Poulsen A, Krause TG, Aaby P, Ravn H. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. ***JAMA*** 2014; 311(8):826-35. doi: 10.1001/jama.2014.470.
137. Andersen A, Jensen KJ, Erikstrup C, Ravn H, Fisker AB, Lisse IM, Sartono E, Aaby P, Yazdanbakhsh M, **Benn CS**. Both very low- and very high in vitro cytokine responses were associated with infant death in low-birth-weight children from Guinea Bissau. ***PLoS One*** 2014;9(4):e93562. doi:10.1371/journal.pone.0093562. eCollection 2014.
138. Eriksen HB, Lund N, Biering-Sørensen S, Correia C, Barbosa A, Andersen A, AabyP, Jeppesen DL, **Benn CS**. Does oral polio vaccine at birth affect the size of the thymus? Observations within a randomized trial. ***Vaccine*** 2014 Apr 8. pii:S0264-410X(14)00473-3. doi: 10.1016/j.vaccine.2014.03.082.
139. Jensen KJ, Søndergaard M, Andersen A, Sartono E, Martins C, Garly ML, Eugen-Olsen J, Ullum H, Yazdanbakhsh M, Aaby P, **Benn CS**, Erikstrup C. A randomized trial of an early measles vaccine at 4½ months of age in Guinea-bissau: sex-differential immunological effects. ***PLoS One*** 2014;9(5):e97536. doi: 10.1371/journal.pone.0097536.
140. Aaby P, Martins CL, Garly ML, Andersen A, Fisker AB, Claesson MH, Ravn H, Rodrigues A, Whittle HC, **Benn CS**. Measles vaccination in the presence or absence of maternal measles antibody: Impact on child survival. ***Clin Infect Dis*** 2014 May 14. pii: ciu354.
141. Kleinnijenhuis J, Quintin J, Preijers F, **Benn CS**, Joosten LA, Jacobs C, van Loenhout J, Xavier RJ, Aaby P, van der Meer JW, van Crevel R, Netea MG. Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity. ***J Innate Immun*** 2014;6:152-8
142. Eriksen HB, Biering-Sørensen S, Lund N, Correia C, Rodrigues A, Andersen A,Ravn H, Aaby P, Jeppesen DL, **Benn CS**. Factors Associated with Thymic Size at Birth among Low and Normal Birth-Weight Infants. ***J Pediatr*** 2014 Jul 30. pii: S0022-3476(14)00596-4. doi: 10.1016/j.jpeds.2014.06.051.
143. **Benn CS**, Diness BR, Balde I, Rodrigues A, Lausch KR, Martins CL, Fisker AB,Aaby P. Two Different Doses of Supplemental Vitamin A Did Not Affect Mortality of Normal-Birth-Weight Neonates in Guinea-Bissau in a Randomized Controlled Trial. ***J Nutr*** 2014. pii: jn.114.192674.
144. Yoshida S, Rudan I, Lawn JE, Wall S, Souza JP, Martines J, Bahl R; neonatal health research priority setting group. Newborn health research priorities beyond 2015. ***Lancet*** 2014;384(9938):e27-9. doi: 10.1016/S0140-6736(14)60263-4.
145. Bärnighausen T, Berkley S, Bhutta ZA, Bishai DM, Black MM, Bloom DE, Constenla D, Driessen J, Edmunds J, Evans D, Griffiths U, Hansen P, Hashmani FN, Hutubessy R, Jamison DT, Jha P, Jit M, Johnson H, Laxminarayan R, Lee BY, Mhatre S, Mills A, Nordström A, Ozawa S, Prosser L, Silver K, **Benn CS**, Standaert B, Walker D. Reassessing the value of vaccines. ***Lancet Glob Health*** 2014:e251-2. doi:10.1016/S2214-109X(13)70170-0.
146. Fisker AB, Hornshøj L, Rodrigues A, Balde I, Fernandes M, **Benn CS**, Aaby P. Effects of the introduction of new vaccines in Guinea-Bissau on vaccine coverage, vaccine timeliness, and child survival: an observational study. ***Lancet Glob Health*** 2014:e478-87. doi: 10.1016/S2214-109X(14)70274-8.
147. Fisker AB, Bale C, Rodrigues A, Balde I, Fernandes M, Jørgensen MJ, Danneskiold-Samsøe N, Hornshøj L, Rasmussen J, Christensen ED, Bibby BM, Aaby P, **Benn CS**. High-dose Vitamin A With Vaccination After 6 Months of Age: A Randomized Trial. ***Pediatrics*** 2014 Aug 18. pii: peds.2014-0550.
148. **Benn CS**, Martins CL, Fisker AB, Diness BR, Garly ML, Balde I, Rodrigues A,Whittle H, Aaby P. Interaction between neonatal vitamin A supplementation and timing of measles vaccination: A retrospective analysis of three randomized trials from Guinea-Bissau. ***Vaccine*** 2014. pii: S0264-410X(14)01072-X. doi: 10.1016/j.vaccine.2014.07.090.
149. Lund N, Biering-Sørensen S, Andersen A, Monteiro I, Camala L, Jørgensen MJ, Aaby P, **Benn CS**. Neonatal vitamin A supplementation associated with a cluster of deaths and poor early growth in a randomised trial among low-birth-weight boys of vitamin A versus oral polio vaccine at birth. ***BMC Pediatr*** 2014 Aug 28;14(1):214.
150. Jensen KJ, Karkov HS, Lund N, Andersen A, Eriksen HB, Barbosa AG, Kantsø B, Aaby P, **Benn CS**. The immunological effects of oral polio vaccine provided with BCG vaccine at birth: a randomised trial. ***Vaccine*** 2014 Oct 14;32(45):5949-56. doi: 10.1016/j.vaccine.2014.08.062.
151. Jensen KJ, Larsen N, Biering-Sørensen S, Andersen A, Eriksen HB, Monteiro I, Hougaard D, Aaby P, Netea MG, Flanagan KL, **Benn CS**. Heterologous immunological effects of early BCG vaccination in low-birth weight infants in Guinea-Bissau: a randomized-controlled trial. ***J Infect Dis*** 2014 Sep 9. pii: jiu508.
152. Bjerregaard-Andersen M, Biering-Sørensen S, Gomes GM, Bidonga A, Jensen DM, Rodrigues A, Christensen K, Aaby P, Beck-Nielsen H, **Benn CS**, Sodemann M. Infant twin mortality and hospitalisations after the perinatal period - a prospective cohort study from Guinea-Bissau. ***Trop Med Int Health*** 2014 Sep 22. doi: 10.1111/tmi.12388.

153. Thysen SM, Byberg S, Pedersen M, Rodrigues A, Ravn H, Martins C, **Benn CS**, Aaby P, Fisker AB. BCG coverage and barriers to BCG vaccination in Guinea-Bissau: an observational study. ***BMC Public Health*** 2014 Oct 4;14(1):1037.
154. Aaby P, Kollmann TR, **Benn CS**. Nonspecific effects of neonatal and infant vaccination: public-health, immunological and conceptual challenges. ***Nat Immunol*** 2014 Sep 18;15(10):895-9. doi: 10.1038/ni.2961.
155. Sørup S, **Benn CS**, Stensballe LG, Aaby P, Ravn H. Measles-mumps-rubella vaccination and respiratory syncytial virus-associated hospital contact. ***Vaccine*** 2015 Jan 1;33(1):237-45. doi: 10.1016/j.vaccine.2014.07.110.
156. Aaby P, Martins CL, Ravn H, Rodrigues A, Whittle HC, **Benn CS**. Is early measles vaccination better than later measles vaccination? ***Trans R Soc Trop Med Hyg*** 2015 Jan;109(1):16-28. doi: 10.1093/trstmh/tru174.
157. Aaby P, Nielsen J, **Benn CS**, Trape JF. Sex-differential and non-specific effects of routine vaccinations in a rural area with low vaccination coverage: an observational study from Senegal. ***Trans R Soc Trop Med Hyg*** 2015 Jan;109(1):77-84. doi: 10.1093/trstmh/tru186.
158. **Benn CS**, Fisker AB, Aaby P. Response to: J Mason et al. Vitamin A policies need rethinking. ***Int J Epidemiol*** 2015 Feb;44(1):366-7. doi: 10.1093/ije/dyu279.
159. Kotzé SR, Zinyama-Gutsire R, Kallestrup P, **Benn CS**, Gomo E, Gerstoft J, van Dam G, Mortensen OH, Ullum H, Erikstrup C. HIV and schistosomiasis in rural Zimbabwe: the association of Retinol-binding protein with disease progression, inflammation and mortality. ***Int J Infect Dis*** 2015 Apr;33:159-64. doi: 10.1016/j.ijid.2015.01.015.
160. Biering-Sørensen S, Jensen KJ, Aamand SH, Blok B, Andersen A, Monteiro I, Netea MG, Aaby P, **Benn CS**, Hasløv KR. Variation of growth in the production of the BCG vaccine and the association with the immune response. An observational study within a randomised trial. ***Vaccine*** 2015;33(17):2056-65. doi: 10.1016/j.vaccine.2015.02.056.
161. Byberg S, **Benn CS**. Placebo use in vaccine trials: Caution when using active vaccines as placebo. ***Vaccine*** 2015 Mar 21. pii: S0264-410X(15)00323-0. doi: 10.1016/j.vaccine.2015.03.024.
162. Thysen SM, Aaby P, **Benn CS**, Fisker AB. Changes in BCG vaccination policy should consider the effect on child health. ***J Infect Dis*** 2015 Mar 27. pii: jiv198.
163. Thøstesen LM, Nissen TN, Kjærgaard J, Pihl GT, Birk NM, **Benn CS**, Greisen G, Kofoed PE, Pryds O, Ravn H, Jeppesen DL, Aaby P, Stensballe LG. Bacillus Calmette-Guérin immunisation at birth and morbidity among Danish children: A prospective, randomised, clinical trial. ***Contemp Clin Trials*** 2015; 42:213-8.doi: 10.1016/j.cct.2015.04.006.
164. Arts RJ, Blok BA, van Crevel R, Joosten LA, Aaby P, **Benn CS**, Netea MG. Vitamin A induces inhibitory histone methylation modifications and down-regulates rained immunity in human monocytes. ***J Leukoc Biol*** 2015; 98(1):129-36. doi:10.1189/jlb.6AB0914-416R.
165. Clarke MS, **Benn CS**. Unusual positive effects from vaccines need to be reported - They represent a resource that could lead to new treatment strategies. ***Vaccine*** 2015;33(28):3162-3. doi: 10.1016/j.vaccine.2015.04.076.
166. Aage S, Kiraly N, Da Costa K, Byberg S, Bjerregaard-Andersen M, Fisker AB, Aaby P, **Benn CS**. Neonatal vitamin A supplementation associated with increased atopy in girls. ***Allergy*** 2015;70(8):985-94. doi: 10.1111/all.12641.
167. Storgaard L, Rodrigues A, Martins C, Nielsen BU, Ravn H, **Benn CS**, Aaby P, Fisker AB. Development of BCG Scar and Subsequent Morbidity and Mortality in Rural Guinea-Bissau. ***Clin Infect Dis*** 2015 61(6):950-9. doi:10.1093/cid/civ452
168. Arts RJ, Blok BA, Aaby P, Joosten LA, de Jong D, van der Meer JW, **Benn CS**, van Crevel R, Netea MG. Long-term in vitro and in vivo effects of γ-irradiated BCG on innate and adaptive immunity. ***J Leukoc Biol*** 2015 Jun 16. pii: jlb.4MA0215-059R.
169. **Benn CS**, Aaby P, Arts RJ, Jensen KJ, Netea MG, Fisker AB. An enigma: why vitamin A supplementation does not always reduce mortality even though vitamin A deficiency is associated with increased mortality. ***Int J Epidemiol*** 2015; 44(3):906-18. doi: 10.1093/ije/dyv117.
170. Blok BA, Arts RJ, van Crevel R, **Benn CS**, Netea MG. Trained innate immunity as underlying mechanism for the long-term, nonspecific effects of vaccines. ***J Leukoc Biol*** 2015 98(3):347-56. doi: 10.1189/jlb.5RI0315-096R. Review.
171. **Benn CS**, Aaby P, Fisker AB. Neonatal vitamin A: time to move on? ***Lancet*** 2015 Jul 11;386(9989):132-3. doi: 10.1016/S0140-6736(15)61235-1.
172. Fisker AB, Aaby P, **Benn CS**. Neonatal vitamin A: time to move on? ***Lancet*** 2015 Jul 11;386(9989):134-5. doi: 10.1016/S0140-6736(15)61237-5.
173. Lund N, Andersen A, Hansen AS, Jepsen FS, Barbosa A, Biering-Sørensen S,Rodrigues A, Ravn H, Aaby P, **Benn CS**. The Effect of Oral Polio Vaccine at Birth on Infant Mortality: A Randomized Trial. ***Clin Infect Dis*** 2015; 61(10):1504-11. doi: 10.1093/cid/civ617.
174. Fisker AB, Rodrigues A, Martins C, Ravn H, Byberg S, Thysen S, Storgaard L, Pedersen M, Fernandes M, **Benn CS**, Aaby P. Reduced All-Cause Child Mortality After General Measles Vaccination Campaign in Rural Guinea-

Bissau. ***Pediatr Infect Dis J*** 2015;34(12):1369-76. doi: 10.1097/INF.0000000000000896

175. Yoshida S, Martines J, Lawn JE, Wall S, Souza JP, Rudan I, Cousens S; neonatal health research priority setting group, Aaby P, Adam I, Adhikari RK, Ambalavanan N, Arifeen SE, Aryal DR, Asiruddin S, Baqui A, Barros AJ, **Benn CS**, Bhandari V, Bhatnagar S, Bhattacharya S, Bhutta ZA, Black RE, Blencowe H, Bose C, Brown J, Bührer C, Carlo W, Cecatti JG, Cheung PY, Clark R, Colbourn T, Conde-Agudelo A, Corbett E, Czeizel AE, Das A, Day LT, Deal C, Deorari A, Dilmen U, English M, Engmann C, Esamai F, Fall C, Ferriero DM, Gisore P, Hazir T, Higgins RD, Homer CS, Hoque DE, Irgens L, Islam MT, de Graft-Johnson J, Joshua MA, Keenan W,Khatoon S, Kieler H, Kramer MS, Lackritz EM, Lavender T, Lawintono L, Luhanga R, Marsh D, McMillan D, McNamara PJ, Mol BW, Molyneux E, Mukasa GK, Mutabazi M, Nacul LC, Nakakeeto M, Narayanan I, Olusanya B, Osrin D, Paul V, Poets C, Reddy UM, Santosham M, Sayed R, Schlabritz-Loutsevitch NE, Singhal N, Smith MA, Smith PG, Soofi S, Spong CY, Sultana S, Tshefu A, van Bel F, Gray LV, Waiswa P, Wang W, Williams SL, Wright L, Zaidi A, Zhang Y, Zhong N, Zuniga I, Bahl R. Setting research priorities to improve global newborn health and prevent stillbirths by 2025. ***J Glob Health*** 2016 Jun;6(1):010508. doi: 10.7189/jogh.06.010508.
176. Biering-Sørensen S, Andersen A, Ravn H, Monterio I, Aaby P, **Benn CS**. Early BCG vaccine to low-birth-weight infants and the effects on growth in the first year of life: a randomised controlled trial. ***BMC Pediatr*** 2015;15:137. doi: 10.1186/s12887-015-0452-2.
177. Timmermann CA, Biering-Sørensen S, Aaby P, Fisker AB, Monteiro I, Rodrigues A, **Benn CS**, Ravn H. Tuberculin reaction and BCG scar: association with infant mortality. ***Trop Med Int Health*** 2015 Dec;20(12):1733-44. doi: 10.1111/tmi.12614.
178. Aaby P, Rodrigues A, Kofoed PE, **Benn CS**. RTS,S/AS01 malaria vaccine and child mortality. ***Lancet*** 2015; 386(10005):1735-6. doi:10.1016/S0140-6736(15)00693-5.
179. Jensen KJ, Fisker AB, Andersen A, Sartono E, Yazdanbakhsh M, Aaby P, Erikstrup C, **Benn CS**. The effects of vitamin A supplementation with measles vaccine on leucocyte counts and in vitro cytokine production. ***Br J Nutr*** 2016 Feb;115(4):619-28. doi: 10.1017/S0007114515004869.
180. Kiraly N, Aage S, **Benn CS**. Disparity between vitamin A-induced Th1-dependent oral tolerance in newborn mice and vitamin A-induced atopic sensitization in Guinean girls. ***Mucosal Immunol*** 2016 Mar;9(2):564. doi: 10.1038/mi.2016.6.
181. Sørup S, Stensballe LG, Krause TG, Aaby P, **Benn CS**, Ravn H. Oral Polio Vaccination and Hospital Admissions With Non-Polio Infections in Denmark: Nationwide Retrospective Cohort Study. ***Open Forum Infect Dis*** 2015;3(1):ofv204. doi: 10.1093/ofid/ofv204. eCollection 2016 Jan.
182. Nissen TN, Birk NM, Kjærgaard J, Thøstesen LM, Pihl GT, Hoffmann T, Jeppesen DL, Kofoed PE, Greisen G, **Benn CS**, Aaby P, Pryds O, Stensballe LG. Adverse reactions to the Bacillus Calmette-Guérin (BCG) vaccine in new-born infants-an evaluation of the Danish strain 1331 SSI in a randomized clinical trial. ***Vaccine*** 2016 Apr 6. pii: S0264-410X(16)30097-4. doi: 10.1016/j.vaccine.2016.03.100.
183. Klein SL, Shann F, Moss WJ, **Benn CS**, Aaby P. RTS,S Malaria Vaccine and Increased Mortality in Girls. ***mBio*** 2016 Apr 26;7(2):e00514-16. doi: 10.1128/mBio.00514-16.
184. Aaby P, Ravn H, **Benn CS**. The WHO Review of the Possible Non-Specific Effects of Diphtheria-Tetanus-Pertussis Vaccine. ***Pediatr Infect Dis J*** 2016;35(11):1247-1257.
185. Kjærgaard J, Birk NM, Nissen TN, Thøstesen LM, Pihl GT, **Benn CS**, Jeppesen DL, Pryds O, Kofoed PE, Aaby P, Greisen G, Stensballe LG. Nonspecific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial. ***Pediatr Res*** 2016 Nov;80(5):681-685. doi: 10.1038/pr.2016.142.
186. Rieckmann A, Villumsen M, Sørup S, Haugaard LK, Ravn H, Roth A, Baker JL, **Benn CS**, Aaby P. Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971-2010. ***Int J Epidemiol*** 2016 Jul 5. pii: dyw120.
187. Jensen KJ, **Benn CS**, van Crevel R. Unravelling the nature of non-specific effects of vaccines-A challenge for innate immunologists. ***Semin Immunol*** 2016 Aug;28(4):377-83. doi: 10.1016/j.smim.2016.05.005. Review.
188. Frankel H, Byberg S, Bjerregaard-Andersen M, Martins CL, Aaby P, **Benn CS**, Fisker AB. Different effects of BCG strains - A natural experiment evaluating the impact of the Danish and the Russian BCG strains on morbidity and scar formation in Guinea-Bissau. ***Vaccine*** 2016 Aug 31;34(38):4586-93. doi: 10.1016/j.vaccine.2016.07.022.
189. Fisker AB, Biering-Sørensen S, Lund N, Djana Q, Rodrigues A, Martins CL, **Benn CS**. Contrasting female-male mortality ratios after routine vaccinations with pentavalent vaccine versus measles and yellow fever vaccine. A cohort study from urban Guinea-Bissau. ***Vaccine*** 2016 Aug 31;34(38):4551-7. doi:10.1016/j.vaccine.2016.07.034.
190. Stensballe LG, Sørup S, Aaby P, **Benn CS**, Greisen G, Jeppesen DL, Birk NM, Kjærgaard J, Nissen TN, Pihl GT, Thøstesen LM, Kofoed PE, Pryds O, Ravn H. BCG vaccination at birth and early childhood

hospitalisation: a randomised clinical multicentre trial. ***Arch Dis Child*** 2016 Jul 21. pii: archdischild-2016-310760.doi: 10.1136/archdischild-2016-310760.

191. **Benn CS**, Fisker AB, Whittle HC, Aaby P. Revaccination with Live Attenuated Vaccines Confer Additional Beneficial Nonspecific Effects on Overall Survival: A Review. ***EBioMedicine*** 2016 Aug;10:312-7. doi: 10.1016/j.ebiom.2016.07.016.
192. Aaby P, Nielsen J, **Benn CS**, Trape JF. Sex-differential effects on mortality of BCG and diphtheria-tetanus-pertussis vaccines in a rural area with high vaccination coverage: observational study from Senegal. ***Trans R Soc Trop Med Hyg*** 2016;110(9):527-533.
193. Aaby P, Ravn H, **Benn CS**, Rodrigues A, Samb B, Ibrahim SA, Libman MD, Whittle HC. Randomized Trials Comparing Inactivated Vaccine After Medium or High Titer Measles Vaccine with Standard Titer Measles Vaccine After Inactivated Vaccine: A Meta-Analysis. ***Pediatr Infect Dis J*** 2016 Jul 18.
194. **Benn CS**, Sørup S. Commentary: BCG has no beneficial non-specific effects on Greenland. An answer to the wrong question? ***Int J Epidemiol*** 2016 Nov 17. pii:dyw299.
195. Aaby P, Ravn H, Fisker AB, Rodrigues A, **Benn CS**. Is diphtheria-tetanus-pertussis (DTP) associated with increased female mortality? A meta-analysis testing the hypotheses of sex-differential non-specific effects of DTP vaccine. ***Trans R Soc Trop Med Hyg*** 2016 Dec;110(10):570-581
196. Sørup S, **Benn CS**, Poulsen A, Krause TG, Aaby P, Ravn H. Simultaneous vaccination with MMR and DTaP-IPV-Hib and rate of hospital admissions with any infections: A nationwide register based cohort study. ***Vaccine*** 2016 Dec 7;34(50):6172-6180. doi: 10.1016/j.vaccine.2016.11.005.
197. Byberg S, Fisker AB, Rodrigues A, Balde I, Enemark U, Aaby P, **Benn CS**, Griffiths UK. Household experience and costs of seeking measles vaccination in rural Guinea-Bissau. ***Trop Med Int Health*** 2017 Jan;22(1):12-20. doi:10.1111/tmi.12793.
198. Byberg S, Thysen SM, Rodrigues A, Martins C, Cabral C, Careme M, Aaby P, **Benn CS**, Fisker AB. A general measles vaccination campaign in urban Guinea-Bissau: Comparing child mortality among participants and non-participants. ***Vaccine*** 2017 Jan 3;35(1):33-39. doi: 10.1016/j.vaccine.2016.11.049.
199. Rasmussen SM, Biering-Sørensen S, Byberg S, Andersen A, Bjerregaard-Andersen M, Rodrigues A, **Benn CS**, Martins CL, Aaby P. The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau. ***BMC Pediatr*** 2016 Dec 3;16(1):199.
200. Mogensen SW, Aaby P, Smedman L, Martins CL, Rodrigues A, **Benn CS**, Ravn H. Introduction of standard measles vaccination in an urban African community in 1979 and overall child survival: a reanalysis of data from a cohort study. ***BMJ Open*** 2016 Dec 20;6(12):e011317. doi: 10.1136/bmjopen-2016-011317.
201. Aaby P, Andersen A, Martins CL, Fisker AB, Rodrigues A, Whittle HC, **Benn CS**. Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine. ***BMJ Open*** 2016 Dec 23;6(12):e013335. doi: 10.1136/bmjopen-2016-013335.
202. Do VA, Biering-Sørensen S, Fisker AB, Balé C, Rasmussen SM, Christensen LD, Jensen KJ, Martins C, Aaby P, **Benn CS**. Effect of an Early Dose of Measles Vaccine on Morbidity Between 18 Weeks and 9 Months of Age: A Randomized, Controlled Trial in Guinea-Bissau. ***J Infect Dis*** 2017 Jan 10. pii: jiw512. doi:10.1093/infdis/jiw512.
203. **Benn CS**, Jacobsen LH, Fisker AB, Rodrigues A, Sartono E, Lund N, Whittle HC, Aaby P. Campaigns with oral polio vaccine may lower mortality and create unexpected results. ***Vaccine*** 2017 Feb 22;35(8):1113-1116. doi:10.1016/j.vaccine.2016.11.006.
204. Birk NM, Nissen TN, Zingmark V, Kjærgaard J, Thøstesen LM, Kofoed PE, Stensballe LG, Andersen A, Nielsen SD, **Benn CS**, Pryds O, Jeppesen DL. Bacillus Calmette-Guérin vaccination, thymic size and thymic output in healthy newborns. ***Pediatr Res*** 2017 Feb 3. doi: 10.1038/pr.2017.27.
205. Schaltz-Buchholzer F, Frankel HN, **Benn CS**. The real-life number of neonatal doses of Bacille Calmette-Guérin vaccine in a 20-dose vial. ***Glob Health Action*** 2017;10(1):1-4. doi: 10.1080/16549716.2017.1267964.
206. Hansen NS, Byberg S, Hervig Jacobsen L, Bjerregaard-Andersen M, Jensen AKG, Martins C, Aaby P, Skov Jensen J, **Stabell Benn C**, Whittle H. Effect of early measles vaccine on pneumococcal colonization: A randomized trial from Guinea-Bissau. ***PLoS One***. 2017 May 17;12(5):e0177547. doi: 10.1371/journal.pone.0177547.
207. Mogensen SW, Andersen A, Rodrigues A, **Benn CS**, Aaby P. The Introduction of Diphtheria-Tetanus-Pertussis and Oral Polio Vaccine Among Young Infants in an Urban African Community: A Natural Experiment. ***EBioMedicine*** 2017 Feb 1. pii:S2352-3964(17)30046-4. doi: 10.1016/j.ebiom.2017.01.041.
208. Aaby P, **Benn CS**. Beneficial non-specific effects of oral polio vaccine (OPV): Implications for the cessation of OPV? ***Clin Infect Dis*** 2017 Apr 12. doi: 10.1093/cid/cix340. [Epub ahead of print]

209. Bæk O, Jensen KJ, Andersen A, Balé C, Martins C, Biering-Sørensen S, Poulsen A, **Benn CS**. Seasonal and sex-specific variations in haematological parameters in 4 to 5.5-month-old infants in Guinea-Bissau, West Africa. ***Trans R Soc Trop Med Hyg*** 2017 Mar 27:1-8. doi: 10.1093/trstmh/trx014.
210. Thøstesen LM, Stensballe LG, Pihl GT, Kjærgaard J, Birk NM, Nissen TN, Jensen AKG, Aaby P, Olesen AW, Jeppesen DL, **Benn CS**, Kofoed PE. Neonatal BCG vaccination has no effect on recurrent wheeze in the first year of life: A randomized clinical trial. ***J Allergy Clin Immunol*** 2017 Mar 25. pii: S0091-6749(17)30473-6. doi: 10.1016/j.jaci.2016.12.990.
211. Nissen TN, Birk NM, Smits G, Jeppesen DL, Stensballe LG, Netea MG, van der Klis F, **Benn CS**, Pryds O; Calmette Study Group.. Bacille Calmette-Guérin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial. ***Vaccine*** 2017 Apr 11;35(16):2084-2091. doi: 10.1016/j.vaccine.2017.02.048. Epub 2017 Mar 15.
212. **Benn CS**. We Need Studies of the Mortality Effect of Vitamin A Supplementation, Not Surveys of Vitamin A Deficiency. ***Nutrients*** 2017 Mar 15;9(3). pii: E280. doi: 10.3390/nu9030280.
213. Byberg S, Fisker AB, Thysen SM, Rodrigues A, Enemark U, Aaby P, **Benn CS**, Griffiths UK. Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau. ***Glob Health Action*** 2017;10(1):1329968. doi:10.1080/16549716.2017.1329968.
214. Byberg S, Østergaard MD, Rodrigues A, Martins C, **Benn CS**, Aaby P, Fisker AB. Analysis of risk factors for infant mortality in the 1992-3 and 2002-3 birth cohorts in rural Guinea-Bissau. ***PLoS One*** 2017 May 18;12(5):e0177984. doi: 10.1371/journal.pone.0177984.
215. Nielsen BU, Byberg S, Aaby P, Rodrigues A, **Benn CS**, Fisker AB. Seasonal variation in child mortality in rural Guinea-Bissau. ***Trop Med Int Health*** 2017 May 2. doi: 10.1111/tmi.12889.
216. Thøstesen LM, Kjaer HF, Pihl GT, Nissen TN, Birk NM, Kjaergaard J, Jensen AKG, Aaby P, Olesen AW, Stensballe LG, Jeppesen DL, **Benn CS**, Kofoed PE. Neonatal BCG has no effect on allergic sensitization and suspected food allergy until 13 months. ***Pediatr Allergy Immunol*** 2017 Jun 29. doi: 10.1111/pai.12748.
217. Birk NM, Nissen TN, Ladekarl M, Zingmark V, Kjærgaard J, Jensen TM, Jensen SK, Thøstesen LM, Kofoed PE, Stensballe LG, Andersen A, Pryds O, Nielsen SD, **Benn CS**, Jeppesen DL. The association between Bacillus Calmette-Guérin vaccination (1331 SSI) skin reaction and subsequent scar development in infants. ***BMC Infect Dis*** 2017 Aug 3;17(1):540. doi: 10.1186/s12879-017-2641-0.
218. Nissen TN, Birk NM, Blok BA, Arts RJW, Andersen A, Kjærgaard J, Thøstesen LM, Hoffmann T, Jeppesen DL, Nielsen SD, Kofoed PE, Stensballe LG, Aaby P, Ruhwald M, Netea MG, **Benn CS**, Pryds O. Bacillus Calmette-Guérin vaccination at birth and in vitro cytokine responses to non-specific stimulation. A randomized clinical trial. ***Eur J Clin Microbiol Infect Dis*** 2017 Sep 10. doi:10.1007/s10096-017-3097-2.
219. Rieckmann A, Villumsen M, Jensen ML, Ravn H, da Silva ZJ, Sørup S, Baker JL, Rodrigues A, **Benn CS**, Roth AE, Aaby P. The Effect of Smallpox and Bacillus Calmette-Guérin Vaccination on the Risk of Human Immunodeficiency Virus-1 Infection in Guinea-Bissau and Denmark. ***Open Forum Infect Dis*** 2017 Jun 20;4(3):ofx130. doi: 10.1093/ofid/ofx130.
220. Birk NM, Nissen TN, Kjærgaard J, Hartling HJ, Thøstesen LM, Kofoed PE, Stensballe LG, Andersen A, Pryds O, Netea MG, **Benn CS,** Nielsen SD, Jeppesen DL. Effects of Bacillus Calmette-Guérin (BCG) vaccination at birth on T and B lymphocyte subsets: Results from a clinical randomized trial. ***Sci Rep*** 2017 Sep 29;7(1):12398. doi: 10.1038/s41598-017-11601-6.
221. Thøstesen LM, Kjaergaard J, Pihl GT, Birk NM, Nissen TN, Aaby P, Jensen AKG, Olesen AW, Stensballe LG, Jeppesen DL, **Benn CS**, Kofoed PE. Neonatal BCG-vaccination and atopic dermatitis before 13 months of age. A randomised clinical trial. ***Allergy*** 2017 Sep 20. doi: 10.1111/all.13314.
222. Biering-Sørensen S, Aaby P, Lund N, Monteiro I, Jensen K, Eriksen HB, Schaltz-Buchholzer F, Jørgensen ASP, Rodrigues A, Fisker AB, **Benn CS**. Early BCG and neonatal mortality among low-birth-weight infants: A randomised controlled trial. ***Clin Inf Dis*** 2017: 65: 1183-1190
223. Brønd M, Martins CL, Byberg S, **Benn CS**, Whittle H, Garly ML, Aaby P, Fisker AB. Randomized Trial of 2 Versus 1 Dose of Measles Vaccine: Effect on Hospital Admission of Children After 9 Months of Age. ***J Pediatric Infect Dis Soc*** 2017. doi: 10.1093/jpids/pix042.
224. **Benn CS**, Fisker AB, Aaby P. Serious danger signals: Response to: The effect of neonatal vitamin A supplementation on morbidity and mortality at 12 months: a randomized trial. ***Int J Epidemiol*** 2017; 46(5):1718-1720. doi: 10.1093/ije/dyx139.
225. Jensen KJ, Søndergaard MJ, Andersen A, Martins C, Erikstrup C, Aaby P, Flanagan KL, **Benn CS**. Long-term sex-differential effects of neonatal vitamin A supplementation on in vitro cytokine responses. ***Br J Nutr*** 2017 Dec;118(11):942-948. doi: 10.1017/S0007114517002938. Epub 2017 Nov 23.
226. Fisker AB, Nebie E, Schoeps A, Martins C, Rodrigues A, Zakane A, Kagone M, Byberg S, Thysen SM, Tiendrebeogo J, Coulibaly B, Sankoh O, Becher H, Whittle HC, van der Klis FRM, **Benn CS**, Sie A,

Müller O, Aaby P. A two-centre randomised trial of an additional early dose of measles vaccine: Effects on mortality and measles antibody levels. ***Clin Infect Dis*** 2017 Nov 21. doi: 10.1093/cid/cix1033.

227. Biering-Sørensen S, Jensen KJ, Monterio I, Ravn H, Aaby P, **Benn CS**. Rapid protective effects of early BCG on neonatal mortality among low birth weight boys: observations from randomised trials. ***J Infect Dis*** 2017 Dec 5. doi: 10.1093/infdis/jix612. [Epub ahead of print]
228. Funch KM, Thysen SM, Rodrigues A, Martins CL, Aaby P, **Benn CS**, Fisker AB. Determinants of BCG scarification among children in rural Guinea-Bissau: A prospective cohort study. ***Hum Vaccin Immunother*** 2018 Jan 2:0. doi: 10.1080/21645515.2017.1421879.
229. Arts RJW, Moorlag SJCFM, Novakovic B, Li Y, Wang SY, Oosting M, Kumar V, Xavier RJ, Wijmenga C, Joosten LAB, Reusken CBEM, **Benn CS**, Aaby P, Koopmans MP, Stunnenberg HG, van Crevel R, Netea MG. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. ***Cell Host Microbe*** 2018 Jan 10;23(1):89-100.e5. doi: 10.1016/j.chom.2017.12.010.
230. Mason JB, **Benn CS**, Sachdev H, West KP Jr, Palmer AC, Sommer A. Should universal distribution of high dose vitamin A to children cease? ***BMJ*** 2018 Mar 1;360:k927. doi: 10.1136/bmj.k927
231. Andersen A, Fisker AB, Rodrigues A, Martins C, Ravn H, Lund N, Biering-Sørensen S, **Benn CS**, Aaby P. National Immunization Campaigns with Oral Polio Vaccine Reduce All-Cause Mortality: A Natural Experiment within Seven Randomized Trials. ***Front Public Health*** 2018 Feb 2;6:13. doi: 10.3389/fpubh.2018.00013. eCollection 2018
232. Aaby P, Mogensen SW, Rodrigues A, **Benn CS**. Evidence of Increase in Mortality After the Introduction of Diphtheria-Tetanus-Pertussis Vaccine to Children Aged 6-35 Months in Guinea-Bissau: A Time for Reflection? ***Front Public Health***. 2018 Mar 19;6:79. doi: 10.3389/fpubh.2018.00079.
233. Ugolini M, Gerhard J, Burkert S, Jensen KJ, Georg P, Ebner F, Volkers SM, Thada S, Dietert K, Bauer L, Schäfer A, Helbig ET, Opitz B, Kurth F, Sur S, Dittrich N, Gaddam S, Conrad ML, **Benn CS**, Blohm U, Gruber AD, Hutloff A, Hartmann S, Boekschoten MV, Müller M, Jungersen G, Schumann RR, Suttorp N, Sander LE. Recognition of microbial viability via TLR8 drives T(FH) cell differentiation and vaccine responses. ***Nat Immunol*** 2018 Apr;19(4):386-396. doi: 10.1038/s41590-018-0068-4.
234. Stensballe LG, Ravn H, Birk NM, Kjærgaard J, Nissen TN, Pihl GT, Thøstesen LM, Greisen G, Jeppesen DL, Kofoed PE, Pryds O, Sørup S, Aaby P, **Benn CS.** BCG Vaccination at Birth and Rate of Hospitalization for Infection Until 15 Months of Age in Danish Children: A Randomized Clinical Multicenter Trial. ***J Pediatric Infect Dis Soc***. 2018 Apr 7. doi: 10.1093/jpids/piy029
235. de Bree CLCJ, Marijnissen RJ, Kel JM, Rosendahl Huber SK, Aaby P, **Benn CS**, Wijnands MVW, Diavatopoulos DA, van Crevel R, Joosten LAB, Netea MG, Dulos J. Bacillus Calmette-Guérin-Induced Trained Immunity Is Not Protective for Experimental Influenza A/Anhui/1/2013 (H7N9) Infection in Mice. ***Front Immunol***. 2018 Apr 30;9:869. doi: 10.3389/fimmu.2018.00869. eCollection 2018.
236. Bjerregaard-Andersen M, Lund N, Pinstrup Joergensen AS, Starup Jepsen F, Werner Unger H, Mane M, Rodrigues A, Bergström S, **Stabell Benn C**. Stillbirths in urban Guinea-Bissau: A hospital- and ommunity-based study. ***PLoS One***. 2018 May 23;13(5):e0197680. doi: 10.1371/journal.pone.0197680
237. **Benn CS**, Fisker AB, Rieckmann A, Jensen AKG, Aaby P. How to evaluate potential non-specific effects of vaccines: the quest for randomized trials or time for triangulation? ***Expert Rev Vaccines***. 2018 May 10:1-10. doi: 10.1080/14760584.2018.1471987.
238. Sørup S, Jensen AKG, Aaby P, **Benn CS**. Revaccination with Measles-mumps-rubella Vaccine and Infectious Disease Morbidity: A Danish Register-based Cohort Study. ***Clin Infect Dis***. 2018 May 26. doi: 10.1093/cid/ciy433.
239. Pinstrup Joergensen AS, Bjerregaard-Andersen M, Biering-Sørensen S, Byberg S, Camala L, Martins C, Rodrigues A, Aaby P, **Stabell Benn C**. Admission and mortality at the main neonatal intensive care unit in Guinea-Bissau. Trans R Soc Trop Med Hyg. 2018 Jul 1;112(7):335-341.
240. de Bree LCJ, Koeken VACM, Joosten LAB, Aaby P, **Benn CS**, van Crevel R, Netea MG. Non-specific effects of vaccines: Current evidence and potential implications. ***Semin Immunol***. 2018 Jul 11. pii: S1044-5323(18)30011-3. doi: 10.1016/j.smim.2018.06.002.] Review.
241. Pedersen KB, Holck ME, Jensen AKG, Suppli CH, **Benn CS**, Krause TG, Sørup S. How are children who are delayed in the Childhood Vaccination Programme vaccinated: A nationwide register-based cohort study of Danish children aged 15-24 months and semi-structured interviews with vaccination providers. ***Scand J Public Health***. 2018 Jul 1:1403494818786146. doi: 10.1177/1403494818786146.
242. de Bree CLCJ, Janssen R, Aaby P, van Crevel R, Joosten LAB, **Benn CS**, Netea MG. The impact of sex hormones on BCG-induced trained immunity. ***J Leukoc Biol***. 2018 Sep;104(3):573-578. doi: 10.1002/JLB.5MA0118-027R.
243. **Benn CS**, Fisker AB, Wieringa FT, Coutsoudis A, Sachdev HPS. Vitamin A distribution in danger: should we worry? ***Lancet***. 2018 Aug 25;392(10148):631. doi: 10.1016/S0140-6736(18)31547-2.

244. Schaltz-Buchholzer F, Biering-Sørensen S, Lund N, Monteiro I, Umbasse P, Bærent Fisker A, Andersen A, Rodrigues A, Aaby P, **Benn CS**. Early Bacille Calmette-Guérin vaccination, hospitalizations and hospital deaths: Analysis of a secondary outcome in three randomized trials from Guinea-Bissau. ***J Infect Dis***. 2018 Sep 18. doi: 10.1093/infdis/jiy544.
245. Smits G, **Stabell Benn C**, Whittle H, van Binnendijk R, Aaby P, van der Klis F. Maternal measles antibodies and their influence on all-cause mortality following measles vaccination: an alternative to measure very low maternal antibody levels. ***Clin Infect Dis***. 2018 Oct 16. doi: 10.1093/cid/ciy900
246. Fisker AB, Thysen SM, **Benn CS**, Aaby P. [Limited knowledge of the effect on child mortality of vaccinations and vitamin A supplementation]. ***Ugeskr Laeger***. 2018 Oct 29;180(44). pii: V06180465.
247. **Benn CS**, Aaby P, Sørup S. [Non-specific effects of vaccination in Denmark]. ***Ugeskr Laeger***. 2018 Oct 29;180(44). pii: V07180467
248. Aaby P, **Benn CS**. [Child mortality for children under five years of age declined seven fold in Guinea-Bissau over the latest 40 years]. ***Ugeskr Laeger***. 2018 Oct 29;180(44). pii: V07180470.
249. Beck KB, Hønge BL, Olesen JS, Petersen MS, Jespersen S, Wejse C, da Silva ZJ, Medina C, Té DDS, Moeller BK, **Benn CS**, Aaby P, Erikstrup C. Long-term effects of smallpox vaccination on expression of the HIV-1 co-receptor CCR5 in women. ***PLoS One*** 2018 Nov 15;13(11):e0207259. doi: 10.1371/journal.pone.0207259. eCollection 2018.
250. Welaga P, Debpuur C, Aaby P, Hodgson A, Azongo DK, **Benn CS**, Oduro AR. Is the decline in neonatal mortality in northern Ghana, 1996-2012, associated with the decline in the age of BCG vaccination? An ecological study. ***BMJ Open***. 2018 Dec 14;8(12):e023752. doi: 10.1136/bmjopen-2018-023752.
251. Greiner T, Mason J, **Benn CS**, Sachdev HPS. Does India Need a Universal High-Dose Vitamin A Supplementation Program? ***Indian J Pediatr.*** 2019 Jan 14. doi: 10.1007/s12098-018-02851-x.
252. Blok BA, Jensen KJ, Aaby P, Fomsgaard A, van Crevel R, **Benn CS**, Netea MG. Opposite effects of Vaccinia and modified Vaccinia Ankara on trained immunity. ***Eur J Clin Microbiol Infect Dis***. 2019 Feb 5. doi: 10.1007/s10096-018-03449-z.
253. Berendsen MLT, Øland CB, Bles P, Jensen AKG, Kofoed PE, Whittle H, De Bree C, Netea MG, Martins C, **Benn CS**, Aaby P. Maternal Priming: Bacillus Calmette-Guérin (BCG) Vaccine Scarring in Mothers Enhances the Survival of Their Child With a BCG Vaccine Scar. ***J Pediatric Infect Dis Soc***. 2019 Feb 3. doi: 10.1093/jpids/piy142.
254. Walk J, de Bree LCJ, Graumans W, Stoter R, van Gemert GJ, van de Vegte-Bolmer M, Teelen K, Hermsen CC, Arts RJW, Behet MC, Keramati F, Moorlag SJCFM, Yang ASP, van Crevel R, Aaby P, de Mast Q, van der Ven AJAM, **Benn CS**, Netea MG, Sauerwein RW. Outcomes of controlled human malaria infection after BCG vaccination. ***Nat Commun***. 2019 Feb 20;10(1):874.
255. **Benn CS**, Aaby P, Fisker AB. Lessons Learned from the Testing of Neonatal Vitamin A Supplementation. ***Nutrients***. 2019 Feb 21;11(2). pii: E449. doi: 10.3390/nu11020449.
256. Blok BA, de Bree LCJ, Diavatopoulos DA, Langereis JD, Joosten LAB, Aaby P, Crevel RV, **Benn CS,** Netea MG. INTERACTING NON-SPECIFIC IMMUNOLOGICAL EFFECTS OF BCG AND Tdapf VACCINATIONS: AN EXPLORATIVE RANDOMIZED TRIAL. ***Clin Infect Dis***. 2019 Mar 28. pii: ciz246. doi: 10.1093/cid/ciz246.
257. Rieckmann A, Hærskjold A, **Benn CS**, Aaby P, Lange T, Sørup S. Measles, mumps and rubella vs diphtheria-tetanus-acellular-pertussis-inactivated-polio-Haemophilus influenza type b as the most recent vaccine and risk of early 'childhood asthma'. ***Int J Epidemiol***. 2019 Apr 10. pii: dyz062. doi: 10.1093/ije/dyz062.
258. Thysen SM, Fernandes M, **Benn CS**, Aaby P, Fisker AB. Cohort profile : Bandim Health Project's (BHP) rural Health and Demographic Surveillance System (HDSS)-a nationally representative HDSS in Guinea-Bissau. ***BMJ Open***. 2019 Jun 11;9(6):e028775. doi: 10.1136/bmjopen-2018-028775.
259. Jensen KJ, Hansen MS, Heegaard PMH, **Benn CS**, Jungersen G. The Effect of Inactivated Mycobacterium Paratuberculosis Vaccine on the Response to a Heterologous Bacterial Challenge in Pigs. ***Front Immunol***. 2019 Jul 5;10:1557. doi: 10.3389/fimmu.2019.01557. eCollection 2019.
260. Thysen SM, Jensen AKG, Rodrigues A, Borges IDS, Aaby P, **Benn C**, Fisker A. Can earlier BCG vaccination reduce early infant mortality? Study protocol for a cluster randomised trial in Guinea-Bissau. ***BMJ Open***. 2019 Sep 24;9(9):e025724.doi: 10.1136/bmjopen-2018-025724
261. Rieckmann A, Meyle KD, Rod NH, Baker JL, **Benn CS**, Aaby P, Sørup S. Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years. ***Vaccine***. 2019 Sep 16. pii: S0264-410X(19)31223-X. doi: 10.1016/j.vaccine.2019.09.023. [Epub ahead of print]
262. Aaby P, **Benn CS**. Developing the concept of beneficial nonspecific effect of live vaccines with epidemiological studies. ***Clin Microbiol Infect***. 2019 Aug 23. pii: S1198-743X(19)30452-5. doi: 10.1016/j.cmi.2019.08.011. Review.

263. Rieckmann A, **Benn CS**. The importance of randomised vs non-randomised trials. ***Lancet***. 2019 Aug 24;394(10199):634. doi: 10.1016/S0140-6736(19)31129-8.
264. Aaby P, **Benn CS**. Stopping live vaccines after disease eradication may increase mortality. ***Vaccine***. 2019 Oct 21. pii: S0264-410X(19)31407-0. doi: 10.1016/j.vaccine.2019.10.034.
265. Larsen JWW, Sørensen AF, Jensen AKG, Poulsen A, Gehrt L, **Benn CS**, Sørup S. Hospitalizations for infections by age and sex: register-based study of Danish children 1977-2014. ***Infect Dis (Lond).*** 2020 Feb;52(2):97-106. doi: 10.1080/23744235.2019.1682657.
266. Skajaa N, Nissen TN, Birk NM, Jeppesen DL, Thøstesen LM, **Benn CS**. Cesarean delivery and risk of atopic dermatitis. ***Allergy.*** 2019 Oct 28. doi: 10.1111/all.14093. [Epub ahead of print]
267. Schaltz-Buchholzer F, Bjerregaard-Andersen M, Øland CB, Golding C, Stjernholm EB, Monteiro I, Aaby P, **Benn CS**. Early vaccination with BCG-Denmark or BCG-Japan versus BCG-Russia to healthy newborns in Guinea-Bissau: A randomized controlled trial. ***Clin Inf Dis*** 2019 Nov 3. pii: ciz1080. doi: 10.1093/cid/ciz1080.
268. Berendsen ML, van Gijzel SW, Smits J, de Mast Q, Aaby P, **Benn CS**, Netea MG, van der Ven AJ. BCG vaccination is associated with reduced malaria prevalence in children under the age of 5 years in sub-Saharan Africa. ***BMJ Glob Health***. 2019 Nov 14;4(6):e001862. doi: 10.1136/bmjgh-2019-001862. eCollection 2019.
269. Coutsoudis A, Sanders D, Dhansay MA, Van Stuijvenberg ME, **Benn CS**. Is it time for South Africa to end the routine high-dose vitamin A supplementation programme? ***S Afr Med J.*** 2019 Nov 7;109(12):907-910. doi:10.7196/SAMJ.2019.v109i12.14203.
270. **Benn CS**. Early neonatal vitamin A supplementation and infant mortality: two alternative hypotheses. ***Arch Dis Child***. 2020 Jan 16. pii: archdischild-2018-316764. doi: 10.1136/archdischild-2018-316764.
271. Angelidou A, Conti MG, Diray-Arce J, **Benn CS**, Shann F, Netea MG, Liu M, Potluri LP, Sanchez-Schmitz G, Husson R, Ozonoff A, Kampmann B, van Haren SD, Levy O. Licensed Bacille Calmette-Guérin (BCG) formulations differ markedly in bacterial viability, RNA content and innate immune activation. ***Vaccine***. 2020 Jan 24. pii: S0264-410X(19)31614-7. doi: 10.1016/j.vaccine.2019.11.060.
272. Aaby P, Fisker AB, Björkman A, **Benn CS**. WHO's rollout of malaria vaccine in Africa: can safety questions be answered after only 24 months? ***BMJ***. 2020 Jan 24;368:l6920. doi: 10.1136/bmj.l6920.
273. Thysen SM, **Benn CS**, Gomes VF, Rudolf F, Wejse C, Roth A, Kallestrup P, Aaby P, Fisker A. Neonatal BCG vaccination and child survival in TB-exposed and TB-unexposed children: a prospective cohort study. ***BMJ Open***. 2020 Feb 28;10(2):e035595. doi: 10.1136/bmjopen-2019-035595.
274. Blok BA, Arts RJW, van Crevel R, Aaby P, Joosten LAB, **Benn CS**, Netea MG. Differential effects of BCG vaccine on immune responses induced by vi polysaccharide typhoid fever vaccination: an explorative randomized trial. ***Eur J Clin Microbiol Infect Dis***. 2020 Feb 17. doi: 10.1007/s10096-020-03813-y.
275. Jensen SK, Jensen TM, Birk NM, Stensballe LG, **Benn CS**, Jensen KJ, Pryds O, Jeppesen DL, Nissen TN. Bacille Calmette-Guérin vaccination at birth and differential white blood cell count in infancy. A randomised clinical trial. ***Vaccine***. 2020 Mar 4;38(11):2449-2455. doi: 10.1016/j.vaccine.2020.02.006.
276. **Benn CS**, Martins CL, Andersen A, Fisker AB, Whittle HC, Aaby P. Measles Vaccination in Presence of Measles Antibody May Enhance Child Survival. ***Front Pediatr***. 2020 Feb 7;8:20. doi: 10.3389/fped.2020.00020.
277. Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, Stabell Benn C, Sun JC, Xavier RJ, Latz E. Defining trained immunity and its role in health and disease. ***Nat Rev Immunol***. 2020 Mar 4. doi:10.1038/s41577-020-0285-6.
278. Jensen KJ, Biering-Sørensen S, Ursing J, Kofoed PL, Aaby P, **Benn CS**. Seasonal variation in the non-specific effects of BCG vaccination on neonatal mortality: three randomised controlled trials in Guinea-Bissau. ***BMJ Glob Health***. 2020;5(3):e001873. Published 2020 Mar 5. doi:10.1136/bmjgh-2019-001873
279. **Benn CS**, Roth A, Garly ML, et al. BCG scarring and improved child survival: a combined analysis of studies of BCG scarring. ***J Intern Med.*** 2020;10.1111/joim.13084. doi:10.1111/joim.13084
280. Netea MG, Domínguez-Andrés J, Barreiro LB, Chavakis T, Divangahi M, Fuchs E, Joosten LAB, van der Meer JWM, Mhlanga MM, Mulder WJM, Riksen NP, Schlitzer A, Schultze JL, **Stabell Benn C**, Sun JC, Xavier RJ, Latz E. Defining trained immunity and its role in health and disease. ***Nat Rev Immunol***. 2020 Jun;20(6):375-388. doi: 10.1038/s41577-020-0285-6
281. Golding CN, Schaltz-Buchholzer F, Sanca L, Clipet-Jensen C, **Benn CS**, Au N, Chipperfield K, Kollmann TR, Amenyogbe NA. Feasibility of manual white blood cell counts as a predictor of neonatal sepsis in a low-resource setting. ***Trans R Soc Trop Med Hyg***. 2020 Aug 1;114(8):566-574. doi: 10.1093/trstmh/traa023.
282. Brook B, Harbeson DJ, Shannon CP, Cai B, He D, Ben-Othman R, Francis F, Huang J, Varankovich N, Liu A, Bao W, Bjerregaard-Andersen M, Schaltz-Buchholzer F, Sanca L, Golding CN, Larsen KL, Levy O, Kampmann B; EPIC Consortium, Tan R, Charles A, Wynn JL, Shann F, Aaby P, **Benn CS**, Tebbutt SJ,

Kollmann TR, Amenyogbe N. BCG vaccination-induced emergency granulopoiesis provides rapid protection from neonatal sepsis. ***Sci Transl Med***. 2020 May 6;12(542):eaax4517. doi: 10.1126/scitranslmed.aax4517

283. Aaby P, **Benn CS**, Flanagan KL, et al. The non-specific and sex-differential effects of vaccines. ***Nat Rev Immunol***. 2020;20(8):464-470. doi:10.1038/s41577-020-0338-x
284. Chumakov K, **Benn CS**, Aaby P, Kottilil S, Gallo R. Can existing live vaccines prevent COVID-19? ***Science***. 2020;368(6496):1187-1188. doi:10.1126/science.abc4262
285. Cirovic B, de Bree LCJ, Groh L, Blok BA, Chan J, van der Velden WJFM, Bremmers MEJ, van Crevel R, Händler K, Picelli S, Schulte-Schrepping J, Klee K, Oosting M, Koeken VACM, van Ingen J, Li Y, **Benn CS,** Schultze JL, Joosten LAB, Curtis N, Netea MG, Schlitzer A. BCG Vaccination in Humans Elicits Trained Immunity via the Hematopoietic Progenitor Compartment. ***Cell Host Microbe***. 2020 Jun 9:S1931-3128(20)30296-1. doi: 10.1016/j.chom.2020.05.014
286. **Benn CS**, Fisker AB, Rieckmann A, Sørup S, Aaby P. Vaccinology: time to change the paradigm? ***Lancet Infect Dis***. 2020;S1473-3099(19)30742-X. doi:10.1016/S1473-3099(19)30742-X
287. Koeken VACM, de Bree LCJ, Mourits VP, Moorlag SJ, Walk J, Cirovic B, Arts RJ, Jaeger M, Dijkstra H, Lemmers H, Joosten LA, **Benn CS,** van Crevel R, Netea M. BCG vaccination in humans inhibits systemic inflammation in a sex-dependent manner. ***J Clin Invest***. 2020 Jul 21:133935. doi: 10.1172/JCI133935
288. de Bree LCJ, Mourits VP, Koeken VA, Moorlag SJ, Janssen R, Folkman L, Barreca D, Krausgruber T, Fife-Gernedl V, Novakovic B, Arts RJ, Dijkstra H, Lemmers H, Bock C, Joosten LA, van Crevel R, **Benn CS**, Netea MG. Circadian rhythm influences induction of trained immunity by BCG vaccination. ***J Clin Invest.*** 2020 Jul 21:133934. doi: 10.1172/JCI133934.
289. Timmermann CAG, Jensen KJ, Nielsen F, Budtz-Jørgensen E, van der Klis F, **Benn CS**, Grandjean P, Fisker AB. Serum Perfluoroalkyl Substances, Vaccine Responses, and Morbidity in a Cohort of Guinea-Bissau Children. ***Environ Health Perspect***. 2020 Aug;128(8):87002. doi: 10.1289/EHP6517.
290. Madsen AMR, Schaltz-Buchholzer F, Benfield T, Bjerregaard-Andersen M, Dalgaard LS, Dam C, Ditlev SB, Faizi G, Johansen IS, Kofoed PE, Kristensen GS, Loekkegaard ECL, Mogensen CB, Mohamed L, Ostenfeld A, Oedegaard ES, Soerensen MK, Wejse C, Jensen AKG, Nielsen S, Krause TG, Netea MG, Aaby P, **Benn CS**. Using BCG vaccine to enhance non-specific protection of health care workers during the COVID-19 pandemic: A structured summary of a study protocol for a randomised controlled trial in Denmark. ***Trials.*** 2020 Sep 17;21(1):799. doi: 10.1186/s13063-020-04714-3
291. Andersen A, Fisker AB, Nielsen S, Rodrigues A, **Benn CS,** Aaby P. National immunisation campaigns with oral polio vaccine may reduce all-cause mortality: An analysis of 13 years of demographic surveillance data from an urban African area. ***Clin Infect Dis.*** 2020 Sep 19:ciaa1351. doi: 10.1093/cid/ciaa1351.
292. Gehrt L, Rieckmann A, Kiraly N, Jensen AKG, Aaby P, **Benn CS**, Sørup S. Timeliness of DTaP-IPV-Hib Vaccination and Development of Atopic Dermatitis Between 4 Months and 1 Year of Age-Register-Based Cohort Study. ***J Allergy Clin Immunol Pract***. 2020 Oct 2:S2213-2198(20)31002-3. doi: 10.1016/j.jaip.2020.09.024.
293. Hanifi SMA, Fisker AB, Welaga P, Rieckmann A, Jensen AG, **Benn CS**, Aaby P. Diphtheria-tetanus-pertussis (DTP) vaccine is associated with increased female-male mortality rate ratios. A meta-analysis of studies of DTP administered before and after measles vaccine. ***J Infect Dis.*** 2020 Oct 30:jiaa684. doi: 10.1093/infdis/jiaa684.

Miscellaneous:

Reports

Mutua M, Welega P, Zandoh C, Kagoné M, Hanifi MA, Ravn H, Fisker A, Andersen A, **Benn CS**, Thysen S, Martins C, Aaby P. Analysis of Coverage of Fully Immunized Child, Associated Factors, Outcomes, and Impact Using Routinely Collected Population Cohort Data 2001-2014. Report to Global Alliance for Vaccine Implementation (2015).

Book chapters

Benn CS, Rieckmann A, Jensen KJ, Aaby P. The role of maternal priming and boosting for the non-specific effects of BCG vaccine. Chapter. In: The Value of BCG and TNF in Autoimmunity, 2nd Edition. Editor: Denise Faustmann, Director of Immunology, Massachusetts General Hospital, Harvard. Elsevier. http://elsev.spi-bpo.com/books/EComp/FAUSTMAN978-0-12-814603-3/1/OTc4LTAtMTIt/index.php?Type=E (2018)

Articles in "The Conversation"

Christine Stabell Benn: Vaccines have health effects beyond protecting against target diseases. https://theconversation.com/vaccines-have-health-effects-beyond-protecting-against-target-diseases-1063832019 (2019)

[More than 57000 reads]

Christine Stabell Benn: Declaring vaccine hesitancy one of the ten biggest health threats in 2019 is unhelpful https://theconversation.com/declaring-vaccine-hesitancy-one-of-the-ten-biggest-health-threats-in-2019-is-unhelpful-123628 (2019) **[**More than 46000 reads**]**

TEDx talk: How vaccines train the immune system in ways no one expected | Christine Stabell Benn | TEDxAarhus. https://www.youtube.com/watch?v=_d8PNIXHJ48 (2019) [More than 57000 views]

EXHIBIT B

Peter Aaby, DMSc, professor

Education/training

1974 Mag. Scient., Social Anthropology, University of Copenhagen

1988 Dr. Med. Sc., University of Copenhagen

Positions and Employment

1968-1991 Institute of Anthropology, University of Copenhagen; Associated with SAREC, Sweden (1978-1981); Associated with Danish Church Aid (1987-1991)

1991- Statens Serum Institut; Research Professor DANIDA/SSVF (1995-2001); Novo Nordisk Foundation professorship grant (2002-2014)

Honours

2000 Novo Nordisk prize for "Ground-breaking epidemiological research especially with regard to vaccinations against measles infection"

2009 Ministry of Foreign Affairs: 5th most important Dane for fighting global poverty

2009 + 2011+ 2014: Nominated as one of 10 best Danish research result of the year; on two occasions 2nd prize

2010 Step 2 for ERC, Advanced Grant, not funded

2012-2016 Adjunct Professor, University of Southern Denmark

2012-2017 Co-organiser of Research Center for vitamins and vaccines (CVIVA), center of excellence sponsored by the DNRF (Centre leader: Christine S Benn)

2015 Doctor Honoris Causa, Universidade Nova de Lisboa

2017 SEB Pensions Hæderpris

2017-2022 Adjunct Professor, University of Southern Denmark

2020 Member Academia Europaea

Scientific Focus

Since 1978 I have built a large health and demographic surveillance system in Guinea-Bissau. Under-5 child mortality was 500/1000 when we started. Contrary to all expectations, the high measles case fatality (25%) was not due to malnutrition but to the intensity of exposure as a secondary case within the family. Intensity of exposure was subsequently shown to explain severity in many childhood infections including pertussis, chickenpox, polio and RSV.

We were the first to introduce measles vaccine (MV) in Bissau in 1979. The MV campaign reduced overall child mortality by two-thirds, an effect not explained by prevention of measles infection. This led to a series of discoveries contradicting the specific-disease paradigm. Vaccines affect susceptibility to unrelated infections and these non-specific effects (NSEs) are far more important

for child survival than the specific preventive effects. Live vaccines, including MV, BCG, OPV and smallpox vaccination, have major beneficial NSEs, whereas non-live vaccines, including DTP, inactivated polio vaccine (IPV), hepatitis B vaccine (HBV), Pentavalent, H1N1 influenza vaccine and RTS,S malaria vaccine have negative effects for female survival.

We have also found that boosting with live vaccines, as happens in eradication campaigns, enhances the beneficial NSEs. Under-5 mortality has now declined to 65-70/1000. The numerous eradication campaigns with OPV and MV are responsible for much of this decline. We have also found for both BCG and MV that maternal priming enhances the beneficial NSEs of these vaccines.

An important implication of the NSEs is that if we eradicate a disease and then stop the corresponding live vaccine, we may have done more harm by stopping beneficial immune-training than the good we did by eradicating the disease and preventing the disease-related deaths. We have shown in both Guinea-Bissau and Denmark that smallpox vaccination had beneficial effects on survival long after smallpox was eradicated (1977). A similar problem is likely to occur with polio (to be eradicated 2019-2020) and measles (within the next 10-15 years). If we stop live OPV and MV without finding replacement vaccines we may see increases in child mortality.

A new paradigm emphasizing the immune system as a learning entity which can be trained to reduce susceptibility or misdirected to enhance susceptibility to unrelated infections is needed. Pursuing this paradigm can lead to major reductions in child mortality in low-income countries and to health care cost-savings in the high-income countries.

Peer reviewed publications

Since I started in epidemiology, I have published 613 papers in the medical field; 165 first authored; 202 last/corresponding author; H-index: 89 (Google Scholar): i10:487; 30,110 citations.

Research training

Experience in research training based on work in West Africa: 9 researchers have obtained a doctoral degree, 59 have obtained a PhD degree. The first PhD from Guinea-Bissau, Amabelia Rodrigues became the first director of the National Institute of Health, Guinea-Bissau. Kåre Mølbak became the state epidemiologist of Denmark. Christine S Benn has become the first Danish physician to receive an ERC starting grant and has received a Danish National Research Foundation Centre of Excellence grant. Many previous students are professors or senior registrars.

International collaboration

Extensive international collaboration with the INDEPH Network of demographic surveillance sites in low-income countries and with immunologists within the OPTIMMUNIZE network which focuses on potential biological mechanism for the non-specific effects of vaccines.

PUBLICATIONS: PETER AABY

1981

1. Aaby P, Bukh J, Lisse IM, Smits AJ. Measles vaccination and child mortality. Lancet 1981; ii:93.
2. Aaby P, Bukh J, Lisse IM, Smits AJ, Smedman L, Jeppson O, Lindeberg A. Breastfeeding and measles mortality in Guinea-Bissau. Lancet 1981; ii:1231

1983

3. Aaby P, Bukh J, Lisse IM, Smits AJ. Measles mortality, state of nutrition, and family structure: A community study from Guinea-Bissau. J Infect Dis 1983; 147:693-701
4. Aaby P, Bukh J, Lisse IM, Smits AJ. Spacing, crowding, and child mortality in Guinea-Bissau. Lancet 1983; ii:161
5. Aaby P, Bukh J, Lisse IM, Smits AJ. Les hommes sont-ils plus faibles ou leurs soeurs parlent-elles trop? Essai sur la transmission des maladies infectieuses. Anthropologie et Societe 1983;7:47-59
6. Aaby P, Bukh J, Lisse IM, Smits AJ, Gomes J, Fernandes MA, Indi F, Soares M. High case fatality rate in twins with measles. Lancet 1983;ii:690

1984

7. Aaby P, Bukh J, Lisse IM. Børnedødelighed i Guinea-Bissau. Ugeskr Læger 1984;146:2048
8. Aaby P, Bukh J, Lisse IM, Smits AJ, Gomes J, Fernandes MA, Indi F, Soares M. Determinants of measles mortality in a rural area of Guinea-Bissau: Crowding, age, and malnutrition. J Trop Pediatr 1984; 30:164-69
9. Aaby P, Bukh J, Lisse IM, Smits AJ. Overcrowding and intensive exposure as determinants of measles mortality. Am J Epidemiol 1984; 120:49-63
10. Aaby P, Bukh J, Lisse IM, Smits AJ. Measles vaccination and reduction in child mortality: a community study from Guinea-Bissau. J Infect 1984; 8:13-21
11. Aaby P, Bukh J, Lisse IM, Smits AJ. Risk factors in subacute sclerosing panencephalitis(SSPE): Age- and sex-dependent host reactions or intensive exposure. Rev Infect Dis 1984: 6:239-250

1985

12. Aaby P. Epidemics among Amerindians and Inuits. A preliminary interpretation. In: Brøsted J, Dahl J, Gray A, Gulløv HC, Henriksen G, Jørgensen JB, Kleivan I(eds): Native Power. Bergen: Universitetsforlaget, 1985; 329-339.
13. Aaby P, Bukh J, Lisse IM, Smits AJ. Introduction of measles into a higly immunised West African community: the role of health care institutions. J Epidemiol Comm Hlth 1985; 39:113-116
14. Aaby P, Coovadia H, Bukh J, Lisse IM, Smits AJ, Wesley A, Kiepiela P. Severe measles: A reappraisal of the role of nutrition, overcrowding and virus dose. Med Hypoth 1985; 18:93-111

1986

15. Aaby P, Bukh J, Lisse IM, Smits AJ. Severe measles in Sunderland, 1885: A European-African comparison of causes of severe infection. Int J Epidemiol 1986; 15:101-7
16. Aaby P, Bukh J, Lisse IM, Smits AJ. Cross-sex transmission of infection and increased mortality due to measles. Rev Infect Dis 1986; 8:138-43.
17. Smedman L, Aaby P, Lindeberg A, Zetterstrom R. Survival 0-6 years of age in a periurban community in Guinea-Bissau: a longitudinal assessment. Ann Trop Pediatr 1986;6:67-72
18. Aaby P, Bukh J, Lisse IM, Smits AJ, da Silva C. Determinants des formes severes de rougeole: consequences au niveau de l´action preventive. In: Cantrelle P, Dormont S, Fargues Ph, Goujard J, Guignard J, Rumeau-Rouquette (eds): Estimation de a mortalite du jeune enfant(0-5 ans) pour guider les actions de sante dans les pays en developpement. Paris: INSERM, 1986: 429-442.
19. Aaby P, Bukh J, Hoff G, Leerhøy J, Lisse IM, Mordhorst CH, Pedersen IR. High measles mortality in infancy related to intensity of exposure. J Pediatr 1986; 109:40-4
20. Aaby P, Bukh J, Leerhøy J, Lisse IM, Mordhorst CH, Pedersen IR. Vaccinated children get milder measles infection: a community study from Guinea-Bissau. J Infect Dis 1986; 154:858-63

1987

21. Aaby P, Bukh J, Hoff G, Lisse IM, Smits AJ. Humoral immunity in measles infection: A critical factor? Med Hypoth 1987; 23:287-302
22. Aaby P, Clements J, Cohen N. Key issues in measles immunization research: A review of the literature. WHO, EPI, 1987

1988

23. Aaby P. Observing the unexpected. Nutrition and child mortality in Guinea-Bissau. In: Caldwell JC, Hill A, Hull VJ(eds): Micro approaches in demographic research. London: Kegan Paul, 1988:278-296
24. Aaby P. Introduction to community studies of severe measles: Comparative test of the crowding/exposure hypothesis. Rev Infect Dis 1988;10:451
25. Aaby P. Severe measles in Copenhagen, 1915-1925. Rev Infect Dis 1988;10:452-456
26. Aaby P, Bukh J, Lisse IM, da Silva CM. Measles mortality: Further community studies on the role of overcrowding and intensive exposure. Rev Infect Dis 1988; 10:474-477
27. Aaby P. Malnutrition and overcrowding-exposure in severe measles infection. A review of community studies. Rev Infect Dis 1988;10:478-491

28. Aaby P, Bukh J, Lisse IM, da Silva CM. Measles mortality decline: Nutrition, age at infection, or exposure? Br Med J 1988; 296:1225-1228
29. Aaby P. Severe Measles: A new perspective. Postgr Doct Middle East 1988;11:140-147
30. Aaby P. Le surpeuplement, un facteur déterminant de la mortalité par rougeole en Afrique.Dossiers et recherches no. 15. Paris: INED, 1988.
31. Aaby P, Bukh J, Lisse IM, Seim E, da Silva MC. Increased perinatal mortality among children of mothers exposed to measles during pregnancy. Lancet 1988; 1:516-519
32. Morley D, Aaby P. Severe measles : A new understanding. Medical Digest 1988
33. Morley D, Aaby P. Severe measles : A new understanding. J Rural Pediatr 1988: 6:82-87
34. Whittle H, Hanlon P, O'Neill K, Hanlon L, Marsh V, Jupp E, Aaby P. Trial of high-dose Edmonston-Zagreb measles vaccine in The Gambia: Antibody response and side-effects. Lancet 1988;2:811-814
35. Aaby P, Jensen TG, Hansen HL, Kristiansen H, Thårup J, Poulsen A, Sodemann M, Jakobsen M, Knudsen K, da Silva MC, Whittle H. Trial of high-dose Edmonston-Zagreb measles vaccine in Guinea-Bissau: Protective efficacy.Lancet 1988;2:809-811

1989

36. Aaby P. La promiscuité, un facteur déterminant de la mortalité par rougeole. In: G. Pison, E. van de Walle, M Sala-Diakanda (eds): Mortalité et Société en Afrique. INED Cahier no. 124, Paris: PUF, 1989:295-324.
37. Aaby P, Clements J. Measles immunization research. A review. Bull WHO 1989;67:443-448
38. Aaby P. Malnourished or overinfected. An analysis of the determinants of acute measles mortality. Dan Med Bull 1989; 36:93-113 [thesis]
39. Aaby P, Pedersen IR, Knudsen K, da Silva MC, Mordhorst CH, Helm-Petersen NC, Hansen BS, Thårup J, Poulsen A, Sodemann M, Jakobsen M. Child mortality related to seroconversion or lack of seroconversion after measles vaccination. Pediatr Infect Dis J 1989;8:197-200
40. Aaby P. Tuhkarokko [Severe measles and its control in developing countries: Dogmas and new perspectives]. In: Lankinen KS,Karvonen JT, Mäkelä PH, Peltola H, Peltomaa M (eds): Kehitysmaiden terveys ja sairaus. [Health and disease in developing countries]. Kunstantaja: Kandidaattikustannus Oy, 1989: 441-454.
41. Aaby P. Malnutrition and/vs overcrowding in child survival. Proceedings of IUSSP's International Congress, Delhi, 1989, vol. 1, pp 351-362.
42. Poulsen AG, Kvinesdal B, Aaby P, Mølbak K, Frederiksen K, Dias F, Lauritzen E. Prevalence of and mortality from Human Immunodeficiency Virus Type 2 in Bissau, West Africa. Lancet 1989;1:827-831
43. Gomes J, Fernandes MA, Indi F, da Gama MS, Sami J, Aaby P. Malnutrition and infant mortality in the regions of Tombali, Cacheu, Oio, Biombo, and Gabu (in Portuguese). Bol Inf Socio Econ 1989;5:11-44

1990

44. Aaby P, Leeuwenburg J. Patterns of transmission and severity of measles infection. A reanalysis of data from the Machakos area, Kenya. J Infect Dis 1990;161:171-174
45. Aaby P, Bukh J, Kronborg D, Lisse IM, da Silva MC. Delayed excess mortality after exposure to measles during the first six months of life. Am J Epidemiol 1990;132:211-19
46. Kronborg D, Aaby P. Piecewise comparison of survival functions in stratified proportional hazards models. Biometrics 1990;46:375-380
47. Aaby P, Seim E, Knudsen K, Bukh J, Lisse IM, da Silva MC. Increased post-perinatal child mortality among children of mothers exposed to measles during pregnancy. Am J Epidemiol 1990; 132:531-539
48. Lisse IM, Whittle H, Aaby P, Normark M, Gyhrs A, Ryder LP. Labelling of T-cell subsets under field conditions in tropical countries. Adaptation of the immuno-alkaline phospatase staining method for blood-smears. J Immunol Method 1990;129:49-53
49. Garenne M, Aaby P. Pattern of exposure and measles mortality in Senegal. J Inf Dis 1990;161:1088-1094
50. Aaby P. Social and behavioral factors affecting transmission and severity of measles infection. In: J. Caldwell, S. Findley, Caldwell P, S. Santow, W. Cosford, J. Braid, D. Broers-Freeman (eds): What we know about Health Transition: The cultural, social and behavioural determinants of health. Canberra: Health Transition Center, 1990, 826-842.
51. Aaby P, Mølbak K. Siblings of opposite sex as a risk factor for child mortality. Br Med J 1990;301:143-145
52. Aaby P, Knudsen K, Jensen TG, Thaarup J, Poulsen A, Sodemann M, da Silva MC, Whittle H. Measles incidence, vaccine efficacy, and mortality in two urban African areas with high vaccination coverage. J Infect Dis 1990;162:1043-1048
53. Mølbak K, Højlyng N, Ingholt L, Silva AGJ, Jepsen S, Aaby P. An epidemic outbreak of cryptosporidiosis. A prospective community study from Guinea-Bissau. J Pediatr Infect Dis 1990; 9:566-570
54. Lisse I, Poulsen AG, Aaby P, Normark M, Kvinesdal BB, Dias F, Mølbak K, Knudsen K. Immmunodeficiency in HIV-2 infection. A community study from Guinea-Bissau. AIDS 1990; 4:1263-1266
55. Hall A, Aaby P. Tropical trials and tribulations. Int J Epidemiol 1990;19:777-781.

1991

56. Aaby P. Determinants of measles mortality: Host or transmission factors? In: de la Maza LM, Peterson EM (eds), Medical Virology 10. New York: Plenum Press, 1991:83-116
57. Aaby P. Severity of measles and cross-sex transmission of infection in Copenhagen, 1915-1925. Int J Epidemiol 1991; 20:504-507

58. Aaby P, Leeuwenburg J. Gender and the pattern of transmission of measles infection. A reanalysis of data from the Machakos area, Kenya. Ann Trop Pediatr 1991;11:397-402
59. Aaby P, Lamb WH. The role of sex in the transmission of measles in a Gambian village. J Infect 1991;22:287-292
60. Aaby P, Clements J, Orinda V. Mortality from measles: measuring the impact. Geneva: EPI, WHO, 1991
61. Pison G, Aaby P, Desgrées du Lou A. Child mortality in Bandafassi, Senegal, 1970-1991: Increased risk of measles death for children with a sibling of the opposite sex.Proceedings of the Seminar on Socio-Cultural determinants of morbidity and mortality in developing countries: The role of longitudinal studies, Saly Portudal, Senegal, 1991. IUSSP, Liege, 1991
62. Aaby P. Bandim: An unplanned longitudinal study. Proceedings of the Seminar on Socio-Cultural determinants of morbidity and mortality in developing countries: The role of longitudinal studies, Saly Portudal, Senegal, 1991. IUSSP, Liege, 1991
63. Aaby P. Death houses. Proceedings of the Seminar on Socio-Cultural determinants of morbidity and mortality in developing countries: The role of longitudinal studies, Saly Portudal, Senegal, 1991. IUSSP, Liege, 1991
64. Aaby P. The long-term impact of measles infection. A new perspective. Bulletin of the International Statistical Institute. Proceedings of the 48th Session, Cairo 1991. Vol LIV, Book 4 (A), pp 369-393
65. Aaby P, Samb B, Simondon F, Whittle H, Coll Seck AM, Knudsen K, Bennett J, Markowitz L, Rhodes P. Child mortality after high-titre measles vaccines in Senegal: the complete data set. Lancet 1991; 338:1518.

1992

66. Høgsborg M, Aaby P. Sexual relations, use of condoms and perceptions of AIDS in an urban area of Guinea-Bissau with a high prevalence of HIV-2. In: T. Dyson (ed.): Sexual behaviour and networking: Anthropological and socio-cultural studies on the transmission of HIV. Liege: Ordina, 1992, 203-232
67. Aaby P. Patterns of exposure and severity of measles infection. Copenhagen 1915-1925. Ann Epidemiol 1992; 2:257-262
68. Poulsen AG, Kvinesdal BB, Aaby P, Lisse I, Gottschau A, Mølbak K, Dias F, Lauritzen E. Lack of evidence of vertical transmission of Human Immunodeficiency Virus type 2 in a sample of the general population in Bissau. J AIDS 1992; 5:25-30
69. Pison G, Aaby P, Knudsen K. Increased risk of death from measles in children with a sibling of opposite sex in Senegal. Br Med J 1992; 304:284-287
70. Mølbak K, Aaby P, Ingholt L, Højlyng N, Gottschau A, Andersen H, Brink L, Gansted U, Permin A, Vollmer A,da Silva APJ. Persistent and acute diarrhoea as the leading causes of child mortality in urban Guinea-Bissau. Trans R Soc Trop Med Hyg 1992;86:216-220
71. Kronborg D, Hansen B, Aaby P. Analysis of the incubation period for measles in the epidemic in Greenland in 1951 using a variance components model. Stat Med 1992; 11:579-590
72. Aaby P. Influence of cross-sex transmission on measles mortality in rural Senegal.Lancet 1992;340: 388-391
73. Aaby P. Lessons for the past. Third world evidence and the re-interpretation of developed world mortality declines. Health Transition Review 1992; 2, suppl:155-183 (1993)
74. Aaby P, Burström B, Mutie DM. Measles mortality in same-sex and mixed-sex siblings in Kenya. Lancet 1992; 340:923-4
75. Aaby P. Overcrowding and intensive exposure. Major determinants of variation in measles mortality in Africa. In: E. van de Walle, G. Pison, M. Sala-Diakanda (eds): Mortality and society in Africa. Oxford: Clarendon Press, 1992, 319-48
76. Aaby P, Oesterle H, Dietz K, Becker N. Case-fatality rates in severe measles outbreak in rural Germany in 1861. Lancet 1992; 340:1172
77. Burström B, Aaby P, Mutie DM, Kimani G, Bjerregaard P. Severe measles outbreak in Western Kenya. East Afr Med J 1992; 69:419-423
78. Manderson L, Aaby P. Can rapid anthropological procedures be applied to tropical diseases? Hlth Pol Plan 1992;7:46-55
79. Manderson L, Aaby P. An epidemic in the field? Rapid assessment procedures and health. Soc Sci Med 1992;35:839-850

1993

80. Aaby P, Knudsen K, Pison G. Højere mæslingedødelighed i Senegal for børn med søskende af det modsatte køn. Ugeskr Læger 1993; 155:3126-30 (translated and extended version of no. 80)
81. Aaby P, Andersen M, Knudsen K. Excess mortality after early exposure to measles. Int J Epidemiol 1993; 22:156-162
82. Samb B, Aaby P, Whittle H, Coll Seck AW, Simondon F. Protective efficacy of high-titre measles vaccines administered from the age of five months: a community study in rural Senegal.Trans Roy Soc Trop Med Hyg 1993;87:697-701
83. Poulsen AG, Aaby P, Gottschau A, Kvinesdal BB, Dias F, Mølbak K, Lauritzen E. HIV-2 infection in Bissau, West Africa, 1987-1989: Incidence, prevalences, and routes of transmission.J AIDS 1993;6:941-8
84. Aaby P, Knudsen K, Whittle H, Lisse IM, Thårup J, Poulsen A, Sodemann M, Jakobsen M, Brink L, Gansted U, Permin A, Jensen TG, Andersen H, da Silva MC. Long-term survival after Edmonston-Zagreb measles vaccination in Guinea-Bissau: Increased female mortality rate. J Pediatr 1993;122:904-8

85. Mølbak K, Højlyng N, Gottschau A, Sá JCC, Ingholt L, Silva APJ, Aaby P. Cryptosporidiosis in infancy and childhood mortality in Guinea-Bissau, West Africa. Br Med J 1993:307:417-420
86. Aaby P, Samb B, Simondon F, Knudsen K, Coll Seck AM, Bennett J, Whittle H. Divergent mortality for male and female recipients of low-titre and high-titre measles vaccines in rural Senegal. Am J Epidemiol 1993;138:746-755
87. Aaby P, Andersen M, Sodemann M, Jakobsen M, Gomes J, Fernandes M. Reduced childhood mortality after standard measles vaccination at 4-8 months compared with 9-11 months of age. Br Med J 1993;307:1308-1311
88. Burström B, Aaby P, Mutie DM. Child mortality impact of a measles outbreak in a partially vaccinated rural African community. Scand J Infect Dis 1993; 25:763-9

1994

89. Aaby P, Samb B. Severe measles and its control in developing countries. Dogmas and new perspectives. In: Lankinen KS, Bergström S, Mäkelä PH, Peltomaa M: Health and disease in developing countries. London: Macmillan Press, 1994, pp 163-176
90. Aaby P, Samb B, Simondon F, Knudsen K, Coll Seck AM, Bennett J, Markowitz L, Rhodes P, Whittle H. Sex-specific differences in mortality after high titre measles immunization in rural Senegal. Bull WHO 1994;72:761-770
91. Mølbak K, Wested N, Højlyng N, Scheutz F, Gottschau A, Aaby P, da Silva APJ. The etiology of early childhood diarrhoea. A community study from Guinea-Bissau. J Infect Dis 1994;169:581-587
92. Aaby P, Andersen M, Sodemann M, Jakobsen M, Gomes J, Fernandes M. Mæslingevaccination og alder. Ugeskr Læg 1994;154:5857-61
93. Lisse IM, Aaby P, Whittle H, Knudsen K, Andersen H. Long-term impact of high-titre Edmonston-Zagreb measles vaccine on T lymphocyte subsets. Pediatr Inf Dis J 1994;13:109-112
94. Mølbak K, Aaby P, Højlyng N, da Silva AP. Risk-factors for Cryptosporidium diarrhoea in early childhood: a case-control study from Guinea-Bissau, West Africa. Am J Epidemiol 1994;139:734-40
95. Aaby P, Lisse IM, Whittle H, Knudsen K, Thårup J, Poulsen A, Sodemann M, Jakobsen M, Brink L, Gansted U, Permin A, Jensen TG, Andersen H, da Silva MC. Long-term survival in trial of medium-titre Edmonston-Zagreb measles vaccine in Guinea-Bissau: Five year follow-up. Epidemiol Infect 1994;112:413-420
96. Mølbak K, Lisse IM, Højlyng N, Aaby P. Severe cryptosporidiosis in children with normal T-cell subsets. Parasit Immunol 1994;16:275-77
97. Jensen TG, Whittle H, Mordhorst CH, Pedersen IR, Thårup J, Poulsen A, Sodemann M, Jakobsen M, Brink L, Gansted U, Permin A, da Silva MC, Aaby P. Trials of Edmonston-Zagreb measles vaccine in Guinea-Bissau: Serological responses following vaccination with Edmonston-Zagreb strain at 4-8 months versus vaccination with Schwarz strain at 9-12 months of age. Vaccine 1994;12:1026-31
98. Mølbak K, Gottschau A, Aaby P, Højlyng N, Ingholt L, da Silva AP. Prolonged breastfeeding, diarrhoeal diseases, and survival of children in Guinea-Bissau. Br Med J 1994;308:1403-6
99. Lisse IM, Aaby P, Whittle H, Knudsen K. A community study of T lymphocyte subsets and malaria parasitaemia. Trans Roy Soc Trop Med Hyg 1994;88:709-710.
100. Bennett J, Aaby P, Simondon F, Samb B, Whittle H, Coll Seck AM, Markowitz J. Sex differences in measles fatality and Edmonston-Zagreb measles vaccine. Lancet 1994;344:545
101. Aaby P, Knudsen K, Simondon F, Samb B, Whittle H, Coll Seck AM, Bennett J. High-titre measles vaccines for boys. Lancet 1994;344:1226-1227

1995

102. Aaby P. Measles immunization and child survival: uncontrolled experiments. In: Rashad H, Gray R, Boerma T (eds.) Evaluation of the impact of health interventions, IUSSP, Liege: Derouaux Ordina Editions, 1995, pp 11-45
103. Samb B, Whittle H, Aaby P, Coll Seck AM, Bennett J, Markowitz L, Ngom PT, Zeller H, Michaelsen KF, Simondon F. No evidence of long-term immunosuppression after high-titre Edmonston-Zagreb measles vaccination in Senegal. JID 1995;171:506-8.
104. Aaby P, Jensen H, et al. Crowding and Health in Low-Income Settlements. Case Study Report, Bissau. Copenhagen: Cowi, 1995
105. Aaby P. Assumptions and contradictions in measles and measles immunization research: Is measles good for something? Soc Sci Med 1995;41:673-686
106. Stabell C, Balé C, da Silva AP, Olsen J, Aaby P. No evidence of fontanelle-bulging episodes after vitamin A supplementation of 6 and 9 months old infants in Guinea-Bissau.Eur J Clin Nutr 1995:49:73-4.
107. Aaby P, Samb B, Simondon F, Coll Seck AM, Knudsen K, Whittle H. Non-specific beneficial effect of measles immunisation: analysis of mortality studies from developing countries.Br Med J 1995;311:481-485
108. Desgrées du Loû A, Pison G, Aaby P. The role of immunizations in the recent decline in childhood mortality and the changes in the female/male mortality ratio in rural Senegal. Am J Epidemiol 1995;142:643-52
109. Burström B, Aaby P, Mutie DM. Validity of measles mortality data using hospital registers and community surveys.Int J Epidemiol 1995;24:625-629
110. Samb B, Aaby P, Whittle H, Coll Seck AM, Rahman S, Bennett J, Markowitz J, Simondon F. Serological status and measles attack rates among vaccinated and unvaccinated children in rural Senegal. Pediatr Inf Dis J 1995;14:203-9
111. Aaby P, Pison G, Desgrées du Loû A, Andersen M. Lower mortality for female-female twins than for male-male

and male-female twins in rural Senegal. Epidemiol 1995;6:419-422

112. Burström B, Aaby P, Mutie DM. Measles in infants: a review of studies on incidence, vaccine efficacy and mortality in East Africa. East African Med J 1995;72:155-61
113. Samb B, Simondon F, Aaby P, Whittle H, Coll Seck AM. Prophylactic use of antibiotics and reduced case fatality in measles infection. Pediatr Inf Dis J 1995;14:695-696
114. Stabell Benn C, Whittle H, Aaby P, Balé C, Michaelsen KF, Olsen J. Vitamin A and measles vaccination. Lancet 1995; 346:503-504.

1996

115. Samb B, Simondon F, Aaby P, Whittle H, Coll Seck AM. L'utilisation systématique du cotrimoxazole (Bactrim) pour prévenir les complications infectieuses de la rougeole peut-elle diminuer sa mortalité? Santé et Developpement 1996;1233:19-20 (French version of 133)
116. Aaby P, Samb B, Simondon F, Knudsen K, Coll Seck AM, Bennett J, Markowitz L, Whittle H. Five year follow-up of morbidity and mortality among recipients of high-titre measles vaccines in Senegal. Vaccine 1996; 14:226-9
117. Aaby P, Samb B, Simondon F, Coll Seck AM, Knudsen K, Whittle H. Uspecifik, gavnlig effekt af mæslingevaccination: Analyse af dødelighedsstudier fra udviklingslandene.Ugeskrift Læger 1996;158:5944-8
118. Whittle H, Aaby P. Measles. Weatherall DJ, Ledingham JGG, Warrell DA. Oxford Textbook of Medicine, 3rd edition. Oxford: Oxford University Press 1996; vol 1, pp 375-381
119. Jakobsen MS, Sodemann M, Mølbak K, Aaby P. Reason for termination of breastfeeding and the length of breastfeeding.Int J Epidemiol 1996;25:115-2
120. Knudsen KM, Aaby P, Whittle H, Rowe M, Samb B, Simondon F, Sterne J, Fine P. Child mortality following standard, medium or high titre measles immunization in West Africa. Int J Epidemiol 1996;25;665-73
121. Aaby P, Lisse I, Mølbak K, Knudsen K, Whittle H. No persistent T lymphocyte immunosuppression or increased mortality after measles infection: a community study from Guinea-Bissau. Pediatr Inf Dis J 1996;15:39-44
122. Aaby P, Samb B, Andersen M, Simondon F. No long-term excess mortality after measles infection: A community study from Senegal. Am J Epidemiol 1996; 143:1035-41
123. Ariyoshi K, Berry N, Wilkins A, Ricard D, Aaby P, Nauclér A, Ngom PT, Jobe O, Jaffar S, Dias F, Tedder RS, Whittle H. A community-based study of HIV-2 provirus load in a rural village in West Africa. JID 1996;173:245-8
124. Aaby P, Samb B, Simondon F, Knudsen K, Coll Seck AM, Bennett J, Markowitz L, Whittle H. A comparison of vaccine efficacy and mortality during routine use of high-titre Edmonston-Zagreb and Schwarz standard measles vaccines in rural Senegal. Trans Roy Soc Trop Med Hyg 1996;90:326-30
125. Sodemann M, Jakobsen M, Mølbak K, Martins C, Aaby P. Maternal perception of cause, signs and severity of diarrhoea in a suburban West African community. Acta Paediatr 1996;85:1062-9
126. Lisse IM, Poulsen AG, Aaby P, Knudsen K, Dias F. Serial CD4 and CD8 T-lymphocyte counts and associated mortality in an HIV-2 infected population in Guinea-Bissau.J AIDS & HR 1996;13:355-62
127. Aaby P. "Measles: An Historical Geography of a Major Human Viral Disease from Global Expansion to Local retreat, 1840- 1990" by Cliff A, Haggett P, Smallman-Raynor M. (Book Review) Am J Epidemiol 1996;143:1082-83.
128. Shaheen SO, Aaby P, Hall AJ, Barker DJP, Heyes CB, Shiell AW, Goudjabi A. Measles and atopy in Guinea-Bissau. Lancet 1996;347:1792-96
129. Aaby P, Andersen M, Knudsen K. Nutritional status and excess mortality following early exposure to measles. Epidemiol Infect 1996;117:525-31
130. Shaheen SO, Aaby P, Hall AJ, Barker DJP, Heyes CB, Shiell AW, Goudjabi A. Cell mediated immunity after measles in Guinea-Bissau: historical cohort study. Br Med J 1996;313:969-74
131. M¢lbak K, Lisse IM, Aaby P. T lymphocyte subsets and prolonged diarrhea in young children from Guinea-Bissau. Am J Epidemiol 1996;143:79-84.
132. Aaby P, Ariyoshi K, Buckner M, Jensen H, Berry N, Wilkins A, Richard D, Larsen O, Dias F, Melbye M, Whittle H. Age of wife as a major determinant of male-to-female transmission of HIV-2 infection. A community study from rural West Africa. AIDS 1996;10:1585-90
133. Clauson-Kaas J, Dzikus A, Stephens C, Højlyng N, Aaby P. Urban health: human settlement indicators of crowding. Third World Planning Review 1996;18:349-63
134. Clauson-Kaas J, Dzikus A, Surjadi C, Højlyng N, Baare A, Aaby P. Urban health: risk factors in crowded households. Trialog 1996;50:24-31

1997

135. Mølbak K, Andersen M, Aaby P, Højlyng N, Jakobsen M, Sodemann M, da Silva APJ. Cryptosporidium infection in infancy as a cause of malnutrition: a community study from Guinea-Bissau, West Africa. Am J Clin Nut 1997;65:149-52
136. M. Das Gupta, Aaby P, Pison G, Garenne M (eds): Prospective community studies in developing countries. Oxford University Press. Oxford: Clarendon Press 1997
137. M. Garenne, Das Gupta M, Pison G, Aaby P: Introduction.In: M. Das Gupta, Aaby P, Pison G, Garenne M (eds.): Prospective community studies in developing countries. Oxford University Press. Oxford: Clarendon Press 1997, pp 1-18

138. Aaby P. Bandim: An unplanned longitudinal study. In: M. Das Gupta, Aaby P, Pison G, Garenne M (eds): Prospective community studies in developing countries. Oxford University Press. Oxford: Clarendon Press 1997, pp 276-96
139. Sodemann M, Jakobsen M, Mølbak K, Alvarenga IC, Aaby P. High mortality despite good care seeking behaviour: a community study of childhood deaths in Guinea-Bissau. Bull WHO 1997;75:205-212
140. Samb B, Aaby P, Whittle H, Coll Seck AM, Simondon F. Decline in measles case fatality ratio after the introduction of measles immunization in rural Senegal. Am J Epidemiol 1997;145:51-7
141. Lisse I, Aaby P, Whittle H, Jensen H, Engelman M, Christensen LB.. T-lymphocyte subsets in West Africa children: Impact of age, sex, and season. J Pediatr 1997;130:77-85
142. Poulsen AG, Aaby P, Larsen O, Jensen H, Naucler A, Lisse IM, Christiansen CB, Dias F, Melbye M. 9-year HIV-2 associated mortality in an urban community in Bissau, West Africa. Lancet 1997;349;911-4
143. Kofoed PE, Mapaba E, Lopes F, Pussick F, Aaby P, Rombo L. Comparison of 3, 5, and 7 days´ treatment with Quinemax for Falciparum malaria in Guinea-Bissau. Trans Roy Soc Trop Med Hyg 1997;91:462-4
144. Mølbak K, Jakobsen M, Sodemann M, Aaby P. Is malnutrition associated with prolonged breastfeeding? Int J Epidemiol 1997;26:458-9
145. Aaby P, Poulsen AG, Larsen O, Christiansen CB, Jensen H, Melbye M, Naucler N, Digas F. Does HIV-2 protect against HIV-1?AIDS 1997;11:939-40
146. Clauson-Kaas J, Surjadi C, Højlyng N, Baare A, Dzikus A, Jensen H, Aaby P, Stephens C. Crowding and health in Low-income settlements. Kali Anyar, Jakarta. Aldershot: Avebury, 1997
147. Mølbak K, Jensen H, Ingholt L, Aaby P. Risk factors for diarrheal disease incidence in early childhood: A community cohort study from Guinea-Bissau. Am J Epidemiol 1997; 146:273-82
148. Lisse IM, Böttiger B, Christensen LB, Knudsen K, Aaby P, Gottschau A, Urassa W, Mhalu F, Biberfeld G, Brattegaard K, Diallo K, N'Gom PT, Whittle H. Evaluation of T-cell subsets by an immunocytochemical method compared to flow cytometry in four countries. Scan J Immunol 1997;45:637-44
149. Benn CS, Aaby P, Balé C, Michaelsen KF, Olsen J, George E, Whittle H. Randomised trial of effect of vitamin A supplementation on antibody response to measles vaccine in Guinea-Bissau, West Africa. Lancet 1997;350:101-5
150. Norrgren H, Marquina S, Leitner T, Aaby P, Melbye M, Poulsen AG, Larsen O, Dias F, Escanilla D, Andersson S, Albert J, Nauclér A. HIV-2 genetic variation and DNA load in asymptomatic carriers and AIDS cases in Guinea-Bissau. J AIDS 1997;16:31-38
151. Atabani SF, Obeid OE, Chargelegue D, Aaby P, Whittle H, Steward MW. Identification of an immunodominant neutralizing and protective epitope from measles virus fusion protein by using human sera from acute infection. J Virol 1997;71:7240-5
152. Morley DC, Aaby P. Managing measles: Size of infecting dose may be important. Br Med J 997;314:1692
153. AAby P, Babiker A, Darbyshire J, Nunn A, Barreto S, Alonso P, Badero R, et al. Ethics of HIV trials.Lancet 1997;350:1546
154. Holmgren B, Aaby P. Does HIV-2 infection provide natural protection against HIV-1? SidAfrique 1997;11-12:32-33

1998

155. Basu AM, Aaby P: Introduction: Approaches to Anthropological DemographyIn: AM Basu, P Aaby (eds): The Methods and Uses of Anthropological Demography. Oxford: Oxford University Press, 1998:1-21
156. AM Basu, P Aaby (eds): The Methods and Uses of Anthropological Demography. Oxford: Oxford University Press, 1998:1-322
157. Aaby P. Are men weaker or do their sisters talk too much? In: AM Basu, P Aaby (eds): The Methods and Uses of Anthropological Demography. Oxford: Oxford University Press, 1998:223-245
158. Pison G, Aaby P. Pourquoi la rougeole tue encore en Afrique. Pour la Science 1998; Avril:40-47
159. Melbye M, Poulsen AG, Gallo D, Pedersen JB, Biggar RJ, Larsen O, Dias F, Aaby P. HTLV-1 infection in a population-based cohort of older persons in Guinea-Bissau, West Africa: Risk factors and impact on survival. Int J Cancer 1998;76:293-98
160. Lisse I, Samb B, Whittle B, Jensen H, Soumaré M, Simondon F, Aaby P. Acute and long-term changes in T-lymphocyte subsets in response to clinical and subclinical measles. A community study from rural Senegal. Scand J Inf Dis 1998;30:17-21
161. Nielsen LLW, Nielsen NM, Melbye M, Sodemann M, Jacobsen M, Aaby P. In-utero measles exposure and Crohn's Disease. A Danish Register study. Br Med J 1998;316:196-7
162. Larsen O, da Silva Z, Sandström A, Andersen PK, Andersson S, Poulsen AG, Melbye M, Dias F, Nauclér A, Aaby P. Declining HIV-2 prevalence and incidence among men in a community study from Guinea-Bissau.AIDS 1998; 12:1707-14
163. Grassly NC, Xiang Z, Ariyoshi K, Aaby P, Jensen H, van der Loeff MS, Dias F, Whittle H, Breuer J. Mortality among Human Immunodeficiency Virus Type 2-positive villagers in rural Guinea-Bissau is correlated with viral genotype. J Virol 1998;72:7895-99
164. Aaby P, Martins C, Balé C, Lisse I. Assessing measles vaccination coverage by maternal recall in Guinea-Bissau. Lancet 1998;352:1229
165. Cissé B, Simondon F, Aaby P. Rougeole. Delaunay V (ed). La situation démographique et épidémiologigique dans la zone de Niakhar au Sénégal 1984-1996. Dakar, ORSTOM 1998, pp 91-96

1999

166. Sodemann M, Jakobsen M, Mølbak K, Martins C, Aaby P. Management of childhood diarrhoea and use of ORS in a sub-urban West African community. Am J Trop Med Hyg 1999;60:167-71
167. Høj L, Stensballe J, Aaby P. Maternal mortality in Guinea-Bissau: the use of verbal autopsy in a multi-ethnic population.Int J Epidemiol 1999;28:70-76
168. Jakobsen MS, Sodemann M, Mølbak K, Alvarenga I, Aaby P. Promoting breastfeeding through health education at the time of immunizations: a randomized trial from Guinea-Bissau. Acta Paediatr 1999; 88:741-7
169. Garly ML, Martins CL, Balé C, da Costa F, Dias F, Whittle H, Aaby P. Early two-dose measles vaccination schedule in Guinea-Bissau: Good protection and coverage in infancy. Int J Epidemiol 1999; 28:347-52
170. Bennett J, Whittle H, Samb B, Cisse B, Simondon F, Aaby P. Seroconversions in unvaccinated infants: further evidence for subclinical measles from vaccine trials in Niakhar, Senegal. Int J Epidemiol 1999;28:147-51
171. Whittle H, Aaby P, Samb B, Cisse B, Kanteh F, Soumaré M, Jensen H, Bennett J, Simondon F. Serological responses 5-7 years after immunization with high titre measles vaccines in early infancy. Pediatr Inf Dis J 1999;18:53-57
172. Whittle H, Aaby P, Samb B, Jensen H, Bennett J, Simondon F. Effect of sub-clinical infection on maintaining immunity against measles in vaccinated children in West Africa. Lancet 1999;353:98-101
173. Seng R, Samb B, Simondon F, Cisse B, Soumaré M, Jensen H, Bennett J, Whittle H, Aaby P. Increased long-term mortality associated with rash after early measles vaccination in rural Senegal. Pediatr Inf Dis J 1999;18:48-52
174. Cisse B, Aaby P, Simondon F, Samb B, Soumaré M, Whittle H. Role of schools in the transmission of measles in rural Senegal: Implications for measles control in developing countries. Am J Epidemiol 1999;149:295-301
175. Sodemann M, Jakobsen M, Mølbak K, Alvarenga IC, Martins C, Aaby P. Malaria parasitaemia and childhood diarrhoea in a peri-urban area of Guinea-Bissau. Am J Hyg Trop Med 1999;61:336-8
176. Read AF, Aaby P, Antia R, Ebert D, Ewald PW, Gupta S, Holmes EC, Sasaki A, Shields D, Taddei F, Moxon R. What can evolutionary biology contribute to understanding virulence? IN: Stearns S (ed): Evolution in Health and disease. Oxford University Press 1999:205-215
177. Aaby P. Forskning i International Sundhed: Lokal forankring og internationale konsekvenser eller omvendt. In: Andersen D, Havsteen B, Riis P, Almind G, Bock E, Hørder M(eds): Sundhedsvidenskabelig Forskning. 5. Udgave. København: FADL, 1999, pp 645-59
178. Aaby P, Cisse B, Simondon F, Samb B, Soumaré M, Bennett J, Whittle H. Waning of vaccine-induced immunity: Is it a problem in Africa? Am J Epidemiol 1999;149:304-5
179. Sodemann M, Jakobsen M, Mølbak K, Martins C, Aaby P. Episode specific risk factors for progression of acute diarrhoea to persistent diarrhoea in West African children. Trans R Soc Trop Med Hyg 1999;93;65-68
180. Schim van der Loeff MF, Aaby P. Towards a better understanding of the epidemiology of HIV-2. AIDS 1999;13 (suppl A):S69-S84
181. Valentiner-Branth P, Steinsland H, Gjessing HK, Santos G, Bhan MK, Dias F, Aaby P, Sommerfelt H, Mølbak K. Community-based randomized controlled trial of reduced osmolarity oral rehydration solution in acute childhood diarrhea.Pediatr Infect Dis J 1999;18:789-96
182. Jensen AKV, Pedersen C, Westergaard T, Jensen IP, Lebech M, Andersen PK, Aaby P, Pedersen BN, Melbye M. Risk factors for Parvovirus B19 infection in pregnancy .JAMA 1999;281:1099-1105
183. Kofoed PE, Lopes F, Johansson P, Dias F, Sandström A, Aaby P, Rombo L. Low dose quinine for treatment of Plasmodium falciparum in Guinea-Bissau. Trans Roy Soc Trop Med Hyg 1999;93:547-9
184. Aaby P, Gomes J, Fernandes M, Djana Q, Lisse I, Jensen H. Nutritional status and mortality of refugee and resident children in a non-camp setting during conflict: follow up study in Guinea-Bissau. BMJ 1999;319:878-81
185. Lyamuya EF, Matee MIN, Aaby P, Scheutz F. Serum levels of measles IgG antibody activity in children under five years in Dar Es Salaam, Tanzania. Ann Trop Pediatr 1999;19:175-83
186. Marchant A, Goetghebuer T, Ota M, Wolfe I, Ceesay S, De Groote D, Corrah T, Bennett S, Wheeler J, Huygen K, Aaby P, McAdam K, Newport M. Newborns develop a Th1-type immune response to Mycobacterium Bovis Bacillus Calmette-Guérin vaccination.J Immunol 1999;163:2249-2255
187. Holmgren B, Aaby P, Jensen H, Larsen O, da Silva Z, Lisse I. Increased prevalence of retrovirus infections among older women in Africa.Scan J Inf Dis 1999;31:459-66

2000

188. Stensballe LG, Kofoed PE, Nante JE, Sambo M, Jensen IP, Aaby P. Duration of secretory IgM and IgA antibodies to respiratory syncytial virus in a community study in Guinea-Bissau. Acta Pediatr 2000;89:421-6
189. Whittle H, Aaby P. Measles. In: Ledingham JGG, Warrell DA. Concise Oxford Textbook of Medicine, 3rd edition. Oxford: Oxford University Press 2000;1517-21
190. Aaby P, Shaheen S, Heyes C, Goudiaby A, Shiell A, Jensen H, Marchant A. Early Bcg vaccination and reduction in atopy in Guinea-Bissau. Clin Exp Allergy 2000;30:644-50
191. Larsen O, Andersson S, da Silva Z, Hedegaard K, Sandström A, Nauclér A, Dias F, Melbye M, Aaby P. Prevalences of HTLV-1 infection and associated risk determinants in an urban population in Guinea-Bissau, West Africa. J AIDS 2000;25:157-63
192. Poulsen AG, Aaby P, Jensen H, Dias F. Risk factors for HIV-2 seropositivity among older people in Guinea-Bissau. A search for the early history of HIV-2 infection.Scan J Inf Dis 2000;32:169-75

193. Shann F, Aaby P. Measles immunisation and confounding. BMJ. http://www.bmj.com/cgi/eletters/319/7201/4#EL7
194. Fischer T, Steinsland H, Mølbak K, Ca R, Gentsch JR, Valentiner-Branth P, Aaby P, Sommerfeldt H. Genotype profiles of rotavirus strains from children in a suburban community in Guinea-Bissau, Western Africa.J Clin Microbiol 2000;38: 264-7
195. Kristensen I, Aaby P, Jensen H. Routine vaccinations and child survival: follow up study in Guinea-Bissau, West Africa. Br Med J 2000;321:1435-8
196. Rodrigues A, Sandström A, Cá T, Steinsland H, Jensen H, Aaby P. Protection from cholera by adding lime juice to food - results from community and laboratory studies in Guinea-Bissau, West Africa Trop Med Int Health 2000;5:418-22
197. Nielsen NM, Wohlfahrt J, Melbye M, Rasmussen S, Mølbak K, Askgaard DS, Aaby P. Multiple sclerosis and poliomyelitis. A Danish historical cohort study. Acta Neurol Scand 2000;101:384-7
198. Shann F, Aaby P. Unexpected beneficial effects of measles immunisation. BMJ 2000;320:938-40
199. Dahlsgaard A, Forslund A, Petersen A, Brown DJ, Dias F, Monteiro S, Mølbak K, Aaby P, Rodrigues A, Sandström A. Class 1 integron-borne, multiple-antibiotic resistsnace encoded by a 150-kb conjugative plasmid in epidemic Vibrio cholerae O1 strains isolated in Guinea-Bissau. J Clin Microbiol 2000:3774-79
200. Benn CS, Lisse IM, Balé C, Michaelsen KF, Olsen J, Hedegaard K, Aaby P. No long-term effect of vitamin A supplementation in infancy on CD4 and CD8 T-cell subsets. A community study from Guinea-Bissau. Ann Trop Pediatr 2000;20:259-64

2001

201. Valentiner-Branth P, Steinsland H, Santos G, Perch M, Begstrup K, Bhan MK, Dias F, Aaby P, Sommerfelt H, Mølbak K. Community-based controlled trial of dietary management of children with persistent diarrhea: sustained beneficial effect on ponderal and linear growth. Am J Clin Nut 2001;73:968-74
202. Nielsen NM, Aaby P, Wohlfahrt J, Pedersen JB, Melbye M, Mølbak K. Intensive exposure as a risk factor for severe polio: A study of multiple family cases. Scan J Inf Dis 2001;33:301-5
203. Garly ML, Balé C, Martins C, Monteiro M, George E, Kidd M, Dias F, Aaby P, Whittle H.. Measles antibody responses after early two dose trials in Guinea-Bissau with Edmonston-Zagreb and Schwarz standard-titre measles vaccine: better antibody increase from booster dose of the Edmonston-Zagreb vaccine. Vaccine 2001;19:1951-9
204. Nielsen NM, Wohlfahrt J, Aaby P, Hjalgrim H, Pedersen CB, Askgaard DS, Melbye M. Cancer risk in a cohort of polio patients. Int J Cancer 2001;92:605-8
205. Benn CS, Jeppesen DL, Hasselbalch H, Olesen AB, Nielsen J, Björkstén B, Lisse I, Aaby P. Thymic size and head circumference at birth and the development of allergic diseases. Clin Exp Allergy 2001;31:1862-66
206. Aaby P, Jensen H. Routine vaccination and child survival in Guinea-Bissau. Authors' reply to Commentary. BMJ 2001;322:360
207. Aaby P, Jensen H. Non-specific effects of vaccinations: lacking gradient, strength, and coherence? Bmj.com (www.bmj.com/cgi/eletters/321/7274/1435#EL19
208. Aaby P, Jensen H. Response to WHO. Bmj.com (www.bmj.com/cgi/eletters/321/7274/1435#EL19
209. Aaby P, Jensen H. Authors' response. Bmj.com (www.bmj.com/cgi/eletters/321/7274/1435#EL19
210. Aaby P, Jensen H. Routine vaccination and child survival in Guinea-Bissau. Authors' reply. BMJ 2001;322:360
211. Gustafson P, Gomes VF, Vieira CS, Seng R, Samb B, Nauclér A, Aaby P. Tuberculosis mortality during a civil war in Guinea-Bissau. JAMA 2001;286:599-603
212. Benn CB, Bager P, Lisse I, Jensen H, Aaby P. Measles and atopy - rash on rash? Allergy 2001;56:800-1
213. Perch M, Sodemann M, Jakobsen M, Valentiner-Branth P, Steinsland H, Fischer TK, Lopes DD, Aaby P, Mølbak K. Seven years' experience with Cryptosporidium parvum in Guinea-Bissau, West Africa. Ann Trop Pediatr 2001;21:313-18
214. Schim van der Loeff MF, Aaby P, Aryioshi K, Vincent T, Awasana AA, da Costa C, Penbrey L, Dias F, Harding E, Weiss HA, Whittle HC. HIV-2 does not protect against HIV-1 infection in a rural community in Guinea-Bissau. AIDS 2001;15:2303-10
215. Garly ML, Balé C, Martins CL, Baldé MA, Hedegaard KL, Whittle H, Aaby P. BCG vaccination among West African infants is associated with less anergy to tuberculin and diptheria-tetanus antigens. Vaccine 2001;20:468-74
216. Nielsen NM, Hedegaard K, Aaby P. Intensity of exposure and severity of whooping cough. J Infect 2001;43:177-81
217. Aaby P, Whittle H, Cisse B, Jensen H, Samb B, Simondon F. The frailty hypothesis revisited: mainly weak children die of measles: Vaccine 2002; 20: 949-53
218. Olsen J, Melbye M, Olsen SF, Sørensen TIA, Aaby P, Andersen AMN, Taxbøl D, Hansen KD, Juhl M, Schow TB, Sørensen HT, Andresen J, Mortensen EL, Olsen AW, Søndergaard C. The Danish National Birth Cohort – its background, structure and aim. Scan J Pub Health 2001;29:300-7

2002

219. Benn CS, Balde A, George E, Kidd M, Whittle H, Lisse IM, Aaby P. Effect of vitamin A supplementation on measles-specific antibody levels in Guinea-Bissau. Lancet 2002;359:1313-14

220. Nielsen NM, Wohlfahrt J, Melbye M, Mølbak K, Aaby P.. Does cross-sex transmission increase severity of polio infection? A study of multiple family cases. Scand J Infect Dis 2002;34:273-77
221. Kofoed PE, Cabral F, Poulsen A, Cabral C, Hedegaard KL, Aaby P, Rombo L. Treatment of Plasmodium falciparum malaria with quinine in children in Guinea-Bissau: one daily dose is sufficient. Trans Roy Soc Trop Med Hyg 2002;96:185-88
222. Nielsen NM, Aaby P, Wohlfahrt J, Mølbak K, Melbye M. The Polio Model. Does it apply to polio? Int J Epidemiol 2002;31:181-186
223. Sodemann M, Jensen H, Rodrigues A, Ca T, Aaby P. Bandim DSS, Guinea-Bissau. Population and health in developing countries. In Indepth Network (ed): Vol I: Population, health, and survival at Indepth Sites. Ottawa: International Development Research Centre. 2002; pp 257-62.
224. Nielsen NM, Rostgaard K, Hjalgrim H, Askgaard D, Aaby P. Poliomyelitis and Parkinson's disease. JAMA 2002;287:1650-51
225. Jakobsen M, Kæstel P, Ca T, Rodrigues A, Aaby P. Sexual habits and behaviour among adolescents in Bissau – results from a study of reproductive health. FNUAP, Bissau 2002
226. Holmgren B, Andersson S, Schimm van der Loeff M, Aaby P, Ariyoshi K, Whittle H. Increased prevalence of HTLV-1 among HIV-2 infected women but not HIV-2 infected men in rural Guinea-Bissau. J AIDS 2002;30:342-50
227. Ota M, Vekemans J, Schlegel S, Fielding K, Kidd M, Newport M, Aaby P, Whittle H, Lambert PH, McAdam K, Siegrist CA, Marchant A. Neonatal immunisation with Mycobacterium bovis bacillus Calmette-Guérin promotes immune responses to unrelated vaccine antigens. J Immunol 2002;168:919-25
228. Aaby P, Marx C, Trautner S, Rudaa D, Hasselbalch H, Jensen H, Lisse IM. Thymus size at birth is associated with infant mortality: A community study from Guinea-Bissau. Acta Pediatr 2002:91:698-703
229. Eugen-Olsen J, Gustafson P, Sidenius N, Fischer TK, Parner J, Aaby P, Gomes VF, Lisse IM. The serum level of soluble urokinase receptor is elevated in tuberculosis patients and predicts mortality during treatment. A community stydu from Guinea-Bissau. Int J Tuberc Lung Dis 2002;6:686-92
230. Stensballe LG, Trautner S, Kofoed PE, Nante E, Hedegaard K, Jensen IP, Aaby P. Comparison of nasopharyngeal aspirate and nasal swab specimens for detection of respiratory syncytial virus in different settings in a developing country. Trop Med Internat Health 2002; 7: 317-21
231. Fischer TK, Valentiner-Branth P, Steinsland H, Perch M, Santos G, Aaby P, Mølbak K, Sommerfelt H Protective immunity after natural rotavirus infection. A community cohort study of newborn children in Guinea-Bissau, West Africa. JID 2002;186:593-7
232. Kofoed PE, Co F, Johansson P, Dias F, Cabral C, Hedegaard K, Aaby P, Rombo L. Treatment of uncomplicated malaria in children in Guinea-Bissau with chloroquine, quinine, and sulfadoxine-pyrimethamine. Trans Roy Soc Hyg Trop Med 2002:96:304-9
233. Høj L, da Silva D, Hedegaard K, Sandström A, Aaby P. Factors associated with maternal mortality in rural Guinea-Bissau. A longitudinal population-based study. Br J Obst Gynaecol 2002;109:792-99.
234. Kofoed PE, Lopes F,Johansson P, Sandström A, Hedegaard KL, Aaby P, Rombo L. Treatment of children with malaria with chloroquine in Guinea-Bissau. Am J Trop Med Hyg 2002;67:28-31
235. Aaby P, Samb B, Simondon F, Cisse B, Jensen H, Lisse IM, Soumaré M, Whittle H. Low mortality after mild **measles infection compared to uninfected children in rural west Africa. Vaccine 2002;21:120-6**
236. Aaby P, Jensen H, Garly ML, Balé C, Martins C, Lisse I. Routine vaccinations and child survival in war situation with high mortality: Effect of gender. Vaccine 2002;21:15-20
237. Aaby P, Jensen H. Routine vaccinations and child survival: effect of gender. BMJ 13 Dec 2002; bmj.com/cgi/eletters/321/7274/1435#27803
238. Quinlivan M, Hawrani K, Barrett-Muir W, Aaby P, Arvin A, Chow V, John J, Matondo P, Peiris M, Poulsen A, Siqueira M, Takashi M, Talukder Y, Yamanishi K, Breuer J: The molecular epidemiology of varicella zoster virus: evidence for geographical segregation. JID 2002;186:888-894
239. Poulsen A, Quereshi K, Lisse I, Kofoed PE, Nielsen J, Vestergaard BF, Aaby P: A household study of chickenpox in Guinea-Bissau: Intensity of exposure is a determinant of severity. J Infection 2002;45:237-42
240. Steinsland H, Valentiner-Branth P, Perch M, Dias F, Fischer TK, Aaby P, Mølbak K, Sommerfelt H. Enterotoxigenic Escherichia coli infections and diarrhea in a cohort of young children in Guinea-Bissau. J Infect Dis 2002;186:1740-7
241. Berry N, Jaffar S, Schim van der Loeff M, Ariyoshi K, Harding E, N´Gom PT, Dias F, Wilkins A, Ricard D, Aaby P, Tedder R, Whittle H. Low level viraemia and prolonged survival of HIV-2 infected villagers in rural Guinea-Bissau. AIDS Research & Hum Retrovir 18: 1167-73
242. Benn CS, Balde MA, Lisse IM, Aaby P. Effect of vitamin A supplementation in infancy on development of atopy in Guinea-Bissau, West Africa. J Nutr 2002;132(9S):54

2003

243. Garly ML, Aaby P. The challenge of improving the efficacy of measles vaccine. Acta Trop 2003;85:1-17
244. Jakobsen MS, Sodemann S, Mølbak K, Alvarenga IJ, Nielsen J, Aaby P. Termination of breastfeeding after 12 months of age due to a new pregnancy and other causes is associated with increased mortality in Guinea-Bissau. Int J Epidemiol 2003;32:92-6

245. Aaby P, Bhuyia A, Nahar L, Knudsen K, Francisco A, Strong M. The survival benefit of measles immunisation may not be explained entirely by the prevention of measles disease. Int J Epidemiol 2003;32: 106-115
246. Holmgren B, da Silva Z, Larsen O, Vastrup P, Andersson S, Aaby P. Dual infections of HIV-1, HIV-2, and HTLV-I are more common in older women than men in Guinea-Bissau. AIDS 2003;17:241-53
247. Marret-Muir W, Scott FT, Aaby P, John J, Matando P, Chaudhry QL, Siqueira M, Poulsen A, Yaminishi K, Breuer J: Genetic Variation of Varicella-Zoster Virus: Evidence for Geographical Separation of Strains. J Med Vir 2003, 70:S42-S47.
248. Garly ML, Martins CL, Balé C, Baldé MA, Hedegaard KL, Gustafson P, Lisse IM, Whittle HC, Aaby P. BCG scar and positive tuberculin reaction associated with reduced child mortality: A non-specific beneficial effect of BCG? Vaccine 2003;21:2782-90
249. Aaby P, Garly ML, Balé C, Martins C, Jensen H, Lisse IM, Whittle H. Survival of previously measles-vaccinated and measles-unvaccinated children in an emergency situation: An unplanned study. PIDJ 2003;22:798-805
250. Bager P, Westergaard T, Rostgaard K, Nielsen NM, Melbye M, Aaby P. Smallpox vaccination and risk of atopy and asthma. J Allergy Clin Immunol 2003;111:1227-31
251. Aaby P, Jensen H, Simondon F, Whittle H. High-titre measles vaccination before 9 months of age and increased female mortality: Do we have an explanation? Seminars in Pediatric Infectious Diseases 2003;14: 220-32
252. Kofoed PE, Lopes F, Aaby P, Hedegaard K Rombo L CAN MOTHERS BE TRUSTED IN GIVING MALARIAL TREATMENT TO THEIR CHILDREN AT HOME? Acta Tropica 2003;86:67-70
253. Aaby P,Jensen H, Samb B, Cisse B, Sodeman M, Jakobsen M, Poulsen A, Rodrigues A, Lisse IM, Simondon F, Whittle H. Differences in female-male mortality after high-titre measles vaccine and association with subsequent vaccination with diphtheria-tetanus-pertussis and inactivated poliovirus: reanalysis of West African studies. Lancet 2003;361: 2183-88
254. Nielsen NM, Petersen KR, Juel K, Askgaard D, Aaby P. Long-term mortality following hospitalisation for poliomyelitis: A Danish cohort study. Epidemiology 2003;14:355-60
255. Steinsland H, Valentiner-Branth P, Gjessing HK, Aaby P, Mølbak K, Sommerfelt H. Protection from natural infections with enterotoxigenic Esherichia coli: longitudinal study. Lancet 2003; 362: 286-91.
256. Valentiner-Branth P, Steinsland H, Fischer TK, Perch M, Scheutz F, Dias F, Aaby P, Mølbak K, Sommerfelt H. Cohort study of Guinean Children: incidence, pathogenicity, conferred protection, and attributable risk for enteropathogens in the first 2 years of life. J Clin Microbiol 2003; 41: 4238-45
257. Aaby P, Jensen H, Whittle H. High-titre measles vaccine and female mortality. Lancet 2003;362: 1765
258. Lagarde E, Schim M, Enel C, Holmgren B, Spira, Pison G, Piau, Delaunay V, Mboup, Ndoye, Coeuret-Pellicier M, Whittle H, Aaby P. Mobility and the spread of human immunodeficiency virus into rural areas of West Africa. Int J Epidemiol 2003;32: 744-52
259. Jakobsen MS, Nylén G, Balé C, Martins C, Nielsen J, Sodemann M, Lisse IM, Aaby P. Breastfeeding status as a long-term predictor of mortality among refugee children in an emergency in Guinea-Bissau. Int Hlth Trop Med 2003;8:992-6
260. Campbell SJ, Sabeti P, Fielding K, Sillah J, Bah B, Gustafson P, Manneh K, Lisse I, Sirugo G, Bellamy R, Bennett S, Aaby P, McAdam KPWJ, Lienhardt C, Hill AVS. Variants of the CD40 ligand gene are not associated with increased susceptibility to tuberculosis in West Africa. Immunogenetics 2003:55:502-7
261. Benn CS, Bale C, Sommerfelt H, Friis H, Aaby P. Vitamin A supplementation and childhood mortality: Amplification of the non-specific effects of vaccines? Int J Epidemiol 2003:32: 822-8
262. Sodemann M, Aaby P. Bandim Health Project 1978-2003: Improving child health? Århus: Bandim Health Project, 2003
263. Høj L, da Silva D, Hedegaard K, Sandström A, Aaby P. Maternal mortality: Only 42 days? Br J Obstet Gynaecol 2003;110:995-1000
264. Ariyoshi K, Berry N, Cham F, Jaffar S, Schim van der Loeff M, Jobe O, N´Gom PT, Larsen O, Andersson S, Aaby P, Whittle H. Quantification of Human T-Lymphotropic Virus Type (HTLV-1) proviral load in rural West Africa population: no enhancement of Human Immunodeficiency Virus Type-2 pathogenesis but HTLV-1 proviral load relates to mortality. JID 2003;188:1648-51

2004

265. Kofoed PE, Rodrigues A, Co F, Hedegaard K, Rombo L, Aaby P. Which children come to the health centre for treatment of malaria. Acta Tropica 2004;90:17-22
266. Aaby P. Vet vi vad vi gör när vi vaccinerar? Läkartidningen 2004;101:294-7
267. Kofoed PE. Poulsen A, Co F, Hedegaard K, Aaby P, Rombo L. No benefit from combining chloroquine with artesunate for three days for treatment of Plasmodium falciparum in Guinea-Bissau. Trans Roy Soc Trop Med Hyg 2003; 97:429-33
268. Aaby P, Jensen H, Rodrigues A, Garly ML, Benn CS, Lisse IM, Simondon F. Divergent female-male mortality ratios associated with different routine vaccinations among female-male twin pairs. Int J Epidemiol 2004;33:367-73
269. Aaby P, Jensen H, Gomes J, Fernandes M, Lisse IM. The introduction of diphtheria-tetanus-pertussis vaccine and child mortality in rural Guinea-Bissau: An observational study. Int J Epidemiol 2004,33:374-80
270. Aaby P, Rodrigues A, Biai S, Martins C, Veirum JE, Benn CS, Jensen H. Oral polio vaccination and low case

fatality at the paediatric ward in Bissau, Guinea-Bissau. Vaccine 2004;22:3014-7

271. Simondon KB, Elguero E, Marra A, Diallo A, Aaby P, Simondon F. Season of birth is not associated with risk of early adult death in rural Senegal. Int J Epidemiol 2004;33:130-6
272. Nielsen NM, Rostgaard K, Askgaard D, Skinhøj O, Aaby P. Life long morbidity among Danes poliomyelitis. Arch Phys Med Rehabil 2004;85:385-91
273. Masmas T, Jensen H, da Silva D, Co A, Høj L, Sandström A, Aaby A. Survival among motherless children in rural and urban in Guinea-Bissau. Acta Paediatr 2004;93:99-105
274. Masmas TN, Jensen H, da Silva D, Høj L, Sandström A, Aaby P. The social situation of motherless children in rural and urban areas in Guinea-Bissau. Soc Sci Med 2004;59:1231-9
275. Gustafson P, Gomes VF, Vieira CS, Rabna P, Seng R, Johansson P, Sandström A, Norberg R, Lisse IM, Samb B, Aaby P, Nauclér A. Tuberculosis in Bissau: Incidence and risk actors in an urban community in sub-Saharan Africa. Int J Epidemiol 2004;33:163-72
276. Aaby P. Uses of error: Being wrong in the right direction? Lancet 2004;364:984
277. Sodemann M, Veirum J, Biai S, Nielsen J, Bale C, Jakobsen MS, Gustafson P, Aaby P. Reduced case fatality among hospitalised children during a war in Guinea-Bissau: a lesson in equity. Acta Pædiatr 2004;93:959-64
278. Benn CS, Melbye M, Wohlfahrt J, Björkstén B, Aaby P. Cohort study of sibling effect, infectious diseases, and risk of atopic dermatitis during the first 18 months of life. BMJ 2004;1223-7
279. Lizeng Q, Nilsson C, Sourial S, Andersson S, Larsen O, Aaby P, Ehnlund M, Björling E. Potent neutralizing serum immunoglobulin A (igA) in human immunodefiency virus type-2-exposed IgG-seronegative individuals. J Virol 2004;78:7016-22
280. Benn CS, Wohlfahrt J, Aaby P, Westergaard T, Benfeldt E, Michaelsen KF, Björkstén B, Melbye M. Breastfeeding and Risk of Atopic Dermatitis During The First 18 Months of Life by Parental History of Allergy. Am J Epidemiol 2004;160:217-23
281. Roth A, Jensen H, Garly ML, Djana Q, Martins CL, Sodemann M, Rodrigues A, Aaby P. Should low birth weight infants receive BCG vaccination at birth? Community study from Guinea-Bissau PIDJ 2004;23:544-50
282. Stensballe L, Poulsen A, Nante E, Jensen IP, Kofoed PE, Jensen H, Aaby P. Mothers may transmit RSV infection more easily or severely to sons than daughters: Community study from Guinea-Bissau. Scan J Inf Dis 2004;36:291-5
283. Nielsen J, Valentiner-Branth P, Martins C, Cabral F, Aaby P. Malnourished children and supplementary feeding during war-emergency in Guinea-Bissau 1998-99. Am J Clin Nut 2004; 80:1036-42
284. Steinsland H, Valentiner-Branth P, Aaby P, Mølbak K, Sommerfelt H. Clonal relatedness of enterotoxigenic Escherichia coli strains isolated from a cohort of young children in Guinea-Bissau. JCM 2004;42:3100-7
285. Newport MJ, Goetghebuer T, Weiss HA, The MRC Gambia Twin Study Group, Whittle H, Siegrist C-A, Marchant A. Genetic regulation of immune responses to vaccines in early life. Genes and Immunity 2004:1-8
286. Garly ML, Jensen H, Martins CL, Balé C, Balde MA, Lisse IM, Aaby P Hepatitis B vaccination associated with higher female than male mortality in Guinea-Bissau: an observational study. Pediatr Infect Dis J 2004;23:1086-92
287. Bornmann L, Campbell SJ, Fielding K, Bah B, Sillah J, Gustafson P, Manneh K, Lisse I, Allen A, Sirugo G, Sylla A, Aaby P, McAdam KPWJ, Bah-Sow O, Bennett S, Lienhardt C, Hill AVS. Vitamin D receptor polymorphisms and susceptibility to tuberculosis in West Africa: a case-control and family study. JID 2004;190:1631-41
288. Perch M, Kofoed PE, Fischer TK, Co F, Rombo L, Aaby P, Eugen-Olsen J. Serum levela of soluble urokinase plasminogen activator receptor is associated with parasitaemia in children with acute Plasmodium falciparum malaria infection. Parasite Immunol 2004;26:207-11
289. Jensen H., Brookmeyer R., Aaby P., Andersen PK. Shared Frailty Model for Left-Truncated Multivariate Survival Data. Research Report 2, 2004, Department of Biostatistics, University of Copenhagen, Denmark.
290. Steinsland H, Valentiner-Branth P, Gjessing HK, Aaby P, Sommerfelt H, Mølbak K. Beskyttelse mod infektioner med enterotoksigene Escherichia coli. Ugeskr Læg 2004;166:4051-3
291. Aaby P, Benn CS, Lisse IM, Jensen H. Replicating findings from Guinea-Bissau? BMJ, Rapid responses, November 25, 2004
292. Jensen H, Benn CS, Lisse IM, Aaby P. Non-specific beneficial effects of vaccinations in Burkina Faso: Survival bias? BMJ, Rapid responses, November 25, 2004
293. Aaby P, Benn CS, Lisse IM, Jensen H. Sex-differential "non-effects" of vaccination. BMJ, Rapid responses, December 21, 2004

2005

294. Aaby P, Jensen H. Commentary: Contrary findings from Guinea-Bissau and Papua New Guinea. Int J Epidemiol 2005;34:149-151
295. Lisse IM, Qureshi K, Poulsen A, Kofoed PE, Nielsen J, Vestergaard BF, Aaby P. T-lymphocyte subsets and eosinophil counts in acute and convalescent chickenpox infection: A household study in Guinea-Bissau. J Infection 2005;50:125-9
296. Veirum JE, Sodemann M, Biai S, Jakobsen M, Hedegaard K, Jensen H, Aaby P. Routine vaccinations associated with divergent effects on female and male mortality at the paediatric ward in Bissau, Guinea-Bissau.

Vaccine 2005;23:1197-1204
297. Aaby P, Hedegaard K, Sodemann M, Nhante E, Veirum JE, Jakobsen M, Lisse IM, Jensen H, Sandström A. Childhood mortality after oral polio immunisation campaign in Guinea-Bissau: Vaccine 2005;23:1746-1751
298. Aaby P, Rodrigues A, Biai S, Martins C, Veirum JE, Benn CB, Jensen H. Vaccines and unexpected observations: Flaws or cause for concern? Vaccine 2005;23:2407-8
299. Aaby P, Jensen H. Do measles vaccines have non-specific beneficial effects on mortality. Bull WHO 2005;83:238
300. Poulsen A, Cabral F, Lisse I, Nielsen J, Vestergaard BF, Aaby P. Varicella Zoster in Guinea-Bissau: Intensity of exposure and severity of infection. PIDJ 2005;24:102-7
301. Whittle H, Aaby P. Measles. Weatherall DJ, Ledingham JGG, Warrell DA. Oxford Textbook of Medicine, 4th edition. Oxford: Oxford University Press 2003
302. Roth A, Gustafson P, Nhaga A, Djana Q, Poulsen A, Garly ML, Jensen H, Sodemann M, Rodriques A, Aaby P. BCG-vaccination scar associated with better childhood survival in Guinea-Bissau. Int J Epidemiol 2005;34:540-7
303. Stensballe LG, Nante E, Jensen IP, Kofoed P-E, Poulsen A, Jensen H, Newport M, Marchant A, Aaby P. Acute lower respiratory tract infections and respiratory syncytial virus in infants in Guinea-Bissau: A beneficial effect of BCG vaccination for girls. Vaccine 2005;23:1251-7
304. Poulsen A, Cabral F, Nielsen J, Roth A, Lisse I, Aaby P. Growth, morbidity and mortality after chickenpox infection in young children in Guinea-Bissau. J Infect 2005; 51:307-313.
305. Roth A, Sodemann M, Jensen H, Poulsen A, Gustafson P, Gomes J, Djana Q, Jakobsen M, Garly ML, Rodriques A, Aaby P. Vaccination technique, PPD reaction and BCG scarring in a cohort of children born in Guinea Bissau 2000 – 2002. Vaccine 2005;23:3991-8
306. Nielsen J, Benn CB, Martins C, Bale C, Aaby P. Effect of a vitamin A intervention during an emergency situation. Guinea-Bissau 1998-99. Acta Tropica 2005;93:275-82
307. Jensen H, Benn CS, Nielsen J, Lisse IM, Rodrigues A, Aaby P. Diphtheria-tetanus-pertussis vaccination in low income countries: improved child survival or survival bias? BMJ Rapid Responses February 16, 2005; http://bmj.bmjjournals.com/cgi/eletters/329/7478/1297
308. Sodemann M, Rodrigues A, Nielsen J, Aaby P. Maternel vulnerability and socio-economic inequalities in child mortality in West Africa: an explorative study. Indepth Network: Measuring Health Equity in Small Areas. London: Ashgate 2005; 87-108
309. Benn CS, Melbye M, Wohlfahrt J, Björkstén B, Aaby P. Kohortestudie af effekten af søskende og infektionssygdomme på udvikling af atopisk dermatitis. Ugeskrift for Læger, 2005, 167: 1754-7 (parallelpublikation).
310. Nielsen NM, Eugen-Olsen J, Aaby P, Mølbak K, Rodrigues A, Fischer TK. Characterisation of rotavirus strains among hopsitalised and non-hospitalised children in Guinea-Bissau, 2002. A high frequency of mixed infections with serotype G8. J Clin Virol 2005;34:13-21
311. Broutin H, Mantilla-Beniers NB, Simondon F, Aaby P, Grenfell BT, Guégan JF, Rohani P. Epidemiological impact of vaccination on the dynamics of two childhood diseaees in rural Senegal. Microb Infect 2005;7:593-9
312. Aaby P, Jensen H, Benn CS, Lisse IM. Survival bias may explain findings. BMJ 2005;330;844-5
313. Jensen H, Benn CS, Aaby P. DTP in low income countries: improved child survival or survival bias? BMJ 2005;330:845-6
314. Andersson S, Larsen O, da Silva Z, Linder H, Norrgren H, Dias F, Thorstensson R, Aaby P, Biberfeld G. HIV-2-specific T-lymphocyte proliferative responses in HIV-2-infected and in HIV-2-exposed but uninfected individuals in Guinea-Bissau. Clin Exp Immunol 2005;139:483-9
315. Jaffar S, Schim van der Loeff M, Eugen-Olsen J, Vincent T, Sarje-Njie R, Ngom PT, Meyer AM, Berry N, Aaby P, Whittle H. Immunological predictors of survival in HIV type 2-infected rural villagers in Guinea-Bissau. Aids Res Hum Retrovirol 2005;21:560-4
316. Knudsen TB, Gustafson P, Kronborg G, Kristiansen TB, Moestrup SK, Nielsen JO, Gomes V, Aaby P, Lisse I, Møller HJ, Eugen-Olsen J. Soluble hemoglobin scavenger receptor CD163 predicts survival in Tuberculosis. Clin Microb Infect 2005;11:730-5
317. Kæstel P, Michaelsen KF, Aaby P, Friis H. The effects of prenatal multimicronutrient supplements on birth weight and perinatal mortality: a randomised, controlled trial in Guinea-Bissau. Eur J Clin Nut 2005; 59:1081-9
318. Lienhardt C, Fielding K, Sillah JS, Bah B, Gustafson P, Warndorff D, Palayew M, Lisse I, Donkor D, Diallo S, Manneh K, Adegbola RA, Aaby P, Bah-Sow O, Bennett S, McAdam KP. Investigation of the risk factors for tuberculosis: a case-control study in three counties in West Africa: Int J Epid 2005;34:914-23
319. Stensballe LG, Kristensen K, Nielsen J, Aaby P. Diagnosis coding in The Danish National Patient Registry for respiratory syncytial virus infections. Scan J Inf Dis 2005;37:747-52
320. Kabir Z, Aaby P. Non-Specific Effect of Measles Vaccination on All-cause Child Mortality: Revisited. Indian Pediatrics Journal 2005;42:541-4
321. Nielsen J, Jensen H, Andersen PK, Aaby P. Mortality patterns during a war in Guinea-Bissau 1998-99: changes in risk factors? Int J Epidemiol 2005;epub
322. Benn CS, Martins C, Rodrigues A, Lisse IM, Aaby P. Randomised study of the impact of different doses of vitamin A on childhood morbidity and mortality. BMJ 2005;331:1428-32

323. Westergaard T, Rostgaard K, Wohlfart J, Andersen PK, Aaby P, Melbye M. Sibship characteristics and risk of allergic rhinitis and asthma. Am J Epidemiol 2005;162:125-32
324. Westergaard T, Rostgaard K, Wohlfart J, Andersen PK, Aaby P, Melbye M. Response to "Sibship effects and a comparative disease approach". Am J Epidemiol 2005;162:139
325. Hoj L, Cardoso P, Nielsen BB, Hvidman L, Nielsen J, Aaby P. Effect of sublingual misoprostol on severe postpartum haemorrhage in a primary health centre in Guinea-Bissau: randomised double blind clinical trial. BMJ 2005;331:723-

2006

326. Aaby P, Ibrahim S, Libman M, Jensen H. The sequence of vaccinations and increased female mortality after high-titre measles vaccine: Trials from rural Sudan and Kinshasa. Vaccine 2006;24:2764-71
327. Valentiner-Branth P, Nielsen J, Steinsland H, Perch M, Fischer T, Sommerfeldt H, Mølbak K, Aaby P. Community study of cryptosporidium infection: Sex-differential incidences associated with BCG and diphtheria-tetanus-pertussis vaccine. Vaccine 2006;24:ePub
328. Roth AE, Stensballe LG, Garly ML, Aaby P. Beneficial non-targeted effects of BCG – ethical implications for the coming introduction of new TB-vaccines. Tuberculosis (Edinb.) 2006; 86(6):397-403
329. Roth AE, Garly ML, Jensen H, Nielsen J, Aaby P. Bacille Calmette Guerin vaccination and infant mortality. Expert Rev Vaccines 2006;5:277-93
330. Aaby P, Vessari H, Nielsen J, Maleta K, Benn CS, Jensen H, Ashorn P. Non-specific and sex-differential effects of routine immunizations in rural Malawi. PIDJ 2006;25:721-727
331. Sodemann M[1,2], Biai S[2,3], Jakobsen MS[2], Aaby P[1,2] Knowing a medical doctor reduces mortality among sick children consulting at paediatric ward in Guinea-Bissau, West Africa. TMIH 2006;11:1868-1877
332. Aaby P. Sundhedsforskning i et af verdens fattigste lande. Novo Nordisk Fondens Årskrift 2005, p 34-37
333. Rodrigues A, Fischer TK, Valentiner-Branth P, Nielsen J, Steinsland H, Perch M, Mølbak K, Aaby P. Community cohort study of rotavirus infection and other enteropathogens: Are routine vaccinations associated with sex-differential incidence rates. Vaccine 2006;24:4737-47
334. Nielsen NM, Rostgaard, Hjalgrim H, Askgaard D, Skinhøj P, Aaby P. Poliomyelitis and psychiatric disorders. Am J Epidemiol 2006;ePub (doi: 10.1093/AJE/KWK003)
335. Poulsen A, Stensballe LG, Nielsen J, Benn CB, Balde A, Roth A, Lisse IM, Aaby P. Long-term consequences of lower respiratory tract infection in early childhood in Guinea-Bissau. PIDJ:25:1025-31
336. Garly ML, Balé C, Martins CL, Whittle HC, Nielsen J; Lisse IM, Aaby P. Prophylactic antibiotics to prevent pneumonia and other complications after measles: community based randomised double blind placebo controlled trial in Guinea-Bissau. BMJ 2006;333(7581):1245
337. Roth A, Sodemann M, Jensen H, Poulsen A, Gustafson P, Gomes J, Djana Q, Jakobsen M, Garly ML, Rodriques A, Aaby P. Tuberculin reaction, BCG scar and lower female mortality. Epidemiology 2006: 17(5):562-8.
338. Aaby P, Jensen H, Walraven G. Age-specific changes in female-male mortality ratio related to the pattern of vaccinations: An observational study from rural Gambia. Vaccine 2006; 24:4701-08
339. Aaby P, Gustafson P, Roth A, Rodrigues A, Fernandes M, Sodemann M, Holmgren B, Stabell Benn C, Garly ML, Lisse IM, Jensen H. Vaccinia scars associated with better survival for adults. An observational study from Guinea-Bissau. Vaccine 2006;24:5718-25
340. Nielsen BB, Hoj L, Hvidman LE, Nielsen J, Cardoso P, Aaby P. Reduced post-partum bleeding after treatment with sublingual misoprostol: a randomized double-blind clinical study in a developing country—secondary publication). Ugeskr Laeger. 2006;168(13):1341-3
341. Benn CS, Aaby P. Kønsforskelle i respons på præventive sundhedsprogrammer. Måske behandler vi piger og drenge forskelligt, når vi behandler dem ens? Ugeskr Laeger. 2006; 168:3045-6
342. Benn CS, Fisker AB, Diness BR, Aaby P. Neonatal vitamin A supplementation: Sex-differential effects of on mortality? JID 2006;194:721
343. Stensballe LG, Kristensen K, Simoes EAF, Jensen H, Nielsen J, Benn CS, Aaby P. Asthmatic disposition, wheezing, and subsequent respiratory syncytial virus hospitalisation in Danish children younger than 18 months of age: a nested case-control study. Pediatrics 2006;118:e1360-8
344. Aaby P. International Sundhed derhjemme: At tage erfaringerne med hjem. Ugeskr Laeger. 2006:186:3015-17
345. Tosh K, Campbell SJ, Fielding K, Sillah J, Bah B, Gustafson P, Manneh K, Lisse I, Sirugo G, Bennett S, Aaby P, McAdam KP, Bah-Sow O, Lienhardt C, Kramnik I, Hill AV. Variants in the SP110 gene are associated with genetic susceptibility to tuberculosis in West Africa. Proc Natl Acad Sci U S A. 2006; 103(27):10364-8.
346. Kofoed, P. E., Rodrigues, A., Aaby, P. and L. Rombo. Continued efficacy of sulfadoxine-pyrimethamine as second line treatment for malaria in children in Guinea-Bissau. Acta Tropica 2006;epub; 2007;01:231-238
347. Qureshi K, Mølbak K, Sandström A, Kofoed PE, Rodrigues A, Dias F, Aaby P, Svennerholm AM. Breast milk reduces the risk of illness in children of mothers with cholera. Observations from an epidemic of cholera in Guinea-Bissau. PIDJ 2006;25:1163-6
348. Benn CS, Fisker AB, Jørgensen MJ, Aaby P. Why worry: Vitamin A with DTP vaccine? Vaccine 2006; ePub; 2007;25(5):777-779
349. Aaby P, Biai S, Veirum JE, Sodemann M, Lisse I, Garly ML, Ravn H, Benn CS, Rodrigues A, DTP with or after measles vaccination is associated with increased in-hospital mortality in Guinea-Bissau. Vaccine 2006;ePub;2007;25:1265-1269

350. Jensen ML, Dave S, van der Loeff MS, da Costa C, Vincent T, Leligdowicz A, Benn CS, Roth A, Jensen H, Lisse IM, Whittle H, Aaby P. Vaccinia scars associated with improved survival among adults in rural Guinea-Bissau. PLoS One 2006;1:e101

2007

351. Jensen H, Benn CS, Nielsen J, Lisse IM, Rodrigues A, Andersen PK, Aaby P. Survival bias in observational studies of the impact of routine vaccinations on childhood survival. TMIH 2007;12:5-14
352. Aaby P, Benn CS, Nielsen J, Lisse IM, Rodrigues A, Jensen H. Estimating the effect of DTP vaccination on mortality in observational studies with incomplete vaccination data. TMIH 2007;12:15-24
353. Aaby P. Is susceptibility to severe infection in low-income countries inherited or acquired? J Intern Med 2007;261:112-122
354. Garly ML, Balé C, Martins CL, Whittle HC, Nielsen J; Lisse IM, Aaby P. Measles in developing countries: Vitamin A and prophylactic antibiotics. BMJ 2007;rapid responses, 28 Jan 2007
355. Garly ML, Nielsen J; Aaby P. The measure of effect is not transferable. BMJ 2007;rapid responses, 30 Jan 2007
356. Khor CC, Chapman SJ, Vannberg FO, Dunne A, Murphy C, Ling EY, Frodsham AJ, Walley AJ, Kyrieleis O, Khan A, Aucan C, Segal S, Moore CE, Knox K, Campbell SJ, Lienhardt C, Scott A, Aaby P, Sow OY, Grignani RT, Sillah J, Sirugo G, Peshu N, Williams TN, Maitland K, Davies RJ, Kwiatkowski DP, Day NP, Yala D, Crook DW, Marsh K, Berkley JA, O'neill LA, Hill AV. A Mal functional variant is associated with protection against invasive pneumococcal disease, bacteremia, malaria and tuberculosis. Nat Genet 2007;39:523-8
357. Valentiner-Branth P, Nielsen J, Steinsland H, Perch M, Fischer T, Sommerfeldt H, Mølbak K, Aaby P. Community study of cryptosporidium infection: Sex-differential incidences associated with BCG and diphtheria-tetanus-pertussis vaccine. Vaccine 2007;25:2733-41
358. Larsen JM, Benn CB, Fillie Y, Kleij D, Aaby P, Yazdanbakhsh M. BCG stimulated dendritic cells induce an IL-10 producing T-cell population with no T helper 1 or T helper 2 bias in vitro. Immunology 2007;121:276-82
359. Gustafson P, Gomes VF, Vieira CS, Samb B, Naucler A, Aaby P, Lisse I. Clinical predictors for death in HIV-positive and HIV-negative tuberculosis patients in Guinea-Bissau. Infection 2007;35:69-80
360. Gustafson P, Lisse I, Gomes VF, Vieira CS, Lienhardt C, Nauclér A, Jensen H, Aaby P. Risk factors for positive tuberculin skin test in Guinea-Bissau. Epidemiology 2007 May, 18(3):340-347
361. Aaby P, Garly ML, Jensen H, Martins C, Balé C, Benn CS, Rodrigues A, Lisse IM. Increased female-male mortality ratio associated with inactivated polio and diphtheria-tetanus-pertussis vaccines: Observations from vaccination trials in Guinea-Bissau. Pediatr Infect Dis J 2007;26:247-52.
362. Rodrigues A, Schellenberg JA, Roth A, Benn CS, Aaby P, Greenwood B. Revaccination with Bacillus Calmette-Guerin (BCG) vaccine does not reduce morbidity from malaria in African children. TMIH 2007; 12: 224-9
363. Rodrigues A, Carvalho M, Monteiro S, Mikkelsen CS, Aaby P, Mølbak K, Fischer TK. Hospital surveillance of rotavirus infection and nosocomial transmission of rotavirus disease among children in Guinea-Bissau. Pediatr Infect Dis J. 2007-26:233-7
364. * Nante JE, *Diness BR, Ravn H, Roth A, Aaby P, Benn CS. No adverse events after simultaneous administration of 50,000 IU vitamin A and Bacille Calmette-Guerin vaccination to normal-birth-weight newborns in Guinea-Bissau. Europ J Clin Nutr 2007;epub
365. Olesen R Wejse C, Velez D, Bisseye C, Sodemann M, AabyP, Chapman H, Diatta M, Adegbola R, Hill P, Østergaard L, Williams S, Sirugo G. DC-SIGN (CD209), Pentraxin 3 and vitamin D receptor gene variants associate with pulmonary tuberculosis risk in West Africans. Genes Immunity 2007 Jul 5; http://www.nature.com/doifinder/10.1038/sj.gene.6364410 - 05/07/07 doi: 10.1038/sj.gene.6364410.
366. Eriksson M, Sartono E, Martins CL, Balé C, Garly ML, Aaby P, Pedersen BK, Yazdanbakhsh M, Erikstrup C, Benn CB. A comparison of *ex vivo* cytokine productions in venous and capillary blood. Clin Exp Immunol 2007;150:469-76
367. Benn CS, Aaby P. Sex-differential responses to preventive health interventions. Maybe we treat boys and girls differently when we treat them equally?--Secondary publication. Dan Med Bull. 2007;54(2):153-4.
368. Aaby P. International health at home: learning from low-income countries--secondary publication. Dan Med Bull. 2007;54(2):147
369. Fisker AB, Lisse IM, Aaby P, Erhardt JG, Rodrigues A, Bibby BM, Benn CS. Impact of Neonatal Vitamin A Supplementation with BCG vaccine on vitamin A status at 6 weeks and 4 months of age. Am J Clin Nut 2007;86:1032-9
370. Wejse C, Gustafson P, Nielsen J, Gomes VF, Aaby P, Andersen PL, Sodemann M. TBscore: Signs and symptoms from tuberculosis patients in a low-resource setting have predictive value and may be used to assess clinical course. Scand J Infect Dis. 2008;40(2):111-20.
371. Veirum JE, Biai S, Jakobsen M, Sandstrom A, Hedegaard K, Kofoed PE, Aaby P, Sodemann M Persisting high hospital and community childhood mortality in an urban setting in Guinea-Bissau. Acta Paediatr. 2007;96:526-30
372. Leligdowicz A, Yindom LM, Onyango C, Sarge-Njie R, Alabi A, Cotten M, Vincent T, da Costa C, Aaby P, Jaye A, Dong T, McMichael A, Whittle H, Rowland-Jones S Robust Gag-specific T cell responses characterize viremia control in HIV-2 infection. J Clin Invest. 2007;117:3067-74

373. Schmidt WP, Schim VAN DER Loeff M, Aaby P, Whittle H, Bakker R, Buckner M, Dias F, White RG. Behaviour change and competitive exclusion can explain the diverging HIV-1 and HIV-2 prevalence trends in Guinea-Bissau. Epidemiol Infect 2007 Jun 11;1-11.
374. Diness BR, Fisker AB, Roth A, Yazdanbakhsh M, Sartono E, Whittle H, Nante JE, Lisse IM, Ravn H, Rodrigues A, Aaby P, Benn CS.The effect of high-dose vitamin A supplementation on the immune response to Bacille Calmette-Guerin vaccine. Am J Clin Nut 2007;86:1152-9
375. Wejse C, Olesen R, Rabna P, Gustafson P, Aaby P, Andersen PL, Glerup H, Sodemann M. Serum 25-hydroxy-vitamin D in a West African population of tuberculosis patients and unmatched healthy controls. AJCN 2007;86:1376-83
376. Aaby P, Jensen H. Response to Deborah Lehmann. TMIH 2007;12:1270-1
377. Biai S, Rodrigues A, Gomes M, Ribeiro I, Sodemann M, Alves F, Aaby P. Reduced in-hospital mortality after improved management of children under 5 years admitted to hospital with malaria: randomised trial. BMJ 2007 doi:10.1136/bmj.39345.467813.80
378. Jakobsen MS, Sodemann M, Biai S, Nielsen J, Aaby P. Promotion of exclusive breastfeeding is not likely to be cost effective in West Africa. A randomized intervention study from Guinea-Bissau. Acta Paediatr 2007 Dec 3:epub;2008;97:68-75.
379. Veirum JE, Sodeman M, Biai S, Hedegård KL, Aaby P. Increased mortality in the year following discharge from a paediatric ward in Bissau, Guinea-Bissau. Acta Paediatr 2007;96:1832-38
380. Holmgren B, Da Silva Z, Vastrup P, Larsen O, Andersson S, Ravn H, Aaby P. Mortality associated with HIV-1, HIV-2 and HTLV-1 single and dual infections in a middle-aged and older population in Guinea-Bissau. Retrovirology 2007;4:85 doi:10.1186/1742-4690-4-85
381. Kofoed PE, Ursing J, Poulsen, A, Rodrigues A, Bergquist Y, Aaby P, Rombo L. Different doses of amodiaquine and chloroquine for treatment of uncomplicated malaria in children in Guinea-Bissau. Implications for future treatment recommendations. Transactions of the Royal Society of Tropical Medicine and Hygiene 2007, 101: 231 – 238.

2008

382. Vannberg FO, Chapman SJ, Khor CC, Tosh K, Floyd S, Jackson-Sillah D, Crampin A, Sichali L, Bah B, Gustafson P, Aaby P, McAdam KP, Bah-Sow O, Lienhardt C, Sirugo G, Fine P, Hill AV.CD209 Genetic Polymorphism and Tuberculosis Disease. PLoS ONE. 2008;3:e1388.
383. Rodrigues A, Schellenberg JA, Kofoed PE, Aaby P, Greenwood B. Changing pattern of malaria in Bissau, Guinea-Bissau. TMIH 2008; 13:410-17
384. Aaby P, Benn CS, Nielsen J, Ravn H. Sex-differential non-specific effects of BCG and DTP in Cebu, The Philippines. IJE 2008; epub;2009:38:320-3
385. Stensballe LG, Hjuler T, Andersen A, Kaltoft M, Ravn H, Aaby P, Simoes EA. Hospitalization for respiratory syncytial virus infection and invasive pneumococcal disease in Danish children aged <2 years: a population-based cohort study. Clin Infect Dis 2008;46:1165-71
386. da Silva ZJ, Oliveira I, Andersen A, Dias F, Rodrigues A, Holmgren B, Andersson S, Aaby P. Changes in prevalence and incidence of HIV-1, HIV-2 and dual infections in urban areas of Bissau, Guinea-Bissau. Is HIV-2 disappearing? AIDS 2008;22:1195-1202
387. Benn CS, Diness BR, Roth A, Nante E, Fisker AB, Lisse IM, Yazdanbakhsh M, Whittle H, Rodrigues A, Aaby P. Effect of 50,000 IU vitamin A given with BCG vaccine on mortality in infants in Guinea-Bissau: randomised placebo controlled trial. BMJ 2008;336:1416-20
388. Benn CS, Fisker AB, Jørgensen MJ, Aaby P. Conflicting evidence for neonatal vitamin A supplementation. Vaccine 2008;26:4111-12
389. Garly ML, Trautner SL, Marx C, Danebod K, Nielsen J, Ravn H, Martins CL, Balé C, Aaby P, Lisse IM. Thymus size at 6 months of age and subsequent child mortality. J Pediatr 2008;153;683-8
390. Norrgren H, Bamba S, Larsen O, Da Silva Z, Aaby P, Koivula T, Andersson S, MD, Increased prevalence of HTLV-1 in patients with pulmonary tuberculosis coinfected with HIV, but not in HIV-negative tuberculosis patients. JAIDS 2008;48;607-610
391. Martins CL, Garly ML, Balé C, Rodrigues A, Ravn H, Whittle HC, Lisse IM, Aaby P. Protective efficacy of standard Edmonston-Zagreb measles vaccination in infants aged 4.5 months: interim analysis of a randomised clinical trial. BMJ 2008;337:a661;epub
392. Benn CS, Whittle H, Fisker A, Aaby P. Neonatal vitamin A supplementation in South Asia: Rapid implementation or understanding the variation? BMJ Rapid responses 2008;July 11
393. Sodemann M, Nielsen J, Veirum J, Jakobsen MS, Biai S, Aaby P. Hypothermia of newborns is associated with excess mortality in the first two months of life in Guinea-Bissau, West Africa. TMIH 2008;13:980-6
394. Benn CB, Martins C, Rodrigues A, Fisker AB, Christoffersen D, Aaby P. The effect of vitamin A supplementation administered with missing vaccines during national immunisation days in Guinea-Bissau. IJE 2008;epub;2009:38:304-311
395. Stensballe LG, Simonsen J, Thomsen SF, Larsen AMH, Hovmand SG, Aaby P, Kyvik KO, ,Skytthe A, Backer V, Bisgaard H. The Causal Direction in the Association between Respiratory Syncytial Virus Hospitalization and Asthma. J Allergy Clin Immunol 2009;123:131-137

396. Stensballe LG, Ravn H, Kristensen K, Agerskov K, Meakins T, Aaby P, Simoes E. Respiratory syncytial virus (RSV) neutralizing antibodies in cord blood, RSV hospitalization, and recurrent wheeze. J Allergy Clin Immunol 2008;epub;2009:123:398-403
397. Benn CB, Fisker AB, Rodrigues A, Ravn H, Sartono E, Whittle H, Yazdanbakhsh M, Aaby P. Sex-differential effect on infant mortality of oral polio vaccine administered with BCG at birth in Guinea-Bissau. A natural experiment. PLoS One 2008;3:e4056
398. Sodemann M, Benn CS, Aaby P. Improving child survival. Bandim Health Project 2003-2008. Copenhagen, 2008

2009

399. Benn CB, Lantz S, Fisker A, Jørgensen MJ, Aaby P. Should infant girls receive micronutrient supplements? IJE 2009;38:586-90
400. Wejse C, Gomes VF, Rabna P, Gustafson P, Aaby P, Lisse I, Andersen PL, Glerup H, Sodemann M. Vitamin D as supplementary treatment for tuberculosis – A double-blind randomized placebo-controlled trial. Am J Respir Crit Care Med 2009; 179:843-50
401. Stensballe LG, Ravn H, Kristensen K, Meakins T, Aaby P, Simoes E. Seasonal variation of maternally derived respiratory syncytial virus antibodies and association with infant hospitalizations for respiratory syncytial virus. J Pediatr 2009:154:296-8
402. da Silva ZJ, Nielsen J, Andersen A, Oliveira I, Dias F, Rodrigues A, Holmgren B, Andersson S, Aaby P. Decline in human T-cell lymphotropic virus-1 prevalence in urban areas of Bissau, Guinea-Bissau: exploring the association with HIV infections. AIDS 2009;23;637-9
403. Benn CS, Rodrigues A, Yazdanbakhsh M, Fisker AB, Ravn H, Whittle H, Aaby P. The effect of high-dose vitamin A supplementation administered with BCG vaccine at birth may be modified by subsequent DTP vaccination. Vaccine 2009;27:2891-8
404. Nowroozalizadeh S, Månsson F, da Silva Z, Repits J, Dabo B, Pereira C, Biague A, Albert J, Nielsen J, Aaby P, Fenyö EM, Norrgren H, Holmgren B. Studies on toll-like receptor stimuli responsiveness in HIV-1 and HIV-2 infections. Cytokine 2009;46:325-31
405. Aaby P, Ravn H, Benn CS. Poor control vaccines in two randomised trials of malaria vaccine? Vaccine 2009; 27:2914-5
406. Fine PEM, Williams TN, Aaby P, Källander K, Moulton LH, Flanagan K, Smith PG, Benn CS. Epidemiological studies of the non-specific effects of vaccines: I - data collection in observational studies. TMIH 2009;14:969-76
407. Benn CS, Aaby P, Nielsen J, Binka FN, Ross DA. Does vitamin A supplementation interact with routine vaccinations? An analysis of the Ghana vitamin A supplementation trial. AJCN 2009;90:629-39
408. Aaby P, Benn CS. Assessment of childhood immunisation coverage? Lancet 2009;373:1428
409. Wejse C, Gomes VF, Gustafson P, Aaby P, Lisse I, Andersen PL, Sodemann M. Improved vitamin D status despite allocation to placebo in a tuberculosis treatment trial: contamination bias? Author reply. Am J Respir Crit Care Med. 2009;180(2):189-90
410. Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Andersen MB, Aaby P, Eugen-Olsen J. High mortality risk among individuals assumed to be TB-negative can be predicted using a simple test. Trop Med Intern Health 2009; 9(14):1–9
411. Martins C, Carlitos Bale C, Garly ML, Rodrigues A, Lisse IM, Andersen A, Eriksson M, Benn CS, Whittle H, Aaby P. Girls may have lower levels of maternal measles antibodies and higher risk of subclinical measles infection before the age of measles vaccination. Vaccine 2009;27:5220-5
412. Jallow S, Vincent T, Leligdowicz A, da Silva T, van Tienen C, Alabi A, Sarge-Njie R, Aaby P, Corrah T, Whittle H, Jaye A, Vanham G, Rowland-Jones S, Janssens W. Presenece of multidrug-resistance mutation in an HIV-2 variant infecting a treatment-naïve individual in Caio, Guinea-Bissau. CID 2009;48:1790-3
413. Villumsen* M, Sørup* S, Jess T, Ravn H, Relander T, Baker JL, Benn CS, Sørensen TIA, Aaby P, Roth A. Risk of lymphoma and leukaemia after bacille Calmette-Guérin and smallpox vaccination: a Danish case-cohort study. Vaccine 2009;27:6950-6958
414. van Tienen C, van den Loeff MS, Zaman SM, Vincent T, Sarge-Njie R, Peterson I, Leligdowicz A, Jaya A, Rowland-Jones S, Aaby P, Whittle H. Two distinct epidemics: the rise of HIV-1 and decline of HIV-2 infection between 1990 and 2007 in rural Guinea-Bissau. JAIDS 2010;53:640-7
415. Aaby P, Martins C, Bale C, Garly ML, Rodrigues A, Biai S, Lisse IM, Whittle H, Benn CS. Sex differences in the effect of vaccines on the risk of hospitalisation due to measles in Guinea-Bissau. PIDJ 2010;29:324-328
416. Agergaard J, Lemvik G, Nante E, Helleberg M, Nielsen J, Benn CS, Aaby P, Østergaard L. Serological evidence for *Chlamydia pneumoniae* infection following diphtheria-tetanus-pertussis booster vaccination. J Inf Dis Immun 2009

2010

417. Fischer TK, Aaby P, Mølbak K, Rodrigues A. Rotavirus disease in Guinea-Bissau, west Africa: a review of longitudinal community and hospital studies. J Inf Dis 2010;202;S239-42
418. Diness BR, Christoffersen D, Pedersen UB, Rodrigues A, Fischer TK, Andersen A, Whittle H, Yazdanbakhsh M, Aaby P, Benn CS. The effect of high-dose vitamin A supplementation given with bacilli Calmette-Guérin

vaccine at birth on rotavirus colonization and disease: a randomized prospective study in Guinea-Bissau. J Inf Dis 2010;202:S243-51

419. Nowroozalizadeh S. Månsson F, da Silva F, Repits J, Dabo B, Pereira C, Biague A, Albert J, Nielsen J, Aaby P, Fenyö EM, Norrgren H, Holmgren B, Jansson M. Microbial translocation correlates with the severity of both HIV-1 and HIV-2 infections. J Inf Dis 2010;201:1150-4
420. Nielsen J, Sodemann M, Jakobsen M, Gustafson P, Benn C, Aaby P. Sundhedsmæssige konsekvenser af en væbnet konflikt i Guinea Bissau. Ugeskr Læger 2010;172:132-6
421. Roth A, Benn CB, Ravn H, Rodrigues A, Lisse IM, Yazdanbakhsh M, Whittle H, Aaby P. Effect of revaccination with BCG in early childhood on mortality; randomised trial in Guinea-Bissau. BMJ 2010;340:c671
422. Whittle HC, Aaby P. 7.5.6 Measles. Oxford Textbook of Medicine, fifth edition. Oxford University Press 2010
423. Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Andersen MB, Aaby P, Eugen-Olsen J Urine suPAR levels compared with plasma suPAR levels as predictors of post-consultation mortality risk among individuals assumed to be TB-negative: A prospective cohort study. Inflammation 2010;33: 374-80;DOI: 10.1007/s10753-010-9195-2
424. Benn CS, Fisker A, Roth A, Diness BR, Lausch KR, Ravn H, Yazdanbakhsh M, Rodrigues A, Whittle H, Aaby P. Vitamin A supplementation and BCG vaccination at birth to low-birth-weight children; two by two factorial randomised trial. BMJ 2010;340:c1101
425. Bjerregaard-Andersen M, da Silva ZJ, Ravn P, Ruhwald M, Andersen PL, Sodemann M, Gustafson P, Aaby P, Wejse C. Tuberculosis burden in an urban cohort: a cross sectional tuberculosis survey from Guinea Bissau. BMC Inf Dis 2010;10:96
426. Sartono E, Lisse IM, Terveer EM, van de Sande PJM, Whittle H, Fisker AB, Roth A, Aaby P, Yazdanbakhsh M, Benn CS. Oral polio vaccine influences the immune response to BCG vaccination. A natural experiment. PLoS ONE 2010;5:e10328
427. Andersen GS, Friis H, Michaelsen KF, Rodrigues A, Benn CS, Aaby P, Kæstel P. Effect of Maternal Micronutrient Supplementation on Fetal Loss and Under Two Child Mortality: Long Term Follow-Up of a Randomized Controlled Trial from Guinea Bissau. Afr J Reprod Health 2010;14:17-26
428. van den Loeff MF, Larke N, Kaye S, Berry N, Ariyoshi K, Alabi A, van Tienen C, Leligdowicz A, Sarge-Njie R, da Silva Z, Jaye A, Ricard D, Vincent T, Jones SR, Aaby P, Jaffar S, Whittle H. Unpredictable plasma viral load predicts normal survival in HIV-2 infected people in a West African village. Retrovirology 2010;7:46
429. van Tienen C, Schim van der Loeff MF, Peterson I, Cotton M, Holmgren B, Andersson S, Vincent T, Sarge-Njie R, Rowland-Jones S, Jaye A, Aaby P, Whittle H. HTLV-1 in rural Guinea-Bissau: prevalence, incidence and a continued association with HIV between 1990 and 2007. Retrovirology 2010;7:50
430. Aaby P, Roth A, Benn CB, Ravn H, Rodrigues A, Lisse IM, Yazdanbakhsh M, Whittle H. DSMB and patient safety. BMJ 2010; rapid response
431. Aaby P, Martins CL, Garly ML, Bale C, Andersen A, Rodrigues A, Ravn H, Lisse IM, Benn CS, Whittle H. Non-specific effects of standard measles vaccine at 4.5 and 9 months of age on childhood mortality: Randomised controlled trial. BMJ 2010;341:c6495

2011

432. Hennig BJ, Edwards DRV, van der Loeff MFS, Bisseye C, Edwards TL, Tacconelli A, Novelli G, Aaby P, Kaye A, Scott WK, Jaye A, Whittle HC, Williams SM, Hill AV, Sigurugo G. CD4 intragenic SNPs associate with HIV-2 plasma viral load and CD4 count in a cohort from Guinea-Bissau, West Africa. J AIDS 2011;56:1-8
433. Porskrog A, Bjerregaard-Andersen M, Oliveira I, Joaquim LC, Camara C, Andersen PL, Rabna P, Aaby P, Wejse C. Enhanced tuberculosis identification through one month follow-up of smear negative tuberculosis suspects. IJTLD 2011;15:1-6
434. Aaby P, Benn CS. Non-specific and sex-differential effects of routine vaccines: What evidence is needed to take these effects into consideration in low-income countries? Human Vaccine 2011;epub
435. Agergaard J, Nante E, Poulstrup G, Nielsen J, Flanagan KL, Østergaard L, Benn CS, Aaby P Diphtheria-tetanus-pertussis vaccine administered simultaneously with measles vaccine is associated with increased morbidity and poor growth in girls. A randomised trial from Guinea-Bissau. Vaccine 2011;29:487-500
436. Gomes V, Andersen A, Wejse C, Oliveira I, Vieira FJ, Joaquim LC, Vieira CS, Aaby P, Gustafson P. Impact of tuberculosis exposure at home on mortality in children under 5 years of age in Guinea-Bissau. Thorax 2011;66:163-7
437. Diness B, Martins CL, Bale C, Garly ML, Ravn H, Rodrigues A, Whittle H, Aaby P, Benn CS. The effect of high-dose vitamin A supplementation at birth on measles incidence during the first 12 months of life in boys and girls. An unplanned study within a randomized trial. Br J Nutr 2011; 105:1819-1822
438. Gomes V, Wejse C, Oliveira I, Andersen A, Vieira FJ, Carlos LJ, Vieira CS, Aaby P, Gustafson P. Adherence to isoniazid preventive therapy in children exposed to tuberculosis: a prospective study from Bissau. Int J Tubercul Lung Dis 2011;15:1637-42
439. Vinner L, Holmgren B, Jensen KJ, Esbjornsson J, Borggren M, Hentze JL, Karlsson I, Andresen BS, Gram GJ, Kloverpris H, Aaby P, da Silva ZJ, Fenyö EM, Fomsgaard A. Sequence analysis of HIV-1 isolates from Guinea-Bissau; selection of vaccine epitopes relevant in both West African and European countries. APMIS 119;:487-97

440. Morris1 GAJ, Edwards DRV, Hill PC, Wejse C, Bisseye C, Olesen R, Edwards TL, Gilbert JR, Myers JL, Stryjewski ME, Abbate E, Estevan R, Hamilton CD, Tacconelli A, Novelli G, Brunetti E, Aaby P, Sodemann M, Østergaard L, Adegbola1 R, Williams SM, Scott WK, Sirugo G.Interleukin 12B (*IL12B*) genetic variation and pulmonary 1 tuberculosis: a study of cohorts from The Gambia, Guinea-Bissau, United States and Argentina. PLOS One 2011;6:e16656
441. Nichols R, Poulsen A, Averbeck K, Bassam MA,Cabral F, Aaby P, Breuer J: Household size is critical to Varicella-zoster virus transmission in the tropics despite lower viral infectivity. Epidemics 2011;3:12-18
442. Aaby P, Roth A, Ravn H, Napirna BM, Rodrigues A, Lisse IM, Stensballe L, Diness BR, Lausch KR, Lund N, Biering-Sørensen S, Whittle H, Benn CS. Randomised trial of BCG vaccination at birth to low-birth-weight children: Beneficial non-specific effects in the neonatal period? JID 2011;204:245-52
443. Flanagan KL, Klein SL, Skakkebæk NE, Marriott I, Marchant A, Selin L, Fish EN, Prentice A, Whittle H, Benn CS, Aaby P. Sex differences in the vaccine-specific and non-targeted effects of vaccines. Vaccine 2011;13:2349-54
444. Benn CS, Fisker A, Aaby P. Heterogeneous effects on child survival in neonatal vitamin A supplementation trials. Lancet 2011;377:1314-5
445. Balé C, Garly ML, Martins C, Nielsen J, Whittle H, Aaby P. Risk factors for measles in young infants in an urban African area with high measles vaccination coverage. PIDJ 2011;30:689-93
446. Sørup S, Villumsen M, Ravn H, Benn CS, Sørensen TIA, Aaby P, Jess T, Roth A. Smallpox Vaccination and all-cause Infectious Disease Hospitalization: a Danish register-based cohort study. Int J Epidemiol 2011;40:955-63
447. Biai S, Rodrigues A, Nielsen J, Sodemann M, Aaby P. Vaccination status and sequence of vaccinations as risk factors for hospitalisation among outpatients in a high mortality country Vaccine 2011; 29:3662-9
448. Fisker AB, Benn CS, Diness BR, Martins C, Rodrigues A, Aaby P, Bibby BM. The effect of 50,000 IU vitamin A with BCG vaccine at birth on growth in the first year of life. J Trop Med 2011;2011;570170
449. Fisker AB, Aaby P, Rodrigues A, Frydenberg M, Bibby BM, Benn CB. Vitamin A supplementation at birth might prime the response to subsequent vitamin A supplements in girls. Three year follow-up of a randomized trial. PLoS ONE 2011;6(8):e23265
450. Yakymenko D, Benn CS, Martins C, Diness BR, Fisker A, Rodrigues A, Aaby P. The impact of different doses of vitamin A supplementation on male and female mortality. A randomised trial from Guinea-Bissau. BMC Pediatrics 2011;11:77.
451. van Tienen C, Schim van der Loeff M, Peterson I, Cotton M, Andersson S, Holmgren B, Vincent T, de Silva T, Rowland-Jones S, Aaby P, Whittle H. HTLV-1 and HIV-2 Infection Are Associated with Increased Mortality in a Rural West African Community. PLoS One 2011;e29026
452. Benn CS, Fisker AB, Aaby P. With heterogeneous and potentially harmful effects in existing trials it would be unethical not to conduct further studies of the effect of vitamin A supplementation. BMJ, 2011; rapid responses to *BMJ* 2011;343:doi:10.1136/bmj.d5094

2012

453. van Tienen C, McConkey SJ, de Silva T, Cotton M, Kaye S, Sarge-Njie R, da Costa C, Goncalves N, Parker J, Vincet T, Jaye A, Aaby P, Whittle H, Schim van der Loeff M. Maternal proviral load and vertical transmission of Human T cell Lymphotropic Virus type 1 in Guinea-Bissau. AIDS Research and Human Retroviruses 2012; epub
454. de Silva TI, Aasa-Chapman M, Cotton M, Hué S, Robinson J, Bibollet-Ruche F, Sarge-Njie R, Berry N, Jaye A, Aaby P, Whittle H, Rowland-Jones S, Weiss R. Potent autologous and heterologous neutralizing antibody responses occur in HIV-2 infected across a broad range of infection outcomes. J Virol 2011;epub;2012;86:930-46
455. Ozkaya Sahin G, Holmgren B, da Silva Z, Nielsen J, Nowroozalizadeh S, Esbjörnsson J, Månsson F, Andersson S, Norrgren H, Aaby P, Jansson M, Fenyö EM. Potent intratype neutralizing activity distinguishes Human Immunodeficiency Virus Type 2 (HIV-2) from HIV-1. J Virol 2011; epub;2012;86:961-71
456. Biering-Sørensen S, Aaby P, Napirna BM, Roth A, Ravn H, Rodrigues A, Whittle H, Benn CS. Small randomized trial among low-birth-weight children receiving bacillus Calmette-Guérin vaccination at first health center contact. Pediatr Inf Dis J 2012;31:306-8
457. Aaby P, Roth A, Biering-Sørensen S, Ravn H, Rodrigues A, Whittle H, Benn CS. No evidence of bias in trial showing BCG reduces neonatal mortality. JID 2011;epub; 2012;205:515-7
458. Aaby P, Martins C, Benn CS, Whittle H. The new decade of vaccines. Lancet 2012;379:25-26
459. Aaby P. Measles infection. In: Schenck-Gustafsson K, DeCola PR, Pfaff DW, Pisetsky DS (editors): Handbook of Clinical Gender Medicine. Basel: Karger, 2012, pp 405-413
460. Fisker AB, Aaby P, Bale C, Balde I, Biering-Sørensen S, Agergaard J, Martins C, Bibby BM, Benn CS. Does the effect of vitamin A supplements depend on vaccination status? An observational study from Guinea-Bissau. BMJ Open 2012:2:e000448
461. Fisker AB, Aaby P, Benn CS. RE: There is no need for further placebo-controlled trials. BMJ Open 2012:2:e000448
462. Aaby P, Ravn H, Roth A, Rodrigues A, Lisse IM, Diness BR, Lausch KR, Lund N, Biering-Sørensen S, Whittle H, Benn CS. Early diphtheria-tetanus-pertussis vaccination associated with higher female mortality

and no difference in male mortality in a cohort of low birthweight children: an observational study within a randomised trial. Arch Dis Child 2012:97:685-91

463. Kæstel P, Martinussen T, Aaby P, Michaelsen KF, Friis H. Serum retinol is associated with stage of pregnancy and the acute phase response in pregnant women in Guinea-Bissau. J Nutr 2012;142:942-7
464. Jørgensen MJ, Fisker AB, Sartono E, Andersen A, Erikstrup C, Lisse IM, Yazdanbakhsh M, Aaby P, Benn CS; The effect of at-birth vitamin A supplementation on differential leucocyte counts and in-vitro cytokine production: an immunological study nested within a randomised trial in Guinea-Bissau. Br J Nutr 2012; 11 July 2012:epub
465. Aaby P, Whittle HC, Benn CS. Vaccine programmes must consider their effect on general resistance. BMJ 2012;344:e3769
466. Velez Edwards DR, Tacconelli A, Wejse C, Hill PC, Morris GA, Edwards TL, Gilbert JR, Myers JL, Park YS, Stryjewski ME, Abbate E, Estevan R, Rabna P, Novelli G, Hamilton CD, Adegbola R, Østergaard L, Williams SM, Scott WK, Sirugo G. MCP1 SNPs and pulmonary tuberculosis in cohorts from West Africa, the USA and Argentina: lack of association or epistasis with IL12B polymorphisms. PLoS One. 2012;7(2):e32275
467. Aaby P, Benn CS, Nielsen J, Lisse IM, Rodrigues A, Ravn H. Testing the hypothesis that diphtheria-tetanus-pertussis vaccine has negative non-specific and sex-differential effects on child survival in high-mortality countries. BMJ Open 2012;2:e000707.
468. Benn CS, Aaby. Diphtheria-tetanus-pertussis vaccination administered after measles vaccine: Increased female mortality? Pediatr Inf Dis J 2012;31:1095-7
469. Rasmussen J, Andersen A, Fisker AB, Ravn H, Sodemann M, Rodrigues A, Benn CS, Aaby P. Mid-upper-arm-circumference and mid-upper-arm circumference z-score: The best predictor of mortality? Eur J Clin Nutr 2012;66:998-1003
470. van Tienen C, de Silva TI, Alcantara LCJ, Onyango CO, Jarju S, Goncalves N, Vincent T, Aaby P, Whittle H, van den Loeff MS, Cotten M. Molecular Epidemiology of Endemic Human T-Lymphotropic Virus Type 1 in A Rural Community in Guinea-Bissau. PLoS Negl Trop Dis 2012;6(6): e1690.
471. Aaby P, Martins CL, Garly ML, Rodrigues A, Benn CS, Whittle HC. The optimal age of measles immunization in low-income countries: a secondary analysis of the assumptions underlying the current policy. BMJ Open 2012;2:e000761
472. Rabna P, Andersen A, Wejse C, Oliveira I, Gomes VF, Haaland MB, Aaby P, Eugen-Olsen J. Utility of plasma level of suPAR in monitoring risk of mortality during TB treatment. PLoS One 2012;7:e43933
473. Benn CS, Aaby P. Does IPTi decrease malaria morbidity but not mortality? Lancet 2012; 380(9846):958-60.
474. Welega P, Nielsen J, Adjuik M, Debpuur C, Ross DA, Ravn H, Benn CS, Aaby P. Non-specific effects of diphtheria-tetanus-pertussis and measles vaccinations? An analysis of surveillance data from Navrongo, Ghana. Trop Med Int Health 2012;epub
475. Hirve S, Bavdekar A, Juvekar S, Benn CS, Nielsen J, Aaby P. Non-specific and sex-differential effects of vaccinations on child survival in rural western India. Vaccine 2012;30:7300-7308
476. Lund N, Andersen A, Monteiro I, Aaby P, Benn CS. No effect of oral polio vaccine administered at birth on mortality and immune response to BCG. A natural experiment. Vaccine 2012;30:6694-9
477. Oliveira I, Andersen A, Furtado A, Medina C, da Silva D, da Silva ZJ, Aaby P, Laursen AL, Wejse C, Eugen-Olsen J; for the Bissau HIV cohort study group. Assessment of simple risk markers for early mortality among HIV- infected patients in Guinea-Bissau: a cohort study. BMJ Open 2012;e001587
478. Aaby P, Benn CS. Saving lives by training innate immunity with bacille Calmette-Guérin vaccine. Proc Natl Acad Sci U S A 2012;109:17317-8
479. Hornshøj L, Benn CS, Fernandes M, Rodrigues A, Aaby P, Fisker AB. Vaccination Coverage and Out-of-Sequence Vaccinations in Rural Guinea-Bissau: an observational cohort study. BMJ Open 2012;e001509
480. Lassen J, Jensen AK, Bager P, Pedersen CB, Panum I, Nørgaard-Pedersen B, Aaby P, Wohlfart J, Melbye M. Parvovirus B19 infection in the first trimester of pregnancy and risk of fetal loss: A population-based case-control study. Am J Epidemiol 2012;176:803-7
481. Bjerregaard-Andersen M, Lund N, Jepsen FS, Camala L, Gomes MA, Christensen K, Christiansen L, Jensen DM, Aaby P, Beck-Nielsen H, Benn CS, Sodemann M. A prospective study of twinning and perinatal mortality. BMC Pregnancy Childbirth. 2012 Dec 5;12:140. doi: 10.1186/1471-2393-12-140

2013

482. Bjerregaard-Andersen M, Gomes MA, Joaquím LC, Rodrigues A, Jensen DM, Christensen K, Benn CS, Aaby P, Beck-Nielsen H, Sodemann M. Establishing a twin registry in Guinea-Bissau. Twin Res Hum Gen 2013;16:179-84
483. Ozkaya Sahin G, Holmgren B, Sheik-Khalill E. da Silva Z, Nielsen J, Nowroozalizadeh S, Månsson F, Norrgren H, Aaby P, Fenyö EM, Jansson M. Effect of complement on HIV-2 plasma antiviral activity is intratype-specific and potent. J Virol 2013;87:273-81
484. Danneskiold-Samsøe N, Fisker AB, Jørgensen MJ, Ravn H, Andersen A, Balde ID, Leo-Hansen C, Rodrigues A, Aaby P, Benn CS. Determinants of vitamin a deficiency in children between 6 months and 2 years of age in Guinea-Bissau. BMC Public Health 2013, 13:172. doi is: 10.1186/1471-2458-13-172
485. Gomes VF, Andersen A, Lemvik G, Wejse C, Oliveira I, Vieira FJ, Carlos LJ, Vieira CS, Aaby P, Gustafson P. Impact of isoniazid preventive therapy on mortality among children less than 5 years old following exposure to

tuberculosis at home in Guinea-Bissau in urban Guinea-Bissau. BMJ Open 2013;e001545

486. Andersen A, Roth A, Jensen KJ, Erikstrup C, Lisse IM, Whittle H, Sartono E, Yazdanbakhsh M, Aaby P, Benn CS. The immunological effect of revaccination with Bacille Calmette-Guérin vaccine at 19 months of age. Vaccine 2013;31:2137-44
487. Ørntoft NW, Thorsen K, Benn CS, Lemvik G, Nanque JR, Aaby P, Østergaard L, Agergaard J. Leukocyte transcript alterations in West-African girls following a booster vaccination with diphtheria-tetanus-pertussis vaccine. Scand J Clin Lab Invest 2013;epub
488. Benn CS, Netea MG, Selin LK, Aaby P. A small jab – a big effect: nonspecific immunomodulation by vaccines. Trends Immunol 2013;34:431-9
489. Rasmussen DN, Té DT, Rodkjaer L, Oliveira I, Medina C, Barfod T, Laursen AL, Aaby P, Sodemann M, Wejse C. Barriers and facilitators to antiretroviral therapy adherence among patients with HIV in Bissau, Guinea-Bissau: a qualitative study. African Journal of AIDS Research 2013;1-8
490. Villumsen M, Jess T, Sørup S, Ravn H, Sturegård E, Benn CS, Aaby P, Roth A. Risk of Inflammatory Bowel Disease following Bacille Calmette-Guérin and Smallpox Vaccination: A Population-Based Danish Case-Cohort Study. Inflamm Bowel Dis 2013;19:1717-24
491. Fisker AB, Bale C, Jørgensen MJ, Balde I, Hornshøj L, Bibby BM, Aaby P, Benn CS. High-dose vitamin A supplementation administered with vaccinations after 6 months of age: sex-differential adverse reactions and morbidity. Vaccine 2013;31:3191-8
492. Kiraly N, Benn CB, Biering-Sørensen S, Rodrigues A, Jensen KJ, Ravn H, Allen K, Aaby P. Vitamin A supplementation and BCG vaccination at birth may affect atopy in childhood: long-term follow-up of a randomized controlled trial. Allergy 2013; 68:1168-76
493. Biering Sørensen S, Fisker AB, Ravn H, Camala L, Monteiro M, Aaby P, Benn CS. The effect of neonatal vitamin A supplementation on growth in the first year of life among low-birth-weight infants in Guinea-Bissau: two by two factorial randomised controlled trial BMC Pediatrics 2013;13:87
494. Bjerregaard-Andersen M, Hansen L, Silva LI, Joaquim LC, Hennild DE, Christiansen L, Aaby P, Benn CS, Christensen K, Sodemann M, Jensen DM, Beck-Nielsen H. Risk of metabolic syndrome and diabetes mellitus among young twins and singletons in Guinea-Bissau. Diabetes Care 2013;36:3549-56
495. Benn CS, Fisker AB, Aaby P. Vitamin A supplementation in Indian children. Lancet 2013; 382:593
496. Martins CL, Garly ML, Bale C, Rodrigues A, Benn CS, Whittle H, Aaby P. Measles antibody levels after vaccination with Edmonston-Zagreb and Schwarz measles vaccine at 9 months or at 9 and 18 months of age: a serological study within a randomised trial of different measles vaccines. Vaccine 2013; 31:5766-71
497. Kiraly N, Balde A, Lisse IM, Eriksen HB, Aaby P, Benn CS. Vitamin A supplementation and risk of atopy: long-term follow-up of a randomized trial of vitamin A supplementation at six and nine months of age. BMC Pediatrics 2013, 13:190
498. Mané M, Fisker A, Ravn H, Aaby P, Rodrigues A. Trends and determinants of mortality in women of reproductive age in rural Guinea-Bissau, West Africa – a cohort study. BMC Womens Health 2013;13:48

2014

499. Kleinnijenhuis J, Quintin J, Preijers F, Benn CS, Joosten LA, Jacobs C, van Loenhout J, Xavier RJ, Aaby P, van der Meer JW, van Crevel R, Netea MG. Long-Lasting Effects of BCG Vaccination on Both Heterologous Th1/Th17 Responses and Innate Trained Immunity. J Innate Immun 2014;6:152-8
500. Hønge BL*, Bjarnason Obinah MP*, Jespersen S, Medina C, Té D da S, da Silva ZJ, Østergaard L, Laursen AL, Wejse C, Erikstrup C, Bissau8 HIV Cohort Study Group. Performance of 3 rapid tests for discrimination between HIV-1 and HIV-2 in Guinea-Bissau, West Africa. J Acqui Immun Defic Syndr 2014;65:87-90
501. Rudolf F, Haraldsdottir TL, Mendes MS, Wagner AJ, Gomes VF, Aaby P, Østergaard L, Eugen-Olsen J, Wejse C. Can tuberculosis case finding among health-care seeking adults be improved? Observations from Bissau. IJTLD 2014;18:277-85
502. Fisker AB, Ravn H, Rodrigues A, Østergaard MD, Bale C, Benn CS, Aaby P. Co-administration of live measles and yellow fever vaccines and inactivated pentavalent vaccines is associated with increased mortality compared with measles and yellow fever vaccines only. An observational study from Guinea-Bissau. Vaccine 2014;32:598-605
503. Martins CL, Benn CS, Andersen A, Balé C, Schaltz-Buchholzer F, Do VA, Rodrigues A, Aaby P, Ravn H, Whittle H, Garly ML. A randomized trial of a standard dose of Èdmonston-Zagreb measles vaccine given at 4.5 months of age: effect on total hospital admissions. JID 2014;209;1731-8
504. Eriksen HB, Lund N, Biering-Sørensen S, Correia C, Barbosa A, Andersen A, Aaby P, Jeppesen DL, Benn CS: Does oral polio vaccine at birth affect the size of the thymus? Observations within a randomized trial. Vaccine 2014;32:3293-9
505. Christensen LD, Eriksen HB, Biering-Sørensen S, Balé C, Do VA, Andersen A, Martins CL, Sodemann M, Aaby P, Benn CS: The effect of early measles vaccination on thymic size. A randomized study from Guinea-Bissau. Vaccine 2014;32:1641-4
506. Sørup S, Benn CS, Poulsen A, Krause T, Aaby P, Ravn H. Live vaccine against measles, mumps, and rubella and the risk of hospital admissions for nontargeted infections. JAMA 2014;311:826-35
507. Martins C, Garly ML, Bale C, Rodrigues A, Njie-Jobe J, Benn CS, Whittle H, Aaby P. Measles virus antibody responses in children randomly assigned to receive standard-titre edmonston-zagreb measles vaccine at 4.5 and

9 months of age, 9 months of age, or 9 and 18 months of age. JID 2014;210:693-700
508. Andersen A, Jensen KJ, Erikstrup C, Ravn H, Fisker AB, Lisse IM, Sartono E, Aaby P, Yazdanbakhsh M, Benn CS. Both very low- and very high in vitro cytokine responses were associated with infant death in low-birth-weight children from Guinea Bissau. PloS One 2014;e93562
509. Fisker AB, Benn CS, Ravn H, Aaby P. Reply to Dr Schmid et al. Vaccine 2014;32:2668-9
510. Aaby P, Martins CL, Garly ML, Andersen A, Fisker AB, Claesson MH, Ravn H, Rodrigues A, Whittle HC, Benn CS. Measles vaccination in the presence or absence of maternal measles antibody: impact on child survival. CID 2014;59:484-92
511. Jensen KJ, Søndergaard M, Andersen A, Sartono E, Martins C, Garly ML, Eugen-Olsen J, Ullum J, Yazdanbakhsh M, Aaby P, Benn CS, Erikstrup C. A randomized trial of an early measles vaccine at 4½ months of age in Guinea-Bissau: sex-differential immunological effects. Plos One 2014:e97536
512. Lewden C, Drabo YJ, Zannou DM, Maiga MY, Minta DK, Sow PS, Akakpo J, Dabis F, Eholié SP; IeDEA West Africa Collaboration.Disease patterns and causes of death of hospitalized HIV-positive adults in West Africa: a multicountry survey in the antiretroviral treatment era.J Int AIDS Soc. 2014;17:18797
513. Dicko F, Desmonde S, Koumakpai S, Dior-Mbodj H, Kouéta F, Baeta N, Koné N, Akakpo J, Signate Sy H, Ye D, Renner L, Lewden C, Leroy V; Pediatric IeDEA West Africa Working Group.Reasons for hospitalization in HIV-infected children in West Africa. J Int AIDS Soc. 2014;17:18818
514. Virenfeldt J, Rudolf F, Camara C, Furtado A, Gomes V, Aaby P, Petersen E, Wejse C. Treatment delay affects clinical severity of tuberculosis: a longitudinal cohort study. BMJ Open. 2014 Jun 10;4(6):e004818. doi: 10.1136/bmjopen-2014-004818.
515. Sankoh O, Welaga P, Debpuur C, Zandoh C, Gyaase S, Poma MA, Mutua MK, Hanifi SM, Martins C, Nebie E, Kagoné M, Emina JB, Aaby P. The non-specific effects of vaccines and other childhood interventions: the contribution of INDEPTH Health and Demographic Surveillance Systems. Int J Epidemiol. 2014 Jun;43(3):645-53. doi: 10.1093/ije/dyu101. Epub 2014 May 30. Review.
516. Hansen AS, Lund N, Flanagan KL, Rodrigues A, Njie-Jobe J, Sanyang LC, Salanti A, Andersen A, Aaby P, Benn CS, Whittle H. Randomized trial: The effect of oral polio vaccine at birth on polio antibody titers at 6 weeks and 6 months of age. Trials in Vaccinology 2014;3:33-39
517. Hønge BL, Jespersen S, Medina C, Té Dda S, da Silva ZJ, Lewin S, Østergaard L, Erikstrup C, Wejse C, Laursen AL, Krarup H; Bissau HIV cohort study group. Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study.PLoS One. 2014 Jun 10;9(6):e99971. doi: 10.1371/journal.pone.0099971. eCollection 2014. Erratum in: PLoS One. 2015;10(3):e0119246.
518. Hønge BL, Jespersen S, Medina C, Té DS, da Silva ZJ, Lewin S, Østergaard L, Erikstrup C, Wejse C, Laursen AL, Krarup H; Bissau HIV cohort study group. Hepatitis B and Delta virus are prevalent but often subclinical co-infections among HIV infected patients in Guinea-Bissau, West Africa: a cross-sectional study. PLoS One 2014;9:e99971
519. Benn CS, Diness BR, Balde I, Rodrigues A, Lausch KR, Martins CL, Fisker AB, Aaby P. Two different doses of supplemental vitamin A did not affect mortality of normal-birth-weight neonates in Guinea-Bissau in a randomized controlled trial. J Nutr. 2014 Sep;144(9):1474-9. doi: 10.3945/jn.114.192674. Epub 2014 Jul 2.
520. Fisker AB, Bale C, Rodrigues A, Balde I, Fernandes M, Jørgensen MJ, Danneskiold-Samsøe N, Hornshøj L, Rasmussen J, Christensen ED, Bibby BM, Aaby P, Benn CS. High-dose vitamin A with vaccination after 6 months of age: a randomized trial. Pediatrics. 2014 Sep;134(3):e739-48. doi: 10.1542/peds.2014-0550.
521. Fisker AB, Hornshøj L, Rodrigues A, Balde I, Fernandes M, Benn CS, Aaby P. Effects of the introduction of new vaccines in Guinea-Bissau on vaccine coverage, vaccine timeliness, and child survival: an observational study.Lancet Glob Health. 2014 Aug;2(8):e478-87. doi: 10.1016/S2214-109X(14)70274-8. Epub 2014 Jul 23.
522. Eriksen HB, Biering-Sørensen S, Lund N, Correia C, Rodrigues A, Andersen A, Ravn H, Aaby P, Jeppesen DL, Benn CS. Factors associated with thymic size at birth among low and normal birth-weight infants. J Pediatr. 2014 Oct;165(4):713-21. doi: 10.1016/j.jpeds.2014.06.051. Epub 2014 Jul 30.
523. Bjerregaard-Andersen M, Biering-Sørensen S, Gomes GM, Bidonga A, Jensen DM, Rodrigues A, Christensen K, Aaby P, Beck-Nielsen H, Benn CS, Sodemann M. Infant twin mortality and hospitalisations after the perinatal period - a prospective cohort study from Guinea-Bissau. Trop Med Int Health. 2014 Dec;19(12):1477-87. doi: 10.1111/tmi.12388. Epub 2014 Sep 22.
524. Aaby P, Kollmann T, Benn CS. Non-specific effects of neonatal and infant vaccination - public health, immunological, and conceptual challenges. Nat Immunol. 2014 Oct;15(10):895-9. doi: 10.1038/ni.2961.
525. Lemvik G, Rudolf F, Vieira F, Sodemann M, Østergaard L, Rodrigues A, Gomes V, Aaby P, Wejse C. Decline in overall, smear-negative and HIV-positive TB incidence while smear-positive incidence stays stable in Guinea-Bissau 2004-2011.Trop Med Int Health. 2014 Nov;19(11):1367-76. doi: 10.1111/tmi.12378. Epub 2014 Aug 22.
526. Jensen KJ, Larsen N, Biering-Sørensen S, Andersen A, Eriksen HB, Monteiro I, Hougaard D, Aaby P, Netea MG, Flanagan KL, Benn CS. Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-controlled trial. J Infect Dis. 2015 Mar 15;211(6):956-67. doi: 10.1093/infdis/jiu508. Epub 2014 Sep 9
527. Benn CS, Martins CL, Fisker AB, Diness BR, Garly ML, Balde I, Rodrigues A, Whittle H, Aaby P. Interaction

between neonatal vitamin A supplementation and timing of measles vaccination: a retrospective analysis of three randomized trials from Guinea-Bissau. Vaccine. 2014 Sep 22;32(42):5468-74. doi: 10.1016/j.vaccine.2014.07.090. Epub 2014 Aug 13.
528. Lund N, Biering-Sørensen S, Andersen A, Monteiro I, Camala L, Jørgensen MJ, Aaby P, Benn CS. Neonatal vitamin A supplementation associated with a cluster of deaths and poor early growth in a randomised trial among low-birth-weight boys of vitamin A versus oral polio vaccine at birth. BMC Pediatr. 2014 Aug 28;14:214. doi: 10.1186/1471-2431-14-214.
529. Ursing J, Rombo L, Rodrigues A, Aaby P, Kofoed PE. Malaria transmission in Bissau, Guinea-Bissau between 1995 and 2012: malaria resurgence did not negatively affect mortality. PLoS One. 2014 Jul 1;9(7):e101167. doi: 10.1371/journal.pone.0101167. eCollection 2014.
530. Ndondoki C, Dicko F, Ahuatchi Coffie P, Kassi Eboua T, Ekouevi DK, Kouadio K, Edmond Aka A, Malateste K, Dabis F, Amani-Bosse C, Toure P, Leroy V; Paediatric IeDEA West African Working Group. Antiretroviral treatment response of HIV-infected children after prevention of mother-to-child transmission in West Africa. J Int AIDS Soc. 2014 Jun 2;17:18737.
531. Yoshida S, Rudan I, Lawn JE, Wall S, Souza JP, Martines J, Bahl R; neonatal health research priority setting group. Newborn health research priorities beyond 2015. Lancet. 2014 Jul 12;384(9938):e27-9.
532. Depledge DP, Gray ER, Kundu S, Cooray S, Poulsen A, Aaby P, Breuer J. Evolution of cocirculating varicella-zoster virus genotypes during a chickenpox outbreak in Guinea-Bissau. J Virol. 2014 Dec;88(24):13936-46. doi: 10.1128/JVI.02337-14. Epub 2014 Oct 1
533. Jensen KJ, Karkov HS, Lund N, Andersen A, Eriksen HB, Barbosa AG, Kantsø B, Aaby P, Benn CS. The immunological effects of oral polio vaccine provided with BCG vaccine at birth: a randomised trial. Vaccine. 2014 Oct 14;32(45):5949-56. doi: 10.1016/j.vaccine.2014.08.062. Epub 2014 Sep 16.
534. Hønge BL, Jespersen S, Medina C, da Silva Té D, da Silva ZJ, Lewin SR, Østergaard L, Laursen AL, Krarup H, Erikstrup C, Wejse C; Bissau HIV Cohort Study Group. Hepatitis C prevalence among HIV-infected patients in Guinea-Bissau: a descriptive cross-sectional study. Int J Infect Dis. 2014 Nov;28:35-40. doi: 10.1016/j.ijid.2014.06.007. Epub 2014 Sep 16.
535. Jespersen S, Hønge BL, Oliveira I, Medina C, da Silva Té D, Correira FG, Erikstrup C, Laursen AL, Ostergaard L, Wejse C; for the Bissau HIV Cohort study group. Cohort Profile: The Bissau HIV Cohort-a cohort of HIV-1, HIV-2 and co-infected patients. Int J Epidemiol. 2014 Oct 22. pii: dyu201. [Epub ahead of print]
536. Jespersen S, Hønge BL, Oliveira I, Medina C, da Silva Té D, Correira FG, da Silva ZJ, Erikstrup C, Ostergaard L, Laursen AL, Wejse C; for the Bissau HIV Cohort study group. Challenges facing HIV treatment in Guinea-Bissau: the benefits of international research collaborations. Bull World Health Org 2014;92:909-914.
537. Thysen SM, Byberg S, Pedersen M, Rodrigues A, Ravn H, Martins C, Benn CS, Aaby P, Fisker AB. BCG coverage and barriers to BCG vaccination in Guinea-Bissau: an observational study. BMC Public Health. 2014 Oct 4;14:1037. doi: 10.1186/1471-2458-14-1037.
538. Jaquet A, Horo A, Ekouevi DK, Toure B, Coffie PA, Effi B, Lenaud S, Messou E, Minga A, Sasco AJ, Dabis F; IeDEA West Africa Collaboration. Risk factors for cervical intraepithelial neoplasia in HIV-infected women on antiretroviral treatment in Côte d'Ivoire, West Africa. PLoS One. 2014 Mar 4;9(3):e90625
539. Desmonde S, Dicko F, Koueta F, Eboua T, Balestre E, Amani-Bosse C, Aka EA, Lawson-Evi K, Amorissani-Folquet M, Kouakou K, Koumakpai S, Renner L, Signaté Sy H, Leroy V; IeDEA West Africa Collaboration. Association between age at antiretroviral therapy initiation and 24-month immune response in West-African HIV-infected children. AIDS. 2014 Jul 17;28(11):1645-55.
540. Duda SN, Farr AM, Lindegren ML, Blevins M, Wester CW, Wools-Kaloustian K, Ekouevi DK, Egger M, Hemingway-Foday J, Cooper DA, Moore RD, McGowan CC, Nash D; International Epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration. Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration. J Int AIDS Soc. 2014 Dec 15;17:19045. doi: 10.7448/IAS.17.1.19045

2015

541. Aaby P, Martins CL, Ravn H, Rodrigues A, Whittle HC, Benn CS. Is early measles vaccination better than later measles vaccination? A review. Trans R Soc Trop Med Hyg. 2015 Jan;109(1):16-28. doi: 10.1093/trstmh/tru174.
542. Aaby P, Nielsen J, Benn CS, Trape JF. Sex-differential and non-specific effects of routine vaccinations in a rural area with low vaccination coverage: an observational study from Senegal. Trans R Soc Trop Med Hyg. 2015 Jan;109(1):77-84. doi: 10.1093/trstmh/tru186.
543. Benn CS, Fisker A, Aaby P. Response to: Vitamin A policies need rethinking. Int J Epidemiol. 2015 Feb;44(1):366-7. doi: 10.1093/ije/dyu279. Epub 2015 Jan 23. No abstract available.
544. Sorup S, Benn CS, Stensballe LG, Aaby P, Ravn H. Measles-mumps-rubella vaccination and respiratory syncytial virus-associated hospital contact. Vaccine 2015;33:237-45.
545. Biering-Sørensen S, Jensen KJ, Aamand SH, Blok B, Andersen A, Monteiro I, Netea MG, Aaby P, Benn CS, Hasløv KR. Variation of growth in the production of the BCG vaccine and the association with the immune response. An observational study within a randomised trial. Vaccine 2015;33:2056-65
546. Benn CS, Aaby P, Fisker A. Vitamin A: The immunomodulator. *World Nutrition* Volume 6, Number 4, April 2015, page 318-321.

547. Haraldsdottir T, Joaquim LC, Rudolf F, Krag KS, Gomes V, Ostergaard L, Bjerregaard-Andersen M, Beck-Nielsen H, Aaby P, Wejse C. Diabetes prevalence in tuberculosis patients and healthy controls in Guinea Bissau. TRSTMH 2015 Jun;109(6):400-7
548. Arts R. Blok B, van Crevel R, Joosten L, Aaby P, Benn CS, Netea M. Vitamin A induces inhibitory histone methylation modifications and down-regulates trained immunity in human monocytes. J Leukoc Biol. 2015 Jul;98(1):129-36. doi: 10.1189/jlb.6AB0914-416R. Epub 2015 May 1.
549. Arts R, Blok B, Aaby P, Joosten LAB, de Jong D, van der Meer JWM, Benn CS, van Crevel R, Netea MG. Long-term *in-vitro* and *in-vivo* effects of γ-irradiated BCG on innate and adaptive immunity. J Leukoc Biol. 2015;98:995-1001 - Jun 16. pii: jlb.4MA0215-059R. [Epub ahead of print]
550. Storgaard L, Rodrigues A, Nielsen BU, Ravn H, Benn CB, Aaby P, Fisker AB. Development of BCG Scar and Subsequent Morbidity and Mortality in Rural Guinea-Bissau. Clin Infect Dis. 2015 Sep 15;61(6):950-9. doi: 10.1093/cid/civ452. Epub 2015 Jun 9.
551. Aage S, Kiraly N, Da Costa K, Byberg S, Bjerregaard-Andersen M, Fisker AB, Aaby P, Benn CS.Neonatal vitamin A supplementation associated with increased atopy in girls. Allergy. 2015 Aug;70(8):985-94. doi: 10.1111/all.12641. Epub 2015 May 18.
552. Kæstel P, et al. Markers of iron status are associated with stage of pregnancy and acute phase response, but not with parity among pregnant women in Guinea-Bissau. Br J Nutr. 2015 Oct;114(7):1072-9. doi: 10.1017/S0007114515001993. Epub 2015 Aug 19.
553. Benn CS, Aaby P, Fisker A. Neonatal vitamin A: time to move on? Lancet. 2015 Jul 11;386(9989):132-3. doi: 10.1016/S0140-6736(15)61235-1.
554. Fisker A, Aaby P, Benn CS. Neonatal vitamin A: time to move on? Lancet. 2015 Jul 11;386(9989):132-3. doi: 10.1016/S0140-6736(15)61235-1.
555. Thøstesen LM, Nissen TN, Kjærgaard J, Pihl GT, Birk NM, Benn CS, Greisen G, Kofoed PE, Pryds O, Ravn H, Jeppesen DL, Aaby P, Stensballe LG.Bacillus Calmette-Guérin immunisation at birth and morbidity among Danish children: A prospective, randomised, clinical trial.Contemp Clin Trials. 2015 May;42:213-8. doi: 10.1016/j.cct.2015.04.006. Epub 2015 Apr 18.
556. Lund N, Andersen A, Hansen AS, Jepsen FS, Barbosa AG, Biering-Sørensen S, Ravn H, Aaby P, Benn CS. The Effect of Oral Polio Vaccine at Birth on Mortality. A Randomized Trial. Clin Infect Dis. 2015 Nov 15;61(10):1504-11. doi: 10.1093/cid/civ617. Epub 2015 Jul 28.
557. Benn CS, Aaby P, Arts RJW, Jensen KJ, Netea MG, Fisker AB. An enigma: Why vitamin A supplementation does not always reduce mortality even though vitamin A deficiency is associated with increased mortality. Int J Epidemiol. 2015 Jun;44(3):906-18. doi: 10.1093/ije/dyv117. Epub 2015 Jul 2.
558. Fisker AB, Rodrigues A, Martins C, Byberg S, Thysen S, Pedersen M, Fernandes M, Ravn H, Benn CS, Aaby P. Reduced All-Cause Child Mortality After General Measles Vaccination Campaign in Rural Guinea-Bissau.. Pediatr Infect Dis J. 2015 Sep 15. [Epub ahead of print]
559. Aaby P, Rodrigues A, Kofoed PE, Benn CS. RTS,S/AS01 malaria vaccine and child mortality.Lancet. 2015 Oct 31;386(10005):1735-6. doi: 10.1016/S0140-6736(15)00693-5. No abstract available.
560. Timmermann CAG, Benn CS, Sofie Biering-Sørensen S, Aaby P, Fisker A, Monteiro I, Rodrigues A, Ravn H. Tuberculin reaction and BCG scar: Association with infant mortality. Trop Med Int Health. 2015:20:1733-34 Oct 1. doi: 10.1111/tmi.12614. [Epub ahead of print]
561. Harouna AM, Amorissani-Folquet M, Eboua FT, Desmonde S, N'Gbeche S, Aka EA, Kouadio K, Kouacou B, Malateste K, Bosse-Amani C, Ahuatchi Coffie P, Leroy V; IeDEA paediatric West African Study Group.Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d'Ivoire: a prospective cohort study. BMC Infect Dis. 2015 Aug 7;15:317. doi: 10.1186/s12879-015-1009-6.
562. Jesson J, Koumakpaï S, Diagne NR, Amorissani-Folquet M, Kouéta F, Aka A, Lawson-Evi K, Dicko F, Kouakou K, Pety T, Renner L, Eboua T, Coffie PA, Desmonde S, Leroy V; Paediatric WADA IeDEA Collaboration.Effect of Age at Antiretroviral Therapy Initiation on Catch-up Growth Within the First 24 Months Among HIV-infected Children in the IeDEA West African Pediatric Cohort. Pediatr Infect Dis J. 2015 Jul;34(7):e159-68. doi: 10.1097/INF.0000000000000734.
563. Abo Y, Zannou Djimon M, Messou E, Balestre E, Kouakou M, Akakpo J, Ahouada C, de Rekeneire N, Dabis F, Lewden C, Minga A; IeDEA West Africa Collaboration. Severe morbidity after antiretroviral (ART) initiation: active surveillance in HIV care programs, the IeDEA West Africa collaboration. BMC Infect Dis. 2015 Apr 9;15:176.
564. Jespersen S, Hønge BL, Oliveira I, Medina C, da Silva Té D, Correia FG, da Silva ZJ, Erikstrup C, Østergaard L, Laursen AL, Wejse C; the; Bissau HIV cohort study group. Challenges facing HIV treatment in Guinea-Bissau: the benefits of international research collaborations.Bull World Health Organ. 2014 Dec 1;92(12):909-14. doi: 10.2471/BLT.14.135749. Epub 2014 Sep 26.
565. Duda SN, Farr AM, Lindegren ML, Blevins M, Wester CW, Wools-Kaloustian K, Ekouevi DK, Egger M, Hemingway-Foday J, Cooper DA, Moore RD, McGowan CC, Nash D; International Epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration.Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration. J Int AIDS

Soc. 2014 Dec 15;17:19045.
566. Dyrehave C, Rasmussen DN, Hønge BL, Jespersen S, Correia FG, Medina C, Wejse C, Rodkjaer L; Bissau HIV Cohort Study Group. Nonadherence is Associated with Lack of HIV-Related Knowledge: A Cross-Sectional Study among HIV-Infected Individuals in Guinea-Bissau. J Int Assoc Provid AIDS Care. 2015 Aug 21. pii: 2325957415599211
567. .Jespersen S, Tolstrup M, Hønge BL, Medina C, Té Dda S, Ellermann-Eriksen S, Østergaard L, Wejse C, Laursen AL; Bissau HIV cohort study group.High level of HIV-1 drug resistance among patients with HIV-1 and HIV-1/2 dual infections in Guinea-Bissau. Virol J. 2015 Mar 11;12:41. doi: 10.1186/s12985-015-0273-9.
568. Biering-Sørensen S., Andersen A., Ravn H., Monterio I., Aaby P., Benn C.B. Early BCG to low-birth-weight infants and the effects on growth in the first year of life: A randomised controlled trial. BMC Pediatr. 2015 Sep 28;15:137. doi: 10.1186/s12887-015-0452-2.
569. Harouna AM, Amorissani-Folquet M, Eboua FT, Desmonde S, N'Gbeche S, Aka EA, Kouadio K, Kouacou B, Malateste K, Bosse-Amani C, Ahuatchi Coffie P, Leroy V; IeDEA West African Study Group. Effect of cotrimoxazole prophylaxis on the incidence of malaria in HIV-infected children in 2012, in Abidjan, Côte d'Ivoire: a prospective cohort study. *BMC Infect Dis*. 2015 Aug 7;15:317
570. Jespersen S, Hønge BL, Oliveira I, Medina C, da Silva Té D, Correira FG, Erikstrup C, Laursen AL, Ostergaard L, Wejse C; for the Bissau HIV Cohort study group. Cohort Profile: The Bissau HIV Cohort-a cohort of HIV-1, HIV-2 and co-infected patients. Int J Epidemiol. 2015 Jun;44(3):756-63. doi: 10.1093/ije/dyu201. Epub 2014 Oct 22.
571. Fryer HR, Van Tienen C, Van Der Loeff MS, Aaby P, Da Silva ZJ, Whittle H, Rowland-Jones SL, de Silva TI. Predicting the extinction of HIV-2 in rural Guinea-Bissau. AIDS. 2015 Nov 28;29(18):2479-86. doi: 10.1097/QAD.0000000000000844.
572. Desmonde S, Eboua FT, Malateste K, Dicko F, Ekouévi DK, Ngbeché S, Koueta F, Sy HS, Renner L, Koumakpai SA, Leroy V; IeDEA Pediatric West African Working Group. Determinants of durability of first-line antiretroviral therapy regimen and time from first-line failure to second-line antiretroviral therapy initiation.AIDS. 2015 Jul 31;29(12):1527-36. doi: 10.1097/QAD.0000000000000707.
573. Jensen KJ, Larsen N, Biering-Sørensen S, Andersen A, Eriksen HB, Monteiro I, Hougaard D, Aaby P, Netea MG, Flanagan KL, Benn CS.Heterologous immunological effects of early BCG vaccination in low-birth-weight infants in Guinea-Bissau: a randomized-controlled trial. J Infect Dis. 2015 Mar 15;211(6):956-67. doi: 10.1093/infdis/jiu508. Epub 2014 Sep 9.

2016

574. Yoshida S, Martines J, Lawn JE, Wall S, Souza JP, Rudan I, Cousens S; neonatal health research priority setting group, Aaby P, Adam I, Adhikari RK, Ambalavanan N, Arifeen SE, Aryal DR, Asiruddin S, Baqui A, Barros AJ, Benn CS, Bhandari V, Bhatnagar S, Bhattacharya S, Bhutta ZA, Black RE, Blencowe H, Bose C, Brown J, Bührer C, Carlo W, Cecatti JG, Cheung PY, Clark R, Colbourn T, Conde-Agudelo A, Corbett E, Czeizel AE, Das A, Day LT, Deal C, Deorari A, Dilmen U, English M, Engmann C, Esamai F, Fall C, Ferriero DM, Gisore P, Hazir T, Higgins RD, Homer CS, Hoque DE, Irgens L, Islam MT, de Graft-Johnson J, Joshua MA, Keenan W, Khatoon S, Kieler H, Kramer MS, Lackritz EM, Lavender T, Lawintono L, Luhanga R, Marsh D, McMillan D, McNamara PJ, Mol BW, Molyneux E, Mukasa GK, Mutabazi M, Nacul LC, Nakakeeto M, Narayanan I, Olusanya B, Osrin D, Paul V, Poets C, Reddy UM, Santosham M, Sayed R, Schlabritz-Loutsevitch NE, Singhal N, Smith MA, Smith PG, Soofi S, Spong CY, Sultana S, Tshefu A, van Bel F, Gray LV, Waiswa P, Wang W, Williams SL, Wright L, Zaidi A, Zhang Y, Zhong N, Zuniga I, Bahl R. Setting research priorities to improve global newborn health and prevent stillbirths by 2025. J Glob Health. 2016 Jun;6(1):010508. (PR)(CO)(OA)doi: 10.7189/jogh.06.010508.
575. Jensen KJ, Fisker AB, Andersen A, Sartono E, Yazdanbakhsh M, Aaby P, Erikstrup C, Benn CS. The effects of vitamin A supplementation with measles vaccine on leucocyte counts and in vitro cytokine production.Br J Nutr. 2016: 115:619-28.
576. Kjærgaard J, Birk NM, Nissen TN, Thøstesen LM, Pihl GT, Benn CS, Jeppesen DL, Pryds O, Kofoed PE, Aaby P, Greisen G, Stensballe LG. Nonspecific effect of BCG vaccination at birth on early childhood infections: a randomized, clinical multicenter trial. Pediatr Res. 2016 Nov;80(5):681-685. doi: 10.1038/pr.2016.142. Epub 2016 Jul 18.
577. Al-Emran HM, Eibach D, Krumkamp R, Ali M, Baker S, Biggs HM, Bjerregaard-Andersen M, Breiman RF, Clemens JD, Crump JA, Cruz Espinoza LM, Deerin J, Dekker DM, Gassama Sow A, Hertz JT, Im J, Ibrango S, von Kalckreuth V, Kabore LP, Konings F, Løfberg SV, Meyer CG, Mintz ED, Montgomery JM, Olack B, Pak GD, Panzner U, Park SE, Razafindrabe JL, Rabezanahary H, Rakotondrainiarivelo JP, Rakotozandrindrainy R, Raminosoa TM, Schütt-Gerowitt H, Sampo E, Soura AB, Tall A, Warren M, Wierzba TF, May J, Marks F. A Multicountry Molecular Analysis of Salmonella enterica Serovar Typhi With Reduced Susceptibility to Ciprofloxacin in Sub-Saharan Africa. Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S42-6. doi: 10.1093/cid/civ788. (PR)(CO)(OA) http://cid.oxfordjournals.org/content/62/suppl_1/S42.full.pdf+html
578. Nissen TN, Birk NM, Kjærgaard J, Thøstesen LM, Pihl GT, Hoffmann T, Jeppesen DL, Kofoed PE, Greisen

G, Benn CS, Aaby P, Pryds O, Stensballe LG. Adverse reactions to the Bacillus Calmette-Guérin (BCG) vaccine in new-born infants-an evaluation of the Danish strain 1331 SSI in a randomized clinical trial. Vaccine. 2016 Apr 6. pii: S0264-410X(16)30097-4. doi: 10.1016/j.vaccine.2016.03.100.
579. Nichols C, Cruz Espinoza LM, von Kalckreuth V, Aaby P, Ahmed El Tayeb M, Ali M, Aseffa A, Bjerregaard-Andersen M, Breiman RF, Cosmas L, Crump JA, Dekker DM, Gassama Sow A, Gasmelseed N, Hertz JT, Im J, Kabore LP, Keddy KH, Konings F, Valborg Løfberg S, Meyer CG, Montgomery JM, Niang A, Njariharinjakamampionona A, Olack B, Pak GD, Panzner U, Park JK, Park SE, Rabezanahary H, Rakotondrainiarivelo JP, Rakotozandrindrainy R, Raminosoa TM, Rubach MP, Teferi M, Seo HJ, Sooka A, Soura A, Tall A, Toy T, Yeshitela B, Clemens JD, Wierzba TF, Baker S, Marks F. Bloodstream Infections and Frequency of Pretreatment Associated With Age and Hospitalization Status in Sub-Saharan Africa. Clin Infect Dis. 2015 Nov 1;61 Suppl 4:S372-9. doi: 10.1093/cid/civ730.
580. von Kalckreuth V, Konings F, Aaby P, Adu-Sarkodie Y, Ali M, Aseffa A, Baker S, Breiman RF, Bjerregaard-Andersen M, Clemens JD, Crump JA, Cruz Espinoza LM, Deerin JF, Gasmelseed N, Sow AG, Im J, Keddy KH, Cosmas L, May J, Meyer CG, Mintz ED, Montgomery JM, Olack B, Pak GD, Panzner U, Park SE, Rakotozandrindrainy R, Schütt-Gerowitt H, Soura AB, Warren MR, Wierzba TF, Marks F. The Typhoid Fever Surveillance in Africa Program (TSAP): Clinical, Diagnostic, and Epidemiological Methodologies. Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S9-S16. doi: 10.1093/cid/civ693. (PR)(CO)(OA) http://cid.oxfordjournals.org/content/62/suppl_1/S9.full.pdf+html
581. Al-Emran HM, Krumkamp R, Dekker DM, Eibach D, Aaby P, Adu-Sarkodie Y, Ali M, Rubach MP, Bjerregaard-Andersen M, Crump JA, Cruz Espinoza LM, Løfberg SV, Gassama Sow A, Hertz JT, Im J, Jaeger A, Kabore LP, Konings F, Meyer CG, Niang A, Pak GD, Panzner U, Park SE, Rabezanahary H, Rakotozandrindrainy R, Raminosoa TM, Razafindrabe TJ, Sampo E, Schütt-Gerowitt H, Sarpong N, Soura AB, Tall A, von Kalckreuth V, Wierzba TF, May J, Marks F. Validation and Identification of Invasive Salmonella Serotypes in Sub-Saharan Africa by Multiplex Polymerase Chain Reaction. Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S80-2. doi: 10.1093/cid/civ782. (PR)(CO)(OA) http://cid.oxfordjournals.org/content/62/suppl_1/S80.full.pdf+html
582. Panzner U, Pak GD, Aaby P, Adu-Sarkodie Y, Ali M, Aseffa A, Baker S, Bjerregaard-Andersen M, Crump JA, Deerin J, Cruz Espinoza LM, Gasmelseed N, Heriniaina JN, Hertz JT, Im J, von Kalckreuth V, Keddy KH, Lankoande B, Løfberg S, Meyer CG, Oresto MM, Park JK, Park SE, Rakotozandrindrainy R, Sarpong N, Soura AB, Gassama Sow A, Tall A, Teferi M, Worku A, Yeshitela B, Wierzba TF, Marks F. Utilization of Healthcare in the Typhoid Fever Surveillance in Africa Program. Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S56-68. doi: 10.1093/cid/civ891. (PR)(CO)(OA)http://cid.oxfordjournals.org/content/62/suppl_1/S56.full.pdf+html
583. Im J, Nichols C, Bjerregaard-Andersen M, Sow AG, Løfberg S, Tall A, Pak GD, Aaby P, Baker S, Clemens JD, Espinoza LM, Konings F, May J, Monteiro M, Niang A, Panzner U, Park SE, Schütt-Gerowitt H, Wierzba TF, Marks F, von Kalckreuth V. Prevalence of Salmonella Excretion in Stool: A Community Survey in 2 Sites, Guinea-Bissau and Senegal. Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S50-5. doi: 10.1093/cid/civ789. (PR)(CO)(OA) http://cid.oxfordjournals.org/content/62/suppl_1/S50.full.pdf+html
584. Park SE, Pak GD, Aaby P, Adu-Sarkodie Y, Ali M, Aseffa A, Biggs HM, Bjerregaard-Andersen M, Breiman RF, Crump JA, Cruz Espinoza LM, Eltayeb MA, Gasmelseed N, Hertz JT, Im J, Jaeger A, Parfait Kabore L, von Kalckreuth V, Keddy KH, Konings F, Krumkamp R, MacLennan CA, Meyer CG, Montgomery JM, Ahmet Niang A, Nichols C, Olack B, Panzner U, Park JK, Rabezanahary H, Rakotozandrindrainy R, Sampo E, Sarpong N, Schütt-Gerowitt H, Sooka A, Soura AB, Sow AG, Tall A, Teferi M, Yeshitela B, May J, Wierzba TF, Clemens JD, Baker S, Marks F. The Relationship Between Invasive Nontyphoidal Salmonella Disease, Other Bacterial Bloodstream Infections, and Malaria in Sub-Saharan Africa. Clin Infect Dis. 2016 Mar 15;62 Suppl 1:S23-31. (PR)(CO)(OA) http://cid.oxfordjournals.org/content/62/suppl_1/S23.full.pdf+html
585. Steiniche D, Jespersen S, Erikstrup C, Krarup H, Handberg A, Østergaard L, Haraldsdottir T, Medina C, Gomes Correira F, Laursen AL, Bjerregaard-Andersen M, Wejse C, Hønge BL; Bissau HIV Cohort study group. Diabetes mellitus and impaired fasting glucose in ART-naïve patients with HIV-1, HIV-2 and HIV-1/2 dual infection in Guinea-Bissau: a cross-sectional study. Trans R Soc Trop Med Hyg. 2016 Apr;110(4):219-27. doi: 10.1093/trstmh/trw017
586. Rasmussen DN, Wejse C, Larsen O, Da Silva Z, Aaby P, Sodemann M. The when and how of male circumcision and the risk of HIV: a retrospective cross-sectional analysis of two HIV surveys from Guinea-Bissau. Pan Afr Med J. 2016 Feb 1;23:21. doi: 10.11604/pamj.2016.23.21.7797. eCollection 2016.
587. Klein SL, Shann F, Moss WJ, Benn CS, Aaby P. RTS,S malaria vaccine and increased mortality in girls. mBio 7(2):e00514-16. doi:10.1128/mBio.00514-16. (PR)(CO)(OA)
588. Rieckmann A, Villumsen M, Sørup S, Haugaard LK, Ravn H, Roth A, Baker JL, Benn CS, Aaby P. Vaccinations against smallpox and tuberculosis are associated with better long-term survival: a Danish case-cohort study 1971- 2010. Int J Epidemiol 2017;46:695-705
589. Sørup S, Stensballe LG, Krause TG, Aaby P, Benn CS, Ravn H. Oral Polio Vaccination and Hospital Admissions With Non-Polio Infections in Denmark: Nationwide Retrospective Cohort Study. Open Forum Infect Dis. 2016;3:ofv204. [10.1093/ofid/ofv204]
590. Jespersen S, Hønge BL, Esbjörnsson J, Medina C, da Silva Té D, Correira FG, Laursen AL, Østergaard L,

Andersen A, Aaby P, Erikstrup C, Wejse C; Bissau HIV Cohort study group. Differential effects of sex in a West African cohort of HIV-1, HIV-2, and HIV-1/2 infected patients: Men are worse off. *Trop Med Int Health*. 2016 Feb;21(2):253-62

591. Aaby P, Ravn H, Benn CS, Rodrigues A, Samb B, Ibrahim SA, Libman MD, Whittle HC. Randomized Trials Comparing Inactivated Vaccine After Medium- or High-titer Measles Vaccine With Standard Titer Measles Vaccine After Inactivated Vaccine: A Meta-analysis. Pediatr Infect Dis J. 2016 Nov;35(11):1232-1241.
592. Aaby P, Ravn H, Benn CS. The WHO Review of the Possible Nonspecific Effects of Diphtheria-Tetanus-Pertussis Vaccine. Pediatr Infect Dis J. 2016 Nov;35(11):1247-1257
593. Saadatian-Elahi M, Aaby P, Shann F, Netea MG, Levy O, Louis J, Picot V, Greenberg M, Warren W. Heterologous vaccine effects. Vaccine. 2016 Jul 25;34(34):3923-30. doi: 10.1016/j.vaccine.2016.06.020. Epub 2016 Jun 13.
594. Stensballe LG, Sørup S, Aaby P, Benn CS, Greisen G, Jeppesen DL, Birk NM, Kjærgaard J, Nissen TN, Pihl GT, Thøstesen LM, Kofoed PE, Pryds O, Ravn H. BCG-vaccination at birth and early childhood hospitalization. A randomized clinical multicenter trial. Arch Dis Child. 2016 Jul 21. pii: archdischild-2016-310760. doi: 10.1136/archdischild-2016-310760. (PR)(CO)(OA)
595. Benn CS, Fisker AB, Whittle HC, Aaby P. Revaccination with Live Attenuated Vaccines Confer Additional Beneficial Nonspecific Effects on Overall Survival: A Review. EBioMedicine. 2016 Aug;10:312-7. doi: 10.1016/j.ebiom.2016.07.016. Epub 2016 Jul 15.
596. Frankel H, Byberg S, Bjerregaard-Andersen M, Martins CL, Aaby P, Benn CS, Fisker AB. Different effects of BCG strains – A natural experiment evaluating the impact of the Danish and the Russian BCG strains on morbidity and scar formation in Guinea-Bissau. Vaccine. 2016 Aug 31;34(38):4586-93. doi: 10.1016/j.vaccine.2016.07.022. Epub 2016 Aug 1.
597. Aaby P, Andersen A, Martins CL, Fisker AB, Rodrigues A, Whittle HC, Benn CS. Does oral polio vaccine have non-specific effects on all-cause mortality? Natural experiments within a randomised controlled trial of early measles vaccine. BMJ Open. 2016 Dec 23;6(12):e013335. doi: 10.1136/bmjopen-2016-013335
598. Aaby P, Nielsen J, Benn CS, Trape JF. Sex-differential effects on mortality of BCG and diphtheria-tetanus-pertussis vaccines in a rural area with high vaccination coverage: observational study from Senegal. Trans R Soc Trop Med Hyg. 2016 Sep;110(9):527-533. Epub 2016 Oct 13.
599. Aaby P, Ravn H, Fisker AB, Rodrigues A, Benn CS. Is diphtheria-tetanus-pertussis (DTP) associated with increased female mortality? A meta-analysis testing the hypotheses of sex-differential non-specific effects of DTP vaccine. Trans R Soc Trop Med Hyg. 2016 Dec;110(10):570-581. Epub 2016 Nov 17.
600. Kjærgaard J, Stensballe LG, Birk NM, Nissen TN, Thøstesen LM, Pihl GT, Nielsen AV, Kofoed P-E, Aaby P, Pryds O, Greisen G. Bacillus Calmette-Guérin vaccination at birth: Effects on infant growth. A randomized clinical trial. Early Hum Dev. 2016 Sep;100:49-54. doi: 10.1016/j.earlhumdev.2016.05.015
601. Mogensen SW, Aaby P, Smedman L, Martins CL, Rodrigues A, Benn CS, Ravn H. Introduction of standard measles vaccination in an urban African community in 1979 and overall child survival: a reanalysis of data from a cohort study. BMJ Open. 2016 Dec 20;6(12):e011317. doi: 10.1136/bmjopen-2016-011317
602. Pisani E, Aaby P, Breugelmans JG, Carr D, Groves T, Helinski M, Kamuya D, Kern S, Littler K, Marsh V, Mboup S, Merson L, Sankoh O, Serafini M, Schneider M, Schoenenberger V, Guerin PJ. Beyond open data: realising the health benefits of sharing data. BMJ. 2016 Oct 10;355:i5295. doi: 10.1136/bmj.i5295
603. Rasmussen SM, Biering-Sørensen S, Byberg S, Andersen A, Bjerregaard-Andersen M, Rodrigues A, Benn CS, Martins CL, Aaby P. The effect of early measles vaccination at 4.5 months of age on growth at 9 and 24 months of age in a randomized trial in Guinea-Bissau. BMC Pediatr. 2016 Dec 3;16(1):199
604. Sørup S, Benn CS, Poulsen A, Krause TG, Aaby P, Ravn H. Simultaneous vaccination with MMR and DTaP-IPV-Hib and rate of hospital admissions with any infections: A nationwide register based cohort study. Vaccine. 2016 Dec 7;34(50):6172-6180. doi: 10.1016/j.vaccine.2016.11.005. Epub 2016 Nov 10.

2017

605. Aaby P, Benn C. Beneficial non-specific effects of oral polio vaccine: Implications for the cessation of OPV? Clin Inf Dis 2017;65:420-1
606. Benn CS, Jacobsen LH, Fisker AB, Rodrigues A, Sartono E, Lund N, Whittle HC, Aaby P. Campaigns with oral polio vaccine may lower mortality and create unexpected results. Vaccine 2017;35:1113-1116.
607. Byberg S, Fisker AB, Rodrigues A, Balde I, Enemark U, Aaby P, Benn CS, Griffiths UK. Household experience and costs of seeking measles vaccination in rural Guinea-Bissau. Trop Med Int Health. 2017;22(1):12-20. doi: 10.1111/tmi.12793. [Epub ahead of print]
608. Byberg S, Thysen SM, Rodrigues A, Martins C, Cabral C, Careme M, Aaby P, Benn CS, Fisker AB. A general measles vaccination campaign in urban Guinea-Bissau: Comparing child mortality among participants and non-participants. Vaccine. 2017 Jan 3;35(1):33-39. doi: 10.1016/j.vaccine.2016.11.049. Epub 2016 Nov 24.
609. Byberg S, Fisker AB, Thysen SM, Rodrigues A, Enemark U, Aaby P, Benn CS, Griffiths UK. Cost-effectiveness of providing measles vaccination to all children in Guinea-Bissau. Global Health Action (In press)

610. Do VA, Biering-Sørensen S, Fisker AB, Balé C, Rasmussen SM, Christensen LD, Jensen KJ, Martins C, Aaby P, Benn CS. The effect of early measles vaccination on morbidity between 18 weeks and 9 months of age: A

randomised controlled trial in Guinea-Bissau. J Infect Dis. 2017 Jan 10. pii: jiw512. (PR)(CO)(OA)
611. Marks F, von Kalckreuth V, Aaby P, Adu-Sarkodie Y, El Tayeb MA, Ali M, Aseffa A, Baker S, Biggs HM, Bjerregaard-Andersen M, Breiman RF, Campbell JI, Cosmas L, Crump JA, Espinoza LM, Deerin JF, Dekker DM, Fields BS, Gasmelseed N, Hertz JT, Van Minh Hoang N, Im J, Jaeger A, Jeon HJ, Kabore LP, Keddy KH, Konings F, Krumkamp R, Ley B, Løfberg SV, May J, Meyer CG, Mintz ED, Montgomery JM, Niang AA, Nichols C, Olack B, Pak GD, Panzner U, Park JK, Park SE, Rabezanahary H, Rakotozandrindrainy R, Raminosoa TM, Razafindrabe TJ, Sampo E, Schütt-Gerowitt H, Sow AG, Sarpong N, Seo HJ, Sooka A, Soura AB, Tall A, Teferi M, Thriemer K, Warren MR, Yeshitela B, Clemens JD, Wierzba TF. Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study. Lancet Glob Health. 2017 Mar;5(3):e310-e323. doi: 10.1016/S2214-109X(17)30022-0
612. Mogensen SW, Andersen A, Rodrigues A, Benn CS, Aaby P. The Introduction of Diphtheria-Tetanus-Pertussis and Oral Polio Vaccine Among Young Infants in an Urban African Community: A Natural Experiment. EBioMedicine. 2017 Mar;17:192-198.doi: 10.1016/j.ebiom.2017.01.041. (PR)(OA)
613. Nissen TN, Birk NM, Smits G, Jeppesen DL, Stensballe LG, Netea MG, van der Klis F, Benn CS, Pryds O; Calmette Study Group. Bacille Calmette-Guérin (BCG) vaccination at birth and antibody responses to childhood vaccines. A randomised clinical trial. Vaccine. 2017 Mar 15. pii: S0264-410X(17)30251-7. doi: 10.1016/j.vaccine.2017.02.048. [Epub ahead of print] (PR)(CO)(OA)
614. Welaga P, Oduro A, Debpuur C, Aaby P, Ravn H, Andersen A, Binka F, Hodgson A. Fewer out-of-sequence vaccinations and reduction of child mortality in Northern Ghana.Vaccine. 2017 Apr 25;35(18):2496-2503. doi: 10.1016/j.vaccine.2017.03.004. Epub 2017 Mar 22.
615. Patsche CB, Rudolf F, Gomes V, Østergaard L, Aaby P, Byberg S, Wejse C. Low prevalence of malnourishment among household contacts to patients with tuberculosis in Guinea-Bissau. (Accepted IJTLD)
616. Rudolf F, Wagner AJ, M'Back F, Gomes VF, Aaby P, Østergaard L, Eugen-Olsen J, Wejse C. Tuberculosis case-finding and mortality prediction – Added value of the clinical TBscore and biomarker suPAR. *IntJTubLungDis* 2017; 21(1):67-72
617. Nordentoft PB, Engell-Sørensen T, Jespersen S, Correia FG, Medina C, da Silva Té D, Østergaard L, Laursen AL, Wejse C, Hønge BL; Bissau HIV Cohort study group. Assessing factors for loss to follow-up of HIV infected patients in Guinea-Bissau. Infection. 2017 Apr;45(2):187-197
618. Thøstesen LM, Stensballe LG, Pihl GT, Kjærgaard J, Birk NM, Nissen TN, Jensen AK, Aaby P, Olesen AW, Jeppesen DL, Benn CS, Kofoed PE.Neonatal BCG-vaccination has no effect on recurrent wheeze in the first year of life. A randomized clinical trial. J Allergy Clin Immunol. 2017 Mar 24. pii: S0091-6749(17)30473-6.
619. Nielsen BU, Byberg S, Aaby P, Rodrigues A, Benn CS, Fisker AB. Seasonal variation in child mortality in rural Guinea-Bissau.Trop Med Int Health. 2017 Jul;22(7):846-856. doi: 10.1111/tmi.12889. Epub 2017 Jun 6.
620. Byberg S, Østergaard M, Rodrigues A, Martins C, Benn CS, Aaby P, Fisker AB. Risk factors for infant mortality in Guinea-Bissau: Changing patterns with declining mortality? Plos One (in press)
621. Hansen NS, Byberg S, Jacobsen LH, Bjerregaard-Andersen, Jensen AKG, Martins C, Aaby P, Jensen JS, Benn CS, Whittle H. Effect of Early Measles Vaccine on Pneumococcal Colonization: A Randomized Trial from Guinea-Bissau. Plos One (in press)
622. Biering-Sørensen S, Aaby P, Lund N, Monteiro I, Jensen K, Eriksen HB, Schaltz-Buchholzer F, Jørgensen ASP, Rodrigues A, Fisker AB, Benn CB. Early BCG and neonatal mortality among low-birth-weight infants: A randomised controlled trial. CID 2017;65:1183-90
623. Aaby P, Andersen A, Ravn H, Khalequzzaman Md. Co-administration of BCG and diphtheria-tetanus-pertussis (DTP) vaccinations may reduce infant mortality more than the WHO-schedule of BCG first and then DTP. A re-analysis of demographic surveillance data from rural Bangladesh. EBioMedicine. 2017 Aug;22:173-180. doi: 10.1016/j.ebiom.2017.07.012. Epub 2017 Jul 14
624. Rieckmann A, Villumsen M, Jensen ML, Ravn H, da Silva ZJ, Sørup S, Baker JL, Rodrigues A, Benn CS, Roth AE, Aaby P. Smallpox and BCG vaccination and HIV-1 in Guinea-Bissau and Denmark. OFID 2017;4:ofx130
625. Thøstesen LM, Kjaer HF, Pihl GT, Nissen TN, Birk NM, Kjaergaard J, Jensen AKG, Aaby P, Olesen AW, Stensballe LG, Jeppesen DL, Benn CS, Kofoed PE.Neonatal BCG has no effect on allergic sensitization and suspected food allergy until 13 months. Pediatr Allergy Immunol. 2017 Sep;28(6):588-596. doi: 10.1111/pai.12748.
626. Thøstesen LM, Stensballe LG, Pihl GT, Kjærgaard J, Birk NM, Nissen TN, Jensen AK, Aaby P, Olesen AW, Jeppesen DL, Benn CS, Kofoed PE. Neonatal BCG-vaccination and atopic dermatitis before 13 months of age. A randomised clinical trial
627. Jensen KJ, Sondergaard M, Andersen A, Martins C, Erikstrup C, Aaby P, Flanagan KL, Benn CS. Long-term sex-differential effects of neonatal vitamin A supplementation on in vitro cytokine responses. British Journal of Nutrition (in press)
628. Vieira N, Rasmussen DN, Oliveira I, Gomes A, Aaby P, Wejse C, Sodemann M, Reynolds L, Unger HW. Awareness, attitudes and perceptions regarding HIV and PMTCT amongst pregnant women in Guinea-Bissau-a qualitative study. BMC Womens Health. 2017 Sep 4;17(1):71. doi: 10.1186/s12905-017-0427-6.
629. Nissen TN, Birk NM, Blok BA, Arts RJW, Andersen A, Kjærgaard J, Thøstesen LM, Hoffmann T, Jeppesen DL, Nielsen SD, Kofoed PE, Stensballe LG, Aaby P, Ruhwald M, Netea MG, Benn CS, Pryds O.Bacillus

Calmette-Guérin vaccination at birth and in vitro cytokine responses to non-specific stimulation. A randomized clinical trial.Eur J Clin Microbiol Infect Dis. 2017 Sep 10. doi: 10.1007/s10096-017-3097-2. [Epub ahead of print]

630. Jensen KJ, Søndergaard MJ, Andersen A, Martins C, Erikstrup C, Aaby P, Flanagan KL, Benn CS. Long-term sex-differential effects of neonatal vitamin A supplementation on in vitro cytokine responses. Br J Nutr 2017 Dec;118(11):942-948. doi: 10.1017/S0007114517002938. Epub 2017 Nov 23.
631. Biering-Sørensen S, Jensen KJ, Monterio I, Ravn H, Aaby P, Benn CS.Rapid protective effects of early BCG on neonatal mortality among low birth weight boys: observations from randomised trials. J Infect Dis. 2018 Feb 14;217(5):759-766
632. Fisker AB, Nebie E, Schoeps A, Martins C, Rodrigues A, Zakane A, Kagone M, Byberg S, Thysen SM, Tiendrebeogo J, Coulibaly B, Sankoh O, Becher H, Whittle HC, van der Klis FRM, Benn CS, Sie A, Müller O, Aaby P. A two-centre randomised trial of an additional early dose of measles vaccine: Effects on mortality and measles antibody levels. Clin Infect Dis 2018;66:1573-80
633. Benn CS, Fisker AB, Aaby P.Serious danger signals: Response to: The effect of neonatal vitamin A supplementation on morbidity and mortality at 12 months: a randomized trial. Int J Epidemiol 2017;46(5):1718-1720. doi: 10.1093/ije/dyx139.
634. Benn CS, Sørup S, Aaby P. The sequence of vaccinations to test the non-specific effects of vaccines. BMJ Rapid Responses 2017

2018

635. Arts RJW, Moorlag SJCFM, Novakovic B, Li Y, Wang SY, Oosting M, Kumar V, Xavier RJ, Wijmenga C, Joosten LAB, Reusken CBEM, Benn CS, Aaby P, Koopmans MP, Stunnenberg HG, van Crevel R, Netea MG. BCG Vaccination Protects against Experimental Viral Infection in Humans through the Induction of Cytokines Associated with Trained Immunity. Cell Host Microbe 2018;23(1):89-100.e5.
636. Funch MK, Thysen SM, Rodrigues A, Martins CL, Aaby P, Benn CS, Fisker AB. Determinants of BCG scarification among children in rural Guinea-Bissau: A prospective cohort study. Human Vaccines & Immunotherapeutics 2018;14:2434-42
637. Andersen A, Fisker AB, Rodrigues A, Martins C, Ravn H, Lund N, Biering-Sørensen S, Benn CS, Aaby P. National Immunization Campaigns with Oral Polio Vaccine Reduce All-Cause Mortality: A Natural Experiment within Seven Randomized Trials. Front Public Health. 2018;6:13
638. Aaby P, Mogensen SW, Andersen A, Rodrigues A, Benn CS. The introduction of diphtheria-tetanus-pertussis vaccine to older children in an urban African community: A natural experiment. Frontiers Public Health 2018;6:79
639. Welaga P, Hodgson A, Debpuur C, Aaby P, Ravn H, Binka F, Azongo D, Oduro A. Measles vaccination and MDG4: Increasing coverage and increasing child survival in Northern Ghana. Frontiers Public Health 2018;6:
640. Schoeps A, Nebié E, Fisker AB, Sié A, Zakane A; Müller O, Aaby P, BecherH. No effect of an additional early dose of measles vaccine on hospitalization or mortality in children: a randomized controlled trial. Vaccine 2018;36:1965-71
641. de Bree CLCJ, Marijnissen RJ, Kel JM, Rosendahlb SK, Aaby P, Benn CS, Vijnands MVW, Diavatopoulos DA, van Crevel R, Joosten LAB, Netea MG, Dulos M. The Effect of BCG-induced Trained Immunity on Experimental Influenza A/Anhui/1/2013 (H7N9) Infection in Mice Manuscript ID: 354150 Frontiers in Immunology 2018;9:869
642. Benn CS, Fisker AB, Rieckmann A, Jensen AG, Aaby P. How to evaluate potential non-specific effects of vaccines: The quest for randomized trials or time for triangulation? Expert Rev Vaccines. 2018;17:411-20
643. Hanifi SMA, Ravn H, Aaby P, Bhuiya A Where girls are less likely to be fully vaccinated than boys: Evidence from a rural area in Bangladesh. Vaccine. 2018;36;3323-30
644. Olesen JS, Jespersen S, Da Silva ZJ, Rodrigues A, Erikstrup C, Aaby P, Wejse C, Hønge BL. HIV-2 continues to decrease, while HIV-1 is stabilizing in Guinea-Bissau. AIDS. 2018 Apr 19. doi: 10.1097/QAD.0000000000001827.
645. Stensballe LG, Ravn H, Birk NM, Kjærgaard J, Nissen TN, Pihl GT, Thøstesen LM, Greisen G, Jeppesen DL, Kofoed PE, Pryds O, Sørup S, Aaby P, Benn CS. BCG Vaccination at Birth and Rate of Hospitalization for Infection Until 15 Months of Age in Danish Children: A Randomized Clinical Multicenter Trial. J Pediatric Infect Dis Soc. 2018;piy029
646. Hønge BL, Jespersen S, Medina C, Té DS, da Silva ZJ, Christiansen M, Kjerulff B, Laursen AL, Wejse C, Krarup H, Erikstrup C; Bissau HIV Cohort study group. The challenge of discriminating between HIV-1, HIV-2 and HIV-1/2 dual infections. HIV Med. 2018;19:403-410
647. Pinstrup Joergensen AS, Bjerregaard-Andersen M, Biering-Sørensen S, Byberg S, Camala L, Martins C, Rodrigues A, Aaby P, Benn CS. Admission and mortality at the main neonatal intensive care unit in Guinea-Bissau. Trans R Soc Trop Med Hyg. 2018;112:335-41
648. Whittle H, Aaby P. Measles. Oxford Textbook of Medicine, 2018, 8th edition
649. Brønd M, Martins CL, Byberg S, Benn CS, Whittle H, Garly ML, Aaby P, Fikser AB. Randomized trial of 2 versus 1 dose of measles vaccine: Effec on hospital admission of children after 9 months of age. J Pediatric Infect Dis 2018;7:226-33

650. Hansen JS, Thysen SM, Rodrigues A, Martins C, Fisker AB. Is early measles vaccination associated with stronger survival benefit than late measles vaccination. BMC Pub Hlth 2018;18:984
651. Andersen MN, Hønge BL, Jespersen S, Medina C, Té DS, Laursen A, Wejse C, Erikstrup C, Møller HJ. Soluble macrophage receptor (sCD206/sMR) as a biomarker in HIV-infection. **J Infect Dis**. 2018;218:1291-1295
652. Rasmussen DN, Unger H, Bjerregaard-Andersen M, Té DdaS, Vieira N, Oliveira-Souto I, Hønge BL, Jespersen S, Alves M, Aaby P, Wejse C, Sodemann M. Political instability and supply-side barriers undermine the potential for high participation in HIV testing for the prevention of mother-to-child transmission in Guinea-Bissau: A retrospective cross-sectional study. PLoS ONE 2018;13:e0199819
653. Benn CS, Rieckmann A, Jensen KJ, Aaby P. The role of maternal priming and boosting for the non-specific effects of BCG vaccine. In The Value of BCG and TNF in Autoimmunity, Faustmann D editor http://elsev.spi-bpo.com/books/EComp/FAUSTMAN978-0-12-814603-3/1/OTc4LTAtMTIt/index.php?Type=E
654. de Bree C, Janssen R, Aaby P, van Crevel R, Joosten L, Benn CS, Netea M. The impact of sex hormones on BCG-induced trained immunity. J Leukocyte Biology 2018;104:573-8
655. de Bree C, Koeken VACM, Joosten LAB, Aaby P, Benn CS, van Crevel R, Netea MG. Non-specific effects of vacines: Current evidence and potential implications. Semin Immunol 2018;39:35-43
656. Aaby P, Benn CS. Syvfold fald i børnedødeligheden i Guinea-Bissau de seneste 40 år. Ugeskrift for Læger 2018;180:PIIv07180470
657. Benn CS, Aaby P, Særup S [Non-specific effects of vaccination in Denmark]. Ugeskr Laeger. 2018 Oct 29;180(44). pii: V07180467. Danish.
658. Fisker AB, Thysen SM, Benn CS, Aaby P.[Limited knowledge of the effect on child mortality of vaccinations and vitamin A supplementation].Ugeskr Laeger. 2018 Oct 29;180(44). pii: V06180465. Danish
659. Grønborg HL, Jespersen S, Egedal JH, Correia FG, Medina C, Krarup H, Hønge BL, Wejse C. Prevalence and clinical characteristics of CMV infection among HIV infected individuals in Guinea-Bissau. Trop Med Int Health. 2018;23;896-904
660. Steiniche D, Jespersen S, Medina C, Sanha FC, Wejse C, Hønge BL. Excessive mortality and loss to follow-up among HIV-infected children in Guinea-Bissau, West Africa: A retrospective follow-up study. Trop Med Int Health. 2018;23:1148-1156
661. Se Eun Park, Thanh Duy Pham, Christine Boinett, Vanessa Wong, Gi Deok Pak, Ursula Panzner, Ligia Cruz Espinoza, Vera von Kalckreuth, Justin Im, Heidi Schutt-Gerowitt, John Crump, Robert Breiman, Yaw Adu-Sarkodie, Ellis Owusu-Dabo, Raphael Rakotozandrindrainy, Abdramane Soura, Abraham Aseffa, Nagla Gasmelseed, Karen Keddy, Jurgen May, Amy Gassama Sow, Peter Aaby, Holly Biggs, Julian Hertz, Joel Montgomery, Leonard Cosmas, Beatrice Olack, Barry Fields, Nimako Sarpong, Tsiriniaina Razafindrabe, Tiana Raminosoa, Leon Kabore, Emmanuel Sampo, Mekonnen Teferi, Biruk Yeshitela, Muna Tayeb, Arvinda Sooka, Christian Meyer, Ralf Krumkamp, Denise Dekker, Anna Jaeger, Sven Poppert, Adama Tall, Aissatou Niang, Morten Bjerregaard-Andersen, Sandra Lofberg, Hye Jin Seo, Hyon Jin Jeon, Jessica Deerin, Jinkyung Park, Frank Konings, Mohammad Ali,John Clemens, Peter Hughes, Juliet Sendagala, Tobias Vudriko, Robert Downing, Usman Ikumapayi, Grant Mackenzie, Stephen Obaro, Silvia Argimon, David Aanensen, Andrew Page, Jacqueline Keane, Sebastián Duchêne, Zoe Dyson, Kathryn Holt, Gordon Dougan, Florian Marks, and Stephen Baker. The phylogeography and incidence of multi-drug resistant typhoid fever in sub-Saharan Africa. Nature Comm 2018:9:5094
662. Smits G, Benn CS, Whittle H, van Binnendijk R, Aaby P, van der Klis F.Smits G, et al. Maternal measles antibodies and their influence on all-cause mortality following measles vaccination: an alternative to measure very low maternal antibody levels. CID 2018;ciy900
663. Welaga P, Debpuur C, Aaby P, Hodgson A, Azongo DK, Benn CS, Oduro A Is the decline in neonatal mortality in Northern Ghana, 1996-2012, associated with the decline in the age of BCG vaccination? An observational study. BMJ Open 2018;8:e023752
664. Beck KB, Hønge BL, Olesen JS, Petersen MS, Jespersen S, Wejse C, da Silva ZJ, Medina C, Té DdS, Moeller BK, Benn CS, Aaby P, Erikstrup C. Long-term effects of smallpox vaccination on expression of the HIV-1 co-receptor CCR5 in women. *PLoS One 2018;13:e0207259*

2019

665. Sørup S, Jensen AKG, Aaby P, Benn CS. Revaccination with measles-mumps-rubella vaccine and infectious disease morbidity: a Danish register-based cohort study. CID 2019;68:282-90
666. F Schaltz-Buchholzer, S Biering-Sørensen, N Lund, I Monteiro, P Umbasse, A B Fisker, A Andersen, A Rodrigues, P Aaby, C S Benn; Early Bacille Calmette-Guérin vaccination, hospitalizations and hospital deaths: Analysis of a secondary outcome in three randomized trials from Guinea-Bissau, The Journal of Infectious Diseases 2019;219:624-32
667. Blok B, Jensen KJ, Aaby P, Fomsgaard A, van Crevel R, Benn CS, Netea M. Opposite effects of Vaccinia and Modified Vaccinia Ankara on trained immunity. European Journal of Clinical Microbiology & Infectious Diseases 2019;38:449-56

668. Walk J, de Bree C, Graumans W, Siebelink-Stoter R, van Gemert GJ, van de Vegte-Bolmer M, Teelen K, Hermsen CC, Arts RJW, Behet MJ, Moorlag S, Yang ASP, van Crevel R, Aaby P, de Mast Q, van der Ven AJMA, Benn CS, Netea MG, Sauerwein RW, BCG vaccination induces trained immunity to a controlled human malaria infection. Nature Comm 2019;10:874
669. Berendsen M, Øland CB, Bles P, Jensen AKG, Kofoed PE, Whittle H, de Bree C, Netea MG[6], Martins C, Benn CS, Aaby P. Maternal priming: BCG-scarring in the mother enhances the survival of children with a BCG-scar. JPIDS 2019;piy142
670. Jensen MM, Olesen JS, Kjerulff B, Byberg S, da Silva ZJ, Rodrigues A, Jespersen S, Wejse C, Aaby P, Erikstrup C, Hønge B. HTLV prevalence is no longer following the decreasing HIV prevalence - 20 years of retroviral surveillance in Guinea-Bissau, West Africa. Acta Trop. 2019;192:144-50
671. Benn CS, Aaby P, Fisker AB. Lessons learned from the testing of neonatal vitamin A supplementation. Nutrients 2019;11:pii:E449
672. Blok B, de Bree LCJ, Diavatopoulos DA, Langereis JD, Joosten LAB, Aaby P, van Clevel R, Benn CS, Netea M. Interacting non-specific immunological effects of BCG and Tdapf vaccinations: An explorative randomized trial. Clin Infect Dis 2019;ciz246
673. Rieckmann A, Haerskjold A, Benn CS, Aaby P, Lange T, Sorup S. Measles, mumps and rubella vs diphtheria–tetanus–acellular-pertussis–inactivated-polio–Haemophilus influenzae type b as the most recent vaccine and risk of early 'childhood asthma'. *Int J Epidemiol.* 2019
674. Bjerregaard-Andersen M, Gomes GM, Hennild DE, Jensen DM, Christensen K, Sodemann M, Beck-Nielsen H, Aaby P.The Guinea-Bissau Twin Registry Update: A Platform for Studying Twin Mortality and Metabolic Disease.Twin Res Hum Genet. 2019 Jul 18:1-7. doi: 10.1017/thg.2019.39.
675. Thysen SM, Fernandes M, Benn CS, Aaby P, Fisker AB.Cohort profile : Bandim Health Project's (BHP) rural Health and Demographic Surveillance System (HDSS)-a nationally representative HDSS in Guinea-Bissau. BMJ Open. 2019 Jun 11;9(6):e028775
676. Thysen et al. Can earlier BCG vaccination reduce early infant mortality? Study protocol for a cluster randomised trial in Guinea-Bissau. BMJ Open 2019;9
677. Thysen SM, Rodrigues A, Aaby P, Fisker AB. Out-of-sequence DTP and measles vaccinations and child mortality in Guinea-Bissau – a reanalysis. BMJ Open 2019;9:e24893
678. Jensen KJ, Biering-Sørensen S, Ursing J, Kofoed PE, Aaby P, Benn CS (2019) Seasonal variation in the non-specific effects of BCG vaccination on neonatal mortality: three randomized controlled trials in Guinea-Bissau. BMJ Global Health 2019 (in press).
679. Andreas Rieckmann, Kathrine Damm Meyle, Naja Hulvej Rod, Jennifer Lyn Baker, Christine Stabell Benn, Peter Aaby, Signe Sørup "Smallpox and BCG vaccination in childhood and cutaneous malignant melanoma in Danish adults followed from 18 to 49 years" Vaccine
680. Toy T, et al. Multicountry Distribution and Characterization of Extended-spectrum β-Lactamase–associated Gram-negative Bacteria From Bloodstream Infections in Sub-Saharan Africa. CID 2019
681. Aaby P, Benn CS. Developing the concept of beneficial nonspecific effect of live vaccines with epidemiological studies. Clin Microbiol Infect. 2019 Aug 23. pii: S1198-743X(19)30452-5.
682. Rieckmann et al. Hypothesis: Termination of smallpox vaccination and increase in the female/male HIV-1 prevalence ratio. BMJ Open (in press)
683. Berendsen ML, van Gijzel SW, Smits J, de Mast Q, Aaby P, Benn CS, Netea MG, van der Ven AJ.BCG vaccination is associated with reduced malaria prevalence in children under the age of 5 years in sub-Saharan Africa. BMJ Glob Health. 2019 Nov 14;4(6):e001862. doi: 10.1136/bmjgh-2019-001862. eCollection 2019.
684. Schaltz-Buchholzer F, Bjerregaard-Andersen M, Øland CB, Golding C, Stjernholm EB, Monteiro I, Aaby P, Benn CS. Early vaccination with BCG-Denmark or BCG-Japan versus BCG-Russia to healthy newborns in Guinea-Bissau: A randomized controlled trial. Clin Infect Dis. 2019 Nov 3. pii: ciz1080. doi: 10.1093/cid/ciz1080. [Epub ahead of print] PubMed PMID: 31677386.
685. Varma A, Jensen AKG, Thysen SM, Pedersen LM, Aaby P, **Fisker AB**.Research protocol of two concurrent cluster-randomized trials: Real-life Effect of a CAMPaign with Measles Vaccination (RECAMP-MV) and Real-life Effect of a CAMPaign with Oral Polio Vaccination (RECAMP-OPV) on mortality and morbidity among children in rural Guinea-Bissau.BMC Public Health. **2019** Nov 11;19(1):1506.
686. Madsen T, Jespersen S, Medina C, Té DDS, Wejse C, Laursen AL, Hønge BL; Bissau HIV Cohort Study Group. Acceptance and Feasibility of Partner Notification to HIV Infected Individuals. AIDS Behav. 2019 Nov 8. doi: 10.1007/s10461-019-02717-z
687. Hansen NS, Byberg S, Jacobsen LH, Bjerregaard-Andersen M, Jensen AKG, Martins C, Aaby P, Jensen JS, Benn CS, Whittle H. Correction: Effect of early measles vaccine on pneumococcal colonization: A randomized trial from Guinea-Bissau.PLoS One. 2019 Oct 30;14(10):e0224782.
688. Lise Gehrt, Peter Aaby, Christine Stabell Benn and Signe Sørup. Regarding "Early childhood vaccination and subsequent mortality or morbidity: are observational studies hampered by residual confounding? A Danish register-based cohort study". BMJ Rapid Responses, 30 October 2019
689. Hønge BL, Olesen JS, Jensen MM, Jespersen S, da Silva ZJ, Rodrigues A, Laursen AL, Wejse C, Krarup H, Aaby P, Erikstrup C. Hepatitis B and C in the adult population of Bissau, Guinea-Bissau: a cross-sectional survey. Trop Med Int Health. 2019 Nov 20

690. Lise Gehrt, Peter Aaby, Christine Stabell Benn and Signe Sørup. Response to comment regarding "Early childhood vaccination and subsequent mortality or morbidity: are observational studies hampered by residual confounding? A Danish register-based cohort study". BMJ Rapid Responses, 12 December 2019
691. Aaby P, Benn CS. Stopping live vaccines after disease eradication may increase mortality. Vaccine 2020:38:10-14
692. Aaby P, Fisker AB, Björkman, Benn CS. Rolling out the RTS,S malaria vaccine: To test or not to test the effect on mortality? BMJ 2020;l6920
693. Benn CS, Fisker AB, Rieckmann A, Sørup S, Aaby P. Vaccinology: Time to change paradigm? Lancet Inf Dis 2020 (in press)
694. Clipet-Jensen C, Andersen A, Jensen AKG, Aaby P, Zaman K. Out-of-sequence measles and DTP vaccinations. A re-analysis of demographic surveillance data from rural Bangladesh. CID 2020
695. Jensen KJ, Biering-Sørensen S, Ursing J, Kofoed PL, Aaby P, Benn CS.Seasonal variation in the non-specific effects of BCG vaccination on neonatal mortality: three randomised controlled trials in Guinea-Bissau.BMJ Glob Health. 2020 Mar 5;5(3):e001873. doi: 10.1136/bmjgh-2019-001873. eCollection 2020.
696. Benn CS, Martins CL, Andersen A, Fisker AB, Whittle HC, Aaby P. Measles vaccination in the presence of measles antibody may enhance child survival. Front Pediatr 2020;8:article 20
697. Steiniche MM. Thysen SM, Jensen AKG, Rodrigues A, Martins C, Nyerowitsch DW, Aaby P, Fisker AB. . The effect of early measles vaccination on morbidity and growth: A randomised trial from Guinea-Bissau. Vaccine 2020;38:2487-94
698. Mutua MK, Mohamed SF, Limani-Murange EW, Kiarie L, Janusz CB, Aaby P, Fisker AB, Echoka E, Ravn H. Complete and on-time routine childhood immunization: determinants and association with severe morbidity in urban informal settlements, Nairobi, Kenya. Ann Hum Biology 2020;47:132-41
699. Brook B, Harbeson DJ, Shannon CP, Ben-Othman R, Cai B, He D, Francis F, Huang J, Varankovich N, Liu A, Bao W, Bjerregaard-Andersen M, Schaltz-Buchholzer F, Sanca L, Golding CN, Larsen KL, Levy O, Kampmann B, The EPIC Consoritum, Wynn JL, Shann F, Aaby P, Benn CS, Tebbutt S, Amenyogbe N, Kollmann TR: BCG-vaccination induced emergency granulopoiesis provides rapid protection from neonatal sepsis. Science Translational Medicine 2020 (in press)
700. Blok BA, Arts RJW, van Crevel R, Aaby P, Joosten LAB, Benn CS, Netea MG. Differential effects of BCG vaccine on immune responses induced by vi polysaccharide typhoid fever vaccination: an explorative trandomized trial. Eur J Clin Micro Infect Dis 2020;39:566-74
701. Hanifi SMA, Biering-Sørensen S, Jensen A, and Aaby P. Penta is associated with an increased female-male mortality ratio: cohort study from Bangladesh. Human Vaccine Immunotherapeutics 2020 (in press)
702. Gehrt L, Aaby P, Benn CS, Sørup S. "Response to comment regarding "Early childhood vaccination and subsequent mortality or morbidity: are observational studies hampered by residual confounding? A Danish register-based cohort study"". eLetter URL: https://bmjopen.bmj.com/content/9/9/e029794
703. Benn CS, Roth A, Garly ML, Fisker AB, Schaltz-Buchholzer F, Timmermann A, Berensen M, Aaby P. BCG-scarring and improved child survival: A combined analysis of studies of BCG-scarring. J Int Med 2020;joim.13084
704. Thysen SM, Benn CS, Gomes VF, Rudolf F, Wejse C, Roth A, Kallestrup P, Aaby P, Fisker A. Neonatal BCG vaccination and child survival in TB-exposed and TB-unexposed children: a prospective cohort study. BMJ Open. 2020 Feb 28;10:e035595. doi: 10.1136/bmjopen-2019-035595.
705. Chumakov K, Benn CS, Aaby P, Kottilli S. Gallo R. Can existing live vaccines prevent COVID-19? Science 2020;368:1187-88
706. Stensballe LG, Ravn H, Birk NM, Kjærgaard J, Nissen TN, Pihl GT, Thøstesen LM, Greisen G, Jeppesen DL, Kofoed PE, Pryds O, Sørup S, Aaby P, Benn CS. Corrigendum: BCG Vaccination at Birth and Rate of Hospitalization for Infection Until 15 Months of Age in Danish Children: A Randomized Clinical Multicenter Trial. J Pediatric Infect Dis Soc. 2020 Feb 28;9(1):106. doi: 10.1093/jpids/piaa003.
707. Aaby P, Benn CS, Flanangan K, Klein S, Kollmann T, Lynn D, Shann F. The non-specific and sex-differential effects of vaccines. Nat Rev Immunol 2020;20:464-70
708. Van Damme W, Dahake R, Delamou A, Ingelbeen B, Wouters E, Vanham G, van de Pas R, Dossou JP, Ir P, Abimbola S, van der Borght S, Narayanan D, Bloom G, van Engelgern I, Ahmed MAA, Kiendrébéogo JA, Verdonck K, de Brouwere V, Bello K, Kloos H, Aaby P, Kalk A, Al-Awlaqi S, Prashanth NS, Muyembe.-Tamfum JJ, Mbala P, Ahuka-Mundeke S, Assefa Y. The COVID-19 pandemic: diverse contexts; different epidemics – how and why? BMJ Global Health 2020;5:003098
709. Moorlag SJCFM, van Deuren RC, ven Werkhoven CH, Jaeger M, Debisarun P, Taks E, Mourits VP, Koeken VACM, de Bree LCJ, ten Doesschate T, Cleophas MC, Smeekens S, Oosting M, van de Veerdonk FL, Joosten LAB, ten Oever J, van der Meer JWM, Curtis N, Aaby P, Benn CS, Giarmarellos-Bourboulis EJ, Bonten M, van Crevel R, Netea MG. Safety and COVID-19 symptoms in individuals recently vaccinated with BCG: a retrospective cohort study. Cell Reports Medicine 2020;1:100073
710. Madsen AMR, et al. Using BCG vaccine to enhance non-specific protection of health cre workers during the COVID-19 pandemic: A structures summary of a study protocoal for a randomised in Denmark. Trials 2020 (in press)

711. Andersen A*, Fisker AB*, Rodrigues A, Martins C, Ravn H, Lund N, Biering-Sørensen S, Benn CS, Aaby P. National immunisation campaigns with oral polio vaccine may reduce all-cause mortality: An analysis of 13 years' of demographic surveillance data from an urban African area. CID 2020
712. Schaltz-Buchholzer F, et al. BCG skin reactions by 2 months of age are associated with better survival in infancy: A prospective observational study in Guinea-Bissau
713. Hønge BL, Olesen JS, Jensen MM, Jespersen S, da Silva ZJ, Rodrigues A, Laursen AL, Wejse C, Krarup H, Aaby P, Erikstrup C. Hepatitis B and C in the adult population of Bissau, Guinea-Bissau: a cross-sectional survey. Trop Med Int Health. 2020;25:255-263
714.